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Abstract 
Improved knowledge of the biological role of lectins has raised the demand for 
carbohydrate-based therapeutics in recent years. The potential market is estimated to be 
greater than 20 billion dollars. However, lectins are challenging drug targets due to the 
unique binding properties of their extensively hydroxylated carbohydrate ligands. 
Hydroxyl groups provide directionality and therefore specificity, but are penalized with 
high desolvation costs. Consequently, monovalent carbohydrate-lectin interactions tend 
to be rather weak, often in the millimolar range. Moreover, the polar character of 
carbohydrates creates large obstacles for drug application regarding oral availability and 
long-lasting plasma levels. The key to the successful development of carbohydrate-based 
drugs is the simultaneous optimization of carbohydrate lead structures in terms of 
pharmacodynamics and pharmacokinetics. To further enhance the success rate of 
carbohydrate-based drug candidates, the understanding of carbohydrate-lectin 
interactions on a molecular basis has to be improved. For this purpose, we combined 
structural information (X-ray crystallography and nuclear magnetic resonance 
spectroscopy), binding data (isothermal titration calorimetry, microscale thermophoresis, 
and fluorescence polarization assay) and computational methods (quantum mechanical 
calculations and molecular dynamics simulations) to explore the lectins FimH and 
E-selectin and their interaction with carbohydrates and mimetics thereof. 
FimH is a virulence factor of uropathogenic E. coli located at the tip of the bacterial 
type 1 pili. It interacts with the mannosylated glycoprotein uroplakin 1a in the urothelial 
mucosa and thereby mediates adhesion to the bladder wall as the initial step of urinary 
tract infections (UTI). In manuscript 1 we investigated the energy contribution to binding 
of the hydroxyl groups mediating the interaction between FimH and the carbohydrate 
moiety of its ligands. The rigidity of this bacterial lectin was demonstrated in 
manuscript 2, where we showed that the affinity of a septanose as a mannose mimic is 
reduced by a factor of 10, mainly due to its flexibility in solution and the consequent 
conformational restrictions upon binding. In manuscript 3 we analyzed interactions 
between the tyrosine gate motif of FimH and the aglycones of different ligand classes. 
This motif (Tyr48, Tyr137) forms the entrance of the binding pocket and significantly 
contributes to binding affinity. In manuscript 4 we explored 2-C-branched mannosides as a 
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novel family of FimH antagonists. In manuscript 5, a pharmacodynamically and 
pharmacokinetically optimized FimH antagonist was explored by oral application in a 
mouse model for UTI, resulting in a 1000-fold reduction of the bacterial load in the 
bladder. Finally, in manuscript 6 we reanalyzed ITC results from our previous studies with 
the novel analytical tool kinITC, allowing the determination of kinetics in addition to the 
thermodynamics of binding. The hydrophobic aglycone turned out to be mainly 
responsible for guiding the antagonist to its binding site whereas the hydrogen bond 
network between the mannose moiety and the protein had predominantly an impact on 
the off-rate. 
E-selectin is a lectin expressed on the surface of vascular endothelial cells and is involved 
in the recruitment of leukocytes to the site of inflammation. By interacting with the 
tetrasaccharide epitope sialyl Lewisx, E-selectin establishes the initial contact and enables 
leukocytes to roll along the endothelial surface. Whereas this process is a defense 
mechanism in case of infections and injuries, excessive extravasation of leukocytes can 
have deleterious consequences in case of numerous diseases with an inflammatory 
component, e.g. asthma, psoriasis or stroke. Thus, blocking the interaction of E-selectin 
with its physiological ligands is a promising strategy to suppress the inflammatory 
response at the beginning of the cascade. For reliable and materially efficient affinity 
measurements, we developed and evaluated a novel assay for E-selectin based on 
microscale thermophoresis technology in manuscript 7. In the subsequent manuscripts, we 
applied the microscale thermophoresis assay. In manuscript 8 we performed a competitive 
library screen, whereby four promising small-molecule fragments were identified for 
further development towards a non-carbohydrate E-selectin antagonist. Finally, in 
manuscript 9 we were able to improve the affinity of a sialyl Lewisx mimic to E-selectin by 
pre-organizing the acid in its bioactive conformation.  
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Section I. Introduction – Molecular Interaction  
1. Molecular Interaction
1.1. Milestones in the research history of molecular interaction 
It has been more than 120 years since Emil Fischer discovered a fundamental underlying 
principle of molecular interaction.(1) He observed that methyl-α-D-glucoside but not 
methyl-β-D-glucoside is hydrolyzed in the presence of the yeast extract invertin. In 
contrast, methyl-β-D-glucoside but not its α-anomer was hydrolyzed in the presence of 
the almond extract emulsin. He interpreted his findings with the “lock and key” 
principle: 
“Um ein Bild zu gebrauchen, will ich sagen, dass Enzym und 
Glucosid wie Schloss und Schlüssel zu einander passen müssen, 
um eine chemische Wirkung auf einander ausüben zu können.” 
The “lock and key” principal of Fischer and the finding of Paul Ehrlich that agents can 
only work when they are bound (“corpora non agunt nisi fixata”) provided the basis for 
modern pharmacology.(2,3) They allowed medicinal chemists to synthesize “keys” that 
activate (agonist) or inhibit (antagonist) the function of a given “lock” (protein).(4) Since 
then, the number of known “locks” has been steadily growing and nowadays includes 
proteins of various groups like e.g. enzymes, lectins, hormone receptors, ion channels, 
transporters, structural proteins or transcription regulators.  
However, the static ‘key and lock’ principle could not explain why non-competitive 
inhibition can occur and why, for example, glucose but not water is phosphorylated in 
the binding pocket of hexokinase. In consequence, Daniel E. Koshland introduced the 
dynamic ‘induced-fit model’ in 1958.(5,6)  
“a) a precise orientation of catalytic groups is required for enzyme 
action, b) the substrate causes an appreciable change in the three-
dimensional relationship of the amino acids at the active site, and 
c) the changes in the protein structure caused by the substrate will
bring the catalytic groups into the proper alignment, whereas a 
non-substrate will not.” 
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In recent years, the concept of ‘conformational selection’ introduced from Ruth Nussinov 
and co-workers(7) has become more and more popular as an alternative dynamic model. 
This model assumes a selection for a conformational subpopulation in a system of 
dynamically fluctuating protein and ligand species. It is in contrast to the ‘induced-fit 
model’, where the conformational change is thought to be a consequence of the 
interaction of protein and ligand. Both models might be combined to an initial 
conformational selection followed by a conformational adjustment.(8) 
 
1.2. Mathematical description of a molecular binding event 
The equations to describe a protein-ligand binding event is the law of mass action 
deduced by Guldberg and Waage in 1879.(9)  
 
 aA + bB ⇌  cC + dD (eq. 1) 
 
 K  = k1
k-1
 = 
[C]c[D]d
[A]a[B]b
 (eq. 2) 
 
Equation 2 describes the ratio between the concentrations of the reactants ([A], [B]) and 
products ([C], [D]) at the equilibrium state of the reaction described in equation 1, where 
a, b, c, and d are the stoichiometric coefficients. The equilibrium constant K defines the 
extent of the reaction, whereas the rate is defined by the rate constant of the forward 
reaction (k1) and the reverse reaction (k-1). Equilibrium is reached when the rate of 
reaction in forward and reverse directions is equal.  
 
The law of mass action can be used analogously to describe a protein-ligand binding 
interaction (equations 3 and 4). 
 
 P  +  L  ⇌  PL (eq. 3) 
 
 KA = 
kon
koff
 = 
PL
P L
=
1
KD
 (eq. 4) 
 
 t1 2 = 
ln 2
koff
 (eq. 5) 
 
k1 
k-1 
kon 
koff 
4
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The equilibrium constants (binding constants) are called the association constant (KA) 
and the dissociation constant (KD). They describe the concentration in an equilibrium at 
which half of the protein in a system is complexed by a ligand. The rate constants are 
called the association rate constant kon and the dissociation rate constants koff. From koff 
the half-life (t1/2) of the protein-ligand complex can be obtained (equation 5).  
 
1.3. Driving forces of molecular interactions: Thermodynamics 
A spontaneous interaction between ligand and receptor only takes place when the overall 
change of free energy of binding (ΔG) is negative. ΔG of a reaction is determined by the 
nature of the reactants and their concentrations with R is the universal gas constant 
(8.314 J/mol K) and T being the absolute temperature (equation 6):(10)  
 
 ∆G  = ∆G°+RTln [P][L]
[PL]
=  ∆G°+RT  lnKD (eq. 6) 
 ΔG° is the change in free energy of binding under standard condition that is a reactant 
concentration of 1 M in solution. The system is at equilibrium when ΔG = 0. Therefore, 
the relation between the standard free energy and the equilibrium constant can be derived 
from equations 7 and 8. 
 
 0  =  ∆G°  + RT  lnKD (eq. 7) 
 
 
 ∆G°  = RT  lnKD  = − RT  lnKA (eq. 8) 
 ΔG° is furthermore determined by the change of enthalpy (ΔH°) and change of entropy 
(ΔS°) in dependence of the absolute temperature (T) (equation 9): 
 
 ∆G° = ∆H° − T∆S° (eq. 9) 
 
The change in entropy results from the sum of the changes in solvation entropy, 
conformational entropy, and the rigid body motions (translational and rotational 
entropy). The change in enthalpy reflects the change in bond interaction energy (covalent 
and non-covalent, including short and long-range electrostatics).  
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In drug discovery often a phenomenon called enthalpy-entropy compensation is observed, 
where an enthalpic improvement is linearly correlated with a loss in the entropy and vice 
versa.(11,12) A newly formed interaction between protein and ligand may lead to an 
improved enthalpy, but simultaneously constrains the conformational flexibility of 
protein and ligand, leading to an entropic penalty. It is furthermore accepted that water 
plays a key role in enthalpy-entropy compensation. When a binding event takes place in 
aqueous solution (solvent), both ligand and protein (solutes) shed their solvation shell in 
the contact area. The costs of this desolvation process have to be considered when 
calculating the binding energy. Hence, the change in free energy of binding is the difference 
between the solute-solute and the solute-solvent interactions. Depending on the polarity of the 
binding site and the ligand, this desolvation process is enthalpically more or less costly as 
hydrogen bonds between solute and solvent are to be broken.(13) However, this effect 
might again be partially compensated by a beneficial entropy term as water molecules are 
released to bulk.  
 
1.3.1. Enthalpic driving forces 
Enthalpic driving forces of a binding reaction are characterized by their release or 
consumption of heat. A negative enthalpy means the release of heat and contributes 
beneficially to the free energy of binding. The nature of enthalpic interactions is electrostatic. 
This means that they are formed between charged or dipolar atoms and are therefore subject 
to the Coulomb’s law (equation 10):  
 
 E = 
q1q2
4πε0rD (eq. 10) 
 
E is the electrostatic energy, r is the distance, q1 and q2 are the charges of two interacting 
atoms, ε0 is the vacuum permittivity, and D is the dielectric constant of the surrounding 
medium. Electrostatic interactions are therefore either attractive (oppositely charged) or 
repulsive (same charge). As described in Coulomb’s law, the energy of an interaction 
does not only depend on the individual charges of the interacting, but also on their 
distance and the solvent it takes place in. The solvent of biological systems (water) has a 
dielectric constant of 80. In close proximity to a protein, the dielectric constants drops to 
values in the range of 20 and in protein cavities to 5 or lower. In a vacuum, D is defined 
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to be 1.(14,15) Hence, the magnitude of the energy of an electrostatic interaction is increased in 
proximity to the protein due to the lower dielectric constant. Furthermore, electrostatic energies 
vary according to the nature of the charges and their distance. Between ions with net 
charges, the energy falls off slowly with distance 1/r (long-range electrostatics), while the 
energy of randomly oriented dipoles falls off rapidly with distance 1/r6 (short-range 
electrostatics).(16)  
 
Hydrogen bonds 
A hydrogen bond is a non-covalent interaction between a hydrogen bond donor (Dδ- 
covalently bound to a hydrogen atom Hδ+) and a hydrogen bond acceptor with a free lone 
pair (:Aδ-). Both donor and acceptor are electronegative atoms, usually nitrogen or 
oxygen. 
 
 Dδ- −Hδ++ :Aδ-  ⇌  Dδ- −Hδ+······· :Aδ-  
 
 
Hydrogen bonds are electrostatic dipole-dipole interactions with covalent features: the distance 
between the donor and acceptor is shorter than the sum of the van-der-Waals radii of the 
interacting atoms (but longer than a covalent bond) and their quality depends on 
geometrical rules (bond length between 2.5-3-2 Å; bond angle 130-180°). Directionality 
provides specificity and is therefore crucial for molecular recognition.(17) According to 
Jeffrey and Saenger (1991), a hydrogen bond contributes 1-4 kcal/mol to the free energy 
of binding.(18) A formal charge on one (charge-assisted hydrogen bond) or both (salt 
bridge) interaction partner(s) increases the energy of the bond.(19) However, hydrogen 
bonds are not restricted to the interaction between protein and ligand, but can also be 
formed with the solvent (water). Whether the disruption of these interactions during 
desolvation (desolvation penalty) is compensated by the newly formed interactions 
between ligand and protein depends on the specific case. However, even if hydrogen 
bonds do not always contribute significantly to the free energy of binding they might 
nonetheless be important for the specificity of a molecular binding event.(17) 
 
Hydrogen bond 
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Halogen bonds 
A halogen bond is built between a covalently bound halogen atom (R-Xδ+) (X=halogen 
atom) and a halogen bond acceptor (Aδ-). The halogen atom is the donor, while the acceptor 
is usually a lone pair of a nitrogen or an oxygen atom. However, also π electrons of an 
unsaturated conjugated system or a second halogen atom may act as an acceptor.(20)  
 
R−Xδ+ + :Aδ- ⇌ R−Xδ+·······Aδ- 
 
Although often described as entirely negative, the electrons of halogens are distributed 
anisotropically (Figure 1). The outer lobe of the half-filled p-Orbital is electronically 
depleted and therefore forms a more negative region along the transaxial plane and a 
positive region (σ-hole) along the R-X axis. Hence, the optimal bond angle for a halogen 
bond is 180°.(21) In theory, all halogens are able to form halogen bonds, but the positive 
electrostatic potential and the bond energy increases with the polarizability of the 
halogen atom (F < Cl < Br < I).(21) However, the electronegativity and a high level of 
sp-hybridization of fluorine cause an electron influx that neutralizes the σ-hole.(22) 
 
Figure 1. Molecular electrostatic potential of halogen atoms onto a 0.001 electrons Bohr-3 isodensity surface in 
Hartrees (Eh). Chlorine (B), bromine (C) and iodine (D) but not fluorine (A) form a positively charged σ-hole. The 
covalently attached electron withdrawing CF3 group reinforcing the formal positive charge. (Picture from Clark et al. 
(2007) modified after Metrangolo et al. (2008); reprinted with permission from Springer Science + Business Media)(22,23) 
 
Halogen bond 
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Like hydrogen bonds, halogen bonds are highly directional, electrostatically driven non-
covalent interactions. Halogen bonds are weaker than hydrogen bonds, but nevertheless 
still of importance in drug discovery because halogens are often used to provide 
solubility, metabolic stability and bioavailability to molecules.  
Van der Waals contacts 
Van der Waals (VdW) interactions are non-specific electrostatic interactions formed 
between dipoles. Although one single contact is weak, a large number of interactions 
contribute significantly to the overall binding energy.(24-26) While polar molecules have 
permanent dipoles, non-polar molecules only have induced dipoles formed by short-
termed random fluctuations in the distribution of the electron density. A distinction can 
be made between the interaction of a permanent dipole with an induced dipole (Debye 
force), two permanent dipoles (Keesom interaction) or two induced dipoles (London 
dispersion force). The VdW interactions are mathematically described by the 
12-6 Lennard-Jones potential (V) (equation 11),(27) where A and B are specific molecular 
constants (based on the VdW radii and the magnitude of attraction) of the interacting 
atoms and r describes their distance: 
V = 
A
r12
  − B
r6
(eq. 11) 
A/r12 represents the repulsive potential and B/r6 the attractive potential. The closer two 
atoms approach, the higher the attraction is (negative potential V). Yet, when the atoms 
come too close together, the repulsion term rapidly increases due to overlapping electron 
clouds (positive potential V). At V=0, when attraction and repulsion are in balance, the 
atoms are in VdW contact, which is the sum of the VdW radii of the two interacting 
atoms.(28)  
Stacking with π systems 
The amino acids phenylalanine, tryptophan, tyrosine, and histidine as well as many drug 
molecules contain π-systems. The conjugation of their p-orbitals enables delocalization of 
π electrons. This electron delocalization polarizes the aromatic ring resulting in two 
partially negative charged rings above and below the plane of the partially positive 
9
Section I. Introduction – Molecular Interaction 
charged atom ring (quadrupole).(29) Two aromatic systems mainly interact in a parallel or 
perpendicular configuration. The parallel arrangement is more favored when electron-
withdrawing groups are introduced that weaken the quadrupole.(30) On the contrary, 
electron donating groups increase the quadrupole charge distribution and therefore 
promote the perpendicular constellation between two aromatic rings, but also the 
interaction with other formally positive charged groups (cation-π interaction).(31) 
Furthermore, interactions with aliphatic groups and halogens are able to favorably 
contribute to the free energy of binding.(32)  
1.3.2. Entropic driving forces 
The entropy of a thermodynamic system is the measure of its disorder (motion). In 
contrast to the change in enthalpy, there is no direct measure of the change in entropy. 
However, since the KA and ΔH° can be determined, ΔS° can be calculated according to 
equations 8 and 9. A positive change in entropy contributes beneficially to the change in 
free energy of binding. Like ΔH°, ΔS° is an additive measure of different processes taking 
place during a binding event and it can be further dissected (equation 12):(33,34) 
∆S° = ∆S°solv + ∆S°conf + ∆S°trans/rot (eq. 12) 
The change in solvation entropy (ΔS°solv) depends on the hydration shell that alters upon 
the binding of a ligand to a protein. Water molecules are released to bulk water where 
they are assumed to gain motion. The hydration shell “melts” with increasing 
temperature and it completely passes to bulk water at a temperature of 385 K (TR).(35,36) 
Therefore, determination of the temperature dependence of the thermodynamic constants 
allows the calculation of ΔS°solv (equation 13 and 14), where ∆Cp is the change in heat 
capacity and T is the absolute temperature. 
∆Cp = 
∂∆H°
∂T 
(eq. 13) 
∆S°solv, T  =  ∆Cp  ln T TR (eq. 14) 
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The change in translational and rotational entropy (ΔS°trans/rot) is called the cratic term. It 
is a constant loss of energy due to the loss of degrees of freedom as upon complex 
formation when two rigid bodies (each being able to translate and rotate) join to one. 
Literature values for the cratic term range from -5.4 up to -62 kJ/mol (at 298.15 K).(37-39) 
However, the most often used change in entropy at room temperature is -10 kJ/mol 
calculated from equation 15, where R is the universal gas constant (8.314 J/mol K) and 
55.6 in the divisor corresponds to the molarity of 1 liter water.(39,40)  
∆S°trans/rot  =  R  ln 155.6 (eq. 15) 
The change in conformational entropy (ΔS°conf) can therefore be calculated according to 
equation 12. ΔS°conf is the change of conformational degrees of freedom of the bound 
protein-ligand complex compared to their unbound states in solvent. ΔS°conf is usually 
unfavorable (negative) as the amino acid side chains involved in binding, as well as the 
rotational bonds of the ligand, are more restricted in a complex. Conformational changes 
of the protein (induced fit) may also contribute unfavorably to ΔS°conf.  
1.3.3. Solvent effects 
To understand the role of water is crucial to understand binding. It is often neglected, but 
each water molecule has to be considered as an additional interaction partner when a 
protein-ligand interaction takes place in an aqueous environment. Therefore, the change 
in free energy of binding of a protein-ligand binding event contains the energy change of 
the whole system, including the desolvation of the interaction interfaces, newly formed 
interactions of the protein-ligand complex and water reorganization.  
Liquid water favorably forms approx. three hydrogen bonds while retaining a certain 
amount of mobility.(18) However, water molecules in the first solvation layer with close 
contact to the solute might not be able to form three hydrogen bonds (enthalpically 
frustrated water) or be limited in their mobility (conformationally trapped water).(24,41-44) To 
release these water molecules to the bulk may be highly beneficial. Dunitz calculated an 
entropic gain of up to 2 kcal/mol (at 300 K) for the release of a trapped water 
molecule.(45) In terms of enthalpy, the release of a trapped water molecule might be less 
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beneficial, as some of them play an important role in mediating interactions between 
protein and ligand (structural water).(32,46) Still, by far the most water molecules are loosely 
associated with the protein and can be displaced with minor effect to the overall free 
energy of binding. Hence, the solvation of an unbound protein binding site is 
predetermining the binding characteristics. While some water patterns promote binding, 
others request high desolvation costs and prevent strong interactions. 
Furthermore, the properties of the solute are decisive for solvation, in particular, its 
polarity. The highly polar water molecules tend to form hydrogen bonds to hydrophilic 
solutes. Breaking these hydrogen bonds upon desolvation is enthalpically expensive, but 
is partially compensated by the increased mobility of the water molecules in the bulk. On 
the other hand, hydrophobic solutes do not interact via hydrogen bonds with the solvent 
but rather form a cavity disrupting the water structure. The concept of the classical 
hydrophobic effect proposed by Kauzman assumes a more ordered water structure 
surrounding the non-polar solute.(47-51) Desolvation upon binding is therefore 
accompanied by a gain of entropy. However, ITC measurements revealed a non-classical 
hydrophobic effect characterized by an enthalpy gain upon desolvation.(44,52-55) This effect is 
explained by the gain of electrostatic interactions between the non-polar solutes as well as 
by the optimized formation of hydrogen bonds between the water molecules in the bulk.  
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2. Evaluating Molecular Interaction
2.1. Methods to determine the structure of complexes 
A full understanding of a molecular binding interaction requires not only knowledge of 
the energetics of binding, but also structural information about the bound and unbound 
states of the binding partners. Otherwise, crucial effects such as conformational changes 
and oligomerization might not be detected and can lead to a misinterpretation of binding 
data. Probably the most important source for high resolution structural information is 
X-ray crystallography, where the diffraction pattern of a molecular structure (e.g. lectin-
carbohydrate complex) is gained by the exposure of its crystal to a beam of 
monochromatic X-rays.(56) The X-ray scatters at the atoms in the crystal and the emerging 
diffraction pattern can be transformed into 3-dimensional information regarding 
individual atom positions. However, information about complex structure from X-ray 
crystallography may be compromised by poor resolution or unfavorable crystal contacts 
that prevent binding or distort the structure of the bound state. Moreover, an X-ray 
structure is a static picture of a dynamic system and it is wise to consider other sources of 
structural information like small-angle X-ray scattering (SAXS),(57) cryo-electron 
microscopy (Cryo-EM),(58) nuclear magnetic resonance (NMR) spectroscopy, atomic 
force microscopy (AFM)(59,60) or homology modeling.(61) Computational approaches like 
molecular dynamics (MD) simulations or quantum mechanical (QM) calculations are 
very useful to evaluate questions of motion, conformation, solvation and energy 
composition.(62) The most powerful technique to obtain both structural information and 
binding data is NMR spectroscopy and it is, in contrast to X-ray crystallography, measured 
in solution. A range of informative NMR data such as chemical shifts and intra- or 
intermolecular nuclear Overhauser effects (NOE) can be combined to derive the 3D 
structure of a protein or protein-ligand complex.(63,64) Further experiments can be applied 
to elucidate the dynamics of a protein, ranging from fast backbone or side chain 
fluctuations to global conformational changes on a slow timescale.(65,66) Protein-ligand 
binding events can be detected and quantified by a broad range of experiments with 
either observation of the ligand signals (e.g. saturation transfer difference, transfer NOE 
or relaxation-based experiments)(67-69) or of the protein signals (chemical shift perturbation 
experiments, CSP).(70) CSP experiments are especially suited to the identification of 
unknown binding sites on a protein target.(71) 
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2.2. Methods to determine the inhibitory constant 
Carbohydrate-lectin interactions are frequently weak, having KD values in the high µM to 
mM range. Many techniques that are routinely used to quantify high-affinity interactions 
(KD in the µM to pM range) are not applicable or practicable for measuring such lower 
affinities. Therefore, the next two sections will focus on techniques suitable for the 
measurement of the carbohydrate-lectin interactions. 
Many competitive assay formats have been established to quantify carbohydrate-lectin 
interactions. The phenomenon of hemagglutination that led to the discovery of the first 
lectin by Stillmark in the 19th century, is still the most often used method.(72,73) The 
hemagglutination assay (HA) takes advantage of the heterogeneous glycosylation of 
erythrocytes and the multivalent binding properties of most lectins.(74,75) While the 
presence of anticoagulants red blood cells would segregate in suspension, the addition of 
a multivalent lectin cross-links the blood cells and creates a lattice structure. An assay 
format where the carbohydrate competes with erythrocytes for binding to the lectin 
allows the determination of a carbohydrate concentration that inhibits 50% of the 
agglutination (IC50) (Hemagglutination inhibition assay, HIA). IC50 values are helpful to 
compare and rank the inhibition potency of different ligands, but they are not suitable to 
compare inhibition concentrations measured with different methods or in different 
laboratories (e.g. when differently glycosylated erythrocytes are used). Furthermore, the 
HIA is subject to the numerous limitations, e.g. irreversible cross-linkage without 
formation of an equilibrium or multivalent ligands cross-linking the erythrocytes. These 
drawbacks are eliminated by the enzyme-linked lectin assay (ELLA).(73) In the ELLA 
method, a polyvalent ligand is immobilized on a microtiter plate and a lectin-horseradish 
peroxidase conjugate is incubated with a serial dilution of competing ligand of interest. 
After equilibration, the supernatant containing the unbound ligand of interest and lectin 
is washed off and replaced by a solution of chromogenic peroxidase substrate. The 
protein bound on the microtiter plate can now be quantified using UV spectroscopy. This 
method can be modified, e.g. when the lectin is immobilized on a microtiter plate and the 
ligand is competing with a spectroscopically detectable glycopolymer (Polymer-binding 
assay).(76) However, the output of both assays is an IC50 value with all its drawbacks. A 
possible approach to solve these drawbacks is the fitting of the binding curves using an 
analytical solution to derive the inhibition constant (Ki) for competitive binding derived 
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by Wang.(77) However, for both assays, HIA and ELLA, the Wang equation cannot be 
applied as the exact concentration of all participating molecules as well as the 
dissociation constant (KD) between the standard competitor and the lectin is not known. 
A competitive assay where the Wang equation can be applied is a technique based on 
fluorescence polarization (FP). Here, the competing ligand (tracer) is linked to a 
fluorophore.(78) In steady-state fluorescence polarization measurements, polarized light is 
used to excite a fluorophore-containing tracer compound, and the degree of polarization 
of fluorescence emission is determined by measuring fluorescence through polarizers 
parallel and perpendicular to the axis of excitation polarization. The extent of 
depolarization of fluorescence emission depends upon the rotation of the fluorophore 
during its fluorescence lifetime. This depends upon the tumbling rate of the fluorophore, 
which is influenced by its hydrodynamic radius. Hence, a tracer bound to a protein 
exhibits slower tumbling compared to a free tracer in solution and has increased 
fluorescence polarization. Titrating a dilution series of protein against a constant 
concentration of tracer gives a binding curve from which it is possible to derive the exact 
KD using a standard single-site binding model (e.g. the function given by Cooper(79)). 
Therefore, all constants are known to use the Wang equation for the competitive assay 
format. 
2.3. Methods to determine the binding constants 
More reliable is the direct determination of the KD without the complication of a 
competitive assay format, e.g. using microscale thermophoresis (MST).(80) We routinely use 
MST to determine affinities of E-selectin ligands because the extremely small assay 
volume preserves valuable protein and ligand resources (Manuscripts 7-9). The assay is 
based on the phenomenon that molecules move along a temperature gradient, a 
phenomenon known as thermophoresis. The rate of thermophoresis is sensitive to 
changes in size, charge, and solvation of a molecule, which allows discriminating bound 
from unbound species.(81) For some proteins it is possible to follow thermophoresis by 
intrinsic tryptophan fluorescence, while for many others it is necessary to label one 
interaction partner with a fluorescent dye. 
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Another label-free technique to determine KD, as well as the association rate constant 
(kon) and the dissociation rate constant (koff) is surface plasmon resonance (SPR).(82) Either the 
ligand or the protein is immobilized on a functionalized gold surface. The backside of the 
gold layer reflects a light source through a prism to a detector. At a certain resonance 
angle, the light is absorbed by the electrons of the gold layer causing them to resonate. 
The angle at which this occurs depends upon the refractive index of the solution at the 
functionalized gold surface. A binding event at the surface changes that refractive index 
and is observable as a shift of the minimum in the reflectivity curve. Monitoring the 
change in resonance over time enables to derive the rate constants kon and koff.  
The only technique to determine directly the thermodynamics of a binding reaction is 
isothermal titration calorimetry (ITC).(83) ITC is the most frequently used technique 
throughout this thesis and is therefore explained in more detail. With one ITC 
experiment, it is possible to simultaneously measure the change in enthalpy (ΔH°), the 
binding stoichiometry (N) and KA. According to a recent publication by Burnouf et al. 
even the rate constants kon and koff can be deduced from ITC measurements.(84) For a 
standard ITC experiment, a threefold surplus of ligand is stepwise titrated through a 
syringe into a cell containing the protein solution (Figure 2A). However, also an inverse 
experiment is possible. 
Figure 2. Illustrated mode of operation of an isothermal titration calorimeter. (A) The small temperature changes 
are not measured directly, but the power supply to maintain a constant temperature in the sample cell is compared to a 
reference cell. (B) Enthalpogram of an ITC experiments. Top: The recorded change in heat (μcal/sec) that is set free 
upon complex formation after stepwise injection of ligand. Bottom: By integrating the area under the curve of all 
injections, a binding curve is obtained that contains information on stoichiometry (N), change in enthalpy (ΔH°) and 
the association constant (KA). (2A is a picture from Holdgate and Ward (2005); reprinted with permission from 
Elsevier)(85) 
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The formation of a complex (equation 3) either consumes or releases heat, which can be 
monitored during an experiment by comparing the power supplied to heaters on the 
reference and sample cells to maintain them at equal temperature during the experiment. 
The energy released or consumed (q) is associated with the change in complex 
concentration (Δ[PL]) and depends on the enthalpy change at the given temperature 
(ΔH(T)) and the reaction volume of the sample cell (V) (equation 16): 
q= VΔH(T)Δ[PL] (eq. 16) 
For a tight-binding ligand with an exothermic enthalpy of binding, the surplus of protein 
in the sample cell enables the entire injected ligand to bind at the beginning of the 
experiment. When the experiment proceeds, a steadily increasing number of binding sites 
are occupied leading to a decreased release of heat.  When all binding sites are occupied 
only the heat of dilution is observed (Figure 2B). The integral heat (Q) released or 
consumed after the ith injection is calculated according to equation 17, 
Q= N[P]VΔH(T)θi (eq. 17) 
where [P] is the total protein concentration, θi the fractional saturation and N the 
stoichiometry. Equation 18 is used to calculate the differential heat after the ith injection 
(qi). 
qi = N[P]VΔH T (θi-θi-1) (eq. 18) 
Both, nonlinear fitting to the hyperbolic saturation curve of Q vs. the total ligand 
concentration [L] based on equation 17 or to the sigmoidal saturation curve of qi vs. [L] 
based on equation 18 yield in the parameters KA, N and ΔH°. All three parameters can 
only be determined from one experiment within a certain range of the dimensionless 
Wiseman parameter (c), depending on the affinity of the interacting molecules and the 
receptor concentration (equation 19):(86) 
c=[P]KA=[P] 1KD (eq. 19) 
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An optimal c-value is within a range of 5 and 1000 and allows the determination of all 
three parameters.(87) When the c-value increases, the sigmoidal binding curve becomes 
steeper and insensitive to changes in KA, while the fitting of the parameters ΔH° and N is 
still reliable. For the determination of the binding constants of high-affinity ligands, a 
competitive displacement experiment has to be performed.(88) Because lower c-values 
require higher concentrations of both, ligand and protein(89) problems with solubility and 
material consumption may occur. Thus, using a larger surplus of ligand to completely 
saturate the protein within one experiment, allows the determination of KA and ΔH° 
using a two-parameter fit with a fixed stoichiometry. With this experimental setup, the 
accuracy of the fitted parameters depends entirely on the accurate determination of both 
ligand and protein concentration.  
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3. Carbohydrate-Lectin Interactions
3.1. Carbohydrates 
Carbohydrates (saccharides, sugars) are the product of photosynthesis in plants. They are 
composed of carbon, oxygen and hydrogen atoms (Cn(H2O)n) and cyclize by either via an 
aldehyde or a keto group with a hydroxyl of the distal carbons. 5-membered rings are 
called furanoses, while 6-membered rings are called pyranoses. Carbohydrates are a major 
source of energy for all living organisms and their covalent linkage from polymers 
(polysaccharides) allows the spatially efficient storage of this energy (e.g. starch, glycogen). 
Due to their ability to form large cross-linked, rigid polymers, they also fulfill important 
structural functions (e.g. cellulose, chitin). Furthermore, the surface of cells is coated with a 
broad variety of branched polysaccharides (glycan) forming a layer of carbohydrates 
(glycocalyx). The glycans are either linked to proteins (glycoproteins, proteoglycans) or 
lipids (glycolipids). One example of the clinical relevance of glycans is that differential 
glycosylation of red blood cells determines the human blood groups.(90) The glycosylation 
of a protein may also alter its structure, folding, function or solubility.(91) Moreover, 
glycans are able to promote or inhibit intermolecular binding sterically, but also 
specifically. The coding capacity of polysaccharides is enormous: With the ten mammalian 
monosaccharides(92) glycosidically linked α or β billions of oligosaccharides can be 
formed exhibiting different three-dimensional structures with distinct binding 
specificities. Finally, post-translational modifications (e.g. acetylation, sulfation, 
methylation, phosphorylation) even further increase the coding capacity of 
carbohydrates.(93)  
3.2. Lectins 
When carbohydrates are encoding information, lectins are the structures to read this 
‘glycocode’ by specific binding. Lectins are defined as carbohydrate-binding proteins of non-
immunological origin and without enzymatic activity. The discovery of lectins leads back to 
19th century when Stillmark isolated a protein extract of seeds of Ricinus communis and 
found it to agglutinate with animal erythrocytes.(72,94) The connection between 
carbohydrates and lectins was made when the binding of erythrocytes to Concanavalin A 
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(a lectin isolated form Canavalia ensiformis) could be inhibited by specific saccharides.(95) 
However, not only plants but a broad variety of species, such as bacteria, viruses, and 
animals were found to express lectins with a wide spectrum of functions.(96) 
3.2.1. Microbial lectins 
Many microorganisms make use of lectins for the initial attachment to the cell-surface 
glycan of host cells.(97) Due to this function, these lectins are also termed ‘adhesins’ and 
are important virulence factors of pathogens. Similar to plant lectins, microbial lectins 
were often detected due to their ability to agglutinate erythrocytes (hemagglutination). 
The first detected and still best characterized microbial lectin is hemagglutinin (HA), 
which was detected on the surface of the influenza virus in the 1950s by Alfred 
Gottschalk.(98) The first bacterial adhesins were discovered in the 1970s.(99,100) They were 
found to be associated with filamentous protein structures at the surface of bacteria (pili). 
The most prominent representatives to date are FimH, a mannose-binding lectin at the 
tip of the type 1 pili and PapG, a galabiose binding lectin a the tip of P pili of 
uropathogenic E. coli. FimH and PapG are virulence factors for urinary tract infections 
(see Section II). 
3.2.2. Human lectins 
The role of lectins in humans is more versatile. In 1988, Kurt Drickamer classified 
calcium ion-dependent lectins as C-type lectins and lectin with free thiols as S-type 
lectins.(101) Among the best characterized C-type lectins are the collectins(102) (stimulators of 
the innate immune system by recognizing glycans of pathogens), DC-SIGN(103) (a lectin 
on dendritic cells that binds to oligomannose-type-N-glycan present in the envelope of 
viruses, such as HIV and Hepatitis C) and the selectins(104) (cell-adhesion molecules that 
mediate the initial steps of leukocyte trafficking). Function and structure of the selectin 
family are described in more detail in Section III. In the same way that today lectins are 
being classified according to structural features of their ‘carbohydrate recognition 
domain’ (CRD), the earlier S-type lectins were divided into galectins and P-type lectins. 
P-type lectins are intracellular mannose 6-phosphate receptors and are responsible for the 
routing of lysozymal enzymes.(105) Galectins are a very diverse family of lectins with a 
broad spectrum of functions such as cellular growth and apoptosis regulation, cell-matrix 
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interactions, chemotaxis, immune regulation, and the promotion of pro- and anti-
inflammatory responses.(106) A further group of lectins are the I-type lectins which are 
members of the immunoglobulin superfamily.(107) The most prominent subgroup of the 
I-type, the Siglecs, share sialic acid as their common binding motif and fulfill widespread 
functions such as the maintenance of myelinated axons (Siglec-4 = MAG), or the 
prevention of an overactivation and development of autoimmune reactions of B-cells 
(Siglec-2 = CD22).(108)  
3.3. Lectins and carbohydrates in drug discovery 
Carbohydrates have been used as drugs since 1930 when the polysaccharide heparin was 
clinically prescribed as an antithrombotic.(109) A further early example of a carbohydrate-
based drug is hyaluronic acid used as a vitreous substitution during eye surgery in the 
1950s.(110) However, both heparin and hyaluronic acid were isolated from natural sources, 
as opposed to chemically synthesized what is probably one of the reasons why not more 
carbohydrate-based drugs made their way to clinical application. Compared to other drug 
molecules, the synthesis of oligosaccharides is more complex due to multiple protection and 
deprotection steps, numerous stereocenters and a lack of general methods for routine 
preparation.(111) However, recent developments are beginning to address these 
problems.(112) The first synthetically produced heparin (Fondaparinux, ARIXTRA, 2002) 
may exemplify this progress.(113)  
On the other hand, progress in molecular biology has improved the knowledge of the 
biological role of lectins in cell regulation and recognition at a molecular level and this 
has raised the demand for new drugs and therapeutics. Of special interest for drug 
discovery are microbial adhesins (e.g. FimH, PapG) in prospect of an anti-adhesion 
therapy of bacterial infections, as well as extracellular human lectins (e.g. C-type, 
galectins, I-type lectins). An excellent overview of promising lectin drug targets and 
marketed carbohydrate-based drugs was written by Beat Ernst and John L. Magnani 
(2009) and is recommended for more detailed information.(114) In the year 2010, the 
potential market for carbohydrate-based drugs was estimated to be greater than 20 billion 
dollars a year.(115) Still, at the time of writing, no lectin antagonist has made it to the market. 
Nevertheless, the development of lectin antagonists is in progress and several drug 
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candidates are in clinical evaluation. One candidate that has to be highlighted in this 
context is rivipansel (GMI-1070, Glycomimetics Inc.),(116) which is currently in clinical 
phase III. Rivipansel is a pan-selectin antagonist that mimics the natural binding motif 
sialyl LewisX and gives hope to patients suffering from sickle cell disease (for more details 
see Section III).  
In contrast to lectin antagonists, several inhibitors of glycosidases are already marketed. 
Successful pharmaceuticals are the viral neuraminidase inhibitors oseltamivir (Tamiflu, 
Roche)(117) and zanamivir (Relenza, GlaxoSmithKline),(118) which mimic the structure of 
sialic acid in the transition state of the enzymatic reaction. Other prominent examples are α-glucosidase inhibitors like miglitol (Glyset, Pfizer),(119) acarbose (Glucobay, Bayer),(120) 
and voglibose (Glustat, Takeda)(121) that are used for the treatment of type II diabetes by 
preventing the digestion of carbohydrates. Miglustat (Zavesca, Actelion)(122) inhibits 
glucosylceramide synthase and is prescribed for the treatment of type 1 Gaucher disease. 
The key to the successful carbohydrate-based drugs is to overcome the pharmacokinetic 
drawbacks inherently linked to native carbohydrates. Their polarity has to be 
systematically reduced by substitution of the hydroxyl groups not necessary for the 
biological activity. Subsequent optimization in terms of pharmacodynamics and 
pharmacokinetics (e.g. bioavailability, metabolic stability) give the glycomimetic drug an 
advantage over its natural competitor. An important prerequisite to further improve the 
success rate of carbohydrate-based drug candidates is a better understanding of 
carbohydrate-lectin interactions on a molecular basis. 
3.4. Molecular basis of the regulation of carbohydrate-lectin affinity 
Despite the structural diversity and diverse origins, lectins exhibit some common features 
probably related to their common interaction partners.(123) Fast association and dissociation 
kinetics and therefore short half-lives of the carbohydrate-lectin complexes characterize 
highly dynamic systems.(124) Furthermore, carbohydrates generally bind to their target 
structures with relatively weak affinities, often in the milli- to micromolar range.(73,125) This 
seems of particular importance under physiological conditions, as it allows the regulation 
of an interaction with higher resolution on different levels (Table 1).  
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Table 1. The four levels of regulation of carbohydrate – lectin affinity. From monomer to interaction 
interface to scaffold to cluster. Inspired by Gabius et al. (2011).(126) 
Level 
Carbohydrate Lectin 
Structure Affinity regulation Structure Affinity regulation 
Monomer Monosaccharide Substitution; bidentate 
interactions; 
cooperative hydrogen 
bonding; stacking 
Amino acids Charged interactions; 
cooperative hydrogen 
bonding; solvation; 
stacking 
Interaction 
interface 
Oligosaccharide Conformational 
flexibility; Solvation 
Binding site Shape; dielectric constant; 
preorganization; 
solvation; structural ions 
Scaffold Glycan Branching Protein Catch bond 
Cluster Glycocalyx Multiple glycans; 
microdomains 
Multivalency Multiple lectins; lectin 
oligomers; multiple 
binding sites on one lectin 
3.4.1. Affinity regulation: Carbohydrates 
Not surprisingly, hydroxyl groups are the dominant feature when carbohydrates interact 
with lectins and at the same time, the main reason for the weak affinity. Desolvation of 
carbohydrates is enthalpically extremely costly because hydroxyl groups form strong 
interactions with the surrounding water molecules.(73) Hence, to compensate for this 
desolvation penalty a hydroxyl group needs to form strong hydrogen bonds with a lectin. 
Therefore, with complex hydrogen bond networks between protein and ligand, high 
selectivity and affinity can be reached. Moreover, several substitutions on carbohydrates 
(e.g. amine- and carboxyl groups, sulfation) are also involved in hydrogen bonding and 
charged groups can further increase the interaction energy. Hydroxyl groups frequently act 
simultaneously as both, donor and acceptor of a hydrogen bond (bidentate hydrogen 
bonds).(127) This is beneficial in three ways: first, a single desolvated group forming 
multiple interactions in the bound state allows more efficient compensation of the 
desolvation penalty for that group, because the penalty is paid once but compensated 
multiply. Second, freezing a rotational bond is penalized by entropic costs. Thus, only 
the first interaction is entropically costly, while for further interactions the hydroxyl 
group is already pre-organized. Third, the hydrogen bonds strengthen each other due to a 
phenomenon called ‘cooperative hydrogen bonding’.(18,128-130) Donation of a hydrogen bond 
by a hydroxyl group increases the electron density (partial charge) on the oxygen lone 
pair and improves its H-bond acceptance quality and vice versa. A less known feature of 
carbohydrate-lectin interactions is C-H···π stacking.(131) Partially positive charged 
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hydrophobic C-H patches on the sugar surface are able to stack against the quadrupole of 
a π system of an aromatic amino acid side chain (Trp, Tyr, Phe). The enormous 
importance of the diverse linkage possibilities for the specificity of carbohydrate binding 
was already mentioned before. However, they also play a role in affinity regulation. 
Affinity to a lectin is obviously increased by increasing the maximum number of 
contacts, but also by affecting the conformational flexibility/rigidity of the oligosaccharide 
(e.g. core fucosylation).(126) 
3.4.2. Affinity regulation: Lectins 
On the monomer level (Table 1), similarities between monosaccharides and amino acids 
are detected: hydrogen bonds between carbohydrates and proteins are often charge assisted 
and bidentate.(127) Therefore, it is not surprising that the (at physiological pH) negatively 
charged aspartic and glutamic acid, as well as the positively charged arginine, are over-
represented in the binding sites of lectins.(127,132) All of them are able to form bidentate 
hydrogen bonds. Furthermore, the presence of the aromatic amino acids tryptophan and 
tyrosine (stacking) is above the average.(132) On the level of the interaction interface 
(binding site), the evolution of lectins has resulted in two different adaptions to bind 
carbohydrates with physiologically acceptable affinities: Small and deep binding pockets 
binding monosaccharides (group I), or large and shallow grooves binding 
oligosaccharides (group II).(128) Deep buried binding pockets have the advantage of a 
lower dielectric constant, which increases the energy of electrostatic interactions according 
to Coulomb’s law (equation 10). Hence, group I lectin often provide higher affinities and 
are predominantly observed in plant, viral, and bacterial lectins (adhesins), whereas 
group II lectins are highly specific and predominant among animal lectins. A well pre-
organized binding site thereby facilitates higher affinity binding as it reduces the 
conformational entropy penalty upon binding.(125,133) However, conformational changes of 
the lectin might also be beneficial for the interaction lifetime despite a concomitant 
entropy penalty. An example is the so-called ‘catch-bond behavior’ inducing a slower 
dissociation rate of a bound ligand by a conformational change.(134,135) A further 
adaptation to enhance affinity is the presence of salt-bridges with strategically presented 
Ca2+ions (C-type lectins). 
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3.4.3. Multivalency 
Despite the evolutionarily optimized interactions of lectins and glycans, low affinity 
remains a problem for some applications where firm adhesion is required. Nature’s way 
to bridge the gap is ‘multivalency’.(136) Multiple receptors bind to multiple ligands. There 
are, however, different types of organization clusters: a multi-antennary glycan, different 
glycans on one macromolecule or different glycans on different macromolecules 
(microdomains) may interact with different individual lectins, a lectin with multiple 
binding sites or lectin oligomers.(126,137) The binding strength of a multivalent interaction is 
not equal to the sum of the single binding affinities. It is influenced by structural 
conditions, but also by an increase of local concentration in proximity to a binding event. 
The increase of binding strength provided by multivalent interaction is described by the 
term ‘avidity’. 
3.5. Thermodynamics of carbohydrate-lectin interactions 
Intuitively, one would assume that the abundant hydroxyl groups, which determine 
many properties of carbohydrate-lectin interactions, would also make a dominant 
contribution to the thermodynamics of binding. However, this is not the case.(125,133,138) A 
reaction in aqueous solution is too varied for a general trend to be discerned.(125) 
Nevertheless, Eric J. Toone (1994) recognized three recurrent trends when comparing 
different thermodynamic profiles of carbohydrate-lectin interactions: (i) a more negative 
change in enthalpy than in free energy of binding (enthalpy driven); (ii) a strong linear 
enthalpy-entropy compensatory behavior; (iii) a small and negative heat capacity 
(< 400 J/mol K). The negative enthalpy might be attributed to the hydrogen bond 
network and reorganization of disordered water near the protein surface. Still, it is 
somewhat surprising that only a few cases of entropy-driven carbohydrate-lectin 
interactions are described considering that lectin binding sites are well pre-organized and 
preferably bind the bioactive conformation of their carbohydrate ligand 
(Manuscript 1).(133,139) However, it has to be noted that both, the enthalpy driven binding 
and enthalpy-entropy compensation, are not solely features of carbohydrates binding to 
lectins, but commonly observed phenomena of interactions in aqueous solution.(11,133) 
Hence, heat capacity is the only exclusive parameter related to carbohydrate-lectin 
interactions and reflects the reorganization of solvent.(140) Small ΔCp values indicate minor 
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solvent reorganization processes and are observed for the burial of polar surface area.(141) 
To quantify solvent reorganization for carbohydrate-lectin interactions, Chervenak and 
co-workers evaluated binding reactions in light (H2O) and heavy (D2O) water.(142) Solvent 
reorganization was found to contribute about 25-100% to the observed enthalpy, while 
the binding free energy remained unchanged due to compensatory effects in the entropy 
term.  
A further method to obtain characteristic information of carbohydrate-lectin interactions 
is the systematic substitution of hydroxyl groups of the ligand (Manuscript 1). Many 
studies with monodeoxy analogs were published, but only in a few cases (Table 2) the 
thermodynamics of binding upon a loss of a hydroxyl group involved in a hydrogen bond 
could be determined. The most comprehensive monodeoxy studies were carried out by 
Fred Brewer and co-workers who investigated the binding of concanavalin A to deoxy 
analogs of 3,6-di-O-(α-D-mannopyranosyl)-D-mannose.(143) His research group extended 
the investigations to other (all structurally and thermodynamically related) Leguminosae 
lectins,(144,145) supported thermodynamic data with structural information,(146) and 
determined the solvent reorganization effect in D2O.(147) The measurements in D2O 
revealed that the solvation of deoxy ligands alters significantly with the loss of a hydroxyl 
group. These desolvation costs were considered in the study Daranas et al. (2004)(148) who 
concluded that the intrinsic free energy of D-galactose binding to the L-Arabinose-
binding protein is remarkably constant (30 kJ/mol), independent on the number of 
hydrogen bonds formed. In their publication on the thermodynamics of deoxy analogs of 
3,6-di-O-(α-D-mannopyranosyl)-D-mannose binding to artocarpin, Surolia and co-
workers(149) pointed out the nonlinearity of the enthalpy and free energy contributions to 
binding of individual hydroxyl groups. For example, the sum of all ΔΔH° values for 
monodeoxy analogs (295.4 kJ/mol) was almost 7 times greater than the ΔH° of the 
unmodified reference trimannoside (-44.8 kJ/mol). They speculated that the loss in 
enthalpy and free energy upon the loss of a hydroxyl group represents different 
contributions of the solvent and the protein and not only those related to the loss of the 
hydrogen bond. All of the mentioned lectins (the plant lectins concanavalin A and 
artocarpin and the bacterial lectin L-Arabinose binding protein) share the similarity of 
deeply buried binding pocket. Hence, the thermodynamic fingerprint for the loss of a 
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Table 2. Overview of thermodynamic parameters of lectins binding to monodeoxy ligands. 
Concanavalin A is representatively shown for the Leguminosae lectin family, which all exhibit closely 
related thermodynamics of binding. 
Protein / Ligand / 
Temperature 
Deoxy analog ΔΔG° 
[kJ/mol] 
ΔΔH° 
[kJ/mol] 
-ΔTΔS° 
[kJ/mol] 
Interaction Ref 
Concanavalin A / 
3,6-di-O-(α-D-
mannopyranosyl)-D-
mannose / 300 K 
Man3-3H 5.5 14.2 -8.7 2 (143,144)
Man3-4H 4.2 8.8 -4.6 2 
Man6-3H 6.3 13.4 -7.1 1 
Man6-4H 7.4 11.3 -3.9 2 
Man6-6H 7.0 11.7 -4.7 2 
ManC-2H 3.6 4.2 -0.6 1 
ManC-4H 5.9 9.6 -3.7 1 
Artocarpin /       
3,6-di-O-(α-D-
mannopyranosyl)-D-
mannose / 293 K 
Man1-3H 4.2 33.8 -29.7 1 (149)
Man1-4H 6.4 39.0 -32.6 1 
Man1-6H n.b. n.b. n.b. 3 
Man2-2H 6.8 29.5 -22.7 2 
L-Arabinose binding 
protein /       
D-Galactose / 
308 K 
Gal-1H 22.6 32.0 -9.0 1 (148)
Gal-2H 15.1 34.0 -18.0 2 (1 via H2O) 
Gal-3H 24.4 38.0 -13.0 3 
Gal-4H n.b. n.b. n.b. 2 
Gal-6H 6.3 2.0 5.0 2 (1 via H2O) 
Calreticulin / 
Glcα1-3Man-α1-
2Man / 303 K 
Glc1-6H -1.1 22.3 -23.4 1 via H20 (150)
Glc1-3H 8.7 0.9 7.8 1 
Man2-4H 0.9 0.1 0.8 1 
Man2-6H 7.4 -3.5 10.9 1 
Man3-4H 7.2 -8.7 16.0 1 
Man3-3H 0.5 -0.4 0.9 1 via H20 
hydroxyl group is also very uniform: the loss in enthalpy exceeds the loss in free energy 
due to a partial compensation by the entropy. In contrast, the thermodynamic fingerprint 
of monodeoxy analogs of Glcα1-3Man-α1-2Man binding to the shallow binding site of 
the human chaperone calreticulin is more heterogeneous.(150) The loss of 6-OH of glucose 
results in a gain of free energy of binding due to an overcompensating gain in entropy, 
while the loss of the hydrogen bonds formed by 4-OH on the central mannose moiety 
and 3-OH on the terminal mannose moiety have barely an effect on the binding 
properties. Interestingly, the removal of 6-OH of the central mannose unit and 4-OH on 
the terminal mannose unit leads to a decreased free energy of binding due to an 
unbeneficial entropy term. Unfortunately, the authors of the study do not comment on 
these unusual findings. In summary, the comparison of conservatively modified ligands 
(or proteins) (e.g. ΔΔH°, ΔΔG° and –ΔTΔS° values) allow a more meaningful 
interpretation of binding characteristics than the bare cross-comparison of 
thermodynamic fingerprints of lectins binding carbohydrates  
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1. Introduction 
1.1. Urinary tract infection 
Urinary tract infections (UTI) are among the most prevalent bacterial infections 
worldwide causing high medical costs.(1,2) During these infections, gut bacteria colonize 
in the urethra and ascend to the bladder (lower urinary tract infection, cystitis) and the 
kidneys (upper urinary tract infection, pyelonephritis). 50% of women experience a 
symptomatic UTI at least once during their lifetime.(2) About 25% of the UTIs recur 
within 6 months caused by a genotypically similar bacteria strain.(3) Typical patients are 
young, sexually active women and elderly women with a catheter or diabetes.(4) The 
standard therapy is a three-day antibiotic treatment. However, rising numbers of bacterial 
resistance to antibiotics and high reoccurrence rates reveal the need for an alternative 
treatment.(5) 
 
1.2. Infection cycle of uropathogenic Escherichia coli 
Escherichia coli (E. coli) is a usually mutual, gram-negative, facultatively anaerobic 
bacterium of the human gut flora. Nevertheless, some serotypes of E. coli are pathogenic, 
among them uropathogenic E. coli (UPEC). UPEC causes up to 90% of all UTIs(6) and 
typically expresses adhesins allowing the attachment to the urinary tract epithelium. The 
adhesion is the initial step(7) of an infection cycle,(8) which increases the persistence of 
UPEC in the bladder:  
 
1. Adhesion: UPEC are able to express type 1 pili with a carbohydrate binding lectin 
(FimH) at their tip. This enables the interaction with uroplakin 1a (UPK1a), which is 
an integral component of the luminal membrane of urothelial cells.(9) UPK1a is 
highly mannosylated with N-linked carbohydrates and therefore presents mannose 
carbohydrates to bladder lumen. FimH specifically binds to these mannosides. The 
interaction with the bladder epithelium prevents UPEC from being flushed out with 
the bulk flow of urine.  
2. Invasion: Exocytosis of specialized vesicles (fusiform vesicles) regulates the bladder 
surface when the volume of the bladder increases due to the accumulation of   
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urine.(10-12)  Bladder relaxation and the consequent internalization of fusiform vesicle 
allow attached UPEC to invade bladder cells.  
3. Intracellular bacterial communities (IBC): Once internalized, E. coli bacteria start at 
an early stage to replicate and build IBCs.(13,14) After approx. 6-8 hours they change 
their morphology from the normal rod-shape to a coccoid form and reduce their 
replication time. Furthermore, they build a polysaccharide biofilm protecting the IBC 
from immune responses.(15) 
4. Release: To re-enter the bladder lumen, the bacteria change again their morphology 
from the coccoid form (0.7 µm) to a long filamentous shape (70 µm) to burst the 
urothelial cell. Back in the lumen they are able to change to their normal rod-shaped 
morphology and start expressing type 1 pili.(16,17) 
5. Quiescent intracellular reservoir (QIR): Burst urothelial cells increase the 
accessibility to subjacent intermediate and basal urothelial cells. In these cells, the 
E. coli remains in a latent state. These bacteria build a QIR and persist over a longer 
period of time and are most likely responsible for the high reoccurrence rate of UTI 
within 6 months after an infection.(18,19)  
 
Figure 1. Infection cycle of uropathogenic E.coli (UPEC) in the lower urinary tract. Adhesion is 
established by an interaction between the type 1 pili of UPEC and a mannosylated glycoprotein on the 
bladder epithelium. Subsequent invasion and intracellular bacterial colonies (IBC) with biofilm formation 
facilitate amplification in the absence of immune measures and urine flush. The subsequent release and 
formation of quiescent intracellular reservoirs (QIR) in deeper lying tissue cells increase the persistence of 
UPEC in the bladder. 
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1.3. Structure 
1.3.1. Type 1 pili and the fim operon 
 
Figure 2. Structure of type 1 pili of UPEC. Schematic representation of the assembly of a type 1 pilus (A) 
and the genetic cluster of the fim operon (B) encoding for the structural Fim proteins. fimB, fimE, and the 
invertible switch element regulate the expression of type 1 pili. (C) Electron microscopic picture of a UPEC 
expressing type 1 pili. (Images adapted from Puorger et al. (2008)(20) and Hahn et al. (2002) (21); reprinted 
with permission from Elsevier). 
 
The type 1 pilus is a hetero-oligomeric protein complex protruding from the cell wall of 
UPEC (Figure 2A). The rod-like shape is formed by ~500 to 3000 helically assembled 
copies of FimA, followed by one unit of FimF, FimG, and FimH at the distal end of the 
pilus.(21,22) The terminal lectin domain of FimH is responsible for the adhesion to the 
mannosylated glycans of uroplakin 1a (UPK1a) on the bladder epithelium. The 
incomplete immunoglobulin-like fold (pilin-fold) of FimA, FimF, FimG, and FimH is 
lacking a C-terminal β-strand that is crucial for the protein stability.(23) Before pilus 
assembly by the usher β-barrel pore protein FimD in the outer bacterial membrane, the 
FimC chaperone protein provides the missing β-strand in the periplasmic space (donor 
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strand complementation).(24-26) However, for the assembly of a stable pilus, a donor strand 
exchange is required. Therefore, the subunits (except the terminal subunit FimH) possess 
a prolonged N-terminal β-strand that complements for the lacking C-terminal β-strand of 
the neighboring protein.  
 
Genes of the Type 1 pilus proteins are encoded on the fim operon (Figure 2B). The 
expression of the structural genes in the fim gene cluster (fimA-fimH) can be regulated by 
phase-variable inversion of a 314 bp DNA switch element containing the promoter region 
of the fimA gene.(27) This inversion is catalyzed by two upstream-encoded recombinases 
fimB and fimE.(28) The recombinases are sensitive to external factors such as pH, 
temperature, and osmolarity and allow an adaption to the environment.(29,30)  
 
1.3.2. The lectin FimH 
 
Figure 3. Topology of FimHL. The immunoglobulin-like fold of the FimHL (FimH lectin domain) (A) is 
mainly composed of antiparallel β-strands (arrows) forming a greek key and a jelly roll motif (B).  
 
The tip of type 1 pili is formed by the FimH lectin. The 29 kDa protein consists of 279 
amino acids forming two immunoglobulin-like domains: an N-terminal lectin domain 
(FimHL) (residues 1-156) linked via tree amino acids to a C-terminal pilin domain 
(FimHP) (residues 160-279). As stated before, FimH is unstable due to the missing β-strand. However, the separated FimHL (PDB code: 1AUU) (Figure 3) and the full-
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length FimH protein in complex with the chaperone protein FimC (PDB code: 1QUN) 
or a FimG/FimF peptide donor strand (DsG/DsF) (PDB code: 4XOD/4XO9) are 
stable.  
 
In 2002, Sokurenko and co-workers discovered a special property of FimH: type 1 pili 
expressing E. coli improve their adhesion to erythrocytes under flow conditions.(31) This 
discovery led to the proposal of a two-state catch-bond binding model allosterically 
regulated by FimHP.(32,33) In the so-called ‘low-affinity state’ FimHP and FimHL are in 
close contact, whereas shear force induces a domain separation referred as ‘high-affinity 
state’. This mechanism is of biological relevance as it prevents the bacteria from being 
flushed out by the urinary bulk flow. Mutations that weakened the contact between 
FimHL and FimHP increased the affinity of interaction with mannosides.(34) This is in 
good agreement with the fact that most naturally occurring mutations are in proximity to 
the interdomain interface.(35) Hence, allosteric mutations enable adaption to various 
conditions by regulating the binding properties without changing the binding specificity 
to the natural ligand.  
 
A recent publication from Sauer et al. (2015) revealed further insights into structural and 
kinetic properties of FimH.(36) An additional state and consequently a new nomenclature 
to the previously introduced two-state catch-bond mechanism was proposed (Figure 4). 
Without shear force, FimHL and FimHP remain associated. Via an encounter complex, 
the transition between the associated unbound (Afree) and the associated bound (Abound) 
state is highly dynamic. This allows the bacterium to maintain a certain amount of 
mobility on the urothelium in the absence of flow, while in the presence of flow shear 
force separates FimHL and FimHP (Sbound) providing firm adhesion.  
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Table 1. Overview of the FimH structures deposited in the Protein Data Bank (PDB). Resolution for 
X-ray structures is given in Ångström (Å). DsG/DsF = Donor strand from FimG/FimF. 
PDB-Code Construct Ligand Resolution Remarks Ref 
1QUN FimH-FimC apo 2.8  (23) 
1KIU FimH-FimC methyl-α-D-
mannopyranoside 
3.0 Q133N  (37) 
1KLF FimH-FimC α-D-
mannopyranoside  
2.8  (37) 
3JWN FimH-FimF-FimG- 
FimC 
apo 2.7 V27A 
N70S 
S78N 
(38) 
3RFZ FimD-FimH-FimC apo 2.8  (39) 
4J3O FimD-FimH-FimF-
FimG- FimC 
apo 3.8  (40) 
4AUU FimHL apo 1.6  (41) 
3ZPD FimHL apo  Solution 
NMR 
(42) 
2VCO FimHL Man5-GlcNAc2 2.1  (43) 
4CA4 FimHL heptyl-α-D-
mannopyranoside 
2.8 Y48A  - 
4XOA FimH-DsG heptyl-α-D-
mannopyranoside	   2.5 V27A N70S 
S78N 
(36) 
4XOB FimH-DsF heptyl-α-D-
mannopyranoside	   3.0 V27A N70S 
S78N 
(36) 
4XO8 FimHL heptyl-α-D-
mannopyranoside 
1.7 V27A 
N70S 
S78N 
(36) 
4XO9 FimH-DsG apo 1.1 V27A 
N70S 
S78N 
(36) 
1UWF, 1TR7, 3MCY, 
4AUY, 4AV0, 4AV4, 
4AV5, 4AVH, 4AVI, 
4AVJ, 4AVK, 4ATT, 
4AUJ, 3ZL1, 3ZL2, 
4LOV, 4BUQ, 4CSS, 
4CST, 4X50, 4X5P, 
4X5Q, 4X5R 
FimHL α-D-
mannopyranosides 
with varying 
aglycones 
1.0 - 2.9  (41,42,44
-49) 
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Figure 4. Model for a three-state catch-bond mechanism of FimH. Without shear force, FimHL and 
FimHP remain associated. The transition between the associated bound (Abound) and the associated 
unbound (Afree) state remains highly dynamic via an encounter complex. In the presence of shear force, 
FimHL and FimHP become separated (Sbound). Image adapted from Sauer et al. 2015.(36) 
 
Conformational changes between Afree and Abound are restricted to the ligand binding site 
and conformational changes between Abound and Sbound are restricted to the interdomain 
interface of the lectin domain (Figure 5A). The isolated FimHL construct represents the 
Sbound state. Compared to FimHL, the binding affinity of Abound decreases by a factor of 30 
and the presence of FimHP may be described as a negative allosteric regulator. However, 
the binding site of all bound states (Abound, Sbound, and FimHL) is nearly identical 
(Figure 5B). Hence, FimHL is a valid model for the molecular investigation of ligands 
interacting with the FimH binding site. 
  
fast slow very fast 
FimG  
donor strand 
No tensile mechanical force 
Afree state Encounter complex Abound state 
Shear force 
Afree state Sbound state 
N-linked, terminal 
!-D-mannoside 
FimH 
lectin domain 
FimH 
pilin domain 
Cytoplasm 
Extracellular space 
Fo
rc
e 
43
Section II. The Bacterial Adhesin FimH – Introduction 
 
 
Figure 5. Conformational similarities and differences of the FimH states. (A) 4 crystal structures 
represent a three-state model with catch-bond behavior: In the absence of shear force and ligand (Afree; PDB 
Code: 4XO9), in the absence of shear force and the presence of ligand (Abound; PDB codes: 4XOA/4XOB) 
and in the presence of shear force and ligand (Sbound; PDB code: 4XO8). FimHL represents the Sbound state. 
(B) Structural differences between FimHL, Abound, and Sbound in the binding site (left) and the interdomain 
region (right). Image adapted from Sauer et al. 2015.(36) 
 
1.3.3. FimH binding site 
Many co-crystal structures (Table 1) of FimH and α-D-mannopyranosides revealed a 
rather deep and charged cavity with a hydrophobic ridge at the entrance (Figure 6). 
Manuscript 1 “High-affinity carbohydrate-lectin interaction: How nature makes it 
possible” discusses properties of the FimH binding site in depth with a focus on hydroxyl 
groups. In brief, the interaction between FimH and mannose ligands is a highly 
optimized network of 9 hydrogen bonds (Figure 6).  
A 
B 
Afree state Abound state Sbound state FimHL 
FimHL 
Abound 
Sbound 
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Figure 6. Schematic representation of the FimH binding pocket. From the ligand accepted (red) and 
donated (blue) hydrogen bonds are drawn according to X-ray crystal structure of n-heptyl α-D-mannopyranoside in complex with FimHL (PDB code 4BUQ).  
 
No other monosaccharide was found to bind to FimH with an affinity comparable to that 
of mannose.(44) One hydrogen bond is formed with the amino acid side chains of the 
residues Gln133, Asp140, Asn135 and with the protein backbone of residue Asp47. 
Multiple hydrogen bonds are formed with the negatively charged amino acid side chain 
of Asp54 (2 direct bonds) and with the positively charged N-terminus (2 direct and 1 
bridged bond via the structural water molecule W1). The amino acids forming charged 
interactions contribute the most to the free energy of binding.(50) All hydrogen bonds have 
a reasonable geometry (angles and hydrogen bond length). The hydrophobic ridge at the 
entrance of the cavity is formed by two parallel-aligned tyrosines (Tyr48, Tyr137), the so-
called ‘tyrosine gate’ (Figure 5B, Figure 6). While the cavity provides specificity, the 
tyrosine gate is the key element for the optimization of monovalent α-D-mannopyranosides derivatives.(45,48,51-53) The interaction between different aglycones 
and the tyrosine gate is described in more detail in Manuscript 3: “The Tyrosine Gate of 
the Bacterial Lectin FimH: A Conformational Analysis by NMR Spectroscopy and X-ray 
Crystallography”.(49) 
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1.4. FimH antagonists 
UTI patients could benefit from a long-term anti-adhesion treatment considering that 
25% suffer from recurrent infections within 6 months, and emerging antibiotic resistances 
in UPEC isolates are creating increasing problems.(5) Still, many properties are required 
to launch a FimH antagonist as a drug for UTI: the affinity of a successful candidate has 
to exceed the affinity of FimH to the natural target, needs to be orally available, and must 
be specific to the receptor. 
 
An excellent review of the history of FimH antagonists was published by Hartmann and 
Lindhorst in 2011 and is recommended for a more detailed overview.(54) In brief, the 
research interest in type 1 pili started in the 1970s when Sharon found n-methyl α-D-mannopyranoside (1) (Figure 7B) to inhibit hemagglutination.(55) In the 1980s the 
research was mainly focused on the natural ligand of FimH. On urothelial cells, mannose 
is presented on high-mannose N-linked glycans, consisting of five (Man5-GlcNAc2) to 
nine (Man9-GlcNAc2) mannose residues. While on Man9-GlcNAc2 glycans all terminal 
mannose residues are α1-2 linked, Man5-GlcNAc2 presents α1-2, α1-3 and α1-6 linked 
mannoses to the bladder lumen (Figure 7A). FimH was found to have the highest affinity 
towards α1-3 linked mannosides.(56) These results were later confirmed and rationalized 
by Wellens et al. 2008,(43) who concluded that the central mannose stacks with the 
aromatic ring of Tyr48 and thereby increases the affinity to FimH.  
 
Investigations with natural mannosides and the knowledge about the cluster effect(57) of 
type 1 pili led to the development of multivalent glycomimetics.(58) Indeed, multiple 
presentations of α-D-mannosides significantly increased the affinity compared to 
monovalent ligands. However, this effect is still not fully understood. Multivalent 
constructs are unlikely to bind more than one FimH binding site as they are still too small 
in size to crosslink multiple lectins. A possible explanation is the increase of the local 
concentration of α-D-mannosides and therefore statistically favored binding. The major 
drawback to this class of FimH ligands are their pharmacokinetic properties. Due to their 
polarity and large size, they are very unlikely to permeate through membranes to achieve 
oral bioavailability. 
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The more promising approach in terms of oral bioavailability is the design of monovalent 
high-affinity ligands. A crystal structure solved by Bouckaert et al. 2005 unexpectedly 
contained n-butyl α-D-mannopyranoside (2) in the binding pocket of FimHL (Figure 7B) 
stemming from the bacterial growth medium (PDB Code: 1UWF).(44) Further 
investigations revealed that long-chain alkyl-mannosides strongly increase the affinity by 
interacting with the tyrosine gate. The highest affinity among alkyl-mannosides was 
determined for n-heptyl α-D-mannopyranoside (3), binding about 65 times stronger than 
methyl mannoside (1).(44) Since then, rational design approaches were guided by a broad 
variety of co-crystal structures (Table 1). In terms of affinity improvement and 
pharmacokinetic properties, aryl aglycones turned out to be beneficial over alkyl 
moieties. Already Sharon in 1987 reported p-nitrophenyl α-D-mannopyranoside (4) to be 
a high-affinity FimH binder.(55) Indeed, these results could be confirmed and 4 was shown 
to have a comparable affinity for FimHL as n-heptyl mannoside (3).(44) π-π stacking with 
Tyr48 could be further improved by substitution of the phenyl ring in para position; e.g. 
the squaric acid moiety (5) was shown to increase the affinity by an additional factor of 
10 compared to 4(59,60) and an indolinylphenyl derivative (6) improved affinity as well as 
the pharmacokinetic properties, which were tested in mice and revealed an improved 
renal elimination profile after intravenous application.(51) The affinity of biphenyl α-D-mannopyranosides was found to be optimized by substituents in ortho position of the 
phenyl ring adjacent to the anomeric oxygen (e.g. Cl, Me, CF3) and electron withdrawing 
substituents in para and meta position on the terminal ring of the biphenyl aglycone (e.g. 
carboxylic acid, cyano group).(45,52) Oral availability was finally achieved with 3′-chloro-
4′-(α-D-mannopyranosyloxy)biphenyl-4-carbonitrile (7) using a phosphate buffered saline 
(PBS) formulation containing 5% DMSO and 1% Tween 80 (Manuscript 5).(48) This FimH 
antagonist binds with a 1.3 nM affinity to FimHL and reduces the bacterial load in the 
bladder of mice as efficaciously as a comparable dose of the antibiotic ciprofloxacin, 
which is used for standard treatment of a UTI.  
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Figure 7: Overview of FimH ligand structures. (A) Man5-GlcNAc2 is a naturally occurring 
polysaccharide in the glycan of uroplakin 1a on urothelial cells. FimH binds to α1-3 linked mannose with 
the highest affinity. (B) Milestones in the development of monovalent FimH antagonists towards a highly 
affine and orally bioavailable ligand (7). 
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Abstract 
Lectins belong to the most challenging targets in drug discovery due to the unique 
binding properties of their polyhydroxylated carbohydrate ligands. Whereas the hydroxyl 
groups provide directionality and specificity, the high desolvation costs of carbohydrates 
are the origin for their notoriously low affinities.  
 
Nonetheless, some lectins with high affinity to monovalent carbohydrate ligands have 
been reported.(1-6) One of these rare examples is the bacterial lectin FimH, located at the 
tip of the pili of uropathogenic E. coli (UPEC). It mediates adhesion to the mannosylated 
glycoproteins uroplakin Ia on urothelial host cells. By combining computational methods 
(QM, MD simulations) with structural information (X-ray, NMR) and binding data (FP, 
ITC, kinITC) the complex and cooperative hydrogen bond network formed by 
mannoside ligands interacting with FimH was elucidated. Deoxy- and deoxy-halogeno 
derivatives of n-heptyl α-D-mannoside (1) reveal that the loss individual hydroxyl groups 
not only leads to a decrease of the association rate (kon), but also to an increased 
dissociation rate (koff) and as a result to a dramatic drop of affinity (KD). Furthermore, a 
comparison of thermodynamic profiles obtained by isothermal titration calorimetry 
(ITC) indicates that the loss in affinity (corresponding to a ΔΔG° of 15-21 kJ/mol per 
hydroxyl group) originates from unfavorable enthalpy contributions partly compensated 
by an entropic gain.  
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Introduction 
It is generally accepted that hydrogen bonds (H-bonds) provide directionality and 
therefore specificity to ligand-receptor interactions, whereas hydrophobic interactions, 
although rather unspecific, predominantly contribute to binding energies.(7) Since 
carbohydrate-lectin interactions are mainly based on H-bond formation, they are 
characterized by a high degree of specificity, but often suffer from a lack of affinity.(8) The 
high specificity allows carbohydrates to fulfill their broad biological tasks, such as signal 
transduction,(9,10) cell recognition(11,12) or cell adhesion.(13) Furthermore, considering their 
fundamental importance in numerous disease-related processes, carbohydrate mimetic 
drugs offer potential new therapeutic applications.(14) However, the polar character of 
carbohydrates creates pharmacokinetic challenges related to oral availability, plasma 
half-live or renal excretion. Moreover, tight interactions with lectins seem to be against 
the nature of most carbohydrates, mainly due to the high desolvation costs related to 
their numerous hydroxyl groups. Toone et al. appraised these limitations of carbohydrate-
lectin interactions as “fundamental, severe, and likely insurmountable”(7) and Hopkins et 
al. regarded the likelihood of modulating a lectin with an orally available small molecule 
drug to be very low.(15) Therefore, to analyze and solve the structural drawbacks common 
to carbohydrates is of fundamental importance when therapeutic applications are 
envisaged. 
 
In the present study, the bacterial lectin FimH - one of the rare examples of a lectin 
undergoing high-affinity interactions with carbohydrates - is analyzed and the role of the 
individual hydroxyl groups in terms of thermodynamic and kinetic contribution to 
binding is studied. FimH, a virulence factor of uropathogenic E. coli (UPEC), is located 
at the tip of bacterial type 1 pili.(16,17) By interacting with the urothelial glycoprotein 
uroplakin Ia, it mediates the bacterial adhesion to the bladder wall as the initial step in 
urinary tract infections (UTI). A high-affinity interaction between FimH and the 
oligomannosides of the host’s uroplakin Ia is a prerequisite to prevent UPEC to be 
washed out of the bladder by the urinary bulk flow.(18,19) 
 
With the goal to reveal their individual contributions of the various hydroxyl groups to 
binding, the thermodynamic and kinetic properties of the reference compound n-heptyl 
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α-D-mannopyranoside (1) were compared with those of derivatives deoxygenated in the 
2-, 3-, 4- or 6-position and those where the hydroxyl groups were replaced by halogens. 
By combining structural data from X-ray crystallography and solution NMR experiments 
with computational methods (quantum mechanics, QM) as well as thermodynamic 
(ITC) and kinetic data (kinITC) the individual contributions of the various hydroxyl 
groups to binding were analyzed. Therewith, our study completes previous 
thermodynamic studies with deoxygenated carbohydrates.(6,20-29) 
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Results and Discussion 
The mannose-binding pocket of FimH (Figure 1). The interaction of α-D-mannosides 
with the lectin domain of FimH (FimHLD) has been extensively studied. The pronounced 
loss of affinity induced by the replacement of the D-mannose moiety by other hexoses, 
e.g. D-glucose or D-galactose,(30) corroborates the importance of the extended hydrogen-
bond network which can be established by mannose (Figure 1). As a result, D-mannose 
exhibits a for carbohydrate-lectin interactions remarkable micromolar affinity of 
2.3 µM.24 Furthermore, alkyl or aryl aglycones can establish beneficial hydrophobic 
interactions with the so-called tyrosine gate (residues Tyr48 and Tyr137) forming the 
entrance to the mannose-binding pocket.(31-35) This effect leads to a further 100-fold 
improvement of affinity as documented by n-heptyl α-D-mannoside (1, KD: 22 nM).(36)  
 
 
Acceptor Donor Distance 
[Å] 
Angle 
Donor 
Angle 
Acceptor 
O (2-OH) N (N-terminus) 2.70 161.8 127.2 
O (H2O) O (2-OH) 2.68 134.8 112.1 
O (3-OH) N (Gln133) 3.02 173.0 123.0 
O (Asp140) O (3-OH) 2.78 155.8 119.1 
O (4-OH) N (Asn135) 2.95 155.8 114.8 
O (Asp54) O (OH-4) 2.60 165.6 140.6 
O (6-OH) N (Asp47) 2.96 159.2 115.0 
O (6-OH) N (N-terminus) 2.76 165.6 116.9 
O (Asp54) O (6-OH) 2.56 173.6 120.6 
 
Figure 1. Two-dimensional schematic representation of n-heptyl α-D-mannoside (1, HM) binding to 
FimH according to X-ray crystallography (PDB code 4XO8). H-bonds donated by 1 are shown in blue, 
those accepted in red, the structural water W1 is highlighted in blue; to avoid overlaps, Gln133 was drawn 
twice. In the table, angles and distances from co-crystal structure FimHLD in complex with n-heptyl α-D-
mannoside (1). (PDB 4XO8). Hydrogen atoms were energy minimized with an OPLS_2005 force field. 
OO
O
O
O
O
O
Asp54
O
NAsn135
O
O
H
H
H
O
Asp140
O
Solvent
OHTyr48
OHTyr137
N
O
Asp47
N
Phe1
O
H H
H
H
H
H
H
H
H
N
H
Gln133
O
H
W1
N
O
Gly14
H
N
H
Gln133
O
H
2
3
4
5
6
1
58
Section II. The Bacterial Adhesin FimH – Manuscript 1 
 
The extraordinary high affinity of this carbohydrate-lectin interaction originates from a 
multitude of factors. First, the interaction of α-D-mannopyranosides with FimHLD (e.g. 
PDB code 4XO8, 4CST, 4BUQ) is characterized by a total of 9 hydrogen bonds 
(Figure 1). They exhibit optimal geometries related to distance, donor and acceptor 
angles (see Table in Figure 1) with the high degree of complementarity necessary for tight 
binding.(29,37) According to MD simulations, the charge-assisted hydrogen bonds formed 
by Asp54 (acceptor) as well as by the positively charged N-terminus (donor) provide the 
largest energy contributions.(38) Furthermore, compared to a solvent-exposed binding site, 
electrostatic interactions in the deeply buried binding pocket of FimH benefit from a much 
lower dielectric constant and thus render increased contribution to binding (Table S1).(39)  
 
Second, the loss of rotational freedom of each hydroxyl group is penalized by entropic 
costs. However, since all hydroxyl groups of the mannose moiety form multiple 
hydrogen bonds, entropic costs arise only for the first interaction of a given hydroxyl 
group. Subsequent interactions from the same hydroxyl group do not induce additional 
entropic penalty.  
 
Third, the high desolvation costs of 26 kJ/mol associated with one hydroxyl group(40) might 
be lowered by perturbed water molecules in the solvation shell of the interaction surfaces 
due to their polyamphiphilic character.(29) However, the high desolvation penalty cannot 
be compensated by the formation of single hydrogen bond.(41) Desolvation costs (ΔG°solv) 
for the ligand n-heptyl α-D-mannoside and deoxy derivatives thereof were calculated 
(AMSOL 7.1) and considered for the calculations of the bond energies. The complete 
desolvation of n-heptyl α-D-mannoside was calculated to cost 38.8 kJ/mol, which is 
almost as much as the entire binding energy between n-heptyl α-D-mannoside and 
FimHLD (ΔG° = -43.7 kJ/mol) (Table 2). Hence, forming multiple interactions allows 
compensating the high desolvation penalty, which has to be paid only once, more 
efficiently.  
  
Fourth, H-bonds strengthen each other due to a phenomenon called ‘cooperative hydrogen 
bonding’.(42-45) When a hydroxyl group acts as hydrogen bond donor, the electron density 
on its oxygen lone pair is slightly increased and therefore its hydrogen bond accepting 
properties are improved. Since every hydroxyl group of the mannose moiety is involved 
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in at least two hydrogen bond, the formation of a cooperative hydrogen bond network is 
favored. The structural water (Figure 1, W1) introduces positive cooperativity by 
interacting with the backbone of Phe1 and thereby increasing the positive charge of the 
N-terminus that forms charged hydrogen bonds with 2-OH and 6-OH. Opposed to that, 
negative cooperativity is presumed between 6-OH and 2-OH and between 4-OH and 
6-OH, which both have to share a charge on their interaction partners (Asp54, N-
terminus). Positive cooperativity is furthermore occurring when multiple amino acids of 
one protein loop form interactions with the ligand, i.e. observed in the FimH binding site 
between Asp140 and Asn135 interacting with 3-OH and 4-OH, respectively. This is 
favorable because the interactions stabilize each other and the entropic costs for the loss 
of the loop mobility are redundant.(46,47) It is therefore delicate to investigate contributions 
of a single hydroxyl group in a cooperative system as a pyranose, as any change might 
affect the whole H-bond network.(48) Consequently, to attribute the energy loss to the 
removal of a certain hydroxyl group and to exclude changes of the whole interaction 
system we carefully considered structural changes observed by NMR and X-ray.  
 
Protein pre-organization. In a previous study, we exemplified the rigidity of FimHLD, 
which accommodates also 7-membered ring analogs of D-mannose without any 
conformational adaption.(49) In order to demonstrate the rigidity of FimHLD, the “pseudo-
apo” structure (PDB-Code: 4AUU, containing thioethanol in the binding site) and the 
crystal structure co-crystallized with n-heptyl α-D-mannoside (1, HM) (PDB-Code: 
4XO8) were compared. An RMSD of 0.266 considering the 7 heavy atoms directly 
interacting with the mannose moiety (see Figure 1, heavy atoms highlighted in green) 
revealed that ligand binding-induced only minor rearrangements.  
 
Ligand pre-organization (Figure 2). In order to derive information regarding the degree 
of pre-organization of n-heptyl α-D-mannoside (1) in the bioactive conformation, torsion 
angles of solution structures obtained by molecular dynamics simulations (ωMD) were 
compared with its structure (ωX-ray) in complex with FimHLD (PDB-Code: 4XO8). To 
classify the energy profile of each hydroxyl group, they were rotated stepwise around 
their torsion angles (ω1-ω6) while calculating the energies of the resulting structures by 
quantum mechanics (QM). The solution conformations are broadly distributed because 
they are separated only by low energy barriers. The conformational energy in the bound 
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state was found to be more favorable than the averaged energies of the solution 
conformations (Table 1) in four out of six analyzed dihedral angles (ω1-3, 5). 
 
Figure 2. Calculated energy as a function of the torsion angles of methyl α-D-mannopyranoside. Dotted 
lines correspond to the energy of a given torsion angle. Left y-axis: calculated energy in kJ/mol, right y-
axis: frequency of solution conformation from MD simulation, x-axis: torsion angle, conformation of 
heptyl α-D-mannopyranoside co-crystallized with FimH-CRD (PDB-Code: 4XO8) shown as a black bar, 
frequency distribution of solution conformation shown in blue bars.  
 
Table 1. Comparing the energy of the torsion angles ω1-6 of n-heptyl α-D-mannopyranoside (1) in 
solution and bound to FimHLD. Torsion angles (ωX-ray) according to the co-crystal structure (PDB-code: 
4XO8) and the corresponding calculated energy of the bound conformation in comparison with the 
averaged energy of the solution conformations over the course of a 9.6 ns MD simulation. 
 
Torsion  
angles 
Solution conformation  Bound conformation  
Gain (-) /loss (+) of conformational 
energy upon binding 
Average Energy 
[kJ/mol] 
 
Torsion angle  
(ωX-ray) 
Energy 
[kJ/mol] 
 Energy  
[kJ/mol] 
ω1 1.5  68.5° 0.1  - 1.4 
ω2 9.9  64.7° 4.6  - 5.3 
ω3 8.8  155.4° 6.8  - 2.0 
ω4 6.8  -86.9° 9.0  + 2.2 
ω5 8.2  -57.4° 0.4  - 7.8 
ω6 9.4  -119.8° 17.3  + 7.9 
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Synthesis of deoxy- and deoxy-halogeno-derivatives of n-heptyl α-D-mannosides. To 
study the contribution of the individual hydroxyl groups, a series of deoxy- and deoxy-
halogeno-derivatives of n-heptyl α-D-mannoside (1) were synthesized (Figure 3). Since 
fluorine shares a comparable polarity and a close isosteric relationship with oxygen but is 
unable to form H-bonds,(50,51) a comparison of the parent mannoside 1 with fluorine 
analogs will allow discriminating between the contribution of H-bonds and other 
electrostatic interactions. Because the micromolar affinity of unsubstituted D-Man would 
lead to substantial protein consumption for the thermodynamic analysis, derivatives with 
an n-heptyl aglycone leading to a significantly improved affinity for FimHLD were used 
(D-Mannose: KD = 2.3 µM; n-heptyl α-D-mannoside (1): KD = 22 nM).(30,36) This enabled 
the study of even those deoxy- and deoxy-halogeno-derivatives that have severely 
diminished affinities compared to the unmodified mannoside. The synthesis of 
compounds 2-4, 6, 7 and 9-11 is summarized the Supporting Information, while the 
syntheses of 1, 5 and 8 have been published recently.(36) 
 
Figure 3. Structure of n-heptyl α-D-mannoside (1) and the deoxy- and deoxy-halogeno-derivatives 2 - 11.  
 
Structural analysis of deoxy- (5, 7 & 9) and deoxy-fluoro-derivatives (2, 6 & 8) of n-
heptyl α-D-mannoside (1) bound to FimHLD. To analyze how the substitution of an 
individual hydroxyl group influences ligand and lectin conformation, the structures 2 & 5 
- 9 co-crystallized with FimHLD were determined applying conditions we previously 
reported for n-heptyl α-D-mannoside (1).(32,36) Resolutions between 1.9 and 2.1 Å (except, 
7 at 3.0 Å) and crystals in two different space groups were obtained (Table S2).  
 
 
OR4
R3
R6
R2
O
1:     R2, R3, R4, R6 = OH
2:     R2 = F, R3, R4, R6 = OH
3:     R2 = Cl, R3, R4, R6 = OH
4:     R2 = Br, R3, R4, R6 = OH
5:     R2 = H, R3, R4, R6 = OH
6:     R3 = F, R2, R4, R6 = OH
7:     R3 = H, R2, R4, R6 = OH
8:     R4 = F, R2, R3, R6 = OH
9:     R4 = H, R2, R3, R6 = OH
10:   R6 = F, R2, R3, R4 = OH
11:   R6 = H, R2, R3, R4 = OH
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Figure 4. Superimposition of co-crystal structures of FimHLD with n-heptyl α-D-mannoside and six 
deoxy- and deoxy-fluoro derivatives. A) The parent n-heptyl α-D-mannoside (1) (PDB code 4XO8) and 
all proteins are shown in grey, while the deoxy- (5, 7 & 9) and the deoxy-fluoro-derivatives (2, 6 & 8) are 
colored as indicated. B) Important binding pocket residues and the structural water (W1) are shown as 
sticks and spheres, respectively. 
 
Superposition of the crystal structures revealed RMSD values for the protein backbone 
between 0.11 and 0.20 Å (Figure 4A) and almost identical binding pockets (Figure 4B). 
All binding modes were identical, except for the 2-deoxy-mannoside 5 which, however, 
was slightly tilted (Figure S1). In all crystal structures, the structural water W1 mediates 
the H-bond interaction of the 2-hydroxyl group with the backbone amides of Phe1 and 
Gly14, and as well as to the side chain of Gln133 (Figure 1). In case of the 2-deoxy-2-
fluoro-derivative 2, this water molecule is located significantly closer to the protein 
(Figure 4B).   
 
To analyze the dynamics of the hydrogen bond network of the various complexes 1H,15N-
HSQC NMR spectra were recorded. Whereas 1H chemical shifts of backbone and side 
chain amides report on H-bond formations, 15N shifts respond sensitively to changes in 
the dihedral angles of the protein backbone and side chains.(52) We measured 1H,15N-
HSQC fingerprint spectra of FimHLD in presence of 2 and 5-10 and assigned the signals 
on the basis of chemical shift proximity to the spectrum with unmodified n-heptyl α-D-
mannoside (1). Because of low affinity, mannoside 10 (6-F) and 11 (6-H) modified in 6-
position of the mannose moiety could not be evaluated by ITC (Table 2). From the 
1H,15N-HSQC NMR spectrum of 10 (6-F) it was apparent that 10 (6-F) binds very weakly 
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to FimHLD, as even at high ligand concentration (20 mM) no chemical shift perturbations 
were observed. Since the affinity of 11 (6-H) was expected to be even lower than for 10 
(6-F), 11 was not subjected to NMR experiments. For all other deoxy- and deoxy-fluoro 
mannosides, chemical shift perturbation of residues in the binding pocket indicated 
specific interactions with the protein, while no chemical shift changes of residues remote 
from the binding pocket were observed (Figure S2; Figure S3).  
 
Downfield shifts indicate new H-bond formation or strengthening, while upfield shifts 
indicate H-bond weakening or disruption. It was of particular interest to observe 
chemical shift changes of signals of backbone amide and side chain signals that function 
as H-bond donors to the ligand’s OH groups, i.e. of Gly14 HN (W1 H-bond to 2-OH), 
Asp47 HN (to 6-OH), Gln133 Hε22 (to 3-OH) and Asn135 Hδ21 (to 4-OH) (Figure 5).  
 
The chemical shifts of Gly14 HN are almost identical for 5 (2-H), 6 (3-F), 8 (4-F) and 9 
(4-H), indicating a similar orientation of W1, even though for 5 (2-H) the interacting 
hydroxyl group does not exist (Figure 5). The slight proton upfield shift of Gly14 HN with 
all ligands indicates that the coordination of mannose weakens the H-bond of this residue 
to W1. In agreement with this, the data suggest the strongest Gly14-water interaction for 
5 (2-H), for which W1 is more “free” to coordinate with Gly14. For 2 (2-F), Gly14 cannot 
be assigned and may be shifted significantly due to the close fluorine atom. Indeed, in the 
co-crystal structure with 2 (2-F), W1 is more buried (Figure 4B) which may contribute to 
the large chemical shift change of Gly14. The relative chemical shift changes of Asp47 
HN suggest that compared to n-heptyl α-D-mannoside the direct H-bond to 6-OH is 
weakened (upfield shift) for the ligand 6 (3-F) and 7 (3-H), strengthened for 9 (4-H) 
whereas no significant changes were observed for 2 (2-F), 5 (2-H) and 8 (4-F) (Figure 5). 
The Hε22 of the Gln133 amide side chain signal is shifted downfield by almost 0.8 ppm 
upon addition of n-heptyl α-D-mannoside indicative for the H-bond formation to 3-OH 
(Figure 5). For 2 (2-F), 5 (2-H) and 9 (4-H), similar downfield shifts demonstrate H-bond 
formation to 3-OH, although the smaller shifts (0.33–0.50 ppm) suggest slightly weaker 
H-bonds. Importantly, the Gln133 Hε22 signals with 6 (3-F) and 7 (3-H) show dramatic 
upfield shifts [ca. −1.64 ppm relative to n-heptyl α-D-mannoside (1)] as direct evidence 
for the absence of the corresponding H-bond. Similarly, Asn135 Hδ21 is strongly shifted 
downfield by 0.70 to 0.96 ppm upon addition of n-heptyl α-D-mannoside (1), 2 (2-F), 5 
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(2-H), 6 (3-F) and 7 (3-H) as a consequence of H-bond formation to 4-OH. With 9 (4-H), 
a relative upfield shift of this signal reports on the absence of the corresponding H-bond. 
For 8 (4-F), the Asn135 side chain signals could not be assigned. 
 
In summary, the structural information obtained by NMR and X-ray is in good 
agreement and the conformational changes of protein and ligand are remarkably small 
upon the loss of relevant interactions. This qualifies FimHLD as a model to investigate 
contributions of distinct hydroxyl groups by deoxy- and deoxy-halogeno derivatives. 
 
 
 
Figure 5. 1H,15N-HSQC spectral regions of binding pocket residues directly involved in H-bond 
donation to the mannosyl moiety. Boxes in case of side chain signals of Gln133 and Asn135 indicate 
relative downfield and upfield proton shifts, respectively. Peaks not of interest were faded-out to improve 
the clarity. 
 
Thermodynamic analysis of deoxy- and deoxy-halogeno-derivatives of n-heptyl α-D-
mannoside (1) (Table 2). Measuring interaction by ITC is valuable in several respects. 
First, it is a label-free method that allows the determination of the change in enthalpy of 
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binding (ΔH°), association constant (KA) and stoichiometry (N) in one experiment, and 
second, recent progress in data analysis now allows the deviation of kinetic rate constants 
for association and dissociation from the same raw data. ITC experiments (Table 2) were 
carried out at 25 °C in 10 mM HEPES buffer at pH 7.4 containing 150 mM NaCl. 
Measurements in other buffering systems revealed a significant heat of ionization (ΔH°ion) 
originating from a partial proton transfer from the solvent to the N-terminus of the 
FimHLD protein (Figure S4, Table S3).(53,54) By measuring the enthalpy of n-heptyl α-D-
mannoside (1) binding to FimHLD in different buffers at pH 7.4 (Cacodylate, HEPES, 
Tris), pH 8.5 (Bicine, Tricine, TAPS, Tris) and pH 9.0 (Bicine; TAPS, Tris), the pKa of 
the N-terminus was determined to be approximately 8.3. This proton transfer is 
endothermic and therefore the intrinsic enthalpy is underestimated applying standard 
experiment conditions. However, the relevant ΔΔ-values are constant and we decided to 
omit correction for the heat of ionization in this publication to maintain the 
comparability with earlier publications.  
Table 2. Change in thermodynamic parameters of FimHLD binding to n-heptyl α-D-mannoside (1) and 
deoxy- (5, 7 & 9) and deoxy-halogeno derivatives (2-4, 6 & 8) thereof. All values are relative to the 
absolute values of mannoside 1. Measurements were carried out at 298.15 K in 10 mM HEPES buffer 
containing 150 mM NaCl at pH 7.4. Protein and ligand concentrations, confidence intervals and 
stoichiometries are part of the supplementary information (Table S5). Affinities from a fluorescence 
polarization (FP) assay are shown for comparison.  
 
 FP: KD 
[µM] 
ITC: KD 
[µM] ΔG°  [kJ/mol] ΔH° [kJ/mol] 
-TΔS°  
[kJ/mol] 
n-heptyl 
mannoside (1) 0.028
(32) 0.022 -43.7 -50.5 6.7 
   ΔΔG° [kJ/mol] ΔΔH°  [kJ/mol]  -TΔΔS° 
[kJ/mol] 
2 (2-F) 0.44 0.53 7.9 22.7 -14.8 
3 (2-Cl) 2.26 1.34 10.2 25.9 -15.8 
4 (2-Br) 4.24 1.83 11.0 29.6 -18.7 
5 (2-H) 13.95 9.77 15.1 31.1 -16.0 
6 (3-F) 0.45 1.19 9.9 19.1 -9.2 
7 (3-H) 23.35 19.88 16.9 25.7 -8.8 
8 (4-F) 135.2 103.43 21.0 29.9 -9.0 
9 (4-H) 101.2 88.40 20.6 30.6 -10.0 
10 (6-F) n.d. >1000    
11 (6-H) n.d. >1000    
 
Deoxygenation and substitution of 2-OH of mannose. Substitutions in the 2-position of the 
mannose moiety have the lowest impact on the free energy of binding [e.g. ΔΔG° = 
15.1 kJ/mol for 5 (2-H)]. However, 2-deoxy mannoside 5 suffers from the largest loss in 
enthalpy of the whole series relative to 1 (ΔΔH° = 31.1 kJ/mol), which is partially 
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compensated by a gain in entropy (-TΔΔS° = −16.0 kJ/mol). Overall, this leads to a 440-
fold loss in affinity. The unusually high enthalpic loss originates from the excellent H-
bond of the 2-OH group with the positively charged N-terminus. Furthermore, structural 
analysis by X-ray indicated that the mannose moiety of 5 (2-H) is slightly twisted relative 
to the parent n-heptyl α-D-mannoside (1), weakening the H-bond network and thus 
increasing the flexibility of the ligand in the binding pocket (Figure S1). However, the 
twist could not be confirmed by NMR data, as all binding pocket residues have nearly 
identical chemical shifts compared to 1. Phe1 might indeed be more flexible due to the 
absence of the H-bond to 2-OH, but unfortunately the N-terminal Phe1 signal cannot be 
observed directly in the NMR experiments. A further insight into the binding mode was 
obtained when the 2-hydroxyl group was replaced by halogens. It was expected that the 
electrostatic interaction exerted by the former oxygen atom can be maintained, whereas 
obviously the H-bonds formed with W1 and Phe1 are lost. The increasing 
electronegativity of bromine < chlorine < fluorine induces a repulsion of the structural 
water W1 (Figure 4B), while the interaction with the positively charged N-terminus 
becomes more beneficial. The difference between the loss of all electrostatic interactions 
for 5 (2-H) (ΔΔG° = 15.1 kJ/mol) and the loss of only the H-bonds of 2 (2-F) (ΔΔG° = 7.9 
kJ/mol) leads to the conclusion that the permanent dipole-buried charge interaction 
contributes approximately 7.2 kJ/mol to the free energy of binding.  
 
Deoxygenation and substitution of 3-OH of mannose. Deoxygenation of the 3-position of n-
heptyl α-D-mannoside (1) (→ 7) leads to a substantial loss in enthalpy (ΔΔH° = 
25.7 kJ/mol), which is only partially compensated by an entropy gain (-TΔΔS° 
= -8.8 kJ/mol). As a result, a 900-fold loss in affinity was observed. Compared to 7 (3-H), 
the introduction of a fluoro substituent [→ 6 (3-F)] results in an enthalpic gain (ΔΔH° = -
6.6 kJ/mol), as well as a small entropic advantage (-TΔΔS° = -0.4 kJ/mol). Interestingly, 
crystal structures of n-heptyl α-D-mannoside (1) and the 3-fluoro derivative 6 co-
crystallized with FimHLD (PDB QQ & PDB QQ) reveal repulsion between the fluorine 
atom and the negative charge on Asp140 and consequently an increased distance (0.5 Å) 
between the interacting heavy atoms. However, Asp140 is part of a loop and its 
perpendicular position to the ligand allow for a rearrangement with minor impact on 
binding energy. The difference between the intrinsic loss of all electrostatic interactions 
for 7 (3-H) (ΔΔG° = 16.9 kJ/mol) and the loss of only the H-bonds to Gln133 and 
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Asp140 of 6 (3-F) (ΔΔG° = 9.9 kJ/mol) discloses a contribution of approximately 
7.0 kJ/mol for the charge-permanent dipole interaction and 9.9 kJ/mol for the H-bonds to 
the free energy of binding of 3-OH. The close contact of two complementary surfaces in 
the absence of solvent water may be an explanation for the large contribution of the 
charge-dipole interaction.(55-57) 
 
Deoxygenation and substitution of 4-OH of mannose.  The 4-deoxy derivative 9 (4-H) suffers 
from a 4’000-fold loss of affinity. Compared to the effect of the substitution of the 3-
hydroxyl group, the affinity is reduced by another factor of 4, although number and type 
of H-bond interactions of 3-OH and 4-OH are comparable. However, C-4 is buried more 
deeply in the pocket than C-3, where a lower dielectric constant and consequently an 
increased energy for electrostatic interactions are expected.(58)  Interestingly, in contrast to 
the 2- or 3-position, the introduction of a fluorine substituent in the 4-position does not 
improve binding energy compared to the 4-deoxy derivative. Most likely, the 
electronegative fluoride induces a repulsion of the negatively charged Asp54, which is 
part of a rigid β-sheet. Crystal structures reveal a change of the orientation between 4-OH 
and 4-F (dihedral angle HO4-C4-C5-O = -174.9° and F4-C4-C5-O = -167.3°), which 
supports this assumption. Therefore, the loss of binding energy upon the removal of 4-
OH [→ 9 (4-H), ΔΔG° = 20.6 kJ/mol] is almost identical resulting from the loss of the 
hydrogen bonds [→ 8 (4-F), ΔΔG° = 21.0 kJ/mol]. 
 
Deoxygenation and substitution of 6-OH of mannose. Finally, modifications in the 6-
position of the mannose moiety have the most severe impact on the binding energy. 
Competitive ITC titrations with n-heptyl mannoside (1) when FimHLD was preincubated 
with a 300-fold excess of 10 (6-F) or 11 (6-H) did neither induce a change in binding 
affinity nor enthalpy. Furthermore, direct titration with a 6 mM solution of mannoside 
10 (6-F) did not result in a signal change in the ITC isotherm. We conclude that the 
binding affinity of 10 (6-F) and 11 (6-H) can be expected to be below 1 mM. The 6-
hydroxy group forms 3 excellent hydrogen bonds, whereof two are charge assisted (N-
terminus, Asp54). Considering the reduced desolvation costs and number of rotational 
bonds of derivatives deoxygenated or fluorated in the 6-position when compared to 
mannoside 1, an approximate 30’000-fold loss in affinity is surprising and reveals the 
tremendous importance of this deeply buried hydroxyl group.   
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Kinetic analysis of n-heptyl deoxy- and deoxy-halogeno-α-D-mannosides (Table 3). 
With kinetic isothermal titration calorimetry (kinITC) kinetic data are accessible from 
ITC measurements.(59) It measures the time that the differential power curve takes to 
return to baseline after an injection of ligand solution that is a function binding kinetics. 
Narrower peaks at the beginning and the end of the titration, and wider peaks around the 
inflection point yield a bell-shaped equilibration time curve (ETC) that can be analyzed 
to determine dissociation rate constant koff. The association rate constant kon is calculated 
from koff and the equilibrium constant (KD = koff / kon) (Table 3).  
Table 3. Kinetic binding parameters for the interaction of FimHLD with deoxy- and deoxy-halogeno 
derivatives of n-heptyl α-D-mannoside (1) determined by kinITC. Confidence intervals of the fitted 
parameters kon, koff, KD, and the response time are part of the supplementary information (Table S7). 
Relative changes (rkon, rkoff) are compared to n-heptyl α-D-mannoside (1).  
 
Compound Method kon 
[M-1s-1] 
1/rko
n 
koff 
[s-1] 
rkoff 
t1/2 
[min] 
1 (HM) ITC 3.32*104 1.0 7.27*10-4 1.0 15.90 
2 (2-F) ITC 2.04*104 1.6 1.02*10-2 14.0 1.14 
3 (2-Cl) ITC 8.90*103 3.7 1.19*10-2 16.4 0.97 
4 (2-Br) ITC 7.90*103 4.2 1.45*10-2 19.9 0.80 
5 (2-H) ITC 5.35*103 6.2 4.13*10-2 56.8 0.28 
5 (2-H) SPR 1.05*104 3.1 5.08*10-2 71.1 0.23 
6 (3-F) ITC 1.66*104 2.0 1.98*10-2 27.3 0.58 
7 (3-H) ITC 6.50*103 5.1 1.29*10-1 177.9 0.09 
8 (4-F) ITC 1.00*103 33.2 1.03*10-1 142.3 0.11 
9 (4-H) ITC 9.56*102 34.7 8.45*10-1 116.3 0.14 
 
Binding kinetics for 5 (2-H) determined either by surface plasmon resonance (SPR) or 
kinITC-ETC are in excellent agreement and exhibited deviations smaller than a factor of 
2 (Table 3). In contrast to other carbohydrate-lectin interactions, FimHLD is characterized 
by unusually slow dissociation rates.(60) The reduced affinity of all deoxy- and deoxy-
halogeno derivatives is mainly resulting from increased koff values, leading to 
substantially reduced complex half-lives (t1/2 = ln2/koff). For example, while t1/2 of n-
heptyl α-D-mannoside is more than 16 minutes, it is reduced to less than a minute for all 
deoxy derivatives. Although the removal of a hydroxyl group in general has a smaller 
effect on the kon than koff values, the association rates deliver an interesting insight into the 
binding process. Especially the most buried and charge-assisted interaction of 4-OH turns 
out to be important for the association of 9 (4-H), since its removal leads to a more than 
30-fold reduction of the kon value. A much smaller effect was observed for 5 (2-H) and 7 
(3-H). An interesting trend can be observed for halogen substituents in 2-position, where 
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the decreasing electronegativity (fluorine > chlorine > bromine) affects the kon values to a 
significantly greater extent than koff values. However, we can not rule out that increasing 
atomic radii could have a steric effect on the formation of the protein-ligand complexes. 
In summary, We hypothesize that changes in the short-range electrostatic interactions of 
FimH-mannoside complexes (e.g. hydrogen bonds, dipole-dipole interactions) mainly 
affect the dissociation rate, while medium-range electrostatics, such as the dipole-charged 
interaction of 2-OH with the N-terminus, are additionally of importance for the 
association rate as described before for protein-protein interactions.(61-64) 
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Conclusion 
We demonstrated how the lectin FimH applies a broad spectrum of strategies to 
overcome the intrinsically low binding affinities of a carbohydrate ligand. In particular, 
quantum mechanically derived torsional barriers of a mannoside ligand were calculated 
and the solution conformations were compared to the bound conformation obtained 
from crystal structures. FimHLD turned out to be well pre-organized and to bind hydroxyl 
groups mainly in low energy orientations.   
Furthermore, it was possible to analyze the contributions of three hydroxyl groups of 1 
(HM) and its deoxy- and deoxy-halogeno derivatives by ITC thermodynamically and 
kinetically by considering their structural binding properties. As expected, the removal of 
a hydroxyl group was accompanied by a loss of enthalpy (ΔΔH° = 26 – 31 kJ/mol) and a 
smaller gain in entropy (-TΔΔS° = -9 – -16 kJ/mol). Hence, contributions to ΔG° could 
be determined as 15 kJ/mol for 2-OH close to the protein surface, 17 kJ/mol for 3-OH 
with a medium position, and 21 kJ/mol for the most buried hydroxyl group 4-OH. We 
observed a general tendency that deeper buried hydroxyl groups contribute more to the 
overall binding affinity of mannoside ligands. This effect was most stark for removal of 
the hydroxyl group in position C-6, resulting in the total loss of binding upon. 
Furthermore,  
 
It furthermore became clear that the contribution of a single hydroxyl group is larger than 
the sum of the loss of its H-bonds and van der Waals interactions. Summing up the ΔG° 
values of the hydroxyl groups 2-4 (without including the essential 6-OH) yields a 
cumulative contribution of 53 kJ/mol which exceeds the total free binding energy ΔG° of 
n-heptyl α-D-mannoside. The explanation is that H-bonds build a cross-linked network in 
which only the cooperative interplay between multiple H-bonds is stabilizing the protein-
ligand complex. Consequently, the loss of one single hydroxyl group (6-OH) can prevent 
a molecule from binding, although the remaining hydroxyl groups could form 6 
hydrogen bonds that are structurally identical to those observed for the unmodified 
ligand. 
 
Moreover, by performing an analysis with kinITC, additional kinetic values were 
obtained. As expected, the loss of hydroxyl groups had a stronger influence on koff than 
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on kon. However, the short-range electrostatic H-bonds were found to be less important 
for kon, while the medium-range electrostatic interactions with the positively charged 
N-terminus (2-OH) and the negatively charged Asp54 (4-OH) were of great importance 
for an increased association rate.  
 
The detailed dissection of mannose binding to FimHLD enhances our general 
understanding of carbohydrate binding, and give insights how nature successfully 
developed high affinity carbohydrate-protein interactions. We believe, this knowledge 
will be of great importance for the future design and development of glycomimetic drug 
candidates.  
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Supporting Information 
Table S1. Calculated surface accessible solvation area. SASA was calculated in a bound and unbound 
state of HM and its deoxy and deoxy-fluoro derivatives. Values are given in Å2. 
1 (HM) 2 (2-F) 5 (2-H) 6 (3-F) 7 (3-H) 8 (4-F) 9 (4-H) 
Ligand donor_unbound 52 38 38 35 37 40 40 
Ligand donor_bound 0 0 0 0 0 0 0 
Ligand donor_delta 52 38 38 35 37 40 40 
Ligand donor_delta % 100% 100% 100% 100% 100% 100% 100% 
Ligand acceptor_unbound 123 99 101 98 100 98 100 
Ligand acceptor_bound 1 0 3 0 2 0 0 
Ligand acceptor_delta 123 99 98 98 98 98 100 
Ligand acceptor_delta % 99% 100% 97% 100% 98% 100% 100% 
Ligand total_unbound 552 547 541 548 544 548 544 
Ligand total_bound 137 136 135 135 173 134 111 
Ligand total_delta 415 410 405 412 372 414 432 
Ligand total_delta % 75% 75% 75% 75% 68% 76% 80% 
Receptor total_unbound 532 531 542 506 438 531 598 
Receptor total_bound 337 335 352 321 255 331 405 
Receptor total_delta 195 197 190 185 183 201 192 
Receptor total_delta % 37% 37% 35% 37% 42% 38% 32% 
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Figure S1. Superimposition of X-ray co-crystal structures of FimHLD with HM and 2-H. Both proteins 
are shown in grey, the ligands are shown in pink 1 (HM) and blue 5 (2-H). The missing contact of 2-OH to 
the structural water molecule (W1) and the positively charged N-terminus of 5 slightly tilts its mannose 
moiety, which potentially affects the interactions of the remaining hydroxyl groups to the protein. 
However, the structural changes are within the error of the measurement.  
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Figure S2. Overlap of 1H,15N-HSQC spectra of FimH in absence of ligand (grey) and in presence of 1 (HM, 
black), 2 (2-F, cyan), 5 (2-H, blue), 6 (3-F, light green), 7 (3-H, green), 8 (4-F, orange) and 9 (4-H, red). The 
spectrum in presence of 10 (6-F) is not shown due to the absence of any chemical shift changes. 
Figure S3. 1H,15N-HSQC spectral regions of the backbone signals of Gln133 to Gln143. 
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Table S4. Thermodynamic and kinetic fits of n-heptyl α-D-mannopyranoside mannoside (1) binding to 
FimHLD in varying buffers and pH. Measurements were analyzed using AFFINImeter software. 
Buffer / pH Thermodynamic fit Kinetic fit 
Hepes 
pH 7.4 
Cacodylate 
pH 7.4 
Tris 
pH 7.4 
Bicine 
pH 8.5 
Tricine 
pH 8.5 
TAPS 
pH 8.5 
Tris 
pH 8.5 
Bicine 
pH 9.0 
TAPS 
pH 9.0 
Tris 
pH 9.0 
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Table S6: Structure, and thermodynamic and kinetic fits of n-heptyl α-D-mannopyranoside mannoside (1) 
and its deoxy- and deoxy-halogeno derivatives (2-9) binding to  FimHLD. All measurements were 
performed at 25°C in HEPES buffer adjusted to pH 7.4, containing 150 mM NaCl. Two independent 
experiments were carried out for each ligand and analyzed using AFFINImeter software. 
Cpd Structure Thermodynamic fit Kinetic fit 
1 
2 
3 
4 
5 
OHO
HO
OH
O
HO
OHO
HO
FHO
O
OHO
HO
ClHO
O
OHO
HO
BrHO
O
OHO
HO
HO
O
83
Section II. The Bacterial Adhesin FimH – Manuscript 1 
6 
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Experimental Part 
Protein preparation. FimHLD from E.coli K-12 strain was expressed with a C-terminal 
thrombin cleavage site and a 6His-tag (FimHLD-Th-6His, 173 residues) following a 
previously published protocol.(1) Briefly, the clone containing the FimHLD construct was 
expressed in the protease-deficient E.coli HM 125 strain at 30°C and 180 rpm in M9 
minimal medium supplemented with 100 µg/mL ampicillin. The protein expression was 
induced by 1 mM IPTG at an OD600 of 0.8. The cells were further cultivated for 16 hrs, 
harvested by centrifugation for 20 min at 5’000 rpm and 4°C. The pellet was resuspended 
in lysis buffer containing 50 mM Tris pH 7.4, 150 mM NaCl, 5 mM EDTA and 
1 mg/mL polymyxin B sulfate. The supernatant containing the periplasmic extract was 
dialyzed against sodium phosphate buffer and purified on Ni-NTA columns. The protein 
was finally dialyzed against assay buffer containing 20 mM HEPES pH 7.4, 150 mM 
NaCl and 1 mM CaCl2. For long time storage the protein was frozen at -80°C. For the 
production of uniformly 15N-labeled FimHLD-Th-6His for NMR experiments, E.coli 
HM125 was cultivated in M9 minimal medium containing 1 g/L 15NH4Cl (CortecNet, 
France) as the sole source of nitrogen. The labeled protein was purified as described 
above and dialyzed against 20 mM phosphate buffer pH 7. The exact molecular weight 
(18860.2 Da) was determined by mass spectrometry.  
Fluorescence polarization assay. Competitive FP assays were essentially performed as 
described previously [1]. Briefly, a serial dilution of unlabeled competitor was titrated 
into constant concentrations of GNFP4 (final concentration 5 nM) and FimHLD (final 
concentration 15 nM) in the presence of 5% DMSO. All solutions were prepared in a 
buffer containing 20 mM HEPES (pH 7.4), 150 mM NaCl and 50 µg/ml BSA. Mixtures 
were incubated for 24 hours in a final volume of 100 µl per well in black, flat bottom, 
NBS-treated, 96-well microtiter plates (Corning, U.S.A.). Competitor KDs were 
determined via the displacement of GNFP4. The associated decrease in fluorescence 
polarization was recorded at 528 nm (excitation at 485 nm) through appropriately 
oriented polarizing filters. Resulting binding isotherms were fit to an equilibrium 
competition function(2) and analyzed using Prism (GraphPad Software, U.S.A.). The KD 
of GNFP4 and FimH was defined as constraint and set to 1.7 nM during curve fitting.(3) 
 
Co-crystallization, data processing, and structure refinement. For crystallization, 
FimHLD (residues 1-158) at a final concentration of 12 mg/mL (ca. 0.8 mM) with a 
threefold molar excess of ligand (2.5 mM) in 20 mM HEPES buffer pH 7.4. Crystals 
were grown in sitting-drop vapor diffusion at 4°C, 12°C and 20°C in 0.2 M (NH4)2SO4, 
0.1 M HEPES pH 7 and 25-30% PEG3350. Plate-like crystals appeared after 2 weeks, 
were cryopreserved by addition of 20% glycerol (v/v) and flash-cooled with liquid 
nitrogen. Data were collected at the SLS beamlines X06DA and X06SA of the Swiss 
Light Source (Paul Scherrer Institute, Switzerland) and indexed, integrated and scaled 
with XDS.(4,5) Structures were solved by molecular replacement with PHASER(6) using 
the FimHLD-n-heptyl α-D-mannopyranoside complex  (PDB code 4XO8) as search 
model. The structures were built using the COOT software(7) and periodically refined 
with the PHENIX and Buster-TNT software.(8,9) Geometric restraints for the ligands were 
generated with PRODRG(10) and Molprobity(11) was used for validation. The atomic 
coordinates have been deposited in the RCSB Protein Data Bank and are available under 
the accession code 5L4T, 5L4U, 5L4V, 5L4W, 5L4X, and 5L4Y, respectively.  
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RMSD calculation. RMSD was calculated from the FimHLD apo structure (PDB-Code: 
4AUU) and the co-crystal structure in complex with 1 (HM) (PDB-Code: 4XO8). From 
both structures, the heavy atoms involved in ligand binding (Phe1: N from N-terminus; 
Asp47: N from backbone; Asp54: 2xO form side chain; Gln133: N from side chain; 
Asn135: N from side chain; Asp140: O from side chain) were compared using 
Schrödinger Suite 2014-4.  
Ab initio calculations. The lowest energy conformer of n-heptyl α-D-mannoside from a 
conformational analysis with MacroModel 10.6(12) using the OPLS 2005 force field was 
subjected to geometrical optimization and energy calculation using the density functional 
theory (DFT) with the B3LYP functional and the 6-31G(d,p) basis-set in the gas-phase as 
implemented in Gaussian 09.(13) The torsional potential was determined using a relaxed 
energy potential surface scan with a 2° step size. Vibrational frequency calculations were 
carried out to confirm these minima. No imaginary frequencies were found. 
Molecular dynamics simulations. Molecular dynamics simulations were carried out 
using Desmond(14-18) and the OPLS 2005 force field. Default parameters were applied 
unless stated otherwise. TIP3P was selected as water model and a physiological salt 
concentration (0.15 M) was added to the protein-complex simulation. An energy barrier 
of 5 kcal/mol restricted backbone movement. The MD simulation for the solution 
conformation was run for 9.6 ns, whereas the protein-complex simulation was run for 
4.8 ns. The energies of the per-residue interactions were calculated from 1000 extracted 
MD frames using Prime.(19-21) 
NMR experiments. 1H,15N-HSQC NMR experiments were measured at 298 K on a 
Bruker Avance III 600 MHz NMR spectrometer equipped with a 5 mm TXI room 
temperature probe head. Samples contained 120 of 15N-labeled FimHLD in 20 mM 
phosphate buffer pH 7.4 in water with 7% D2O. Deoxy- and deoxy-fluoro derivatives 
were solved in H2O at 10 to 20 mM concentrations and added stepwise up to 2- to 5-fold 
molar excess. In case of 10 (6-F), the required amount of ligand was added directly as a 
lyophilized powder to the protein. NMR spectra were acquired and processed with 
Topspin 3.2 (Bruker BioSpin, Switzerland) and analyzed with CcpNmr Analysis (version 
2.2).(22) The backbone assignment of FimHLD was available from previous studies.(23) 
Combined chemical shift differences, ΔδAV, between free and ligand-bound protein signals 
were calculated as in equation 1(24) ∆!!" = (∆!!!!)! +   (0.2∆!!")! (eq. 1) 
Isothermal titration calorimetry. ITC experiments were performed at 25°C using a 
VP-ITC (Malvern Instruments, Worcestershire, UK) with an injection volume between 4 
and 10 µl, a reference power of 10 µcal/sec, a stirring speed of 307 rpm, high feedback, a 
spacing time between 360 and 600 seconds and a filter period of 2 seconds. Preceding the 
measurements, FimHLD-Th-His6 was dialyzed against 10 mM of the experimental buffer 
containing 150 mM NaCl. Two independent experiments with 1 (HM) and deoxy- and 
deoxy-halogeno derivatives thereof were performed in a HEPES buffer at pH 7.4. 
Protonation experiments were carried out in different buffers at pH 7.4, pH 8.5 and 
pH 9.0 (Cacodylate pH 7.4; Tris-HCl 7.4, 8.5 and 9.0; Bicine pH 8.5 and 9.0; Tricine 
pH 8.5; TAPS pH 8.5 and 9.0). Ligand and protein were dissolved in the same buffer. 
Protein concentration was determined by NanoDrop ND-1000 Spectrophotometer 
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(Thermo Scientific, MA, USA) using an extinction coefficient of 24’180 M-1 cm-1.(25) The 
ligand and protein concentrations used for the titrations are given in the Supporting 
Information (Table S3). Baseline adjustment and peak integration to determine the 
thermodynamic parameters KA (association constant) and ΔH° (change in enthalpy), the 
kinetic parameters kon (association rate constant) and koff (dissociation rate constant) as 
well as N (stoichiometry), were performed using the fully automated analysis software 
AFFINImeter.(26,27) For the evaluation of the weak binding ligands 7 (3-H), 8 (4-F) and 9 
(4-H) it was necessary to fix the stoichiometry (N=1) for fitting. ΔG° (free energy of 
binding) and ΔS° (change in entropy) were calculated from equation 2 
ΔG° = ΔH° − TΔS° = −RT lnKA (eq. 2) 
with T being the absolute temperature and R the universal gas constant (8.314 J/molK). 
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Synthesis 
General methods. Commercially available reagents were purchased from Aldrich, 
Merck or Alfa Aesar. Methanol was dried by distillation from sodium methoxide. 
Dichloromethane (CH2Cl2) was dried by filtration through Al2O3 (Fluka, basic; 0.05-0.15 
mm). Toluene was dried by distillation from sodium/benzophenone. Optical rotations 
were measured at 20°C on a Perkin Elmer 341 polarimeter with a path length of 1 dm. 
Concentrations are given in g/100 mL. NMR spectra were obtained on a Bruker Avance 
500 UltraShield spectrometer at 500.13 MHz (1H) or 125.76 MHz (13C). Chemical shifts 
are given in ppm and were calibrated on residual solvent peaks or to tetramethyl silane as 
internal standard. Multiplicities are specified as s (singulet), d (doublet), dd (doublet of a 
doublet), t (triplet), q (quartet) or m (multiplet). Assignment of the 1H and 13C NMR 
spectra was achieved using 2D methods (COSY, HSQC). ESI mass spectra were 
recorded on a Waters micromass ZQ instrument. High-resolution mass spectra were 
obtained on an ESI Bruker Daltonics micrOTOF spectrometer equipped with a TOF 
hexapole detector. Reactions were monitored by TLC using glass plates coated with 
silica gel 60 F254 and visualized by using UV light and/or by charring with a molybdate 
solution (a 0.02 M solution of ammonium cerium sulfate dihydrate and ammonium 
molybdate tetrahydrate in aqueous 10% H2SO4) with heating to 140°C for 5 min. 
Column chromatography was performed on a CombiFlash Companion (ISCO, Inc.) 
using RediSep normal phase disposable flash columns (silica gel). Reversed phase 
chromatography was performed on LiChroprep®RP-18 (Merck, 40- 63 µm). 
Synthesis of 1 (6-F) (n-Heptyl 6-Fluoro-6-deoxy-α-D-mannopyranoside) 
Scheme S1. a) i. Trityl chloride, pyridine, DMAP, 80°C, overnight, ii. benzoyl chloride, two steps in one 
pot, (98%); b) FeCl3, DCM, rt, overnight, (87%); c) DAST, DCM, rt, overnight, (45%); d) 0.5 M 
CH3ONa/CH3OH, (80%). 
n-Heptyl 2,3,5-tri-O-benzoyl-6-O-triphenylmethyl-α-D-mannopyranoside (12)(28) 
To a solution of 1 (310 mg, 1.114 mmol) in pyridine (4.0 mL) was added TrCl (388 mg, 
1.392 mmol) and catalytic amount of 4-dimethylaminopyridine (DMAP). The mixture 
a) b)
c)
d)
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1410
O
HO
OH
HO
OH
O
O
BzO
O
BzO
OBz
O
1
Ph
Ph Ph
O
BzO
OH
BzO
OBz
O
O
BzO
F
BzO
OBz
O
O
HO
F
HO
OH
O
89
Section II. The Bacterial Adhesin FimH – Manuscript 1 
was stirred at 80°C overnight and then cooled down to 0°C. To the above reaction 
mixture was added a premixed solution of BzCl (0.52 mL) in pyridine (0.5 mL) dropwise. 
The reaction mixture was stirred at 50°C overnight and then poured into ice-cold water, 
extracted with EtOAc, the organic layer was washed with aqueous NaHCO3, water, 
brine and dried over Na2SO4. The solvent was removed in vacuo and the residue was 
purified by flash chromatography on silica gel (PE-EE, 10:1-6:1) to afford the desired 
compound as a white solid (642 mg, 98%). 1H-NMR (500 MHz, CDCl3): δ 8.16 (d, J = 
7.5 Hz, 2H), 7.83 (d, J = 8.0 Hz, 2H), 7.73 (d, J = 8.0 Hz, 2H), 7.62 (t, J = 7.5 Hz, 1H), 
7.50-7.40 (m, 10H), 7.31 (t, J = 8.0 Hz, 2H), 7.26 (t, J = 7.5 Hz, 2H), 7.16-7.07 (m, 9H), 
6.01 (t, J = 10.0 Hz, 1H, H-4), 5.79 (dd, J = 10.0, 3.0 Hz, 1H, H-3), 5.67 (m, 1H, H-2), 
5.12 (s, 1H, H-1), 4.18 (m, 1H, H-5), 3.86 (dt, J = 9.5, 6.5 Hz, 1H, H-OCH2C6H13), 3.58 
(dt, J = 9.5, 7.0 Hz, 1H, H-OCH2C6H13), 3.37 (dd, J = 10.5, 2.0 Hz, 1H,H-6a), 3.27 (dd, J 
= 10.5, 5.0 Hz, 1H,H-66), 1.71 (m, 2H), 1.43-1.32 (m, 8H), 0.90 (t, J = 7.0 Hz, 3H). 13C-
NMR (125 MHz, CDCl3): δ 165.70, 165.54, 165.11 (3xCO), 143.75, 133.38, 133.01, 
132.96, 129.94, 129.74, 129.65, 129.59, 129.36, 129.26, 129.62, 128.60, 128.23, 128.13, 
127.66, 126.80, 97.48 (C-1), 86.54, 70.97 (C-2), 70.66 (C-3), 70.31 (C-5), 68.36 
(OCH2C6H13), 67.08 (C-4), 62.31 (C-6), 31.82, 29.45, 29.14, 26.16, 22.64, 14.12 
(OCH2C6H13). ESI-MS Calcd for [M+Na]+, 855.35, found 855.28. 
 
n-Heptyl 2,3,5-tri-O-benzoyl-α-D-mannopyranoside (13)(29) 
To a solution of 12 (583 mg, 0.7 mmol) in DCM (10 mL) was added FeCl3 (hydroscopic 
solid) (284 mg, 1.75 mmol) at rt. The reaction mixture was stirred at rt overnight, diluted 
with DCM, washed with brine, dried over Na2SO4. The solvent was removed in vacuo 
and the residue was purified by flash chromatography on silica gel (PE-EE, 10:1-4:1) to 
afford the desired compound as a white solid (359 mg, 87%). [α]D20 = -126.79 (c = 0.60, 
DCM). 1H-NMR (500 MHz, CDCl3): δ 8.10 (d, J = 7.5 Hz, 2H), 7.98 (d, J = 7.5 Hz, 2H), 
7.82 (dd, J = 8.0, 1.0 Hz, 2H), 7.62 (t, J = 7.5 Hz, 1H), 7.55-7.48 (m, 3H), 7.45-7.38 (m, 
3H), 7.26 (m, 2H), 5.99 (dd, J = 10.0, 3.5 Hz, 1H, H-3), 5.82 (t, J = 10.0 Hz, 1H, H-4), 
5.66 (dd, J = 3.0, 1.5 Hz, 1H, H-2), 5.09 (d, J = 1.0 Hz, 1H, H-1), 4.06 (m, 1H, H-5), 
3.85-3.75 (m, 3H, H-6a, H-6b, H-OCH2C6H13), 3.54 (dt, J = 9.5, 6.5 Hz, 1H, H-
OCH2C6H13), 2.63 (m, 1H, 6-OH), 1.68 (m, 2H), 1.42-1.25 (m, 8H), 0.91 (t, J = 7.0 Hz, 
3H). 13C-NMR (125 MHz, CDCl3): δ 166.56, 165.57, 165.49 (3xCO), 133.66, 133.52, 
133.16, 129.91, 129.68, 129.33, 129.14, 128.73, 128.62, 128.50, 128.29, 97.68 (C-1), 
70.82 (C-2), 70.77 (C-5), 69.69 (C-3), 68.67 (OCH2C6H13), 67.39 (C-4), 61.39 (C-6), 31.77, 
29.38, 29.08, 26.08, 22.64, 14.11 (OCH2C6H13). HR-MS Calcd. for C34H38O9 [M+Na]+, 
613.2414, found 613.2420. 
 
n-Heptyl 2,3,5-tri-O-benzoyl-6-deoxy-6-fluoro-α-D-mannopyranoside (14) 
To a solution of 13 (125 mg, 0.2116 mmol) in dry DCM (0.5 mL) was added DAST (0.44 
mL) at 0°C, then stirred at rt overnight. After cooling to 0°C, the reaction mixture was 
quenched with methanol, concentrated, the residue was purified by flash 
chromatography on silica gel using PE-EE (9:1-6:1) to afford the desired compound as 
colorless oil (56 mg, 45%). [α]D20 = -126.76 (c = 0.61, DCM). 1H-NMR (500 MHz, 
CDCl3): δ 8.10 (m, 2H), 7.97 (m, 2H), 7.83 (m, 2H), 7.62 (t, J = 7.0 Hz, 1H), 7.55-7.48 
(m, 3H), 7.45-7.38 (m, 3H), 7.26 (m, 2H), 5.92 (dd, J = 10.0, 3.0 Hz, 1H, H-3), 5.88 (t, J 
= 10.0 Hz, 1H, H-4), 5.67 (dd, J = 3.0, 1.5 Hz, 1H, H-2), 5.09 (d, J = 1.5 Hz, 1H, H-1), 
4.64 (ddd, J = 47.5, 10.5, 4.5 Hz, 1H, H-6a), 4.60 (ddd, J = 47.0, 10.5, 2.5 Hz, 1H, H-
6b), 4.28 (m, 1H, H-5), 3.82 (dt, J = 9.5, 6.5 Hz, 1H, H-OCH2C6H13), 3.57 (dt, J = 9.5, 6.5 
Hz, 1H, H-OCH2C6H13), 1.71 (m, 2H), 1.37 (m, 8H), 0.91 (t, J = 7.0 Hz, 3H). 13C-NMR 
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(125 MHz, CDCl3): δ 165.56, 165.51, 165.45 (3xCO), 133.52, 133.17, 129.91, 129.80, 
129.70, 129.28, 129.05, 128.86, 128.60, 128.47, 128.29, 97.59 (C-1), 81.75 (d, J = 173.88 
Hz, C-6), 70.55 (C-2), 69.94 (C-3), 69.59 (d, J = 19.0 Hz, C-5), 68.81 (OCH2C6H13), 66.36 
(d, J = 9.0 Hz, C-4), 31.77, 29.36, 29.06, 26.06, 22.63, 14.10 (OCH2C6H13). HR-MS Calcd 
for C34H37FO8 [M+Na]+, 615.2370, found 615.2373. 
n-Heptyl 6-deoxy-6-fluoro-α-D-mannopyranoside (10) 
To a solution of n-heptyl 14 (44.8 mg, 0.0756 mmol) in dry methanol (1.0 mL) was added 
0.5 M CH3ONa/MeOH (80 µL) at rt. The reaction mixture was stirred overnight, then 
neutralized HOAc, concentrated to dryness. The residue was purified by flash 
chromatography on silica gel (DCM:MeOH 15:1 to 10:1) to afford 10 as a colorless syrup 
(17 mg, 80%). [α]D20 = +98.8 (c = 0.28, DCM). 1H-NMR (500 MHz, CD3OD): δ 4.73 (d, 
J = 1.5 Hz, 1H, H-1), 4.65 (m, 1H, H-6a), 4.55 (m, 1H, H-6b), 3.79 (dd, J = 3.0, 2.0 Hz, 
1H, H-2), 3.72-3.61 (m, 4H, H-OCH2C6H13, H-3, H-4, H-5), 3.42 (dt, J = 9.5, 6.5 Hz, 1H, 
H-OCH2C6H13), 1.59 (m, 2H), 1.32 (m, 8H), 0.91 (t, J = 7.0 Hz, 3H, CH3). 13C-NMR (125 
MHz, CD3OD): δ 101.74 (C-1), 84.23 (d, J = 169.88 Hz, C-6), 73.35 (d, J = 17.75 Hz, C-
5), 72.63 (C-3), 72.10 (C-2), 68.71 (OCH2C6H13), 67.48 (d, J = 7.25 Hz, C-4), 32.99, 30.60, 
30.21, 27.32, 23.69, 14.42 (OCH2C6H13). 19F-NMR (376 MHz, CD3OD): δ -230.46 (m). 
ESI-MS Calcd for [M+Na]+, 303.16, found 303.07. HR-MS Calcd. for C13H25FO5 
[M+Na]+, 303.1578, found 303.1575.  
Synthesis of 54 (6-H) (n-Heptyl 6-deoxy-α-D-mannopyranoside) 
Scheme S2. a) i. CBr4, Ph3P, pyr, 0-65°C, 3 h, ii. Ac2O/pyr, DMAP, two steps (81%); b) Bu3SnH/toluene, 
reflux, overnight, (80%); c) CH3ONa/CH3OH, (66%). 
n-Heptyl 2,3,4-tri-O-acetyl-6-bromo-6-deoxy-α-D-mannopyranoside (15) 
To a solution of 1 (110 mg, 0.359 mmol) in pyridine (3 mL) was added 
triphenylphosphine (189 mg, 0.72 mmol) in one portion at 0°C, then added CBr4 (179 
mg, 0.54 mmol) in portions at 0°C. The reaction mixture was stirred at 0°C for 0.5 h, 
then was heated at 65°C for 3 h. After cooling, methanol (2 mL) was added dropwise and 
the mixture was concentrated to dryness. The residue was acetylated with Ac2O (1 mL), 
pyridine (2 mL) and DMAP (2 mg). The reaction mixture was stirred at rt for 3 h and 
then concentrated, the residue was purified by flash chromatography on silica gel (PE-EA 
6:1-4:1) to give the desired product (136 mg, 81%) as a colorless syrup. [α]D20 = +51.60 (c 
= 0.89, CHCl3); 1H NMR (500 MHz, CDCl3): δ 5.33 (m, 1H, H-3), 5.21 (d, J = 1.0 Hz, 
1H, H-2), 5.16 (t, J = 10.0 Hz, 1H, H-4), 4.81 (s, 1H, H-1), 3.97 (m, 1H, H-5), 3.76 (m, 
1H, OCH2C6H13), 3.42 (m, 3H, H-6a, H-6b, OCH2C6H13), 2.13, 2.06, 1.98 (3xs, 9H, 
3xCOCH3), 1.59  (m, 2H), 1.30 (m, 8H, OC2H4C4H8CH3), 0.87 (t, J = 6.5 Hz, 3H, 
OC2H4C4H8CH3); 13C NMR (125 MHz, CDCl3): δ 170.06, 169.84 (3xCOCH3), 97.28 (C-
1), 69.88 (C-5), 69.67 (C-2), 68.91 (C-3), 68.84 (C-4), 68.41 (OCH2C6H13), 31.44 (C-6), 
31.68, 29.16, 28.98, 25.99, 22.57, 14.05 (OCH2C6H13), 20.86, 20.74, 20.66 (3xCOCH3); 
ESI-MS Calcd for [M+Na+2]+, 491.13, found 491.11. HR-MS Calcd. for C19H31BrO8 
[M+Na]+, 489.1100, found 489.1099. 
O
OAc
AcO
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O
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OH
HO
OH
O
HO a) b)
1 15 16
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O
AcO O
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n-Heptyl 2,3,4-tri-O-acetyl-6-deoxy-α-D-mannopyranoside (16) 
A solution of Bu3SnH (0.26 mL, 0.96 mmol) in toluene (2.5 mL) was added dropwise to 
a gently refluxing solution of 15 (300 mg, 0.64 mmol) in toluene (4 mL) over 10 min and 
the mixture was refluxing overnight. After cooling, the mixture was concentrated and the 
residue was purified by flash chromatography on silica gel (PE-EA 3:1-3:2) to give the 
desired compound (198 mg, 80%) as a colorless oil. [α]D20 = +52.72 (c = 0.30, MeOH); 
1H NMR (500 MHz, CDCl3): δ 5.30 (dd, J = 10.0, 3.5 Hz, 1H, H-3), 5.22 (dd, J = 3.5, 
1.5 Hz, 1H, H-2), 5.05 (t, J = 10.0 Hz, 1H, H-4), 4.71 (s, 1H, H-1), 3.87 (m, 1H, H-5), 
3.65 (dt, J = 9.5, 6.5 Hz, 1H, OCH2C6H13), 3.40 (dt, J = 9.5, 6.5 Hz, 1H, OCH2C6H13), 
2.15, 2.05,1.98 (3xs, 9H, 3xCOCH3), 1.57 (m, 2H, OCH2CH2C5H11), 1.30 (m, 8H, 
OC2H4C4H8CH3), 1.21 (d, J = 6.0 Hz, 3H, H-6), 0.88 (t, J = 7.0 Hz, 3H, 
OC2H4C4H8CH3); 13C NMR (125 MHz, CDCl3): δ 170.21, 170.05, 170.00 (3xCOCH3), 
97.38 (C-1), 71.23 (C-4), 70.02 (C-2), 69.18 (C-3), 68.23 (OCH2C6H13), 66.16 (C-5), 17.40 
(C-6), 31.73, 29.30, 29.01, 26.00, 22.59, 14.06 (OCH2C6H13), 20.95, 20.81, 20.74 
(3xCOCH3); HR-MS calcd. for C19H32O8 [M+Na]+, 411.1995, found 411.1992. 
n-Heptyl 6-deoxy-α-D-mannopyranoside (11) 
To a solution of 16 (80 mg, 0.206 mmol) in methanol (2 mL) was added 0.5 M 
CH3ONa/MeOH (41 µL) at rt. The reaction mixture was stirred at rt overnight, then 
neutralized with Amberlyst 15. The reaction mixture was filtered and the residue was 
washed thoroughly with MeOH. The filtrate was concentrated and the residue was 
purified with flash chromatography on silica gel (PE:EA 1:1-1:2) to give compound 11 
(36 mg, 66%) as a colorless oil. [α]D20 = +50.40 (c = 0.33, MeOH); 1H NMR (500 MHz, 
CD3OD): δ 4.65 (s, 1H, H-1), 3.78 (m, 1H, H-2), 3.69-3.62 (m, 2H, H-OCH2C6H13, H-3), 
3.57 (m, 1H, H-5), 3.42-3.35 (m, 2H, H-OCH2C6H13, H-4), 1.58 (m, 2H, 
OCH2CH2C5H11), 1.32 (m, 8H, OC2H4C4H8CH3), 1.26 (d, J = 6.0 Hz, 3H, H-6), 0.91 (t, J 
= 7.0 Hz, 3H, OC2H4C4H8CH3); 13C NMR (125 MHz, CD3OD): δ 101.61 (C-1), 73.96 (C-
4), 72.44 (C-3), 72.34 (C-2), 69.70 (C-5), 68.52 (OCH2C6H13), 32.97, 30.64, 30.20, 27.30, 
23.68, 14.43 (OCH2C6CH13), 18.00 (C-6); HR-MS Calcd for C13H26O5 [M+Na]+, 
285.1675, found 285.1678. 
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The price of ﬂexibility – a case study on septanoses
as pyranose mimetics†
Christoph P. Sager, ‡a Brigitte Fiege, ‡a Pascal Zihlmann,‡a Raghu Vannam, ‡b
Said Rabbani,a Roman P. Jakob, c Roland C. Preston,a Adam Zalewski, a
Timm Maier, c Mark W. Peczuh *b and Beat Ernst *a
Seven-membered ring mimetics of mannose were studied as ligands for the mannose-speciﬁc bacterial
lectin FimH, which plays an essential role in the ﬁrst step of urinary tract infections (UTI). A competitive
binding assay and isothermal titration calorimetry (ITC) experiments indicated an approximately ten-fold
lower aﬃnity for the seven-membered ring mannose mimetic 2-O-n-heptyl-1,6-anhydro-D-glycero-D-
galactitol (7) compared to n-heptyl a-D-mannopyranoside (2), resulting exclusively from a loss of
conformational entropy. Investigations by solution NMR, X-ray crystallography, and molecular modeling
revealed that 7 establishes a superimposable H-bond network compared to mannoside 2, but at the
price of a high entropic penalty due to the loss of its pronounced conformational ﬂexibility. These results
underscore the importance of having access to the complete thermodynamic proﬁle of a molecular
interaction to “rescue” ligands from entropic penalties with an otherwise perfect ﬁt to the protein
binding site.
Introduction
The exibility of a molecule denes its intrinsic conformational
entropy. Rigid molecules adopt a highly populated conforma-
tional ground state with no or only a few alternative confor-
mations. In contrast, exible molecules populate multiple
conformers with low barriers for interconversion between them.
Flexibility has implications on intermolecular interactions in
diﬀerent manners (Fig. 1).1 Emil Fischer's lock-and-key model
(A) assumes two rigid partners and therefore requires precise
complementary shapes to allow tight binding.2–6 However, in
most cases, either the ligand (B)7–12 or the receptor (C)13,14
exhibits exibility while its binding partner is rather rigid. In
these cases, complex formation requires an induced t5 or
a conformational selection mechanism.15–18 Finally, consider-
able reorganizational energy is required for interactions in
which both ligand and receptor are exible (D).19 A detailed
knowledge of the thermodynamic prole allows for categoriza-
tion of a binding event with respect to these four scenarios and
aﬀects the design of ligands. The enthalpic and entropic
contributions to these intermolecular associations, funda-
mental for characterizing the thermodynamic prole of an
Fig. 1 The four types of receptor–ligand interactions. (A) Rigid
receptor, rigid ligand. (B) Rigid receptor, ﬂexible ligand. (C) Flexible
receptor, rigid ligand. (D) Flexible receptor, ﬂexible ligand.
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Scheme 1 Syntheses of FimH antagonists with a septanose core as
replacement for a-D-mannopyranoside 1 and 2. Methyl b-septanoside
3 and 1,2-di-deoxy-septanose 5 have been previously described.40
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View Article Onlineassociation, can be determined by isothermal titration calo-
rimetry (ITC).
In the present study, an example of a receptor–ligand inter-
action according to type B (Fig. 1) was studied in detail. The
receptor is the lectin FimH, located at the tip of bacterial pili. It
mediates the attachment of uropathogenic E. coli (UPEC) to uro-
thelial cells of the mammalian host and therefore represents the
rst step of the process leading to urinary tract infection (UTI).20–22
This adhesion impedes the clearance of bacteria from the urinary
tract and is therefore essential for the infection of urothelial
cells.23–25 Since the physiological ligand of FimH is the highly
mannosylated glycoprotein uroplakin 1A located on urothelial
cells,20–22 a broad variety of mannose-based FimH antagonists
have been developed for blocking this interaction and thereby the
bacterial infection of bladder cells.26–34 Their successful applica-
tion in a UTI mouse model clearly supports their therapeutic
potential for treatment and prevention of UTI.26,31,35
To date, only the aglycone ofmannosidic FimHantagonists has
been successfully varied,26–37 whereas the replacement of mannose
by other hexoses, e.g. D-glucose or D-galactose, led to a severe
reduction or even loss of aﬃnity.38 We were interested to know
whether septanose derivatives, i.e. seven-membered ring homo-
logs of pyranoses,39 could be utilized as ring-expanded FimH
antagonists. Our interest was motivated by previous studies where
the jackbean lectin concanavalin A (ConA) bound methyl septa-
nosides in its carbohydrate binding pocket, albeit with reduced
aﬃnity relative to the pyranose ligand.40,41 ConA naturally recog-
nizes the a1-3, a1-6-dimannosylmannoside42 as well as methyl a-
pyranosides of mannose and glucose.43,44 In contrast to the natural
selectivity for a-congured saccharides, methyl b-septanosides
were bound by ConA whereas a-septanosides were not.
Here we report results from an investigation of septanoses
binding to the isolated lectin domain of FimH (FimHLD), which
is locked in the high-aﬃnity state.45,46 Flexibility was funda-
mentally important for binding of the best seven-membered
ring ligand, 2-O-n-heptyl-1,6-anhydro-D-glycero-D-galactitol (7)
(informally referred to as 2-O-n-heptyl-1-deoxy-septanose), as
FimHLD selected one conformation among those on its shallow
conformational energy surface.
Results
Synthesis of septanose ligands
The design of the septanose ligands was guided by the structure
of the mannose-binding pocket of FimH. It consists of a deep
pocket lined with polar amino acid residues forming an
extended H-bond network with the natural ligand. The entrance
to the mannose-binding pocket, the so-called “tyrosine gate”, is
furnished with two tyrosines and an isoleucine and interacts
with aliphatic or aromatic aglycones of FimH antagonists.38 For
mimicking mannose-based FimH antagonists, methyl b-D-glyc-
ero-D-galacto-septanosides 3 and 4 along with the related 1,6-
anhydro-D-glycero-D-galactitols 5–7 were synthesized (3 and 4
will be referred to as methyl septanosides, and 5–7 as 1-deoxy-
septanoses). For all these seven-membered ring analogs of a-
D-mannose, the conguration at C3 to C6 (septanose
numbering) is identical to the conguration at C2 to C5 in D-Chem. Sci.
98mannose. In addition, the n-heptyl substituent on the C2
hydroxyl group of septanose 4 and 7 was expected to mimic the
n-heptyl aglycone at the anomeric center (C1) of a-D-man-
nopyranoside 2 (Scheme 1).
For the syntheses of 3 & 4 and 6 & 7, acetonide protected
oxepine 8 was utilized as a key starting material.47 The previ-
ously described diastereoselective epoxidation and meth-
anolysis of 8 provided methyl b-D-glycero-D-galacto-septanoside
9 (84%).47,48 Alkylation of its C2 hydroxyl group gave 2-O-n-heptyl
septanoside 10 in 73% yield. By removal of the acetonide group
on 9 and 10, methyl septanosides 3 and 4 were obtained in 93%
and 82% yields, respectively. The preparation of 6 and 7 relied
on the regio- and diastereoselective hydroboration–oxidation of
8 to give 11 (65%).49 Deprotection of 1-deoxy-septanose 11 then
yielded 6 (90%). Alternatively, 7 was obtained by alkylation of 11
at C2 to form compound 12 followed by deprotection (77% over
two steps).This journal is © The Royal Society of Chemistry 2017
Competitive binding assay
Compounds 1–7, along with other analogs (see ESI†), were
evaluated for their binding to FimHLD. Compounds were rst
screened in a competitive binding assay,36 where a polymeric
oligomannose–biotin conjugate coupled via streptavidin to
horseradish peroxidase is added simultaneously with a serial
dilution of the test ligand to wells coated with FimHLD. Aer
incubation, the peroxidase substrate 3,30,5,50-tetrame-
thylbenzidine is added and the binding is quantied by
colorimetric detection. For the compounds 1–7, the competitive
binding assay revealed IC50 values ranging from 64 nM to 400
mM (Table 1). The addition of an n-heptyl substituent at C2 of 3
(/ 4) and 6 (/ 7) led to signicantly improved inhibition.
Septanoside 4 exhibits an 11-fold increase in aﬃnity over 3, and
1-deoxy-septanose 7 a 307-fold improvement over 6. Thus, the n-
heptyl substituent in 4 and 7 likely mimics the aglycone of the
corresponding pyranoside 2.
ITC experiments with compounds 2, 4 and 7
Isothermal titration calorimetry (ITC) provided a deeper insight
into the nature of the intermolecular interaction of FimHLD
with 2-n-heptyl-septanoside 4 and 2-n-heptyl-1-deoxy-septanose
7 in comparison with n-heptyl a-D-mannopyranoside (2). All
three test compounds contain an n-heptyl unit – either as
aglycone (/ 2) or as substituent in the 2-position (/ 4 and 7,
respectively). The n-heptyl group is essential to establish the
important hydrophobic contacts within the tyrosine gate. The
KD values obtained from ITC experiments were in relative
agreement with the IC50 values from the competitive binding
assay, i.e. in both assays 2was the strongest binder followed by 7
and then 4 (Table 1).
ITC data (Table 1 and Fig. 2A) revealed that the almost 100-
fold loss in aﬃnity of compound 4 compared to compound 2 is
due to a diminished enthalpic contribution ðDHobsÞ that is
partly compensated by a more favorable entropy term ðTDSobsÞ.
The less benecial enthalpy term for septanoside 4 likely results
from an increased desolvation penalty due to its increased polar
surface area (108.6 A˚ for 4 compared to 99.4 A˚ for 2)50 as well as
from looser interactions with the FimHLD. As a consequence of
a looser t, the exibility of septanoside 4 is less compromised,
explaining the substantially improved entropy term by
11.7 kJ mol1 (Table 1).
In contrast, the binding enthalpies of 2 and 7 are almost
identical, so that the aﬃnity loss of 1-deoxy-septanose 7 in
comparison to mannoside 2 is exclusively due to a signicant
entropic penalty (TDS

obs term). According to eqn (1), the
entropy DS consists of desolvation entropy DS

solv,
Table 1 Aﬃnity (IC50 & KD) and thermodynamic data for the interaction of mannosides 1 & 2, septanosides 3 & 4 and 1-deoxy-septanoses 5–7
with FimHLD
Compound IC50
a [mM] KD
b [mM] DG

obs
b [kJ mol1] DH

obs
b [kJ mol1] TDSobsb [kJ mol1] Nb
1 (methyl a-D-mannoside) 5.6  0.5 n.d.
2 (n-heptyl a-D-mannoside) 0.064  0.02 0.029 43.0 50.3 7.3 1.00
3 31.6  4.2 n.d.
4 2.83  0.4 2.20 32.3 27.9 4.4 0.98
5 86.8  7.9 n.d.
6 421  30.5 n.d.
7 1.37  0.3 0.26 37.5 49.4 11.8 1.00
a IC50 values were measured in a competitive binding assay.36
b KD values and thermodynamic parameters were determined by ITC experiments at
a temperature of 25 C.
Fig. 2 (A) Thermodynamic ﬁngerprints of compounds 2, 4, and 7 binding to FimHLD. (B) Heat capacity (DCp) of compounds 2 and 7 binding to
FimHLD from ITC experiments performed at three diﬀerent temperatures (details in ESI†).
This journal is © The Royal Society of Chemistry 2017 Chem. Sci.
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Table 2 Dissected entropic contributions of mannoside 2 and 1-
deoxy-septanose 7 binding to FimHLD at 298.15 K
Contributor
Mannoside 2
[kJ mol1]
1-Deoxy-septanose 7
[kJ mol1]
TDSsolv 69.1 68.8
TDSconf 66.4 70.6
TDSmix 10.0 10.0
TDSobs 7.3 11.8
Chemical Science Edge Article
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View Article Onlineconformational entropy DS

conf , and a term DS

mix reecting the
loss in translational and rotational degrees of freedom of both
binding partners upon complex formation. Because DS

mix for
the two antagonists is equal (10 kJ mol1, eqn (2), where R is the
universal gas constant and 55.6 the molarity of water in [M]),51,52
the entropy penalty originates exclusively from a loss of
conformational exibility ðDSconfÞ – either caused by the ligand
and/or the receptor.
DS

obs ¼ DS

solv þ DS

conf þ DS

mix (1)
DS

mix ¼ R ln

1
55:6

(2)
To quantify the contributions of DS

solv and DS

conf , ITC
experiments were conducted at three diﬀerent temperatures to
determine the heat capacity (DCp) of mannoside 2 and 1-deoxy-
septanose 7 (Fig. 2B and Table 2). DCp (eqn (3)), reporting on the
entropy contributions from desolvation of ligand and protein, is
equal for both complex formations (Fig. 2B). Since at 385 K,
DS

solv reaches zero, i.e. the hydration shell no longer exists,
DS

solv; 298 K can be calculated according to eqn (4).
52–54
DCp ¼

vDH

obs
vT

(3)
DS

solv; 298:15 K ¼ DCp ln

298:15 K
385 K

(4)
The identical DCp values (0.902 kJ K
1  0.018 and 0.907 kJ
K1  0.016, respectively) obtained for the interaction of
FimHLD with 1-deoxy-septanose 7 and mannoside 2 are a clear
indication that both complex formations release comparable
numbers of water molecules leading to a comparable gain of
desolvation entropy DS

solv. Consequently, the entropic penalty
for 7 originates from a loss of conformational freedom of either
the ligand and/or the protein upon binding (Table 2).
To comprehensively interpret the thermodynamics of
binding, additional information regarding solution and bound
conformations of mannoside 2 and 1-deoxy-septanose 7 are
indispensible. The conformational exibility of septanoses vs.
pyranoses as well as the n-heptyl aglycone deserves special
attention in this regard. Furthermore, the degree of conforma-
tional exibility of FimHLD has to be addressed. Finally, struc-
tural analysis by X-ray crystallography to elucidate the hydrogenChem. Sci.
10bond network established by the two ligands is essential for
a nal assessment of the two binding processes.
In silico comparison of the solution conformation of
mannoside 2 and 1-deoxy-septanose 7
The large conformational entropy penalty for 1-deoxy-septanose
7 in comparison to mannoside 2 could be related to the extent of
exibility of their respective solution conformations. Therefore,
the dynamic behavior in solution of each was studied by moni-
toring two collected variables using metadynamics simulations.
The collected variables were dened as the angle between O1–
C1–C4 and the dihedral torsion of O1–C1–O5–C5 for mannoside
2 and the corresponding angle O2–C2–C5 and dihedral torsion
O2–C2–C1–O6 for compound 7 (for numbering see Fig. 3).
Metadynamics simulations revealed an energy landscape for
mannoside 2 with one distinct minimum of 154.8 kJ mol1 of
99 for the angle O1–C1–C4 and 54 for the dihedral angle
(indicated by a circle in Fig. 3A), whereas the energy surface for 1-
deoxy-septanose 7 was much shallower, showing two minima of
90.4 kJ mol1 at 99 and 36, and 89.5 kJ mol1 at 90 and
90, respectively (indicated by circles in Fig. 3B). Thus, the
metadynamic simulations clearly indicate that 1-deoxy-
septanose 7 exhibits a much larger ring exibility in compar-
ison to mannoside 2. In addition, the minima observed in the
metadynamics simulations coincide closely with the bound
conformation of the crystal structure. However, compound 7
shows an additional minimum that does not overlap with the
bound conformation and therefore adds to the entropic loss.
To further quantify the exibility issue, all ring conforma-
tions were normalized to their respective global minimum.
Cumulative frequency analysis revealed that compound 7
exhibits 23 accessible conformations within 16 kJ mol1 corre-
sponding to the energy range of a hydrogen bond, whereas
compound 2 has only access to 3 conformations. When
a 44 kJ mol1 energy range is taken into consideration (equal to
the highest barrier in a cyclohexane ring-ip), compound 7 has
access to 72 conformations in contrast to the rather rigid
mannoside 2 with only 14 accessible conformations (Fig. 3C). In
summary, the much higher number of conformations available
to septanose derivative 7 results in a higher loss of conforma-
tional exibility upon complexation to FimH and accounts for
the diﬀerence in entropies of binding to FimHLD for 7 compared
to 2.
Ab initio calculations involving interactions of the n-heptyl
group
The preference of 1-deoxy-septanose 7 to position its n-heptyl
tail in an axial orientation was demonstrated qualitatively by
solution NMR experiments in the absence of protein. Karplus
analysis of coupling constants 3J2,3 and
3J3,4 (septanose
numbering) of 7 obtained from a 1D 1H NMR spectrum at
900 MHz indicated torsion angles in agreement with those
expected for the axial conformation (see ESI† for details). To
assess whether the tyrosine gate aﬀects the n-heptyl tail in 2 and
7 identically, non-covalent interaction energies were calculated
based on the available crystal structures (cf. Fig. 5) withThis journal is © The Royal Society of Chemistry 2017
0
Fig. 3 (A, B) Energy surface diagrams of the solution conformation of 2 (A) and 7 (B) obtained frommetadynamics analysis. Circles represent the
distinct minima observed in metadynamic simulations and crosses indicate the bound conformations in the crystal structures [PDB code 4BUQ
(A) & 5CGB (B)]. Energies are given in kJ mol1 and are color-coded from bordeaux-red (0 kJ mol1) to dark-blue (150 kJ mol1). Vertical axes
describe the observed dihedral angle (red), horizontal axes the observed angle (blue), both indicated in the structures to the right. (C) Cumulative
frequency distribution analysis of all conformations (within 80 kJ mol1 from the global minimum). Dashed lines indicate examples that occur at
similar energies as denoted in the text.
This journal is © The Royal Society of Chemistry 2017 Chem. Sci.
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Jaguar.55–57 For the proper quantication of the non-covalent
interactions, we performed ab initio DFT calculations using
the B3LYP-MM functional in combination with the cc-pVDZ++
basis-set in the gas phase. The calculations led to comparable
interaction energies of 18.5 kJ mol1 and 19.2 kJ mol1 for
the n-heptyl tails of 2 and 7 with the tyrosine-gate. We therefore
assume that their contributions to enthalpy as well as entropy
are of comparable size.
Conformation of FimHLD upon binding of ligand 2 and 7
assessed by NMR CSP experiments
NMR chemical shi perturbation (CSP) experiments of the
FimHLD backbone amide resonances were used to assess the
conformation of the protein backbone.58 Thus, 1H,15N-HSQC
experiments of uniformly 15N-labeled FimHLD (see ESI†) were
conducted in the absence and presence of an excess of each
ligand. The resonance assignment of FimHLD was available
from previous studies.58,59 For both antagonists 2 and 7, the set
of protein residues of the mannose binding pocket (e.g. Ala2,
Asp54 and Gln133) and a nearby loop (e.g. Thr134, Asn138,
Asp141, Gln143) exhibited highly similar CSP eﬀects (Fig. 4; see
also Fig. S5 in ESI†). The absence of line broadening eﬀects
demonstrates that the protein is rather rigid in complex with
both antagonists. Furthermore, the almost identical signals for
amino acids remote from the mannose-binding pocket indicate
that FimHLD does not undergo global conformational adaptions
Fig. 4 NMR chemical shift perturbation experiments of FimHLD with mannoside 2 and 1-deoxy-septanose 7.
1H,15N-HSQC spectra of FimHLD in
the absence of antagonist (green) and in the presence of an excess of 2 (blue) and 7 (magenta). Important residues in the binding sites are shown
in detail on the panel at the right.
Fig. 5 (A) Co-crystal structure of FimHLD with mannoside 2 (PDB code 4BUQ) and (B) co-crystal structure of FimHLD with 1-deoxy-septanose 7
(PDB code 5CGB); the intermolecular hydrogen bond network is depicted by dashed lines.
Chem. Sci. This journal is © The Royal Society of Chemistry 2017
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View Article Onlineupon ligand binding. Thus, we can assume that the protein
conformation upon binding mannoside 2 and 1-deoxy-
septanose 7 is highly similar, consistent with the comparable
thermodynamic outcomes of the interactions.Crystal structure of FimHLD in complex with mannoside 2 and
1-deoxy-septanose 7
The previously reported co-crystal structure of mannoside 2–
FimHLD60 (PDB code 4BUQ, Fig. 5A) and the new high-resolution
X-ray structure of FimHLD co-crystallized with 7 (PDB code 5CGB;
Fig. 5B and Table S3 in ESI†) exhibit a surprisingly high structural
similarity with a backbone RMSD of 0.2 A˚. Noteworthy, the well-
dened, tight FimH mannose-binding pocket installs identical
hydrogen bond networks with mannoside 2 and 1-deoxy-
septanose 7 (Fig. 5). For both ligands, nine hydrogen bonds
with the side-chains of the residues Asn46, Asp54, Gln133, Asn135
and Asp140, and to the backbone of Phe1 and Asp47 are formed
(for statistics on diﬀraction data and structure renement of
ligand 7–FimHLD complex see ESI†).
The dynamic stability of the hydrogen bond networks was
assessed by MD simulations starting from the conformations of
compound 2 and 7 from the crystal structures in Fig. 5. The
simulations were run for the duration of 4.8 ns, followed by an
analysis of the hydrogen bond network, where the occupancy of
a given hydrogen bond interaction was monitored. The crucial
hydrogen bonds with Phe1, Asp54 and Gln133 were retained
with comparable occupancies by both compounds 2 and 7 (see
Table S3 in ESI†). Therefore, in accordance with ITC experi-
ments, enthalpic contributions from ligand–protein interac-
tions can be predicted to be of similar size.Discussion
The bacterial lectin FimH mediates the adhesion of uropatho-
genic E. coli to the bladder epithelium of its host. FimHLD
consists of a mannose-binding pocket, which is reached
through a hydrophobic cle equipped with two tyrosines and an
isoleucine (tyrosine gate). Its high aﬃnity interaction with
mannoside 2 is achieved by an extended hydrogen bond
network established between the mannose moiety and the
carbohydrate recognition domain of the lectin and by hydro-
phobic s–p interactions of the n-heptyl aglycone with the tyro-
sine gate.38,58,61 Replacement of the mannose moiety by other
hexoses, e.g. D-glucose or D-galactose, leads to a substantial
reduction or even loss of binding aﬃnity.38
Seven-membered ring analogs designed to mimic a-D-man-
nopyranosides in general exhibit reduced aﬃnities for FimHLD.
From a series of septanosides and analogs, methyl septanoside
4 and 1-deoxy-septanose 7 were identied as the best repre-
sentative binders. The n-heptyl substituent on their 2-position
enables s–p stacking interaction with the tyrosine gate in
analogy to mannoside 2.58,61 Nevertheless, 4 (2.2 mM) and 7
(260 nM) showed a 75- and 9-fold loss of inhibitory potency
compared to mannoside 2 (29 nM).
To explain the large diﬀerence in aﬃnity, a comparison of
the thermodynamic ngerprints of their interactions withThis journal is © The Royal Society of Chemistry 2017
10FimHLD turned out to be instructive. The ITC prole of n-heptyl
mannoside (2) served as reference. Binding of 2, like many other
mannoside-based antagonists, is largely enthalpy-driven with
a major contribution by the nine hydrogen bonds formed
between the mannose moiety and the lectin.29,35,38,58 The severe
drop in aﬃnity of methyl septanoside 4 compared to manno-
side 2 is predominantly due to a substantially smaller enthalpy
term (DDH

obs ¼ 22.4 kJ mol1), accompanied by a pronounced
improvement of the entropy term (TDDSobs ¼ 11.7 kJ mol1).
One possible explanation for the severe enthalpy penalty is
a steric clash induced by the methoxy group in the 1-position,
disordering the essential hydrogen bond network. A less well-
dened hydrogen bond network on the other hand would be
consistent with an entropy gain of 4 in comparison to manno-
side 2 because of the increased conformational exibility.
Interestingly, the almost identical enthalpy terms for manno-
side 2 and 1-deoxy-septanose 7 (DH

obs  50 kJ mol1) suggest
that FimH adopts very similar conformations enabling the
formation of all critical hydrogen bonds to both ligands,
a hypothesis supported by solution NMR and X-ray co-
crystallography.
The origin for the reduced aﬃnity of 7 compared to 2 is
a signicantly higher entropic penalty. ITC measurements at
diﬀerent temperatures revealed almost identical heat capacities
DCp for both mannoside 2 and 1-deoxy-septanose 7, indicating
comparable desolvation entropies ðDSsolvÞ. Since DS

mix reect-
ing the loss in translational and rotational degrees of freedom
upon complex formation can be assumed to be identical, the
increased entropic penalty for 7 can be attributed solely to
a reduced conformational freedom of the ligand and/or the
protein. With NMR chemical shi perturbation experiments it
was shown that 1-deoxy-septanose 7 exhibited comparable
chemical shi changes and line widths for amino acid residues
of the FimH binding pocket as mannoside 2. Thus, both ligands
form comparable complexes with FimHLD and therefore exhibit
comparable DS

conf terms. Quantum-mechanical calculations
revealed almost identical contributions of the aglycones of 2
and 7 to the interaction energy, suggesting that the loss of
conformational entropy is solely due to the higher exibility of
the seven-membered ring of 7 compared to the six-membered
ring of 2 in solution. Upon binding to FimHLD, a specic
conformation of the septanose ring is required, leading to
a signicant rigidication of the compound relative to its
unbound state. Metadynamics simulations, revealing a at
energy prole for 1-deoxy-septanose 7 with various ring
conformations separated by relatively low energetic barriers,
support this assumption.
The bound conformation of 7 can therefore be regarded as
the result of a conformational selection of the ligand. Whereas
conformational selection in terms of protein dynamics has been
widely described and quantied by the use of NMR dynamics
experiments of the protein,7,15–18 a quantitative description of
the impact of ligand exibility on the thermodynamics of
binding is still rare, likely due to the numerous contributing
factors, which could be separated and analyzed in this specic
example.Chem. Sci.
3
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View Article OnlineConclusions
ITC results, NMR CSP experiments, computational consider-
ations, and X-ray crystallographic data support the conclusion
that 2-n-heptyl 1-deoxy-septanose 7 adopts a conformation
enabling the formation of a H-bond network with FimHLD
identical to the corresponding mannoside 2. Furthermore, the
loss of aﬃnity of 7 is almost exclusively due to a loss in
conformational entropy DSconf. In silico-analysis and solution
NMR data ultimately showed that, although the main solution
conformation of the seven-membered ring is similar to the
bound conformation, the pronounced exibility of the ring in
solution causes signicant entropic penalties upon complex
formation.
In view of this result, the evaluation of glycomimetics should
always include thermodynamic proling because the quanti-
cation of enthalpic and entropic terms can be highly informa-
tive for the design of improved antagonists. In the case of FimH
antagonists, 1-deoxy-septanose 7 provides an excellent man-
nopyranoside mimic, i.e. can established an identical H-bond
network as the parent compound. However, it suﬀers from
a substantial entropic penalty due to rigidication of the
inherent ring exibility upon complexation. This study excel-
lently exemplies that exibility can be an important element in
the design of small molecule ligands of target proteins.62,63Conﬂicts of interest
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The Tyrosine Gate of the Bacterial Lectin FimH: A
Conformational Analysis by NMR Spectroscopy and X-ray
Crystallography
Brigitte Fiege,[a] Said Rabbani,[a] Roland C. Preston,[a] Roman P. Jakob,[b] Pascal Zihlmann,[a]
Oliver Schwardt,[a] Xiaohua Jiang,[a] Timm Maier,*[b] and Beat Ernst*[a]
Introduction
Urinary tract infection (UTI) is one of the most frequent infec-
tious diseases, affecting millions of people every year.[1]
Women have a 50% risk of experiencing at least one sympto-
matic UTI during their lifetime. The large majority of UTIs are
caused by uropathogenic Escherichia coli (UPEC) that are able
to invade the urothelial cells in the bladder, form biofilms, and
cause recurrent infections.[2] To date, UTIs are mainly treated
with antibiotics, thus inducing antimicrobial resistance, a seri-
ous threat to patients worldwide.[3] Therefore, new treatment
strategies are urgently needed.
Adherence of UPEC to the urothelial surface is mediated
through the mannose-specific lectin FimH, located at the tip of
bacterial type 1 pili.[4] FimH therefore represents a major viru-
lence factor of UPEC. It consists of two immunoglobulin-like
domains: the N-terminal lectin domain, or carbohydrate recog-
nition domain (CRD), and, connected by a short linker, the C-
terminal pilin domain. The pilin domain anchors the adhesin to
the pilus and regulates the switch between the two conforma-
tional states—with either high or low affinity for manno-
sides—of the CRD.[5] Most in vitro interaction studies with
FimH antagonists have been performed only with the lectin
domain FimH-CRD that is trapped in the high-affinity state.[6]
The natural ligand for FimH is the mannosylated glycopro-
tein uroplakin Ia present on urothelial cells.[7] Mannose-based
FimH antagonists compete with this interaction and prevent
bacterial adhesion and hence infection. A substantial advant-
age of this anti-adhesion therapy over antibiotics treatment is
the reduced risk of resistance development, because no direct
selection pressure is imposed on the pathogen.[8] The first suc-
cessful demonstration of the anti-adhesion strategy was of the
protective effect of methyl a-d-mannoside in a UTI mouse
model.[9] Since then, significant progress has been made in the
optimization of FimH antagonists, yielding improved affinities
in the low nanomolar range.[10]
In part, these modifications are the result of rational drug
design based on X-ray crystal structures of FimH bound to vari-
ous a-d-mannosides.[11] The mannose moiety is in each case
tightly bound and involved in an extended hydrogen bond
network. A promising prospect for optimizing binding is of-
fered by a rim of hydrophobic residues lining the entrance to
the mannose pocket. This so-called tyrosine gate, consisting of
Tyr48 and Tyr137, with Ile52 positioned in-between, is involved
in interactions with oligomannosides, as revealed by the X-ray
co-crystal structure of FimH-CRD with oligomannose-3.[12] For
drug design, the tyrosine gate has been exploited for hydro-
phobic stacking interactions with suitable aglycones. In partic-
ular, the finding that mannosides with hydrophobic aryl and
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alkyl aglycones show stronger affinities has led to many prom-
ising drug candidates. Through binding studies with a series of
alkyl mannosides, n-heptyl a-d-mannoside (1, Table 1, below)
was identified as the most efficient non-aromatic FimH bind-
er.[11a] For aryl and heteroaryl derivatives a large variety of an-
tagonists differing in the number of aromatic rings and sub-
stituents and the type of linkers exist. Chemically easily accessi-
ble aromatic derivatives such as 4-nitrophenyl and 4-methyl-
umbelliferyl mannosides were soon discovered.[11a, 13] These
were followed by derivatives of squaric acid,[14] biphenyls and
other diaryls,[15] triazoles,[16] and indolines,[17] among others.
We routinely test new candidates for in vitro binding to
FimH-CRD[15b,16–18] and to UPEC,[19] as well as for efficacy in
a UTI mouse model.[20] A special focus is placed on the PK/PD
(pharmacokinetic/pharmacodynamic) properties for oral bio-
availability.[21] The ideal FimH antagonist for UTI treatment
needs to be balanced between a reasonable solubility for ef-
fective dosage and a certain degree of lipophilicity for efficient
membrane permeation during oral absorption. Despite the
availability of structural information, rational design of FimH
antagonists has not always led to the expected improvement
in binding affinities. Specifically, thermodynamic profiles from
isothermal titration calorimetry (ITC) have frequently revealed
enthalpy–entropy compensations,[15d,21] the reasons for which
are not yet fully understood.
In this study, we analyzed the binding of a representative
set of FimH antagonists to FimH-CRD by means of a combina-
tion of high-resolution X-ray crystal structures and NMR chemi-
cal shift perturbation (CSP) experiments. NMR spectroscopy
allows the study of protein–carbohydrate interactions in solu-
tion, with the native dynamic behavior of the protein thus
being maintained.[22] In contrast, X-ray crystallography provides
structural information from a “static” crystal with limited infor-
mation on flexibility. The two methods are therefore highly
complementary.
The potential of NMR spectroscopy to contribute to the
drug design process has been widely acknowledged.[23] The
chemical shifts of protein resonances are highly sensitive to
the chemical environment, for example to hydrogen bonds
and aromatic ring currents.[24] CSP effects hence identify resi-
dues in direct proximity to a bound ligand and, in addition,
indicate conformational changes in allosteric sites. We used
1H,15N HSQC experiments with 15N-enriched FimH-CRD in the
presence of various antagonists to monitor the CSP effects on
the backbone amide groups. Previous NMR studies of binding
of methyl a-d-mannoside[6] and n-heptyl a-d-mannoside[25] to
FimH-CRD only noted a general match of the CSP maps and
the ligand binding interface identified from X-ray co-crystal
structures. With our analysis we demonstrate that NMR and X-
ray structural data can be combined to characterize FimH–an-
tagonist complex formation in unprecedented detail. In addi-
tion to the structural information, ITC experiments were per-
formed to quantify the thermodynamics of antagonist binding
to FimH-CRD.
Results and Discussion
FimH antagonist classes studied in this work
In this study we examined FimH antagonists composed of an
a-d-mannosyl residue linked to an aliphatic or aromatic agly-
cone (Table 1). n-Heptyl a-d-mannoside (1)[11a] is the only non-
aromatic antagonist with an affinity (low nanomolar range)
Table 1. FimH antagonists analyzed for binding to FimH-CRD by X-ray
crystallography (PDB ID and reference for reported structures given) and/
or CSP NMR experiments (indicated with +).
Compd Structure X-ray NMR
1 4BUQ[27] +
2 4X50 +
3 n.d. +
4 4CST[21] +
5 4X5Q +
6 4X5R +
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similar to those of the aromatic antagonists 2 to 7 (Table 1 and
Table 2, below). Although its pharmacokinetic properties
render 1 ineffective for oral administration, it is often used as
a reference compound in screening studies. Biphenyl manno-
side 2[15a] was rationally designed to form aromatic stacking in-
teractions with the side chains of Tyr48 and Tyr137 in the tyro-
sine gate. Later on, the aryl moieties were derivatized to opti-
mize this interaction, as reported by our group and others.[15]
An impressive example of this is represented by biphenyl man-
noside 4, with an ortho-chloro substituent on the inner aro-
matic ring and a cyano group in the para position of the outer
ring as a bioorthogonal replacement for the carboxylate group
present in antagonist 3.[21] Both ring substituents of 4 reduce
the electron density in the aglycone and thereby enhance the
p–p interaction, thus leading to a more than tenfold affinity
improvement relative to the unsubstituted antagonist 2
(Table 2, below). Besides the biphenyls 2 to 4, three other
compound classes with multiple aromatic rings in nonplanar
arrangements have been tested: 5 features a 5-nitroindolinyl
moiety N-linked to an inner phenyl ring,[17] 6 extends an ortho-
chlorophenyl system with squaric acid and N-methyl-piperazi-
ne,[14b] and in 7 (for synthesis see the Supporting Information)
an amide bond is inserted between two phenyl rings with
ortho-chlorine and para-carboxylate substituents.
In addition to high-affinity antagonists, we also studied
methyl a-d-mannoside (8), n-butyl a-d-mannoside (9), and 1,5-
anhydromannitol (10). Finally, the 4-deoxy-4-fluoro derivate 11
(for synthesis see the Supporting Information) exhibits a dra-
matically reduced affinity relative to 1, emphasizing the impor-
tance of the hydrogen bond network in the mannose binding
pocket.
X-ray crystal structures of FimH with antagonists
We obtained high-resolution X-ray structures of FimH-CRD co-
crystallized with antagonists 2 and 5–7, with resolutions rang-
ing from 1.00 to 2.00 æ (Table 1 and Table S1 in the Supporting
Information), and compared them with the reported structures
with antagonists 1 and 4.[21] FimH-CRD consists of eleven
mainly antiparallel b-strands and two short helices (Figure 1).
Superposition of the six protein structures reveals a high struc-
tural similarity with a backbone RMSD of around 0.5 æ be-
tween any two structures. In all six structures the ligand is
bound within the mannoside binding pocket. The mannosyl
moieties form hydrogen bonds to the side chains of residues
Asp54, Gln133, Asn135, and Asp140 and to the backbone
atoms of Phe1 and Asp47 (Figure S1). Tyr48 is involved in
stacking interactions with the outer aromatic ring of the agly-
cones or, in the case of 1, with the alkyl chain of the ligand
(Figure 1). Tyr137 stabilizes the loop containing Tyr48 through
a hydrophobic interaction with Ile52. In the cases of 6 and 7,
the side chain hydroxy group of Tyr137 can form a hydrogen
bond with the oxygen atoms of the squaric acid and the
amide bond, respectively. Moreover, the backbone amide
groups of Tyr137, Asn138, and Asp140 and the side chains of
Asn135, Asn138, and Asp140 form a complex hydrogen bond
network within the loop and with the 3- and 4-positions of the
mannosyl residues of the ligands.
Table 1. (Continued)
Compd Structure X-ray NMR
7 4X5P +
8 n.d. +
9
1UWF,
1TR7[11a]
+
10 n.d. +
11 n.d. +
Figure 1. Superposition of X-ray co-crystal structures of FimH-CRD with six
antagonists: A) only protein is shown, with Tyr48 and Tyr137 as gray sticks,
and B) with antagonists shown as colored sticks (1 cyan, 2 green, 4 orange,
5 magenta, 6 blue, and 7 salmon). C) b-sheet topology diagram of FimH-
CRD.[11a, 29]
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It is noteworthy that in all six structures the side chain of
tyrosine gate residue Tyr137 has a single orientation whereas
Tyr48 shows two slightly different orientations. In all cases, the
side chain positions correspond to the closed conformation of
the tyrosine gate as described previously.[11a,15a,d,26] The closed
conformation was also observed in co-crystal structures of
FimH-CRD with n-butyl a-d-mannoside (9) (PDB ID: 1UWF)[11a]
or with a biphenyl mannoside with a methylcarboxylate group
in the meta-position of the outer aromatic ring (PDB ID:
3MCY).[15a]
A significantly different orientation of the tyrosine gate,
termed the open conformation, was observed in the crystal
structure of the full-length FimH in complex with a-d-mannose
stabilized by the chaperone FimC (PDB ID: 1KLF),[11b] and of
FimH-CRD with ethane-1,2-diol in the mannose binding site
(PDB ID: 4AUU).[26] The latter is considered a “pseudo-apo”
structure, although the bound ethane-1,2-diol could still have
an influence on the binding site. Whereas the Tyr137 side
chain in these structures remains in the orientation seen in the
closed conformation, the Tyr48 side chain is rotated towards
the mannose pocket by about 3.5 æ. This open conformation
of FimH-CRD was also observed in the co-crystal structure with
the native ligand epitope oligomannose-3, Mana1,3(Mana1,6)-
Manb1,4GlcNAcb1,4GlcNAc (PDB ID: 2VCO).[12] Here, the a1,3-
linked mannose at the nonreducing end is recognized in the
orientation typical for all mannosides. This brings the first
GlcNAc residue into a position in which it would clash with
Tyr48 in the closed conformation. In view of the limited confor-
mational freedom around the glycosidic linkages, it can be
speculated that oligomannose-3 might only be able to bind to
FimH in the open conformation.
In computational studies, FimH antagonists with flexible
aglycones have been docked to FimH in both conformations
of the tyrosine gate.[11a,15d] As an experimental verification,
n-butyl a-d-mannoside (9)[11a] and several monoaryl antago-
nists[27] have been co-crystallized with FimH-CRD in both the
open and the closed forms. Wellens et al. proposed that the
open conformation represents the minimum-energy conformer
of FimH and that the closed conformation is only stabilized by
favorable interactions with hydrophobic aglycones.[26] This
would correspond to a conformational selection process in
which the ligand binds to a conformer from a preexisting set
of substates.[28] Nevertheless, an induced-fit mechanism also
seems possible.
To conclude, Tyr48 can be regarded as a key element in
ligand interaction, and knowledge of the Tyr48 side chain con-
formation is critical to the discussion. Unfortunately, in many
FimH–mannoside co-crystal structures the binding pocket resi-
dues or the ligand are involved in crystal lattice contacts po-
tentially affecting the binding pocket geometry.[26–27] Therefore,
more experiments are needed to study the structure and dy-
namics of FimH–antagonist complex formation in solution.
NMR experiments with FimH-CRD
We performed NMR experiments to obtain structural informa-
tion on FimH–antagonist complexes in solution. This allows full
retention of the molecule dynamics and avoids potential dis-
tortion from crystal packing. The binding of antagonists to 15N-
labeled FimH-CRD (173 residues) was monitored by CSP analy-
sis of 1H,15N HSQC fingerprint spectra representing the back-
bone amide groups. For efficient affinity purification, the pro-
tein contained a C-terminal His6-tag, which does not influence
mannoside binding.[18] A complete backbone resonance assign-
ment was performed by measuring a set of triple-resonance
NMR spectra with a 13C,15N-labeled FimH-CRD sample. The high
chemical shift dispersion of the amide resonances allowed se-
quential backbone assignment mainly on the basis of HNCACB
and CBCACONH spectra.[30] A total of 152 (94.4%) out of 161
assignable residues were assigned.[31] The His6-tag remained
unassigned. Three residues were absent in the 1H,15N HSQC
spectrum: the backbone and side chain signals of Asn96 and
Arg98, which are located in a loop close to the binding pocket,
as well as Gly79, which is located in a solvent-exposed loop
about 20 æ away from the binding pocket. Carbon and proton
signals of the side chains of these three residues were ob-
served as (i¢1) correlations of the succeeding residues, thus
suggesting that fast exchange with the solvent and not (solely)
conformational exchange was responsible for the absence of
signals. The assignment matches that from a recently pub-
lished study of FimH-CRD (BMRB entry: 19066)[25] that lacked
a His6-tag. Those authors were able to observe and assign
Gly79, Asn96, and Arg98 amide signals. This is likely due to
different measuring conditions, in particular a lower pH of
6.0,[25] in comparison with pH 6.8 (for assignment) and pH 7.0
(for CSP experiments) in this study.
Chemical shift perturbation experiments : We subjected 15N-la-
beled FimH-CRD to CSP experiments with antagonists 1 to 11
(Table 1). Methyl a-d-mannoside (8) and n-heptyl a-d-manno-
side (1) have been analyzed in similar studies before.[6, 25] With
all compounds, separate signals for the bound and free forms
were observed in the 1H,15N HSQC spectra at 500 MHz, thus in-
dicating slow exchange on the NMR timescale. The observation
is in accordance with nanomolar to low micromolar affinities
(Table 2) and with kinetic data obtained from surface plasmon
resonance experiments.[32] Interestingly, even antagonist 11,
which binds to FimH-CRD with a greatly diminished affinity of
83 mm (Table 2), was found to be in slow or intermediate ex-
change. Slow exchange kinetics might suggest rearrangements
of conformation during complex formation.
For the non-overlapping signals in the 1H,15N HSQC spectra,
combined chemical shift changes (DdAVG) with respect to the
protein signals in the absence of ligand were determined (Fig-
ure 2A). 1,5-Anhydromannitol (10) is the smallest structural
motif that still shows specific binding to the mannose pocket
of FimH-CRD. Its CSP effects were therefore used to calculate
differential CSP effects (DDdAVG) for the other ligands that
should mainly reflect the influence of the aglycone moieties
(Figure 2B and C). In the presence of antagonists 1 to 11,
FimH-CRD displayed chemical shift changes for residues near
the known mannose binding site. Only minor CSP effects of
below 0.1 ppm were observed for residues distal from this site.
Because proton chemical shifts are highly sensitive to changes
in hydrogen bond length,[24] global conformational changes of
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FimH-CRD in response to antagonist binding can be excluded,
in view of the fact that the protein is mainly composed of anti-
parallel b-sheets that form numerous hydrogen bonds.[29] The
observation is in agreement with the high structural similarity
of the X-ray co-crystal structures discussed above. In presence
of the “core” motif 10, significant DdAVG values, above 0.1 ppm,
were observed for (in order of decreasing DdAVG) Tyr48,
Asn138, Thr53, Asn136, Asp54, VaL56, Cys3, Tyr55, Asp47,
Tyr95, Ile52, Ile13, Gly14, Thr134, and Asn46. Most of these resi-
dues directly constitute the binding pocket, in particular resi-
dues from the loop regions between b-sheets A’ and A2 (Ile11
to Gly16), B2 and C (Asn46 to VaL56), and F and G (Arg132 to
Phe144). Of these, Tyr48, Ile52, and Tyr137 form the tyrosine
gate that is known to interact with the aglycone moieties of
FimH antagonists. In addition, CSP effects were observed for
residues Ala2 and Cys3, located at the bottom of the binding
pocket, and for Tyr95, which forms a hydrogen bond with the
pocket residue Asp54. For most residues, only very small
DDdAVG values were observed. Larger deviations were observed
for loop residues around Tyr137 in the presence of 11 (see
later discussion) and for loop residues around Tyr48.
CSP data report on the Tyr48 side chain conformation : The
strongest and most heterogeneous chemical shift changes of
FimH-CRD with different antagonists were observed for the
loop residues Tyr48, Glu50, Thr51, Ile52, and Thr53 (Figures 2
and 3). In the X-ray structures of FimH-CRD co-crystallized with
1, 2, and 4 to 7, the Tyr48 side chain directly interacts with the
aglycone moieties and adopts an orientation significantly dif-
Figure 2. Chemical shift changes of FimH-CRD backbone amide signals upon addition of FimH antagonists. A) Absolute combined chemical shift changes
(DdAVG) of 1, 8, and 10. B), C) Differential CSP effects (DDdAVG) of B) aliphatic, and C) aromatic ligands relative to 1,5-anhydromannitol (10). Secondary structure
elements are schematized on top. Residues missing from the chart are Phe1 (N terminus), 11 proline residues (residues 12, 26, 49, 83, 85, 91, 102, 104, 111,
157, and 162), Gly79, Asn96 and Arg98 (not observed), Asp47, Tyr108 and Phe142 (overlap), Ser139 (exchange broadening), as well as the C-terminal His6-tag
(residues His168 to His173).
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ferent from that observed in the “pseudo-apo” X-ray struc-
ture[26] and in a recently solved NMR solution structure[25] (Fig-
ure S2). Apart from Tyr48, the conformation of the loop resi-
dues is remarkably conserved in all FimH-CRD crystal struc-
tures. This includes hydrogen bonds between Tyr48 HN and
Asn46 Od1, between Glu50 HN and its side chain oxygen (stabi-
lized by interaction with the guanidinium group of Arg98, Fig-
ure S3), and between Thr51 HN and Tyr48 O. We hypothesized
that the observed backbone CSP effects of Tyr48 to Thr53
mainly reflect the change in conformation of the Tyr48 side
chain rather than direct ligand effects. In general, aromatic
rings dramatically influence the chemical shifts of nearby
nuclei through the local magnetic fields induced by their delo-
calized p electrons. For protons located on the outside of the
ring, the local magnetic field is parallel to the external field,
causing a downfield shift (higher ppm values). In contrast, pro-
tons located inside or above the ring experience an opposing
field and hence an upfield shift. For Tyr48 and Glu50, we ob-
served strong downfield shifts of both proton and
15N chemical shifts in the presence of antagonists,
whereas Thr51 experienced a strong proton upfield
shift of up to 1 ppm and above (Figure 3). The shifts
were larger for aromatic aglycones than for aliphatic
ones. In the open conformation seen in the “pseudo-
apo” crystal structure[26] the Tyr48 ring is distant from
the loop residues. In the closed conformation, it is ro-
tated towards the loop such that Glu50 HN comes
closer and within 308 of the ring plane, where it ex-
periences a strong deshielding aromatic ring current.
In contrast, Thr51 HN points almost directly into the
ring in a T-shaped orientation in which a strong
shielding field causes upfield shifts.[33] Previous stud-
ies had demonstrated that T-shaped N¢H···p interac-
tions can significantly contribute to ligand binding af-
finities.[34] Enhancement of the aromatic ring current
effect through p–p stacking provides the explanation
for the generally larger CSP effects observed for aro-
matic antagonists than for their aliphatic counter-
parts. Importantly, Glu50 and Thr51 show almost no
shifts in the presence of 10 ; this strongly indicates
that FimH-CRD remains in the unperturbed open con-
formation.
A more detailed analysis of the CSP effects with ar-
omatic antagonists allows even further differentiation
of the Tyr48 orientation in the closed conformation.
The signals of Glu50 and Thr51 are grouped together
in the presence of compounds 2, 3, 4, 6, and 7
(Figure 3, dashed line boxes). With antagonist 5,
slightly different shifts were observed, thus suggest-
ing a different orientation of Tyr48. Aliphatic com-
pounds 1 and 8–11 cannot be directly compared to
the aromatic antagonists, because the aromatic ring
current effect of Tyr48 as the main source of the
shifts is drastically different. In good agreement with
the NMR results, the high-resolution X-ray structure
of FimH-CRD in complex with 5 shows a distinct ori-
entation of the Tyr48 ring, which is tilted by about
408 in relation to the co-crystal structures with compounds 1,
2, 6, and 7 (Figure 4, bottom). This tilt is likely the result of the
unique geometry of the nonplanar indolinylphenyl moiety of 5
and the propensity of the system to optimize the stacking in-
teraction. Interestingly, in the co-crystal structure with biphenyl
derivate 4 the electron density clearly allows positioning of the
Tyr48 ring in both conformations (Figure 4). We cannot find
any confirmation for this in the NMR experiments, because
only a single set of bound signals is observed with 3 and the
CSP effects are very similar to those with compounds 2 and 6
with a single Tyr48 orientation in the crystal structure. Never-
theless, it is conceivable that Tyr48 could retain a certain
degree of flexibility in the bound state (see later discussion on
ITC data). NMR chemical shifts of the binding loop residues
thereby would show an average of rapidly exchanging Tyr48
orientations in the complex.
Water coordination in the FimH binding pocket : Some CSP ef-
fects are expected to be due to direct interactions of the pro-
Figure 3. Chemical shift changes of the binding loop residues Tyr48, Glu50, Thr51, Ile52,
and Thr53 in the presence of antagonists 1 to 11. Spectra in absence of ligand are col-
ored in green. Signals corresponding to Tyr48 conformations a and b in Figure 4 are
marked by dashed and solid line boxes, respectively.
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tein with the mannosyl moiety. X-ray structural data implicate
the formation of a direct hydrogen bond between Asp47 HN
and Man OH6 and of a water-mediated hydrogen bond be-
tween Gly14 HN and Man OH2 (Figure 5). Against the expecta-
tion of a 1H downfield shift from deshielding upon hydrogen
bond formation, both amide protons showed upfield shifts
(Figure 5). This instead points to weakening of an existing hy-
drogen bond. Although other more complex effects cannot be
excluded, the results indicate that Gly14 and Asp47 coordinate
water in the absence of ligand, and that upon mannoside
binding this is replaced by polar groups of the ligand in an
effectively weaker hydrogen bond. The higher degree of free-
dom of water molecules might indeed allow hydrogen bonds
with more ideal geometries than in the ligands. In the X-ray
co-crystal structures with antagonists 1, 2, and 4 to 7 the dis-
tances between the bridging water and Gly14 HN are 0.1 to
0.2 æ less than in the “pseudo-apo” crystal structure, in agree-
ment with our hypothesis (Figure 5). Finally, molecular dynam-
ics simulations also indicated the presence of a structural
water molecule close to Gly14.[35]
Hydrogen bond network in the binding loop with Tyr137: The
loop residues Asn135 to Asp141 display similar CSP effects in
the presence of all tested antagonists except 11 (Figure 2). X-
ray co-crystal structures revealed a complex interresidue hydro-
gen bond network between backbone and side chain atoms
within this loop (Figure 6). Asn138 HN, for example, forms a hy-
drogen bond to the side chain oxygen of Asn135. The strong
deshielding of Asn138 HN in the presence of ligand suggests
a strengthening of this hydrogen bond (Figure 6). The shift
could also be the result of a change in the conformation of
the aromatic ring of Tyr137. However, Tyr137 HN displayed no
or only very small shifts, thus suggesting that its aromatic ring
remains largely unchanged, in agreement with very similar ori-
entations in the X-ray structures. Furthermore, deshielding of
Asp140 HN with all ligands except 1 and 9 indicates a slight
shortening of the hydrogen bond to the side chain oxygen of
Asn138 (Figure 6).
Figure 4. Orientation of the Tyr48 side chain in FimH-CRD crystal structures.
Top: Loop residues Tyr48 to Thr53 in the co-crystal structure with 1 (back-
bone in cyan, amides shown as spheres); Tyr48 side chain in the “pseudo-
apo” structure[26] (green) and with 1 (cyan), 2 (pale green), 6 (dark blue), and
7 (salmon). Bottom: Different Tyr48 orientations (a and b) with 2, 4 and 5.
Figure 5.Water coordination in the FimH binding pocket. Top: X-ray struc-
tures of “pseudo-apo” FimH-CRD (with ethane-1,2-diol in the binding
pocket, green sticks and transparent surface)[26] and in complex with
1 (yellow, asterisk indicates attachment point of aglycone) ; water molecules
are shown as spheres, and hydrogen bond lengths are given in æ. Bottom:
Chemical shift changes of Asp47 (only assigned for nonaromatic antago-
nists) and Gly14 (only subset of spectra shown).
Figure 6. Hydrogen bond network in the binding loop with Tyr137. Top left:
X-ray crystal structures of “pseudo-apo” FimH-CRD (green)[26] and in complex
with 1 (yellow, attachment point of aglycone marked with an asterisk). Ob-
served hydrogen bonds: Asn135 Hd22···Asn138 Od1, Tyr137 HN···Asn135 Od1,
Asn138 HN···Asn135 Od1, and Asp140 HN···Asn138 Od1. With ligand: Man O-
H3···Asp140 Od1 and Asn135 Hd21···Man O4. Bottom and right: Chemical shift
changes of Asn138 and Asp140 with antagonists 1 to 11.
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In summary, mannoside coordination seems to induce
subtle but specific conformational changes in the hydrogen
bond network within the binding loop. The differences in the
CSP effects of Asn135, Tyr137, and Asp141 with the 4-deoxy-4-
fluoro derivate 11 are hence caused by a different electronic
environment of the fluorine atom that also imposes a different
loop arrangement through disruption of hydrogen bonds. The
X-ray structural data are not entirely conclusive on the effect
of mannoside binding to the loop conformation. In all six co-
crystal structures discussed above, the loop residues are well
ordered, but hydrogen bonds in the loop are identical within
error to those in the “pseudo-apo” structure. Apparently, very
small conformational changes, notably in a solvent-exposed
loop with low-populated fluctuating states, cannot be cap-
tured by X-ray crystallography.
Conformational changes in the pocket zipper motif : The CSP
effects for Cys3 are unlikely to be caused by direct ligand ef-
fects, in view of its remoteness (>8.5 æ) from the bound man-
nose. In FimH-CRD, Cys3 is part of a highly structured and
stable hydrogen bond network to neighboring b-strands fur-
ther stabilized by a disulfide bond to Cys44 (Figure 7). This so-
called “pocket zipper” motif is one of four regions that are sus-
pected to play a key role in the conformation transition be-
tween the low- and the high-affinity states in the full-length
FimH.[6, 36] Upon transition to the high-affinity state, the “pocket
zipper” becomes tightly hydrogen bonded, causing a constric-
tion of the binding pocket.[6] The isolated lectin domain FimH-
CRD is believed to be locked in the high-affinity state. In the
CSP experiments with FimH antagonists, we observed relatively
uniform downfield shifts for Cys3 HN, which forms a hydrogen
bond to the backbone oxygen of Ile11 (Figure 7). A similar,
albeit smaller, effect was seen for Ile11 HN, which forms an ad-
jacent hydrogen bond to the Cys3 backbone oxygen. This sug-
gests a strengthening of the hydrogen bonds, although a con-
tribution of nearby aromatic rings, in particular of Phe144 (ca.
3 æ from Cys3 HN) also seems possible. In the six FimH-CRD
crystal structures discussed above, the hydrogen bond be-
tween Cys3 HN and Ile11 O is 0.2 to 0.3 æ shorter than in the
“pseudo-apo” structures, in agreement with the CSP effects
(Figure 7). Such a difference is considered to be significant at
the given resolution.[37] A strengthening of the “pocket zipper”
upon ligand binding could point to a residual conformation
transition of FimH-CRD. However, no CSP effects were ob-
served in the other allosteric regions, thus confirming that the
isolated lectin domain is not undergoing significant conforma-
tion adaptions characteristic of the full-length protein. Corre-
sponding NMR solution studies of full-length FimH would be
highly desirable but have so far been hampered by limited
protein yield and stability.
Thermodynamics data from ITC experiments
FimH antagonists 1 to 11 have been subjected to thermody-
namic profiling by ITC analysis with FimH-CRD (Table 2 and
Table S2). To obtain reliable thermodynamics data, the high af-
finities of some of the compounds required the establishment
of a competitive ITC assay[38] (see the Supporting Information).
The results indicate that all tested antagonists bind in an en-
thalpy-driven manner with mostly unfavorable entropic contri-
butions, in accordance with previous studies.[15d,21, 26] The en-
thalpy term DH8obs=¢42.9 kJmol¢1 of 1,5-anhydromannitol
(10) includes the binding energies from van der Waals contacts
and ten specific hydrogen bonds with the protein.[11] These fa-
vorable terms are partly compensated by enthalpic penalties
from desolvation of ligand and protein. The enthalpic cost for
desolvation of a single hydroxy group had been estimated at
29 kJmol¢1.[39] On the protein side, X-ray and NMR data and
molecular dynamics simulations found evidence of highly
structured hydrogen-bonded water in the binding pocket, with
this being replaced by the hydroxy groups of the ligand. The
classic hydrophobic effect predicts a strong entropic gain for
the release of bound water upon complex formation.[40] How-
ever, other studies also suggested an enthalpy-driven “non-
classical” hydrophobic effect that is usually explained by water
Figure 7. Conformational changes in the pocket zipper motif. Left : Chemical
shift changes of Cys3 and Ile11 in the presence of 1 to 11. Right: X-ray crys-
tal structures of “pseudo-apo” FimH-CRD (green)[26] and in complex with
1 (yellow); hydrogen bond lengths are given in æ, and aromatic residues in
the vicinity are shown as lines.
Table 2. Thermodynamics of binding of FimH antagonists analyzed by
ITC.
Compd KD [nm] DG8obs [kJmol
¢1] DH8obs [kJmol
¢1] ¢TDS8obs [kJmol¢1]
1[a] 28.9 ¢43.0 ¢50.3 7.3
2[a] 17.7 ¢44.2 ¢45.0 0.8
3[b] 3.5 ¢48.3 ¢56.2 8.0
4[b] 1.3 ¢50.7 ¢60.9 10.1
5[b] 1.0 ¢51.3 ¢62.1 10.8
6[a] 14.0 ¢44.8 ¢63.6 18.8
7[a] 6.2 ¢46.8 ¢71.8 25.0
8[a] 1222 ¢33.8 ¢37.2 3.5
9[a] 144 ¢39.1 ¢39.1 0.1
10[a] 1125 ¢34.0 ¢42.9 9.0
11[a] 89990 ¢23.1 ¢21.1 ¢2.0
[a] Direct ITC assay format. [b] Competitive ITC assay format with
a medium-affinity ligand.
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being forced into an enthalpically unfavorable configuration in
the binding pocket.[41] The entropy term for 10 suggests that
any entropic gain from the release of water into the bulk is
overcompensated by unfavorable contributions such as the
loss of rotational and translational entropy of the ligand (esti-
mated at about 25 kJmol¢1 in aqueous solutions),[42] as well as
by conformational restriction of ligand and protein in the com-
plex. Relevant for the latter is the formation of several hydro-
gen bonds that reduce the flexibility of the ligand’s hydroxy
groups and the protein residues involved. Quantification of the
individual entropic contributions is cumbersome and in fact
still represents a major obstacle in current research.[41,43]
The thermodynamic data for methyl a-d-mannoside (8)
reveal a less favorable enthalpy (DDH8obs : 5.7 kJmol
¢1) and a
smaller entropy penalty (¢TDDS8obs : ¢5.5 kJmol¢1) than in the
case of 10. The additional methoxy group of 8 would be
expected to increase the binding enthalpy through van der
Waals interactions with the protein (Ile13, Asp47, and Tyr48
within 4 æ). The effective enthalpy loss is due to an additional
desolvation penalty for the methoxy group, whereas the entro-
py gain reflects the release of additional water molecules into
the bulk. From NMR CSP experiments we also expect a change
in the Tyr48 side chain conformation for all mannosides with
methyl or larger aglycones. The implications for the thermody-
namics depend on whether the complex formation follows an
induced-fit mechanism or conformational selection or a mixture
of both.[28] In a recent solution NMR study of FimH-CRD, 15N re-
laxation and CPMG relaxation dispersion experiments investi-
gating the backbone amides did not provide any indication of
multiple conformations of Tyr48 in the apo protein, neither of
a significant change in the backbone flexibility in the presence
of 1.[25] The data therefore rather argue for an induced-fit
mechanism of the tyrosine gate instead of conformational se-
lection. Nevertheless, conformational equilibria of Tyr48 in the
apo state might exist on a timescale not easily accessible by
NMR experiments (ms to ms). Hence, the exact binding mecha-
nism remains to be elucidated. Elongation of the aglycone
from methyl (compound 8) to butyl (compound 9) and heptyl
(compound 1) led to significant improvement in the binding
enthalpy, due to the enhanced C¢H···p interaction between
the elongated alkyl chain and the Tyr48 ring. An expected im-
provement in the entropy term from the release of more water
into the bulk is observed for 9 but not for 1, which even
shows a loss of entropy relative to 8. We postulated that the
stacking interaction of the heptyl chain of 1 with Tyr48 leads
to rigidification of both interaction partners and hence to sig-
nificant entropic costs. For compound 11, the 4-deoxy-4-fluoro
analogue of 1, a significantly smaller enthalpy term was ob-
served, as would be expected from the disruption of the hy-
drogen bonds in position 4. The CSP experiments also indicat-
ed structural changes in the binding loop containing Tyr137
that can translate into enthalpic costs. Interestingly, the entro-
py is improved by more than 9 kJmol¢1 relative to 1, due to
the greater flexibility of the protein binding pocket and the
ligand.
For the aromatic antagonists 2 to 7, strongly favorable en-
thalpy terms ranging from ¢45.0 to ¢71.8 kJmol¢1 were ob-
tained. Again, an increase in enthalpy is always accompanied
by an increase in entropic costs, as becomes obvious in the en-
thalpy–entropy compensation plot (Figure S4). X-ray structure
data indicate that the outer aromatic rings of antagonists 2
and 4–7 make parallel-displaced p–p interactions with the
Tyr48 ring in the closed conformation, in analogy to the C¢
H···p interaction of the heptyl chain of 1. However, a direct
comparison of the thermodynamic data for aliphatic and aro-
matic antagonists is difficult in view of the large structural dif-
ference of the aglycones and because of the many contribu-
ting factors. The unsubstituted biphenyl mannoside 2 dis-
played the smallest enthalpy term and likewise the smallest
entropic penalty of all aromatic antagonists. For the substitut-
ed biphenyls 3 and 4 we observed significant increases in the
enthalpy, by 11.2 and 15.9 kJmol¢1, respectively, relative to 2.
Firstly, the ortho-chloro substituent is positioned to enhance
the binding enthalpy through favorable van der Waals interac-
tions with the protein in a small pocket formed by Ile52,
Tyr137, and Asn138.[15d] Secondly, the electron-withdrawing
character of the substituents allows stronger p–p interaction
of the aglycones with Tyr48. As already suggested for the com-
parison of 1 with 8, a stronger stacking interaction accounts
for a reduced flexibility both in the Tyr48 side chain and in the
aglycone, leading to compensating entropic penalties. For an-
tagonist 5, the enthalpy is slightly better than for the best bi-
phenyl compound 4. The entropy compensation is only partial,
resulting in the strongest dissociation constant of all tested an-
tagonists. Compounds 6 and 7 display the most favorable en-
thalpies but also the highest entropic penalties. Compound 6
could suffer from entropic costs for rigidification of additional
rotatable bonds in the aglycone moiety. Compound 7 is struc-
turally very similar to biphenyl 3 apart from insertion of an
amide bond linkage. The dramatically enhanced enthalpy
(DDH8obs : ¢15.6 kJmol¢1) and entropic cost (¢TDDS8obs :
17.0 kJmol¢1) of 7 relative to 3 can only be explained in terms
of a very efficient stacking interaction with Tyr48 and subse-
quent loss of conformational entropy in the complex. A com-
parison of all thermodynamic data demonstrates that the an-
tagonist with the highest enthalpic contribution, presumably
from the strongest interaction with Tyr48, is not necessarily the
strongest binder. Antagonist 5 exhibits an optimal thermody-
namic profile, although its enthalpy term is nearly 10 kJmol¢1
weaker than that of 7. From the NMR and X-ray data we de-
duced a distinct orientation of Tyr48 in the presence of 5,
likely as a result of the unique geometry of its indolinylphenyl
aglycone. We assume that this complex conformation is opti-
mal in terms of interaction efficiency and minimized compen-
sating entropic penalties.
Conclusion
We have combined NMR chemical shift perturbation (CSP) ex-
periments with high-resolution X-ray structures to elucidate
the interaction of the FimH lectin domain with antagonists.
One advantage of NMR spectroscopy is its ability to identify
even subtle conformational changes of the protein in solution.
This is particularly helpful for the determination of ligand bind-
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ing modes in cases in which either crystallization was unsuc-
cessful or crystal packing effects distorted the ligand binding
site. We demonstrated that the CSP effects of FimH-CRD can
be used as an indicator for the conformation of the tyrosine
gate motif in the binding pocket. The open conformation was
observed in the apo protein and with 1,5-anhydromannitol
(10), whereas antagonists with aliphatic or aromatic aglycones
are bound to FimH in the closed conformation of the tyrosine
gate. The CSP data additionally revealed slight differences in
the Tyr48 conformation as a result of different aglycone geo-
metries. Furthermore, the NMR results indicate the presence of
highly structured water in the binding pocket of FimH-CRD. In
combination with information from crystal structures and mo-
lecular modeling, CSP experiments might therefore help to
analyze water coordination as an important contributor to the
thermodynamics of ligand binding.
We also performed ITC experiments to access full thermody-
namic profiles of the antagonists. The results suggest enthal-
py–entropy compensation in which enthalpically favorable
stacking of hydrophobic aglycones with the Tyr48 side chain
leads to conformational restriction of both the protein and the
ligand and hence to unfavorable entropy. NMR relaxation ex-
periments with FimH-CRD did not show any changes in the
backbone flexibility upon binding of antagonists.[25] However,
we speculate that the flexibility of the protein side chains, in
particular of Tyr48, plays a pivotal role in the modulation of
FimH–antagonist binding. These effects can be dissected by
NMR relaxation experiments for side chain dynamics, and
incorporation of the results into rational design might lead to
further improved FimH antagonists urgently needed for UTI
therapy.
Experimental Section
Protein preparation : FimH-CRD from the E. coli K-12 strain was ex-
pressed with a C-terminal thrombin cleavage site and a His6-tag
(FimH-CRD-Th-His6, 173 residues) by a previously published proto-
col.[18] The clone containing the FimH-CRD construct was expressed
in protease-deficient E. coli HM125 at 30 8C and 180 rpm in M9
minimal medium supplemented with MgSO4 (2 mm), CaCl2
(0.1 mm), glucose (2 gL¢1), and ampicillin (100 mgmL¢1). The pro-
tein expression was induced by addition of IPTG (1 mm) at an
OD600 of 0.8. The cells were further cultivated for 16 h and harvest-
ed by centrifugation for 20 min at 2000g and 4 8C. The pellet was
resuspended in lysis buffer containing Tris (pH 7.4, 50 mm), NaCl
(150 mm), EDTA (5 mm), and polymyxin B sulfate (1 mgmL¢1). The
supernatant containing the periplasmic extract was dialyzed
against sodium phosphate buffer and purified on Ni-NTA columns.
For crystallization, the protein without tag was prepared as de-
scribed in ref. [44] and dialyzed against HEPES buffer (pH 7.4,
20 mm). For production of 15N- and 13C,15N-labeled FimH-CRD-Th-
His6 for NMR experiments, E. coli HM125 was cultivated in M9 mini-
mal medium containing 15NH4Cl (1 gL
¢1) or 5NH4Cl (1 gL
¢1 1) and
13C-glucose (2 gL¢1) (Sigma–Aldrich) as the only sources of nitro-
gen and carbon, respectively. The labeled proteins were purified as
described above and dialyzed against phosphate buffer (pH 6.8,
25 mm) in the case of 13C,15N-FimH-CRD-Th-His6 or phosphate
buffer (pH 7.0, 20 mm) in that of 15N-FimH-CRD-Th-His6. The purities
of the proteins were verified by nonreducing SDS-PAGE analysis,
and the concentrations were determined by UV absorption (Nano-
Drop ND-1000, Thermo Scientific). The molecular weights of 15N-
FimH-CRD-Th-His6 (18860.2 Da) and
13C,15N-FimH-CRD-Th-His6
(19687.0 Da), determined by mass spectrometry, demonstrated iso-
tope incorporation of >99.9%.
NMR spectroscopy : NMR assignment experiments were performed
at 298 K with a Bruker Avance III 700 MHz NMR spectrometer
equipped with a 5 mm QCI-P cryogenic probe. A set of triple-reso-
nance NMR spectra of a sample of 13C,15N-FimH-CRD (600 mm) in
phosphate buffer (pH 6.8, 25 mm) and H2O/D2O (90%/10%) in
a 5 mm Shigemi Tube (Shigemi Inc. , USA) was recorded for back-
bone assignment: HNCA, HN(CO)CA, HNCO, HN(CA)CO, HNCACB,
and CBCA(CO)NH. Protein stability during data acquisition was
tested by regular inspection of 1D 1H and 1H,15N HSQC NMR spec-
tra. Spectra were acquired and processed with Topspin 3.2 (Bruker
BioSpin, Switzerland). CcpNmr Analysis (versions 2.2 and 2.3) was
used for NMR resonance assignment.[45] The backbone assignment
of FimH-CRD has been deposited in the Biological Magnetic Reso-
nance Data Bank (http://www.bmrb.wisc.edu, accession code
26541).
Chemical shift perturbation (CSP) experiments with FimH antago-
nists were performed with 15N-FimH-CRD (100 to 200 mm) in non-
deuterated phosphate buffer (pH 7.0, 20 mm). FimH antagonists
were dissolved in D2O at 2.5 to 100 mm stock concentrations. Bi-
phenyl compound 4 was dissolved at 6.3 mm in D2O with
[D6]DMSO (40%), due to poor solubility. The antagonists were
added at slight molar excesses to ensure complete saturation of
the protein. NMR samples were prepared in 3 mm NMR tubes (Hil-
genberg, Germany) with 5% D2O and [D4]TSP [3-(trimethylsilyl)-
2,2’,3,3’-tetradeuteropropionic acid, Armar Chemicals, Switzerland]
(0.1 mm) added as an internal reference. 1H,15N HSQC spectra were
measured with a Bruker Avance III 500 MHz spectrometer equipped
with a BBO double resonance probe at 298 K. Spectra were ac-
quired and processed with Topspin 2.1 and analyzed with CcpNmr
Analysis (versions 2.2 and 2.3).[45] All antagonists bound in the slow
exchange regime, and amide signals of the bound protein were as-
signed from chemical shift proximity. Combined chemical shift
changes of FimH-CRD signals were calculated as weighted averag-
es of 1H and 15N chemical shift changes according to Equa-
tion (1):[46]
DdAV ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðDd1HNÞ2 þ ð0:2Dd15NÞ2
p ð1Þ
Co-crystallization of FimH antagonists : Crystallization of all FimH-
CRD/ligand complexes was performed by sitting-drop vapor diffu-
sion. For crystallization trials of ligands 5–7, FimH-CRD (residues 1–
158) was used at a final concentration of 18 mgmL¢1 (ca. 1 mm)
with a fivefold molar excess of ligand (5 mm) in HEPES buffer
(pH 7.4, 20 mm). For crystallization trials with ligand 2, an FimH-
CRD solution (18 mgmL¢1) was diluted to 10 mgmL¢1 with a satu-
rated solution of ligand 2 in HEPES buffer (pH 7.4, 20 mm). Crystals
with ligand 5 were grown as previously described.[21] Co-crystals
with ligand 6 were grown in the Proplex HT-96 screen (Molecular
Dimensions, USA) with (NH4)2SO4 (1.5m) and HEPES (pH 7.0, 0.1m).
After four weeks equilibration at 20 8C, crystals appeared after sub-
sequent equilibration at 4 8C within a few days. Crystals with
ligand 7 were grown in PEG 4000 (20%) and NaH2PO4 (pH 4.7,
0.2m) at 20 8C. After two days equilibration, streak seeding with
FimH-CRD/5 co-crystals yielded crystals within 24 h. Crystals with
ligand 2 grew within a few days with (NH4)2SO4 (0.2m), PEG 8000
(19%), and HEPES (pH 7.4, 0.1m) at 20 8C. All crystals were flash-
cooled to 100 K with perfluoropolyether cryo oil (Hampton Re-
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search, USA). Data were collected with synchrotron radiation at the
PXI (ligand 2) or PXIII (ligands 5–7) beamlines of the Swiss Light
Source (Paul Scherrer Institute, Switzerland).
Structure determination and refining : Data were indexed, inte-
grated, and scaled with XDS[47] or iMOSFLM.[48] Structures were
solved by molecular replacement with PHASER[49] with use of the
FimH-CRD–n-butyl a-d-mannopyranoside complex (PDB ID:
1UWF[11a]) as search model. The structures were built by use of the
COOT software[50] and periodically refined with the PHENIX soft-
ware.[51] Geometric restraints for the ligands were generated with
PRODRG[52] or Grade Version 1.1.1.[53] Molprobity[54] was used to vali-
date the available atomic coordinates and to add protons to PDB
files without hydrogens for distance calculation. The structures are
deposited in the Protein Data Bank with PDB codes: 4X50 (2),
4X5Q (5), 4X5R (6), and 4X5P (7).
Isothermal titration calorimetry (ITC): All ITC experiments were
performed with FimH-CRD-Th-His6 and use of a MicroCal VP-ITC in-
strument (Malvern Instruments Ltd, Worcestershire, UK) with
a sample cell volume of 1.4523 mL. Measurements were performed
at 25 8C with a stirring speed of 307 rpm and 10 mcal s¢1 reference
power. The protein was dialyzed against assay buffer [HEPES
(10 mm), NaCl (150 mm), pH 7.4] . Injections of ligand solution (3–
12 mL) were added at 10 min intervals to a sample cell containing
protein (5–50 mm). The c values [c=Mt(0)KD
¢1, where Mt(0) is the in-
itial protein concentration] were in a reliable range between 5 and
1000 for compounds 1, 2, and 6–10. For compounds 3, 4, and 5,
the c values of the direct titrations were above 1000, so additional
competitive ITC experiments were performed.[38] The ligands were
titrated into protein preincubated with an eight- to ninefold excess
of compound 12 (structure and synthesis in the Supporting Infor-
mation), resulting in sigmoidal titration curves. For the low-affinity
compound 11 the c value was only 0.5, but reliable thermodynam-
ics data could be extracted by fixing the stoichiometry to 1.0. Base-
line correction and peak integration was performed with Origin 7
software (OriginLab, USA). Baseline subtraction and curve fitting
with the three variables N (concentration correction factor), KD (dis-
sociation constant), and DH8 (change in enthalpy) were performed
with SEDPHAT version 10.40 (National Institutes of Health).[55]
Global fitting to obtain KD values was performed for the competi-
tive titrations of compound 12 with 3, 4, and 5 and for the direct
titration of 12. The DH8 and N values were then obtained by fitting
of the direct titrations of 3, 4, and 5. For directly titrated com-
pounds 1, 2, and 6–11, all three variables were determined from
a global analysis. The 95% confidence intervals of KD and DH8
were calculated with the 1-dimensional error surface projection.
The DG8 and ¢TDS8 (change in entropy) values were calculated
from Eq. (2)
DG ¼ DH¢TDS ¼ ¢RT InKA ð2Þ
with T being the absolute temperature and R the universal gas
constant (8.314 Jmol¢1K¢1).
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Summary Urinary tract infections (UTIs), which are among the most prevalent bacterial infec-
tions worldwide, are mainly attributed to uropathogenic Escherichia coli (UPEC). Because of
frequent antibiotic treatment, antimicrobial resistance constitutes an increasing therapeutic
problem. Antagonists of the mannose-speciﬁc bacterial lectin FimH, a key protein mediating
the adhesion of UPEC to human bladder cells, would offer an alternative anti-adhesive treat-
ment strategy. In general, FimH antagonists consist of a mannose moiety and a wide range of
lipophilic aglycones. Modiﬁcations of the mannose core led to a distinct drop in afﬁnity. A visual
inspection of the crystal structure of FimH revealed a previously unexplored cavity surrounded
by Ile13, Phe142 and Asp140, which could be reached by functional groups in the equatorial
2-position of the mannose. Here, we describe the synthesis of 2-C-branched mannosides and
evaluation of their pharmacodynamic properties. ITC experiments with the selected antagonists
revealed a drastic enthalpy loss for all 2-C-branched antagonists, which, however, is partially
compensated by an entropy gain. This supports the hypothesis that the target cavity is too small
to accommodate 2-C-substituents.
© 2016 Published by Elsevier G
(http://creativecommons.org/li
Abbreviations: UPEC, uropathogenic Escherichia coli; UTI, urinary
maximal inhibitory concentration; ITC, isothermal titration calorimetry;
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Figure 1 The crystal structure of FimHLD co-crystallized with
n-heptyl -D-mannopyranoside (1, PDB ID: 4BUQ) (Fiege et al.,
2015). A mainly hydrophobic cavity formed by Ile13, Phe142 and
Asp140 is located next to the entrance of the mannose binding
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ntroduction
rinary tract infections (UTIs) are among the most prevalent
acterial infections affecting millions of people (Foxman
t al., 2000). They are mainly associated with uropathogenic
scherichia coli (UPEC) (Roland, 2002). Currently, the
rst-line treatment involves antibiotics (Hooton et al.,
004; Fihn, 2003) which can induce resistance, especially
hen frequently applied (Sanchez et al., 2012). Therefore,
ovel and efﬁcient non-antibiotic approaches are urgently
eeded.
In the ﬁrst step of the infection cycle, UPEC attach to
rothelial cells of the host by means of the bacterial adhesin
alled FimH, which is located at the tip of the approximately
00 bacterial type 1 pili (Mulvey et al., 2000; Schilling et al.,
001). This allows UPEC to evade elimination from the host
rganism by the bulk ﬂow of the urine. FimH is composed of
lectin domain (FimHLD) containing a carbohydrate recog-
ition domain (CRD) and a pilin domain (FimHPD) regulating
he switch between the high and low afﬁnity states of the
RD (Le Trong et al., 2010).
More than thirty years ago, Firon et al. (1982, 1983, 1987)
eported on aryl -D-mannosides abolishing FimH-mediated
ggregation of UPEC with mannan-containing yeast cells
Saccharomyces cerevisiae) in in vitro assays. Over the
ourse of the last few years, a range of highly potent mono-
alent antagonists consisting of a mannose moiety and a
ipophilic aglycone was reported (Bouckaert et al., 2005;
perling et al., 2006; Han et al., 2010; Klein et al., 2010;
usumano et al., 2011; Han et al., 2012; Pang et al., 2012;
iang et al., 2012; Schwardt et al., 2011; Kleeb et al., 2015;
rument et al., 2013; Jarvis et al., 2016; Chalopin et al.,
016). The various aglycones provide hydrophobic contacts
r — stacking interactions to amino acids forming the
ntrance to the mannose binding pocket. This entrance
alled ‘tyrosine gate’ is composed of two tyrosines and one
soleucine. However, the pharmacokinetic properties, e.g.,
olubility and/or permeability, of most of the reported FimH
ntagonists are not suitable for an oral application. For
hysicochemical and pharmacokinetic reasons, the numer-
us reported multivalent FimH antagonists (Lindhorst et al.,
998; Nagahori et al., 2002; Appeldoorn et al., 2005; Patel
nd Lindhorst, 2006; Touaibia et al., 2007; Durka et al.,
011; Bouckaert et al., 2013) are rather suited for the
herapy of E. coli induced colitis ulcerosa, a form of inﬂam-
atory bowel disease (Barnich et al., 2007; Carvalho et al.,
009).
When interacting with FimH, the mannose moiety estab-
ishes a perfect hydrogen bond network (Hung et al., 2002).
ince every hydroxyl group of mannose is part of this
etwork, the removal/replacement of individual various
ydroxyl groups or the replacement of the whole mannose
oiety by other hexoses (e.g., glucose, galactose, fruc-
ose) resulted in a signiﬁcant loss of afﬁnity (Bouckaert
t al., 2005; Han et al., 2010; Old, 1972; Fiege et al.,
015). Moreover, recently reported 1-C-branched mannose
erivatives bearing additional equatorial groups at the
nomeric carbon also showed reduced activity compared to
ethyl -D-mannoside (Gloe et al., 2015). In contrast, when
he anomeric oxygen was replaced by carbon or nitrogen,
y
e
i
p
124ite and can be reached by equatorial substituents in the 2-
osition of the mannose moiety.
anomolar afﬁnity could still be reached (Schwardt et al.,
011; Brument et al., 2013; Chalopin et al., 2016).
A visual inspection of the crystal structure of FimHLD
o-crystallized with n-heptyl -D-mannoside (1, PDB ID:
BUQ) (Fiege et al., 2015) revealed a previously unexplored
ydrophobic cavity formed by Ile13, Phe142 and Asp140,
hich is located close to the entrance to the mannose-
inding pocket (Fig. 1). By extending the 2-position of the
annose moiety with equatorial substituents (→derivatives
a—k, Fig. 2), an interaction with the hydrophobic cavity
hould become possible.
An adaption of the synthetic pathway of previously
eported 2-C-branched mannose derivatives, in which the
-position is modiﬁed at an early stage, lead to rather labori-
us approaches (Mitchell et al., 2007). We therefore planned
more convergent synthesis with a more ﬂexible introduc-
ion of aglycones as well as equatorial substituents in the
-position.
esult and discussion
he synthetic route to 2-C-branched FimH antagonists fulﬁls
wo requirements: The facile introduction of various agly-
ones as well as various equatorial C-substituents in the
-C-position of the mannose moiety.
ynthesis
he synthesis of the 2-C-branched mannoside donor 5 is
epicted in Scheme 1. The 2-C-modiﬁed D-mannofuranose
was synthesized according to a literature procedure
tarting from commercially available D-mannose (Witczak
t al., 1984). Selective benzylation of the hydroxymethyl
roup using dibutyltin oxide (Malleron and David, 1998) fol-
owed by cleavage of the acetonides under acidic conditions
ielded the 2-C-branched D-mannopyranose 4 (Waschke
t al., 2011). For its perbenzoylation with benzoyl chloride
n presence of a catalytic amount of 4-dimethylamino-
yridine (DMAP) in dry pyridine, elevated temperature
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AFigure  2  Modiﬁcations  of  the  mannose  moiety  of  n-heptyl  -D
(110—120 ◦C)  had  to  be  applied.  Subsequently,  the  gly-
cosyl donor  5  was  obtained  by  reaction  with  thiophenol
using BF3·Et2O  as  a  promoter.  To  couple  donor  5  with  1-
heptanol, different  promoters  were  tested.  Whereas  with
NIS/TMSOTf or  NIS/TfOH  donor  5  was  only  partially  con-
sumed after  24  h,  it  reacted  within  minutes  in  the  presence
of commercially  available  p-nitrobenzenesulfenyl  chloride
(p-NO2PhSCl)  accompanied  by  silver  triﬂate  (AgOTf)  (Crich
et al.,  2008).  Apart  from  the  desired  -anomeric  mannoside
6 (32%),  the  2-OH  deprotected  -anomer  7  (32%)  and  the  2-
OH deprotected  -anomer  8  (5%)  were  obtained  as  well.  As
silver triﬂate-mediated  glycosylation  has  been  reported  to
lead to  partial  transesteriﬁcation  affecting  acetyl  groups  at
the 2-O-position,  low  stereoselectivity  of  the  glycosylation
reaction was  not  unexpected  (Ziegler  et  al.,  1990;  Nukada
et al.,  1999;  Murakami  et  al.,  2007).
To  functionalize  the  equatorial  substituent  in  the  2-C-
position, 6  was  debenzylated  by  catalytic  hydrogenolysis  to
afford the  primary  alcohol  9.  However,  attempts  to  mesy-
late its  primary  hydroxyl  group  failed.  Since  we  attributed
the low  reactivity  of  the  hydroxyl  group  in  9  to  steric  hin-
drance, we  switched  to  mannoside  7  with  an  unprotected
axial hydroxyl  group  in  the  2-position.
Indeed,  after  hydrogenolysis  of  7  (→11),  we  were  able
to selectively  mesylate  the  primary  hydroxyl  groups  (→12).
However, displacement  of  the  mesylate  by  ﬂuoride  using  KF
in  aprotic  solvent  in  presence  of  crown  ether  at  elevated
temperature afforded  epoxide  14  instead  of  the  desired  ﬂu-
oride 13.  Under  these  reaction  conditions,  the  strongly  basic
ﬂuoride is  obviously  deprotonating  the  axial  hydroxyl  group
followed by  conversion  of  mesylate  12  into  the  epoxide  14
by an  intramolecular  SN2  mechanism.  With  an  excess  of  LiCl,
epoxide 14  could  be  opened,  leading  to  the  chloride  15  in
41% yield.  By  acting  as  Lewis  acid,  the  large  excess  of  lithium
ions can  facilitate  opening  of  the  epoxide.  Apart  from  the
epoxide route,  substituents  can  be  introduced  directly  by
nucleophilic substitution  (see  Scheme  2).  However,  preva-
lence of  one  mechanism  over  the  other  may  depend  on  the
nucleophile, i.e.,  its  nucleophilicity  and  basicity  as  well  as
temperature and  concentration.
T
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125nnopyranoside  (1)  by  equatorial  substituents  in  the  2-position.
The  synthesis  of  a series  of  2-C-branched  FimH  antago-
ists is  depicted  in  Scheme  2.  Debenzoylation  of  6  under
emplén conditions  (→2b)  followed  by  Pd(OH)2-catalyzed
ydrogenolysis afforded  test  compound  2a.  The  conﬁgura-
ion at  the  anomeric  carbon  of  deprotected  derivative  2a
1JH,C =  169  Hz)  was  unambiguously  conﬁrmed  by  the 13C—1H
oupling constant  of  the  anomeric  nuclei  using  undecoupled
3C  NMR.  In  general,  the  coupling  constant  for  the  equato-
ial anomeric  proton  amounts  to  ∼170  Hz,  while  a  value  of
160 Hz  is  indicative  for  an  anomeric  proton  in  axial  orien-
ation (Bubb,  2003).
Upon  mesylation  of  11,  chloride  was  introduced  using  LiCl
ollowed by  deprotection  of  the  intermediate  with  sodium
ethoxide to  afford  derivative  2d.  Direct  introduction  of
hloride starting  from  mesylate  was  faster  and  gave  a  higher
ield than  the  already  discussed  opening  of  epoxide  14.
ince only  traces  of  epoxide  were  observed  by  TLC  control,
N2  reaction  seems  to  be  the  prevailing  mechanism  in  this
articular case.  However,  more  basic  nucleophiles  may  lead
o different  results.
Using an  identical  synthetic  approach,  iodide  2c,  cyanide
e and  azide  2h  were  obtained  with  NaI,  KCN  and  NaN3
s  nucleophiles.  Hydrogenation  of  iodide  2c,  cyanide  2e
nd azide  2h  in  presence  of  Pd(OH)2 on  carbon  yielded
he methyl  derivative  2f  and  amine  derivatives  2g  and
i, respectively.  In  addition,  when  2h  was  hydrogenated
nd subsequently  acylated  with  acetyl  chloride  or  propionyl
hloride followed  by  deacetylation  under  Zemplén  condi-
ions, amides  2j  and  2k  were  obtained.
To  evaluate  the  -anomeric  derivative  as  well  in
he biological  assay,  -mannoside  8  was  debenzoylated
→16b, Scheme  3)  followed  by  hydrogenolysis  to  yield  16a
1JH,C =  159  Hz).
fﬁnity  and  thermodynamic  proﬁlehe  afﬁnities  of  the  2-C-branched  mannosides  were  deter-
ined in  a  cell-free  competitive  binding  assay  (Table  1)
Rabbani et  al.,  2010).  The  assay  uses  FimHLD-Th-His6
Th:  thrombin  cleavage  site)  as  a  target  protein  and  a
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Scheme  1  (a)  i.  BnBr,  Bu2SnO,  TBAB,  toluene,  120 ◦C  →  80 ◦C,  24  h;  ii.  Amberlyst-15  (H+),  EtOH,  H2O,  50 ◦C,  43  h,  90%;  (b)  i.
BzCl, DMAP,  pyridine,  120 ◦C,  48  h;  ii.  PhSH,  BF3·Et2O,  DCM,  0 ◦C  →  rt,  24  h,  42%;  (c)  1-heptanol,  p-NO2PhSCl,  AgOTf,  DCM,  4Å  MS,
0 ◦C  →  rt,  5  h,  32%  for  6,  32%  for  7,  5%  for  8;  (d)  Pd(OH)2/C,  H2,  EtOH,  AcOH,  rt,  22  h,  86%;  e)  MsCl,  TEA,  DCM,  0 ◦C  →  65 ◦C,  7  h,
0 ◦C  →
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t%; (f)  Pd(OH)2/C,  H2,  EtOH,  rt,  5  h,  93%;  (g)  MsCl,  TEA,  DCM,  0
iCl,  DMF,  90 ◦C,  7  h,  41%.
iotinylated  polyacrylamide  glycopolymer  as  competitor.
onjugation of  biotin  with  streptavidin-horseradish  per-
xidase allows  quantiﬁcation  of  the  bound  polymer  and
herefore the  determination  of  the  IC50.  The  activity  of
ll antagonists  was  measured  twice  in  duplicates.  The
ntagonist n-heptyl  -D-mannopyranoside  (1)  was  used  as
 reference  compound  and  tested  in  parallel  to  ensure  com-
arability. The  afﬁnities  are  referred  to  the  activity  of  1  as
IC50.
In  addition  to  the  competitive  binding  assay,  ITC  exper-
ments were  performed  with  mannosides  1,  2a  and  2f  to
eveal a  thermodynamic  ﬁngerprint  of  mannose-modiﬁed
imH antagonists  (Table  2).  ITC  enables  direct  measurement
f the  dissociation  constant  (KD)  and  the  change  in  enthalpy
H◦),  which  are  further  used  to  calculate  the  changes  in
ree energy  (G◦)  and  entropy  (S◦)  (Chen  and  Wadsö,  1982;
reire et  al.,  1990).
r
s
T
126 rt,  6  h,  86%;  (h)  KF,  Kryptoﬁx  2.2.2,  DMSO,  100 ◦C,  2  h,  85%;  i)
Unfortunately,  all  2-C  modiﬁcations  proved  to  be  detri-
ental to  the  afﬁnity.  Already  the  smallest  substituent,
 methyl  group  (→2f),  resulted  in  a  2.8-fold  higher  IC50
alue.  A comparable  4.1-fold  drop  in  activity  was  observed
n ITC.  This  ﬁnding  might  be  explained  by  an  unexpected
nfavourable steric  clash  of  Ile13  and/or  Phe142  with  the
ethyl group  already  too  big  to  ﬁt  to  the  targeted  cavity.
his hypothesis  is  supported  by  the  considerably  improved
ntropy term  (−TS◦ −17.2  kJ/mol)  compared  to  the  ref-
rence 1,  indicating  an  increased  conformational  ﬂexibility
f the  ligand.  The  resulting  disruption  of  the  hydrogen  bond
etwork within  the  pocket  is  also  reﬂected  by  a  substan-
ial decline  of  enthalpy  (H◦ +20.6  kJ/mol).  A  further
eduction in  afﬁnity  to  the  micromolar  level  for  larger  sub-
tituents, e.g.,  iodomethyl  and  chloromethyl  (→2c  and  2d,
able 1)  is  in  full  agreement  with  this  argumentation.
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Scheme  2  (a)  MeONa/MeOH,  rt,  4  h,  85%;  (b)  Pd(OH)2/C,  H2,  EtOH,  rt,  6  h,  75%;  (c)  i.  MsCl,  TEA,  DCM,  0 ◦C  →  rt,  1.5—6  h;  ii.  NaI,
LiCl, KCN  or  NaN3,  DMF  or  DMSO,  70—100 ◦C,  3—64  h;  iii.  MeONa/MeOH,  rt,  1—6  h,  39%  for  2c,  38%  for  2d,  11%  for  2e,  73%  for  2h;
(d) Pd(OH)2/C,  H2,  EtOH,  TEA,  rt,  44  h,  91%;  (e)  i.  Pd(OH)2/C,  H2,  MeOH  or  EtOH,  rt,  3—11  h;  ii.  0.1%  TFA  or  0.01  M  HCl,  H2O,  MeOH,
Cl  or
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A76% for  2g,  86%  for  2i;  (f)  i.  Pd(OH)2/C,  H2,  EtOH,  rt,  7  h;  ii.  Ac
rt, 1.5—4  h,  20%  for  2j,  38%  for  2k.
Unexpectedly,  the  benzyloxymethyl  group  in  2b,  despite
its bulkiness,  only  slightly  reduced  the  activity  compared  to
the methyl  substituent  (→2f).  Furthermore,  2b  performed
better compared  to  the  halogens  2c  and  2d.  This  may  result
from a  smaller  van  der  Waals  radius  of  oxygen  compared
to chloride  or  iodide.  Moreover,  a  solvent  exposed  phenyl
ring can  be  involved  in  non-speciﬁc  hydrophobic  interactions
with the  surface  of  the  protein,  attenuating  the  negative
effect of  the  size  of  the  2-C-branch.
The  antagonists  bearing  hydrogen  bond  donating  groups,
such as  a  hydroxyl  group  (→2a),  an  amine  (→2i)  or  an
amide (→2j  and  2k),  were  among  the  most  active  deriva-
tives. The  hydroxymethyl  group  (→2a)  led  to  roughly  a
5-fold drop  in  afﬁnity  in  both,  competitive  binding  assay
and ITC.  Compared  to  the  methyl  group  (→2f),  this  sub-
stituent was  expected  to  disrupt  the  hydrogen  bond  network
even further  due  to  its  larger  size  and  to  cause  additional
i
i
a
l
127 CH3CH2COCl,  pyridine,  DCM,  rt,  2.5—5.5  h;  iii.  MeONa/MeOH,
nthalpy  costs  due  to  a desolvation  penalty  related  to  the
ydroxyl group.  However,  the  enthalpy  loss  in  this  case  was
maller (H◦2a—2f =  6.1  kJ/mol)  implying  additional  bene-
cial interactions  formed  by  2a.  As  a  consequence,  the
ntropy gain  was  limited  (−TS◦ −10.4  kJ/mol)  compared
o 2f.  However,  this  beneﬁcial  effect  was  almost  compen-
ated by  a  loss  in  entropy.  Furthermore,  the  structurally
imilar aminomethyl  derivative  2i  was  the  most  active  com-
ound  within  the  series  with  only  2.1-fold  lower  afﬁnity
ompared to  reference  1.  Presumably,  the  hydroxymethyl
→2a) and  aminomethyl  (→2i)  groups  are  involved  in  elec-
rostatic interactions  with  a  hydrogen  bond  acceptor,  i.e.,
sp140 or  the  backbone  amide  of  Ile13.  The  improved  afﬁn-
ty of  2i  may  result  from  the  fact  that  the  ammonium  group
n 2i  can  form  a  slightly  stronger  interaction  (Lopes  Jesus
nd Redinha,  2011).  Finally,  when  we  incorporated  a  longer
inker between  the  nitrogen  and  the  sugar  moiety  (→2g)
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Scheme  3  (a)  MeONa/MeOH,  rt,  2  h,  68%;  (b)  Pd(OH)2/C,  H2,  EtOH,  rt,  3  h,  93%.
Table  1  Afﬁnity  of  FimH  antagonists.  The  rIC50 values  were  calculated  by  dividing  the  IC50 of  the  compound  of  interest  by  the
IC50 of  the  reference  compound  n-heptyl  -D-mannopyranoside  (1).  rIC50 values  below  1.0  are  obtained  for  antagonists  more
active  than  reference  compound  1,  whereas  rIC50 above  1.0  are  obtained  for  antagonists  less  active  than  reference  compound
1.
Entry  Compound  R  IC50 [nM]  rIC50
1  1
O
OH
OH
HO
HO
O
48.9—65.2  1
O
OH
OH
HO
HO
OR
2  2a  OH  311.0  4.9
3 2b O 340.9  5.4
4 2c  l  >2000  38.9
5  2d  Cl  >2000  304
6  2e  CN  522.3  9.7
7 2f  H  181.2  2.8
8 2g  CH2NH2·HCl  >2000  37.1
9  2h  N3 437.0  6.9
10 2i  NH2·CF3COOH  135.0  2.1
11 2j
H
N CH3
O
182.5  3.4
12 2k
H
N CH2CH 3
O
295.2  5.5
O
OH
OH
HO
HO
R
O
13  16a  OH  446.4  7.0
14 16b O 4400  69.4
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Table  2  Thermodynamic  proﬁle  of  FimH  antagonists  in  binding  to  FimHLD-Th-His6 at  25 ◦C  and  pH  7.4.
Entry  Compound  R  KD [nM]  G◦ [kJ/mol]  H◦ [kJ/mol]  −TS◦ [kJ/mol]
 
O
OH
OH
HO
HO
O
1  1  28.9  −43.0  −50.3  7.3
O
OH
OH
HO
HO
OR
2  2f  H  118.6  −39.5  −29.7  −9.9
−
t
t
h
d
d
t
A
F
F
A
S
c
h
R
A
B
B3  2a  OH  154.0  
the  afﬁnity  was  lowered  to  the  micromolar  level.  Similarly
to the  aminomethyl  derivative  2i,  the  amide  2j  had  one  of
the best  afﬁnities  in  the  series.  However,  elongation  of  the
aliphatic chain  attached  to  the  amide  (→2k)  again  resulted
in reduction  of  potency.
Quite surprisingly,  the  -anomeric  derivative  16a
(Table 1,  entry  13)  performed  only  slightly  worse  than  its  -
anomeric analogue  2a.  However,  when  a  benzyloxymethyl
group was  introduced  (→16b,  entry  14)  the  afﬁnity  was
almost 13-fold  lower  than  for  its  -anomeric  counterpart
2b, according  to  docking  studies  (data  not  shown)  due  to  a
steric clash  with  Ile13.
Conclusions
A  new  family  of  mannose-based  FimH  antagonists  equipped
with equatorial  substituents  at  the  2-position  of  the  sugar
moiety was  designed  and  synthesized  to  target  a  cavity
located close  to  the  entrance  of  FimH-CRD.  Only  when  the
axial 2-hydroxyl  group  was  unprotected  (→11),  the  other-
wise unsuccessful  substitution  at  the  equatorial  2-position
of the  mannose  moiety  could  be  performed,  leading  to  the
test compounds  2c—k.  In  one  case,  the  intermediate  epox-
ide 14  could  be  isolated,  indicating  two  possible  reaction
pathways; one  via  direct  SN2-substitution  and  one  via  the
epoxide 14.  The  resulting  epoxide  intermediate  could  be
opened, however,  affording  only  a  moderate  yield.
The  activities  of  the  2-C-branched  FimH  antagonists
were evaluated  in  a  cell-free  competitive  binding  assay
and compared  to  the  reference  compound  n-heptyl  -D-
mannopyranoside (1).  None  of  the  modiﬁcations  proved
to be  advantageous  for  binding  to  FimH-CRD.  The  loss
of afﬁnity  is  probably  related  to  steric  hindrance  as  it
was already  observed  upon  introduction  of  the  smallest
substituent, a  methyl  group  (→2f).  With  hydrogen  bond
donating substituents  (→2a,  2i—k),  afﬁnity  could  be  par-
tially regained.  Unexpectedly,  the  -anomer  16a  performed
only slightly  worse  than  its  -anomeric  counterpart  2a.
However, as  already  experienced  in  the  -series,  a  larger
benzyloxymethyl substituent  (→16b)  severely  compromised
afﬁnity.
Finally, ITC  experiments  with  the  selected  antago-
nists 1,  2a  and  2f  revealed  a  drastic  enthalpy  loss  for
B
12938.9  −35.8  −3.1
he  2-C-branched  antagonists,  which,  however,  is  par-
ially compensated  by  an  entropy  gain.  This  supports  the
ypothesis that  the  target  cavity  is  too  small  to  accommo-
ate 2-C-substituents.  However,  with  larger,  hydrogen  bond
onating  substituents  the  enthalpy  loss  could  be  substan-
ially reduced.
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ABSTRACT: Urinary tract infections (UTIs), predominantly caused by
uropathogenic Escherichia coli (UPEC), belong to the most prevalent infectious
diseases worldwide. The attachment of UPEC to host cells is mediated by FimH, a
mannose-binding adhesin at the tip of bacterial type 1 pili. To date, UTIs are mainly
treated with antibiotics, leading to the ubiquitous problem of increasing resistance
against most of the currently available antimicrobials. Therefore, new treatment
strategies are urgently needed. Here, we describe the development of an orally
available FimH antagonist. Starting from the carboxylate substituted biphenyl α-D-
mannoside 9, aﬃnity and the relevant pharmacokinetic parameters (solubility,
permeability, renal excretion) were substantially improved by a bioisosteric
approach. With 3′-chloro-4′-(α-D-mannopyranosyloxy)biphenyl-4-carbonitrile
(10j) a FimH antagonist with an optimal in vitro PK/PD proﬁle was identiﬁed.
Orally applied, 10j was eﬀective in a mouse model of UTI by reducing the bacterial
load in the bladder by about 1000-fold.
■ INTRODUCTION
Urinary tract infection (UTI) is one of the most frequent
infectious diseases worldwide and aﬀects millions of people every
year.1 In more than 70% of the reported cases, uropathogenic
Escherichia coli (UPEC) is the causal pathogen.2 Acute,
uncomplicated lower urinary tract infection, commonly referred
to as cystitis, requires an antibiotic treatment for symptom relief
(i.e., reduction of dysuria, frequent and urgent urination,
bacteriuria, pyuria) and for prevention of more devastating or
even life threatening complications like pyelonephritis and
urosepsis.3,4 However, the repeated use of antibacterial chemo-
therapeutics provokes antimicrobial resistance leading to treat-
ment failure.5 Hence, a new approach for the prevention and
treatment of UTI with orally applicable therapeutics is urgently
needed.6
UPEC undergo a well-deﬁned infection cycle within the host.7
The key step in pathogenesis is bacterial adhesion to the
epithelial cells in the lower urinary tract.8 This interaction
prevents UPEC from clearance by the bulk ﬂow of urine and
enables the bacteria to colonize the epithelial cells. The adhesion
is mediated by the virulence factor FimH located at the tip of
bacterial type 1 pili.9,10 FimH consists of two immunoglobulin-
like domains: the N-terminal lectin domain and (connected by a
short linker) the C-terminal pilin domain.11 The lectin domain
encloses the carbohydrate recognition domain (CRD) that binds
to the oligomannosides of the glycoprotein uroplakin Ia on the
epithelial cell surface.12 The pilin domain anchors the adhesin to
the pilus and regulates the switch between two conformational
states of the CRD with high and low aﬃnity for mannosides,
respectively.
More than 3 decades ago, Sharon and co-workers described
various oligomannosides and aryl α-D-mannosides as potential
antagonists of the FimH-mediated bacterial adhesion.13,14
However, only weak interactions in the milli- to micromolar
range were observed. In recent years, several high-aﬃnity
monovalent mannose-based FimH antagonists with various
aglycones like n-alkyl,15 phenyl,16 dioxocyclobutenyl-
aminophenyl,17 umbelliferyl,16 biphenyl,18−22 indol(in)-
ylphenyl,23 triazolyl,24 and thiazolylamino25 have been reported.
In addition, diﬀerent multivalent presentations of the mannose
have been synthesized26−32 and a heptavalent presentation of n-
heptyl α-D-mannoside (1) tethered to β-cyclodextin proved to be
highly eﬀective when applied together with the UTI89 bacterial
strain through a catheter into the bladder of C3H/HeN mice.32
Importantly, adverse side eﬀects resulting from nonselective
binding of FimH antagonists (they are all α-D-mannopyrano-
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sides) to mannose receptors of the human host system have
recently been ruled out.33
The high aﬃnities of the monovalent α-D-mannopyranosides
are based on optimal interactions with the main structural
features of the CRD:34−37 ﬁrst, the mannose binding pocket
accommodating the mannose moiety by means of an extended
hydrogen bond network and, second, the entrance to the binding
site composed of three hydrophobic amino acids (Tyr48,
Tyr137, and Ile52) and therefore referred to as “tyrosine gate”
hosting aliphatic and aromatic aglycones. As an example, n-heptyl
α-D-mannopyranoside (1) exhibits nanomolar aﬃnity due to
hydrophobic contacts of the alkyl aglycone with the hydrophobic
residues of the tyrosine gate.15 Furthermore, aromatic aglycones,
such as present in mannosides 2 and 3 (Figure 1), provide strong
π−π stacking interactions with the tyrosine gate. This interaction
is further favored by the addition of an electron withdrawing
substituent on the terminal ring of the biaryl portion (→4).18,19
Recent in vivo PK studies in mice proved the high potential of
the biphenyl α-D-mannosides 5−8 for an oral treatment,
although high doses (≥50 mg/kg) were necessary to achieve
theminimal concentrations required for the antiadhesive eﬀect in
the urinary bladder.19−21 Moreover, the therapeutic eﬀect could
only be maintained for a few hours, i.e., 4 h for a po (per os)
single-dose application of 7 (50 mg/kg), because of rapid
elimination by glomerular ﬁltration and low reabsorption from
the primary urine in the renal tubules.20
To date, the physicochemical properties aﬀecting the rate of
renal excretion, i.e., lipophilicity and plasma protein binding
(PPB), or metabolic liabilities promoting nonrenal elimination
pathways have been barely investigated for FimH antagonists.
The goal of the present study was to optimize the biphenyl α-D-
mannoside with respect to oral bioavailability and renal
excretion. Starting from antagonist 919 (Figure 2), we
synthesized new biphenyl derivatives, characterized their aﬃnity
to the CRD, structurally investigated their binding mode, and
determined physicochemical and pharmacokinetic parameters
predictive for intestinal absorption and renal elimination.
Furthermore, we determined in vivo PK (pharmacokinetics) of
the most promising new antagonists in a mouse model. After oral
administration, the compound with the best PK proﬁle proved
eﬀective in reducing the bacterial loads upon bladder infection in
a mouse model of UTI.
■ RESULTS AND DISCUSSION
As previously reported, the carboxylate substituent present in the
biphenyl mannoside 9 (its electron withdrawing potential being
essential for an enhanced drug target interaction) strongly
decreases the lipophilicity of the antagonist (log D7.4 < −1.5 19)
in comparison to the n-heptyl (→1, log P = 1.7 19) or the
unsubstituted biphenyl aglycone (→3, log P = 2.1 22). Since low
lipophilicity is a major reason for low intestinal absorption and
rapid renal excretion of the systemically available antagonist,19,23
we aspired to improve oral bioavailability as well as renal
excretion by replacing the carboxylate in 9 with various
bioisosteric groups39 (Figure 2).
Synthesis. Iodide 11 was prepared from peracetylated
mannose and 4-iodophenol in the presence of BF3·Et2O.
22 In a
palladium-catalyzed Miyaura−Suzuki coupling40 with the
boronic acid or boronate derivatives 12a−g, the biphenyl
derivatives 13a−g were obtained in good to excellent yields.
Final deprotection yielded the test compounds 10a−g. When
microwave-assisted reaction conditions41 were utilized, the
conversion of arylnitrile 13g to tetrazole 14 proceeded rapidly
and with good yield. After deprotection of 14 using Zempleń
conditions, the test compound 10h was obtained (Scheme 1).
The cyanobenzamide derivative 10i (Scheme 2) was obtained
from 9 by peracetylation (→15) followed by conversion of the
Figure 1. Monovalent FimH antagonists 1−4 acting as reference compounds and 5−8 which have been orally explored in in vivo disease models.
Figure 2. Bioisosteric replacement of the carboxylic acid substituent of
biphenyl α-D-mannopyranoside 9.
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carboxylic acid into its acid chloride with 1-chloro-N,N,2-
trimethyl-1-propenylamine.42 Without isolation, the acid
chloride was reacted with sodium hydrogen cyanamide in
DMF followed by deacetylation under Zempleń conditions to
yield the test compound 10i.
Finally, to further improve the pharmacokinetic properties of
mannoside 10g18 (see Table 3), a chloride substituent was
introduced to the ortho-position of the aromatic ring adjacent to
the anomeric oxygen. For its synthesis, peracetylated α-D-
mannose (16) was coupled with 2-chloro-4-iodophenol (17)
using BF3·Et2O as promotor (→18, 76%). After the introduction
of the second aromatic ring by Miyaura−Suzuki coupling (→19,
75%), deprotection yielded mannoside 10j (Scheme 3).
Binding Aﬃnity.The binding aﬃnity of heptyl mannoside 1,
the biphenyl mannosides 3, 9, 20,18 and the bioisosteres 10a−j
was determined in a competitive ﬂuorescence polarization assay
(FP assay) and with isothermal titration calorimetry (ITC). A
protein construct consisting of the CRD with a C-terminal His-
tag with a thrombin cleavage site (FimH-CRD-Th-His6) was
used for all experiments.43
Competitive Fluorescence Polarization Assay. For the
rapid evaluation of binding aﬃnity, we established a competitive
Scheme 1a
a(a) Pd(Cl2)dppf·CH2Cl2, K3PO4, DMF, 80 °C, 4 h (13a−g, 44−99%); (b) NaOMe, MeOH, rt, 4 h (10a−h, 29−86%); (c) TMSN3, Bu2Sn(O),
DME, 150 °C, microwave, 10 min (81%).
Scheme 2a
a(a) (i) Ac2O, DMAP, pyridine, 0 °C to rt, overnight; (ii) sat. NaHCO3 aq, DCM, rt, 2 h (15, 53%); (b) 1-chloro-N,N,2-trimethyl-1-propenylamine,
toluene, 0 °C to rt, 2 h; (c) NaH, NH2CN, DMF, 0 °C to rt, overnight; (d) NaOMe, MeOH, rt, 4 h (10i, 21% for three steps).
Scheme 3a
a(a) BF3·Et2O, CH2Cl2, 40 °C (76%); (b) Pd(Cl2)dppf·CH2Cl2, K3PO4, DMF, 80 °C (75%); (c) NaOMe, MeOH, rt, 4 h (48%).
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binding assay based on ﬂuorescence polarization (FP). Similar
formats have been applied before for the detection of
carbohydrate−lectin interactions.18,44 In this assay, the antago-
nist of interest displaces a ﬂuorescently labeled competitor from
the binding site, thereby causing a reduction in ﬂuorescence
polarization.45 To identify the optimal competitor, ﬂuorescein
isothiocyanate (FITC) was connected to the FimH ligand 21 by
three linkers of diﬀerent lengths (→22−24, Scheme 4). For
Scheme 4a
a(a) 1-[(1-(Cyano-2-ethoxy-2-oxoethylideneaminooxy)dimethylaminomorpholinomethylene)]methanaminium hexaﬂuorophosphate (COMU),
NEt3, ﬂuoresceinamine, DMF, rt, 7 h (22, 19%); b) (i) DIC, NHS, N-Boc-ethylenediamine, DMF, rt, 12 h; (ii) TFA, DCM, rt, 10 min (68%
over two steps), (iii) ﬂuorescein isothiocyanate (FITC), NEt3, DMF, rt, 3 h (23, 48%); (c) (i) DIC, NHS, N-Boc-PEG2-NH2, DMF, rt, 14 h; (ii)
TFA, DCM, rt, 30 min (62% over two steps); (iii) FITC, DMF, rt (24, 65%).
Figure 3. (A) Direct binding curve of the labeled competitor 23 obtained by adding a linear dilution of FimH-CRD (0−100 nM) and a constant
concentration of competitor 23 (5 nM). The KD was determined by ﬁtting the experimental data to a single-site binding ﬁt that accounts for ligand
depletion. In three FP based direct binding experiments the KD of competitor 23 was determined to be 1.7 nM. (B) Inhibition curve of n-heptyl
mannoside (1) from the competitive FP assay. The IC50 value was determined by nonlinear least-squares ﬁtting to a standard four-parameter equation. A
modiﬁed Cheng−Prusoﬀ equation45 was used to calculate the corresponding KD value (KD = 28.3 nM).
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optimal sensitivity and signal-to-noise ratio, three main
parameters need to be considered: (i) the aﬃnity of the
competitor should not be impaired by the ﬂuorescent label; (ii)
the conformational ﬂexibility of the label upon binding of the
competitor to the CRD should be low; (iii) the ﬂuorescence
properties of the label should not be aﬀected by the connected
ligand.46−48 A change in ﬂuorescence properties was observed for
reporter ligand 22 in which the label was linked to the biphenyl
agylcone by an amide bond. The absorption spectrum revealed a
lack of the characteristic ﬂuorescein absorption peak at 494 nm
(Scheme 4), likely due to an extension of the conjugated system
to the biphenyl moiety of the ligand. The elongated saturated
spacer groups in competitors 23 and 24 ensured that the
expected spectral properties of the dye were retained (Scheme
4).
For the determination of their binding aﬃnity, ﬁxed
concentrations of the reporter ligands 23 and 24 were incubated
for 24 h with a linear dilution of the FimH-CRD (0−100 nM). FP
was measured using a plate reader, with polarized excitation at
485 nm and emission at 528 nmmeasured through appropriately
oriented polarizers. Fitting the single-site binding function of
Cooper49 to the observed FP data resulted for compound 23 in a
dissociation constant (KD = 1.7 nM, Figure 3A) similar to that of
the unlabeled parent compound 21,19 whereas 24 showed a 5-
fold lower aﬃnity (9.9 nM) (Scheme 4). Therefore, the reporter
ligand 23 fulﬁlls all characteristics as an optimal competitor and
was used for the FP assay.
For the test compounds 1, 3, 9, 20, and 10a−j, a 24 h
incubation time was applied before FP was measured because of
the long residence time of FimH antagonists (t1/2 > 3.5 h, Figure
3B50). The 24 h incubation period was empirically determined to
be necessary to reach equilibrium between reporter ligand and
compound of interest. IC50 values were obtained by nonlinear
least-squares regression (standard four-parameter dose−re-
sponse curve) and converted to KD values using a modiﬁed
Cheng−Prusoﬀ equation.45 This equation accounts for the
ligand depletion eﬀect in competitive titrations involving high-
aﬃnity interaction partners present in similar concentrations.
Under these conditions, the free concentration of an interacting
species cannot be assumed to equal the total concentration.
The KD values determined for the test compounds 1, 3, 9, 20,
and 10a−j are summarized in Table 1. Against our expectations,
the biphenyl mannosides 3 and 9 exhibit similar aﬃnities (Table
1), despite the presence of an electron withdrawing carboxylate
substituent in antagonist 9. According to the crystal structure of
FimH cocrystallized with the sulfonamide derivative 10e (Figure
4A), the outer aromatic ring of the biphenyl aglycone forms π−π
interactions with the electron rich Tyr48, which is part of the
tyrosine gate of FimH.15 A reduction of electron density of the
aglycone by the electron withdrawing carboxylate was expected
to enforce these π−π stacking interactions and lead to improved
aﬃnity. However, this beneﬁcial eﬀect might be compensated by
an entropic penalty originating from the improved π−π stacking
to Tyr48 that might lead to the reduced ﬂexibility of both protein
and antagonist. Furthermore, a beneﬁcial enthalpy eﬀect might
be partially compensated by an enthalpy penalty originating from
the desolvation of the charged carboxylate in 951 (see also
Experimental Section). Although this substituent is solvent
exposed, at least a partial desolvation may be necessary upon
antagonist binding. To prove this assumption, we replaced the
carboxylate by the corresponding methyl ester (→20)18 in order
to reduce the desolvation penalty and, as predicted by the
Hammett constant σp,
52 to further improve the π−π stacking.
Table 1. Aﬃnities (KD) of FimH Antagonists to FimH-CRD-
Th-His6
b
aThe KD value of 10j was approximated to be in the subnanomolar
range. The IC50 value obtained in the competitive FP assay was equal
to the lowest value that can be resolved by the assay, indicating
stoichiometric titration of 10j due to its high aﬃnity. Consequently, its
KD must be below the KD of competitor 23.
bDissociation constants
(KD) were determined in a competitive ﬂuorescence polarization assay.
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Indeed, a 6-fold improvement in aﬃnity was achieved. However,
since the methyl ester undergoes rapid enzyme-mediated
hydrolysis in vivo,19 it will not be available at the place of action
in the urinary bladder. The methyl ester was therefore replaced
by metabolically stable bioisosteres39 exhibiting comparable
electron withdrawing properties52 (Table 1, entries 5−13). The
most potent derivatives 10d, 10e, and 10g showed aﬃnities in
the low nanomolar range.
As previously reported,22 a chloro substituent in the ortho-
position of the aromatic ring adjacent to the anomeric oxygen is
favorable for aﬃnity and improves the physicochemical proper-
ties relevant for oral bioavailability. Indeed, the corresponding
antagonist 10j was the most potent compound tested in this
study.
Isothermal Titration Calorimetry (ITC). To further
conﬁrm our hypothesis regarding π−π stacking and desolvation,
we performed ITC experiments with the reference compound 1,
the unsubstituted biphenyl mannoside 3, the carboxylic acid 9,
and the bioisosteres 10b−e,g,j (Table 2). ITC allows the
simultaneous determination of the stoichiometry (N), the
change in enthalpy (ΔH) and the dissociation constant (KD)
for ligand−protein binding.53,54 The reliable determination of
these three parameters requires well-deﬁned sigmoidal titration
curves characterized by the dimensionless Wiseman parameter c
(c = Mt(0) KD
−1, where Mt(0) is the initial macromolecule
concentration).55 To be sure that data can be ﬁtted with
conﬁdence, the c-value should be between 1 and 1000 (ideally
between 5 and 500),56 which could be achieved for the
antagonists 3 and 9. For titrations involving low micromolar
Mt(0) and interactions in the low nanomolar or picomolar range,
as suggested for the bioisosteres 10b−j, c-values above 1000 were
expected. Since these conditions lead to steep titration curves
that do not allow the determination of the curve slope
representing 1/KD, we applied an alternative, competitive format
referred to as displacement assay.57,58 First, FimH-CRD-Th-His6
was preincubated with the low aﬃnity antagonist n-heptyl 2-
deoxy-α-D-mannopyranoside (25, for synthesis see Supporting
Information). The high-aﬃnity bioisosteres of interest were
titrated into the protein−ligand complex giving well-deﬁned
sigmoidal titration curves.
The resulting KD values (Table 2) correspond well with the
data obtained from the FP assay (Table 1). A comparison of the
thermodynamic ﬁngerprints of antagonists 3 and 9 reveals that
the more favorable enthalpic contribution resulting from
facilitated π−π stacking leads to a net enthalpy gain (ΔΔH =
−3.7 kJ/mol). However, an even greater increase in enthalpy is
likely countered by the enthalpy costs for desolvation of the
electron withdrawing carboxylate.
The gain in enthalpy is in turn compensated by an unfavorable
entropy (−TΔΔS = 3.2 kJ/mol) as a result of the reduced
ﬂexibility of both the antagonist and the Tyr48 side chain caused
by the improved interaction. This is not entirely outweighed by
the beneﬁcial entropy contribution related to the partial
desolvation of the carboxylate and the related release of water
into the bulk. Added together, the enthalpy and entropy
contributions of antagonists 3 and 9 result in similar aﬃnities
(KD of 17.7 and 15.0 nM, respectively).
In contrast, the replacement of the carboxylate group by
various neutral bioisosteres (entries 4−7) reduces the enthalpy
costs for desolvation (see calculated free energies of desolvation,
Experimental Section) and therefore leads to a markedly
improved enthalpy (ΔΔH from −3.5 to −5.8 kJ/mol). As a
result, an up to 5-fold improvement of the KD values was
achieved. Finally, with a cyano substituent (entries 8 and 9), the
enthalpy term was further improved (ΔΔH = −3.7 kJ/mol)
because of a reduced desolvation penalty and improved π−π
stacking interactions. However, this beneﬁcial component is
again partially compensated by a decrease in entropy. This can be
attributed, ﬁrst, to the loss of ﬂexibility of the tightly bound ligand
(Figure 4B) and, second, to the smaller surface area of the cyano
substituent compared to amide, sulfonamide, and sulfone, which
results in a smaller number of water molecules being released to
bulk upon binding.
X-ray Crystallography. To determine the binding poses of
the bioisosters, we cocrystallized the compounds 10e and 10j
with the FimH-CRD (Figure 4). Atomic resolution crystal
structures were obtained at 1.07 Å (10e) and 1.10 Å (10j). As
observed in previous mannoside cocrystal structures,15,18,36 the
mannose moiety forms an extensive hydrogen bond network to
the well-deﬁned binding site with all of its hydroxyl groups. The
biphenyl aglycone is located between the tyrosine gate residues
(Tyr48/Tyr137). The π−π stacking of the second aromatic ring
of the aglycone to the side chain of Tyr48 contributes most to the
interaction energy of the aglycone moiety. Interactions to the
Tyr137 side chain on the other hand are only limited. Whereas a
previously published crystal structure of a biphenyl mannoside in
complex with FimH-CRD suﬀers from crystal contacts of
binding site residues (Tyr48 side chain to backbone oxygen of
Val27) possibly causing the distortion of the binding site,18 the
binding sites of our structures are mostly solvent exposed. This
Figure 4. Ligand binding poses determined by X-ray cocrystallization with compounds 10e resolved to 1.07 Å (A) and 10j resolved to 1.10 Å (B). The
electron density surrounding the aglycone of 10e indicates ﬂexibility of the aglycone and was modeled in two poses. Both compounds bind in a similar
pose with a well-deﬁned hydrogen network surrounding the mannose moiety and π−π stacking interactions between the second aromatic ring and
Tyr48 side chain (A). In contrast, in the FimH-CRD/10j structure the amino acid side chain of Y48 can be modeled in two distinct rotamers, suggesting
ﬂexibility also of the receptor (B).
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revealed the ﬂexibility of the aglycone in the FimH-CRD/10e
structure, since the electron density toward the solvent-exposed
sulfonamide indicates that there is not one single orientation.
Therefore, the aglycone was modeled in two distinct poses. In
contrast, in the FimH-CRD/10j structure the amino acid side
chain of Y48 can be modeled in two distinct rotamers, suggesting
ﬂexibility also of the receptor.
Physicochemical Properties and in Vitro Pharmacoki-
netics. Intestinal absorption and renal excretion are prereq-
uisites for a successful oral treatment of UTI with FimH
antagonists. Furthermore, reabsorption of antagonist from the
renal ultraﬁltrate is desirable for maintaining the minimal
antiadhesive concentration in the target organ, namely, the
bladder, over an extended period of time. To estimate the
inﬂuence of the bioisostere approach on oral bioavailability and
the rate of renal excretion, we determined lipophilicity by means
of the octanol−water distribution coeﬃcient (log D7.4),59
aqueous solubility, and membrane permeability in the artiﬁcial
membrane permeability assay (PAMPA)60 and the colorectal
adenocarcinoma (Caco-2) cell monolayer model.61
Table 2. Thermodynamic Parameters from ITC for Selected FimH Antagonists Binding to FimH-CRD-Th-His6
d
a95% conﬁdence interval from ﬁtting in parentheses. bGlobal ﬁt including two direct titration measurements. cITC data were previously published
with an n-value of 0.82.37 dn, stoichiometric correction factor.
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Oral Bioavailability. Oral bioavailability of a compound
relies on solubility, permeation through the membranes lining
the intestine, and stability against ﬁrst pass metabolism.64,65 As
discussed by Lipinski66 and Curatolo,67 dose and permeability
deﬁne the minimum aqueous solubility required for oral
administration. Thus, a dose of 1 mg/kg of a moderately
permeable compound requires a solubility of at least 52 μg/mL.
Whereas suﬃcient aqueous solubility (>3000 μg/mL) was
reported for n-heptyl α-mannopyranoside (1),19 the unsub-
stituted biphenyl α-D-mannopyranoside 3 and the antagonists
bearing a methylcarboxylate, carboxamide, or tetrazole sub-
stituent (compounds 20, 10a, and 10h) were found to be scarcely
soluble.22 As proposed by Ishikawa,68 a possible reason is the
apolar and planar aglycone. By contrast, the polar carboxylic acid
moiety present in antagonist 9 or the substituents in the
bioisosteres 10b−j enhance solubility to 122−273 μg/mL, a level
suﬃcient for in vivo PK studies. For in vivo disease studies,
however, dosages of up to 10 mg/kg were foreseen (see below),
requiring a solubility of 520 μg/mL.66,67 For this reason,
surfactant Tween 80 (1%) had to be added.
Furthermore, permeability data derived from PAMPA69 and
the Caco-2 model70 suggest moderate to high permeation of the
moderately lipophilic antagonists 1, 3, and 20 (logD7.4 > 1.6)
through the intestinal membranes. The bioisosteres 10a−f,h,i,
although slightly more permeable than the strongly hydrophilic
carboxylic acid derivative 9, show only low values of permeability
compared to n-heptyl α-D-mannopyranoside (1) or the
unsubstituted biphenyl mannoside 3. However, the p-cyanobi-
phenyl derivatives 10g and 10j display elevated log D7.4 and
eﬀective permeability (log Pe) in the range for successful
intestinal absorption. Regarding both suﬃcient aqueous
solubility and elevated membrane permeability, the p-cyano
substituted bioisosteres 10g and 10j are thus the most promising
candidates for oral absorption. Moreover, combining the
bioisosteric replacement with the addition of a chloro substituent
in the ortho-position of the aromatic ring adjacent to the
anomeric oxygen (→10j)22 resulted in the most advantageous
physicochemical proﬁle for oral bioavailability.
Renal Excretion. The rate of renal excretion depends on the
rate of glomerular ﬁltration and the propensity to tubular
secretion and reabsorption of an antagonist.71 Only the fraction
that is not bound to plasma proteins is expected to enter the
glomerular ﬁltrate.72 Plasma protein binding (PPB) data
indicating the fraction bound ( f b) are listed in Table 2.
62 The
biphenyls 9 and 10c were identiﬁed as moderate binders to
plasma proteins ( f b≤ 65%), which suggests a low impact of PPB
on antagonist ﬁltration. The fb values of the antagonists 1, 3, 20,
and 10j were between 80% and 93%, whereas the bioisosteres
10d,e,g showed particularly high protein binding ( f b ≥ 99%)
implying slow compound entry into the primary urine. However,
the kinetic aspects of PPB, that is, association and dissociation
rate constants, remain to be determined to quantify precisely the
inﬂuence of PPB on ﬁltration.73
Furthermore, log D7.4 was identiﬁed as key determinant of
tubular reabsorption.74−76 Accordingly, lipophilic compounds
are predominantly reabsorbed from the renal ﬁltrate. Given that
renal clearance is the major route of elimination, this will result in
a slow but steady excretion into the bladder. In contrast,
hydrophilic compounds are poorly reabsorbed and thus quickly
renally eliminated, which leads to high initial compound levels in
the urine but narrows the time range where the minimal
antiadhesive concentration is maintained. Consequently, low
log D7.4 as shown for the antagonists 9, 10h, and 10i implies low
tubular reabsorption and rapid elimination of the ﬁltered
molecules by the urine. Otherwise, log D7.4 between 0.2 and
0.7, such as determined for the bioisosteres 10a-e, suggests
Table 3. Physicochemical and in Vitro Pharmacokinetic Parametersh
Caco-2 Papp [10
−6 cm/s]e
compd pKa
a log D7.4
b
solubility
[μg/mL]/pHc
PAMPA log Pe
[cm/s]/pHd a→ b b→ a
PPB f b
[%]f
metabolic stability t1/2
[min]g
1 1.65 >3000 −4.89 7.0 ± 0.6 9.4 ± 0.2 81 13
3 2.1 ± 0.1 21 ± 1/7.4 −4.7 ± 0.1/7.4 10.0 ± 0.9 19.0 ± 1.2 93 ± 1 nd
20 2.14 33.8/6.51 −4.7 4.23 nd 93 1.0
9 3.88 <−1.5 >3000/6.61 no permeation nd nd 73 >60
10a 0.5 ± 0.1 12 ± 1/7.4 −6.8 ± 0.3/7.4 0.12 ± 0.01 0.61 ± 0.03 nd nd
10b 0.8 ± 0.0 122 ± 13/7.4 −9.2 ± 1.4/7.4 1.10 ± 0.82 0.87 ± 0.15 nd nd
10c 0.2 ± 0.1 >250/7.4 −7.8 ± 0.3/7.4 0.18 ± 0.07 1.30 ± 0.03 48 ± 2 >60
10d 0.4 ± 0.0 246 ± 17/7.4 −7.2 ± 0.0/7.4 0.36 ± 0.01 1.76 ± 0.12 99 ± 1 >60
10e 0.7 ± 0.1 >250/7.4 −8.6 ± 0.2/7.4 0.28 ± 0.23 1.82 ± 0.14 >99 >60
10f 6.5 1.1 ± 0.0 >150/3.0 −7.7 ± 0.8/5.0 0.40 ± 0.02 1.90 ± 0.17 nd nd
>150/7.4 −8.8 ± 0.1/7.4
10g 1.4 ± 0.0 186 ± 4/7.6 −5.7 ± 0.0/7.4 2.0 ± 0.1 13.2 ± 2.1 99 ± 0 >60
10h 3.7 −1.4 ± 0.1 11 ± 0/3.0 −9.3 ± 1.4/5.0 0.17 ± 0.00 0.22 ± 0.01 nd nd
273 ± 2/7.4 −8.8 ± 1.4/7.4
10i 2.5 −1.1 ± 0.1 >150/3.0 −6.8 ± 0.2/5.0 0.22 ± 0.14 0.29 ± 0.03 nd nd
>150/7.4 −7.0 ± 0.1/7.4
10j 2.1 ± 0.0 192 ± 5/7.4 −5.2 ± 0.0/7.4 2.2 ± 0.4 22.1 ± 1.5 89 ± 1 >60
apKa values were determined by NMR spectroscopy.
bOctanol−water distribution coeﬃcients (log D7.4) were determined by a miniaturized shake-
ﬂask procedure at pH 7.4. Values represent the mean ± SD of sextuplicate measurements.59 cKinetic solubility was measured in a 96-well format
using the μSOL Explorer solubility analyzer at the indicated pH in triplicate. dPe = eﬀective permeability. Passive permeation through an artiﬁcial
membrane was determined by the parallel artiﬁcial membrane permeation assay (PAMPA). Values represent the mean ± SD of quadruplicate
measurements performed at the indicated pH.60 ePapp = apparent permeability. Permeation through a Caco-2 cell monolayer was assessed in the
absorptive (a → b) and secretory (b → a) directions in triplicate.61 fPlasma protein binding (PPB) was determined by equilibrium dialysis in
triplicate.62 gMetabolic stability was determined by incubating the compounds (2 μM) with pooled rat liver microsomes (RLM, 0.5 mg/mL) in the
presence of NADPH (1 mM, compounds 1, 9, 10c−e,g,j) or without NADPH (compound 20).63 hnd = not determined.
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increasing propensity to tubular reuptake, whereas logD7.4 > 1 as
shown for heptyl mannoside 1 and the biphenyl mannosides 3,
20, 10g, 10f, and 10j is optimal for tubular reabsorption from the
glomerular ﬁltrate and thus for slow renal clearance.
Metabolic Stability. Increasing lipophilicity is usually
paralleled by increasing susceptibility to metabolism.77 Liabilities
toward metabolic clearance pathways that prevent the intact
antagonist from reaching the target in the bladder were therefore
of interest. To assess their propensity to cytochrome P450
(CYP450) mediated metabolism, heptyl mannoside 1, the
carboxylic acid derivative 9, and the bioiosteres 10c−e,g,j were
incubated with rat liver microsomes (RLM, 0.5 mg/mL) in the
presence of the cofactor β-nicotinamide adenine dinucleotide
phosphate (NADPH).63 To conﬁrm the high propensity of the
methyl ester present in antagonist 20 to carboxylesterase (CES)
mediated hydrolysis, this antagonist was incubated with RLM
only. The proﬁles of unchanged compound versus time revealed
high susceptibility of heptyl mannoside 1 to CYP450-mediated
metabolism (t1/2 = 13 min) and rapid hydrolysis of the ester 20
by the hepatic CES (t1/2 = 1.0 min). Otherwise, the bioisosteres
10c−e,g,j were stable against enzyme-mediated bioconversion
(t1/2 > 60 min), suggesting lower propensity to metabolic,
nonrenal elimination pathways.
Considering PPB, lipophilicity, andmetabolic stability data, we
therefore expected (i) a steady release of compounds 10d,e,g,j
into the bladder because of high PPB decelerating glomerular
ﬁltration (10d,e,g) and/or high log D7.4 supporting tubular
reabsorption (10g,j), (ii) a fast excretion of antagonists 9 and 10c
via the urine due to low PPB and low log D7.4, and (iii) a rapid
clearance of heptyl mannoside 1 from the body by renal and
metabolic pathways. Compounds featuring high propensity to
renal excretion as major route of elimination (10c, 10e and 10j)
were selected for in vivo PK studies in a mouse model.
Pharmacokinetic Studies in C3H/HeN Mice. This ﬁrst
part of our study explored the predicted eﬀects of lipophilicity,
PPB, and metabolic stability on antagonist disposition and
elimination upon a single dose iv application (50 mg/kg) of
compounds 10c and 10e. The PK parameters of these
applications and those of the previously published carboxylate
9 are summarized in Table 4. The table also contains the results
of the iv administration of compound 10j (0.625 mg/kg).
Table 4. Pharmacokinetic Parameters Determined after a Single iv Application of Compounds 9, 10c, 10e, and 10j in Female C3H/
HeN Micea
plasma
compd C0 (μg/mL) dose (mg/kg) Vz (mL) t1/2 (h) AUC0−inf (μg·h/mL) CLtot (mL/h) urine, Cmax (μg/mL)
9 40 50 25.2 0.33 23.5 53.1 300
10c 109.7 50 28.3 0.4 25.3 49.4 4611
10e 151.6 50 19.5 1.9 175.1 7.1 387
10j 0.36 0.625 52.8 0.17 0.07 218 10
aValues were calculated using PKSolver.78 C0, initial concentration; Vz, volume of distribution in terminal phase; AUC, area under the curve; CLtot,
total clearance; Cmax, maximal concentration.
Figure 5. Antagonist concentrations in (A) plasma and (B) urine after a single iv application of 9, 10c, and 10e (50 mg/kg).
Figure 6.Antagonist concentrations in (A) plasma and (B) urine after a single iv and po application of compound 10j (iv, 0.625mg/kg; po, 1.25mg/kg).
MAC90 is the minimal antiadhesive concentration to inhibit 90% adhesion (0.094 μg/mL).
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In contrast to the fast plasma clearance of antagonists 9 and
10c (Figure 5A), the methylsulfonamide bioisostere 10e attained
higher initial concentration in plasma (C0) and lower total
clearance (CLtot). Therefore, it could be detected until 6 h after
application, resulting in markedly higher plasma AUC. The
observed high C0 of compound 10e may be attributed to a small
volume of distribution (Vz) resulting from the high PPB ( f b ≥
99%).72 In urine (Figure 5B), the carboxylic acid 9 and the
morpholinomethanone 10c displayed high levels immediately
following administration and a rapid concentration decrease
within the ﬁrst 2 h, reﬂecting the rapid elimination from plasma.
Fast renal excretion as major route of elimination can be
rationalized by the physicochemical properties of the antagonists
9 and 10c, that is, moderate PPB and log D7.4, as well as high
metabolic stability. Otherwise, the methylsulfonamide bioisos-
tere 10e showed sustained compound levels in urine over a
period of 2 h and subsequent slow decrease until 6 h after
administration. This sustained renal excretion is a result of the
interplay of the antagonist’s elevated PPB and log D7.4.
In a second study, the p-cyano bioisostere 10j, characterized by
a high oral absorption potential, was administered as a single dose
iv (0.625 mg/kg) and po (1.25 mg/kg). The plasma
concentration curve upon iv dosing displays a steep decline
within the ﬁrst hour after application, while the po curve shows a
prolonged period where absorption and elimination are in
equilibrium (Figure 6A). The urine concentration proﬁles
(Figure 6B) parallel the plasma curves obtained by the two
modes of application; i.e., high plasma clearance upon iv bolus
injection led to high initial antagonist levels in urine and a rapid
concentration decline. By contrast, sustained plasma concen-
trations upon po administration resulted in prolonged urine
levels.
As a result, urine concentrations exceed the minimum level
required for the antiadhesive eﬀect as estimated from the in vitro
cell infection model79 (minimal antiadhesion concentration,23
MAC90 = 0.094 μg/mL) for more than 8 h upon oral single-dose
administration (Figure 6B).
Infection Study in C3H/HeN Mice. In a preventive study,
six mice were inoculated with UTI89 following an oral
application of 10j (1.25 mg/kg) 40 min prior to infection.
Three hours after inoculation, the animals were sacriﬁced and
bladder and kidneys were removed. Organs were homogenized
and analyzed for bacterial counts. The eﬀect of the FimH
antagonist was compared to a 8 mg/kg dose of ciproﬂoxacin
(CIP), applied subcutaneously (sc) 10 min before infection. CIP
is used as standard antibiotic therapy in humans for the treatment
of UTI.80 In mice, the dose of 8 mg/kg sc was shown to mimic
the standard human dose regarding peak levels and the AUC24 in
serum.81 The median reductions in bacterial counts in mice
treated with 10j and CIP compared to the control group 3 h after
infection are displayed in Figure 7.
Figure 7. Preventive eﬃcacy of 10j in the UTI mouse model 3 h after infection. The bars depict the median bacterial load with the interquartile range in
the diﬀerent study groups. Shown are the results of the control group (PBS), control group formulation (5% DMSO in PBS containing 1% Tween 80),
and the intervention groups with the preventive applications of either 1.25 or 10 mg/kg 10j po or 8 mg/kg CIP sc (representing the murine dose
equivalent to a human standard dose).81 DL, detection limit. CFU, colony forming units.
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The median value in the untreated control group showed
bacterial counts of 6.6 log10 colony forming units (CFU) in the
bladder and 6 log10 CFU in the kidneys. After oral application of
1.25 mg/kg 10j, bacterial loads in the bladder decreased by 1.78
log10 CFU and 1.07 log10 CFU in the kidneys. The lower
reduction in the kidneys is most likely due to the diﬀering
adhesion mechanisms between bladder and kidneys (type 1 pili
vs P-pili), which is not targeted by 10j.82 With CIP (8 mg/kg sc)
a substantial reduction in both bladder and kidneys (median
reductions of 2.44 log10 and 2.47 log10, respectively) was
observed. Despite the low oral dose of 10j (1.25 mg/kg), the
approximately 100-fold reduction of CFU in the bladder
promised an even higher eﬀect upon dose increase to 10 mg/
kg. Since the solubility of 10j for this increased dose is too low
(192 μg/mL), we used 5% DMSO and surfactant Tween 80
(1%) as solubilizer. To eﬀectively compare the eﬀect of a higher
dose of 10j, a control group receiving the formulation only (5%
DMSO in PBS containing 1% Tween 80, termed control group
formulation) was tested in parallel. When 10 mg/kg 10j was
applied, bacterial loads in the bladder decreased by 2.68 log10
CFU/mL compared to the control group formulation, clearly
exceeding the eﬀect of CIP with a reduction of 2.44 log10 CFU/
mL. However, only a moderate reduction of 1.04 log10 CFU was
achieved in the kidneys.
■ SUMMARY AND CONCLUSION
Recently, numerous monovalent alkyl and aryl α-D-mannopyr-
anosides have been described as potent FimH antagonists.
However, most of them suﬀer from insuﬃcient pharmacokinetic
properties, i.e., modest bioavailability and short duration of the
therapeutic eﬀect in the bladder, their site of action. As a
consequence, high doses at short intervals are required to achieve
antiadhesive eﬀects over an extended period of time. Therefore,
the goal of the present study was an appropriate optimization of
the pharmacokinetic proﬁle of biphenyl α-D-mannopyranosides
while keeping their high aﬃnity to the CRD of FimH. The
starting point was the biphenylcarboxylate 9 where the critical
carboxylate was replaced by bioisosteres.39,83
With a series of bioisosteres, a 3- to 5-fold improvement of
aﬃnity was achieved compared to 9. Although binding
necessitates only partial desolvation of the carboxylate and its
bioisosteric replacements, a reduction of the enthalpy penalty for
desolvation51 was identiﬁed as the source of the improved aﬃnity
exhibited by the bioisosteres. Thermodynamic evaluation of
antagonists 10b−e revealed almost identical enthalpy contribu-
tion to binding. However, for antagonists with the p-cyano
substituent (10g and 10j) an enhancement of up to −8.7 kJ/mol
was observed, indicating a reduced desolvation penalty and an
improved stacking as derived from the crystal structure of 10j
cocrystallized with the CRD of FimH (Figure 4B). On the other
hand, higher aﬃnity originating from a reduction of conforma-
tional ﬂexibility of ligand and protein resulted in a concomitant
entropy penalty of up to 6.5 kJ/mol.
In addition to the improved pharmacodynamics, the relevant
pharmacokinetic parameters (solubility, permeability, renal
excretion) were substantially improved. With 3′-chloro-4′-(α-
D-mannopyranosyloxy)biphenyl-4-carbonitrile (10j), a FimH
antagonist with an optimal in vitro PK/PD proﬁle was identiﬁed.
The p-cyano substituent conferred lipophilicity and high binding
to plasma proteins, which slowed the rate of renal excretion.
Despite higher lipophilicity, antagonist 10j was insusceptible to
CYP450-mediated metabolism and therefore predominantly
eliminated via the renal pathway. In vivo experiments conﬁrmed
the excellent PK proﬁle of 10j with steady renal excretion for
more than 8 h after oral application (1.25 mg/kg), suggesting a
long-lasting antiadhesive eﬀect. Finally, the preventive oral
application of 10j (10 mg/kg) reduced the bacterial load in the
bladder by almost 1000-fold 3 h after infection. Although the ﬁrst
3 h of the infection do not represent the complete infection cycle,
they represent the time span of bacteria adhering and invading
urothelial cells.84,85 Nevertheless, the eﬀect of FimH antagonist
10j within a longer infection time and at higher dosing will be the
subject of future investigations.
■ EXPERIMENTAL SECTION
Synthesis. The synthesis of compounds 10a−d, 10f, 10g, 10i, 13a−
d, 13f, 13g, 15, 18, and 25, including compound characterization data,
can be found in the Supporting Information.
General Methods.NMR spectra were recorded on a Bruker Avance
DMX-500 (500.1 MHz) spectrometer. Assignment of 1H and 13C NMR
spectra was achieved using 2D methods (COSY, HSQC, HMBC).
Chemical shifts are expressed in ppm using residual CHCl3, CHD2OD,
or HDO as references. Optical rotations were measured using
PerkinElmer polarimeter 341. Electron spray ionization mass spectra
were obtained on a Waters micromass ZQ. The LC/HRMS analyses
were carried out using a Agilent 1100 LC equipped with a photodiode
array detector and a Micromass QTOF I equipped with a 4 GHz digital
time converter. Microwave-assisted reactions were carried out with a
CEM Discover and Explorer. Reactions were monitored by TLC using
glass plates coated with silica gel 60 F254 (Merck) and visualized by using
UV light and/or by charring with a molybdate solution (a 0.02 M
solution of ammonium cerium sulfate dihydrate and ammonium
molybdate tetrahydrate in aqueous 10% H2SO4). MPLC separations
were carried out on a CombiFlash Companion or Rf (Teledyne Isco)
equipped with RediSep normal-phase or RP-18 reversed-phase ﬂash
columns. LC−MS separations were done on a Waters system equipped
with sample manager 2767, pump 2525, PDA 2525, andMicromass ZQ.
All compounds used for biological assays are at least of 95% purity based
on HPLC analytical results. Commercially available reagents were
purchased from Fluka, Aldrich, Alfa Aesar, or abcr GmbH & Co. KG
(Germany). Solvents were purchased from Sigma-Aldrich or Acros and
were dried prior to use where indicated. Methanol (MeOH) was dried
by reﬂuxing with sodium methoxide and distilled immediately before
use. Dimethoxyethane (DME) was dried by ﬁltration over Al2O3 (Fluka,
type 5016 A basic).
4′-(2,3,4,6-Tetra-O-acetyl-α-D-mannopyranosyloxy)-N-meth-
ylbiphenyl-4-sulfonamide (13e). A Schlenk tube was charged with
aryl iodide 1122 (116 mg, 0.21 mmol), 4-(N-methylsulfamoyl)-
phenylboronic acid (12e, 50 mg, 0.23 mmol), Pd(dppf)Cl2·CH2Cl2 (5
mg, 0.006 mmol), K3PO4 (67 mg, 0.32 mmol), and a stirring bar. The
tube was closed with a rubber septum and was evacuated and ﬂushed
with argon. This procedure was repeated once, and then anhydrous
DMF (1 mL) was added under a stream of argon. The mixture was
degassed in an ultrasonic bath and ﬂushed with argon for 5 min and then
stirred at 80 °C overnight. The reaction mixture was cooled to rt, diluted
with EtOAc (50 mL), and washed with water (50 mL) and brine (50
mL). The organic layer was dried over Na2SO4 and concentrated in
vacuo. The residue was puriﬁed by MPLC on silica gel (petroleum
ether/EtOAc) to aﬀord 13e (105 mg, 84%) as a white solid. [α]D
20
+56.4 (c 0.50, MeOH). 1H NMR (500 MHz, CDCl3): δ = 7.92−7.90
(m, 2H, Ar−H), 7.70−7.68 (m, 2H, Ar−H), 7.57−7.55 (m, 2H, Ar−H),
7.21−7.19 (m, 2H, Ar−H), 5.60−5.57 (m, 2H, H-1, H-3), 5.48 (dd, J =
1.8, 3.4 Hz, 1H, H-2), 5.40 (t, J = 10.0 Hz, 1H, H-4), 4.38 (dd, J = 5.4,
10.8 Hz, 1H, NH), 4.30 (dd, J = 4.9, 12.3 Hz, 1H, H-6a), 4.13−4.08 (m,
2H, H-5, H-6b), 2.72 (d, J = 5.4 Hz, 3H, NCH3), 2.22, 2.07, 2.05, 2.04 (4
s, 12H, 4 COCH3).
13C NMR (126 MHz, CDCl3): δ = 170.55, 170.06,
170.03, 169.75 (4 CO), 155.97, 144.81, 137.16, 134.09, 128.62, 127.85,
127.39, 117.01 (Ar−C), 95.78 (C-1), 69.34 (C-5), 69.31 (C-2), 68.81
(C-3), 65.86 (C-4), 62.07 (C-6), 29.44 (NHCH3), 20.92, 20.74, 20.72
(4C, 4 COCH3). ESI-MS m/z, calcd for C27H31NNaO12S [M + Na]
+:
616.1. Found: 616.1.
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4′-(α-D-Mannopyranosyloxy)-N-methylbiphenyl-4-sulfona-
mide (10e). To a solution of 13e (40 mg, 0.07 mmol) in dry MeOH (5
mL) was added freshly prepared 1MNaOMe/MeOH (0.1 equiv) under
argon. The mixture was stirred at rt until the reaction was complete
(monitored by TLC), then neutralized with Amberlyst-15 (H+) ion-
exchange resin, ﬁltered, and concentrated in vacuo. The residue was
puriﬁed by MPLC on silica gel (DCM/MeOH, 10:1 to 7:1) to aﬀord
10e (22 mg, 76%) as white solid. [α]D
20 +105.7 (c 0.30, MeOH). 1H
NMR (500 MHz, CD3OD): δ = 7.90−7.88 (m, 2H, Ar−H), 7.80−7.79
(m, 2H, Ar−H), 7.66−7.64 (m, 2H, Ar−H), 7.26−7.25 (m, 2H, Ar−H),
5.58 (d, J = 1.7 Hz, 1H, H-1), 4.06 (dd, J = 1.8, 3.3 Hz, 1H, H-2), 3.96
(dd, J = 3.4, 9.5 Hz, 1H, H-3), 3.79−3.74 (m, 3H, H-4, H-6a, H-6b), 3.63
(ddd, J = 2.5, 5.2, 9.7 Hz, 1H, H-5), 2.57 (s, 3H, NHCH3).
13C NMR
(126 MHz, CD3OD): δ = 158.34, 146.13, 138.67, 134.55, 129.53,
128.82, 128.21, 118.29 (Ar−C), 100.09 (C-1), 75.53 (C-5), 72.42 (C-
3), 71.96 (C-2), 68.32 (C-4), 62.68 (C-6), 29.31 (NHCH3). HRMS m/
z, calcd for C19H23NNaO8S [M + Na]
+: 448.1037. Found: 448.1038.
5-(4′-(2,3,4,6-Tetra-O-acetyl-α-D-mannopyranosyloxy)-
biphenyl-4-yl)-1H-tetrazole (14). A Schlenk tube was charged with
13g (30 mg, 0.06 mmol), trimethylsilyl azide (16 μL, 0.12 mmol),
dibutyltin oxide (2 mg, 0.006 mmol), DME (1 mL), and a stirring bar.
The mixture was heated to 150 °C for 10 min by microwave irradiation.
The reaction mixture was cooled to rt and then concentrated in vacuo.
The residue was puriﬁed by MPLC on silica gel (DCM/MeOH, 9:1 to
8:1) to aﬀord 14 (26 mg, 81%) as a colorless oil. [α]D
20 +56.1 (c 0.3,
MeOH). 1H NMR (500 MHz, CDCl3): δ = 8.25−8.15 (m, 2H, Ar−H),
7.75−7.65 (m, 2H, Ar−H), 7.60−7.55 (m, 2H, Ar−H), 7.20−7.17 (m,
2H, Ar−H), 5.64−5.55 (m, 2H, H-1, H-3), 5.49 (dd, J = 1.7, 3.3 Hz, 1H,
H-2), 5.40 (t, J = 10.1 Hz, 1H, H-4), 4.31 (dd, J = 5.3, 12.4 Hz, 1H, H-
6a), 4.17−4.06 (m, 2H, H-5, H-6b), 2.22, 2.07, 2.06, 2.05 (4 s, 12H, 4
COCH3).
13C NMR (126 MHz, CDCl3): δ = 170.67, 170.14, 170.11,
169.81 (4 CO), 155.61, 128.36, 127.84, 127.49, 116.93 (Ar−C), 95.78
(C-1), 69.36 (C-5), 69.26 (C-2), 68.90 (C-3), 65.89 (C-4), 62.12 (C-6),
20.92, 20.76, 20.73 (4 COCH3). ESI-MSm/z, calcd for C27H28N4NaO10
[M + Na]+: 591.2. Found: 591.1.
5-(4′-(α-D-Mannopyranosyloxy)biphenyl-4-yl)-1H-tetrazole
(10h). Prepared according to the procedure described for 10e from 14
(26 mg, 0.03 mmol). Yield: 18 mg (quant) as a white solid. [α]D
20
+112.1 (c 0.1, MeOH/H2O, 2:1).
1H NMR (500 MHz, CD3OD): δ =
7.98−7.96 (m, 2H, Ar−H), 7.72−7.71 (m, 2H, Ar−H), 7.58−7.54 (m,
2H, Ar−H), 7.16−7.13 (m, 2H, Ar−H), 5.46 (d, J = 1.7 Hz, 1H, H-1),
3.94 (dd, J = 1.9, 3.5 Hz, 1H, H-2), 3.83 (dd, J = 3.4, 9.5 Hz, 1H, H-3),
3.68−3.61 (m, 3H, H-4, H-6a, H-6b), 3.52 (ddd, J = 2.5, 5.4, 9.7 Hz, 1H,
H-5). 13C NMR (126 MHz, CD3OD): δ = 158.19, 145.07, 134.97,
129.29, 128.74, 128.55, 118.26 (Ar−C), 100.13 (C-1), 75.52 (C-5),
72.42 (C-3), 71.98 (C-2), 68.33 (C-4), 62.69 (C-6). HRMS m/z, calcd
for C19H21N4O6 [M + H]
+: 401.1456. Found: 401.1450.
4′-(2,3,4,6-Tetra-O-acetyl-α-D-mannopyranosyloxy)-3′-chlor-
obiphenyl-4-carbonitrile (19). Prepared according to the procedure
described for 13e from aryl iodide 1823 (79 mg, 0.135 mmol), 12g (22
mg, 0.15mmol), Pd(dppf)Cl2·CH2Cl2 (3.3 mg, 4 μmol), and K3PO4 (57
mg, 0.27mmol). Yield: 57mg (75%) as a white solid. [α]D
20 +77.7 (c 0.5,
CHCl3).
1H NMR (500 MHz, CDCl3): δ = 7.72 (d, J = 8.3 Hz, 2H, Ar−
H), 7.63 (m, 3H, Ar−H), 7.43 (dd, J = 2.2, 8.6 Hz, 1H, Ar−H), 7.27 (d, J
= 8.6 Hz, 1H, Ar−H), 5.64−5.59 (m, 2H, H-1, H-2), 5.54 (dd, J = 1.9,
3.2 Hz, 1H, H-3), 5.41 (t, J = 10.1 Hz, 1H, H-4), 4.28 (dd, J = 5.2, 12.3
Hz, 1H, H-6a), 4.17 (ddd, J = 2.1, 5.1, 10.0 Hz, 1H, H-5), 4.10 (dd, J =
2.2, 12.3 Hz, 1H, H-6b), 2.21 (s, 3H, COCH3), 2.12- 2.00 (m, 9H, 3
COCH3).
13C NMR (126 MHz, CDCl3): δ = 170.54, 170.08, 169.90,
169.84, (4C, CO) 151.67, 143.61, 135.29, 132.87, 129.41, 127.53,
126.60, 125.20, 118.79, 117.36, 111.47 (Ar−C, CN), 96.72 (C-1), 70.00
(C-5), 69.39 (C-3), 68.82 (C-2), 65.86 (C-4), 62.16 (C-6), 20.98, 20.81,
20.79, 20.78 (4 COCH3). ESI-MS m/z, calcd for C27H26ClNNaO10 [M
+ Na]+: 582.1. Found: 582.1.
3′-Chloro-4′-(α-D-mannopyranosyloxy)biphenyl-4-carboni-
trile (10j). Prepared according to the procedure described for 10e from
19 (36 mg, 0.06 mmol). Yield: 12 mg (48%) as a white solid. [α]D
20
+109.4 (c 0.23, MeOH). 1H NMR (500 MHz, CD3OD): δ = 7.80−7.72
(m, 5H, Ar−H), 7.59 (dd, J = 2.2, 8.6 Hz, 1H, Ar−H), 7.48 (d, J = 8.7Hz,
1H, Ar−H), 5.62 (d, J = 1.4 Hz, 1H, H-1), 4.12 (dd, J = 1.8, 3.3 Hz, 1H,
H-2), 4.00 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 3.83−3.68 (m, 3H, H-4, H-6a,
H-6b), 3.63 (ddd, J = 2.3, 5.4, 9.6 Hz, 1H, H-5). 13C NMR (126 MHz,
CD3OD): δ = 153.65, 145.15, 135.42, 133.86, 129.82, 128.53, 127.87,
125.47, 119.70, 118.59 (Ar−C), 111.97 (CN), 100.66 (C-1), 76.05 (C-
5), 72.39 (C-3), 71.80 (C-2), 68.20 (C-4), 62.65 (C-6). IR (KBr), ν =
3400 (OH), 2227 (CN), 1606, 1487 (Ar−CC) cm−1. HRMSm/z,
calcd for C19H18ClNNaO6 [M + Na]
+: 414.0715. Found: 414.0721.
3 ′ - Ch l o r o -N - ( 3 ′ , 6 ′ - d i h yd ro xy - 3 - o xo - 3H - s p i r o -
[ i s o b e n z o f u r a n - 1 , 9 ′ - x a n t h e n ] - 5 - y l ) - 4 ′ - ( α - D -
mannopyranosyloxy)biphenyl-4-carboxamide (22). Compound
21 (10.0 mg, 0.024 mmol), ﬂuoresceinamine isomer I (12.7 mg, 0.037
mmol), and COMU (20.9 mg, 0.049 mmol) were dissolved in dry DMF
(1mL). ThenNEt3 (10 μL, 0.073mmol) was added and themixture was
stirred at rt for 7 h. 1 NHCl in DMFwas added until acid reaction on pH
paper and the mixture was concentrated. The residue was dissolved in
DCM/MeOH (3:1) and loaded onto a silica gel column. The complex
mixture of compounds was only partially resolved. The fractions
containing the product were collected, concentrated, and puriﬁed by
preparative HPLC (gradient H2O/MeCN, +0.2% HCO2H) to aﬀord
compound 22 (5 mg, 19%). [α]D
20 +21.1 (c 0.10, MeOH). 1H NMR
(500MHz, CD3OD): δ = 8.26 (d, J = 8.4Hz, 2H, Ar−H), 7.88−7.74 (m,
3H, Ar−H), 7.66 (dd, J = 2.2, 8.6 Hz, 1H, Ar−H), 7.51 (d, J = 8.7 Hz,
1H, Ar−H), 7.29 (dd, J = 1.9, 5.3 Hz, 2H, Ar−H), 7.19 (dd, J = 2.1, 8.3
Hz, 1H, Ar−H), 7.08−6.99 (m, 2H, Ar−H), 6.95 (d, J = 8.7 Hz, 1H, Ar−
H), 6.72 (dd, J = 5.5, 10.6, Hz, 2H, Ar−H), 6.61 (dd, J = 2.3, 8.7 Hz, 1H,
Ar−H), 5.65 (s, 1H, H-1), 4.15 (dd, J = 1.8, 3.2 Hz, H-2), 4.03 (dd, J =
3.4, 9.5, Hz, H-3), 3.87−3.72 (m, 3H, H-4, H-6a, H-6b), 3.65 (m, 1H, H-
5). 13C NMR (126 MHz, CD3OD): δ = 137.50, 136.01, 131.90, 130.24,
130.20, 129.87, 129.24, 128.03, 127.91, 125.79, 125.46, 124.73, 118.99,
118.76, 118.65 (Ar−C), 100.73 (C-1), 76.06 (C-5), 72.42 (C-3), 71.85
(C-2), 68.24 (C-4), 62.69 (C-2). ESI-MS m/z, calcd for C39H31ClNO12
[M + H]+: 740.2. Found: 740.2.
3′-Chloro-N-(2-(3-(3′ ,6′-dihydroxy-3-oxo-3H-spiro-
[isobenzofuran-1,9′-xanthen]-5-yl)thioureido)ethyl)-4′-(α-D-
mannopyranosyloxy)biphenyl-4-carboxamide (23). To a stirred
solution of compound 21 (25 mg, 0.061 mmol) in dry DMF (1 mL),
NHS (21 mg, 0.183 mmol) was added, followed by DIC (9.2 mg, 0.073
mmol). The mixture was stirred at rt for 2 h. Then N-Boc-
ethylendiamine (10.7 mg, 0.067 mmol) was added and the reaction
was stirred for 10 h. It was then cooled down to 0 °C, diluted with water,
and concentrated. Chromatography on silica gel (DCM/MeOH)
yielded 23 mg (0.042 mmol, 68%) of tert-butyl (3′-chloro-4′-(α-D-
mannopyranosyloxy)biphenyl-4-yl-carboxamido)ethyl)carbamate. This
product was dissolved in DCM (3 mL), and TFA (1 mL) was added.
The solid dissolved during addition of TFA. After 10 min the reaction
was complete. The mixture was evaporated, and excess TFA was
removed in high vacuum. The intermediate N-(2-aminoethyl)-3′-
chloro-4′-(α-D-mannopyranosyloxy)biphenyl-4-carboxamide TFA salt
(23 mg, 0.042 mmol, quant) was used directly in the next step. It was
dissolved in dry DMF (0.5 mL), and NEt3 (12.8 mg, 0.127 mmol) was
added. The mixture was cooled to 0 °C. Then FITC (14.8 mg, 0.038
mmol) was added and the mixture was stirred for 3 h in the dark. The
mixture was then coevaporated with water, taken up in MeOH/10% aq
acetic acid and evaporated. Chromatography on silica gel (DCM/
MeOH) yielded compound 23, contaminated with triethylammonium
acetate. The compound was then redissolved in MeOH, and 0.5 N HCl
in MeOH was added. The mixture was evaporated and chromato-
graphed on silica gel to yield pure 23 (15mg, 47%). [α]D
20 +12.1 (c 0.30,
MeOH). 1H NMR (500 MHz, CD3OD): δ = 8.12 (s, 1H), 7.92 (d, J =
8.3 Hz, 2H, Ar−H), 7.70 (dd, J = 5.0, 13.1 Hz, 2H, Ar−H), 7.64 (d, J =
8.3 Hz, 2H, Ar−H), 7.54 (dd, J = 2.2, 8.6 Hz, 1H, Ar−H), 7.46 (d, J = 8.7
Hz, 1H, Ar−H), 7.09 (d, J = 8.2 Hz, 1H, Ar−H), 6.74 (s, 2H), 6.69 (d, J
= 1.4Hz, 2H, Ar−H), 6.55 (d, J = 8.4Hz, 2H, Ar−H), 5.63 (d, J = 1.3Hz,
H-1), 4.15 (dd, J = 1.8, 3.1 Hz, H-2), 4.03 (dd, J = 3.4, 9.5 Hz, H-3), 3.94
(s, 2H, CH2), 3.86−3.64 (m, 6H, H-4, H-5, H-6, CH2). 13C NMR (126
MHz, CD3OD): δ = 153.21, 143.84, 136.41, 129.66, 129.18, 127.76,
127.70, 125.37, 118.64, 103.62 (Ar−C), 100.75 (C-1), 76.00 (C-5),
72.41 (C-3), 71.86 (C-2), 68.24 (C-4), 62.69 (C-6), 40.76 (CH2). ESI-
MS m/z, calcd for C42H37ClN3O12S [M + H]
+: 842.2. Found: 842.2.
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3′-Chloro-N-(2-(2-(2-(3-(3′,6′-dihydroxy-3-oxo-3H-spiro-
[isobenzofuran-1,9′-xanthen]-5-yl)thioureido)ethoxy)ethoxy)-
ethyl)-4′-(α-D-mannopyranosyloxy)biphenyl-4-carboxamide
(24).Compound 21 (280 mg, 0.68 mmol) was dissolved in dry DMF (5
mL) under argon. ThenNHS (235mg, 2.04 mmol) was added, followed
by DIC (0.12 mL, 0.78 mmol) and the mixture was stirred at rt for 4 h.
Then Boc-PEG2-NH2 (186 mg, 0.75 mmol) was added, and the mixture
was stirred at rt under argon for 10 h. It was then slowly diluted with
water and concentrated. The residue was puriﬁed by chromatography on
silica gel (DCM/MeOH) to give tert-butyl (2-(2-(2-(3′-chloro-4′-(α-D-
mannopyranosyloxy)biphenyl-4-ylcarboxamido)ethoxy)ethoxy)ethyl)-
carbamate (300 mg, 0.468 mmol, 69%). Then the carbamate was
suspended in DCM (3 mL), and TFA (1 mL) was added dropwise at rt.
After 30 min, the solvents were evaporated and the crude mixture was
dissolved in CHCl3/MeOH (6:4, +0.5% conc NH4OH) and transferred
to a silica gel column, eluting with the same solvent mixture, to yield N-
(2 -(2 -(2 - aminoe thoxy)e thoxy)e thy l ) -3 ′ - ch lo ro -4 ′ - (α -D -
mannopyranosyloxy)biphenyl-4-carboxamide (228 mg, 90%). A
fraction of the amine (10 mg, 0.018 mmol) was dissolved in dry DMF
(0.5 mL) and cooled to 0 °C. FITC (6.5 mg, 0.017 mmol) was added,
and the mixture was stirred for 1 h. The mixture was concentrated and
the residue was puriﬁed by chromatography on silica (DCM/MeOH) to
yield 24 (10 mg, 65%). 1H NMR (500 MHz, CD3OD): δ = 8.21 (d, J =
1.4 Hz, 1H, Ar−H), 7.88 (d, J = 8.3 Hz, 2H, Ar−H), 7.68 (d, J = 2.2 Hz,
2H, Ar−H), 7.63 (d, J = 8.3 Hz, 2H, Ar−H), 7.53 (dd, J = 2.2, 8.6 Hz,
1H, Ar−H), 7.43 (d, J = 8.7 Hz, 1H, Ar−H), 7.09 (d, J = 8.2 Hz, 1H, Ar−
H), 6.68 (d, J = 2.3Hz, 2H, Ar−H), 6.65 (dd, J = 2.6, 8.6Hz, 2H, Ar−H),
6.53 (dd, J = 1.6, 8.7 Hz, 2H, Ar−H), 5.61 (d, J = 1.3 Hz, 1H, H-1), 4.14
(dd, J = 1.8, 3.2, Hz, 1H, H-2), 4.03 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 3.93−
3.53 (m, 16H), 3.37 (s, 2H, NCH2), 1.30 (s, 2H, CH2).
13C NMR (126
MHz, CD3OD): δ = 170.01 (CO), 153.17, 143.72, 136.37, 134.37,
130.39, 129.69, 129.04, 127.78, 127.73, 125.35, 118.60, 103.60 (Ar−C),
100.72 (C-1), 75.97 (C-5), 72.41 (C-3), 71.86, 71.40, 70.59 (5C, C-2,
OCH2), 68.23 (C-4), 62.64 (C-6), 49.88, 45.49, 40.97 (CH2). ESI-MS
m/z, calcd for C46H45ClN3O14S [M + H]
+: 930.2. Found: 930.4.
Competitive Fluorescence Polarization Assay. Expression and
Puriﬁcation of CRD of FimH. A recombinant protein consisting of the
CRD of FimH linked to a 6His-tag via a thrombin cleavage site (FimH-
CRD-Th-His6) was expressed in E. coli strain HM125 and puriﬁed by
aﬃnity chromatography as previously described.43
KD Determination of FITC-Labeled Ligands. The functionalized
ligands (23, 24) were prepared as a 10 mM stock solution in pure
DMSO (Sigma-Aldrich, Buchs, Switzerland). All further dilutions of
compounds and FimH-CRD-Th-His6 protein were prepared in assay
buﬀer (20 mM HEPES, 150 mM NaCl, 50 μg/mL BSA, pH 7.4). BSA
was added to the assay buﬀer to prevent nonspeciﬁc binding of protein
to the plastic surface. Binding isotherms for the ﬂuorescent ligands were
obtained in direct binding studies by adding a constant concentration of
ligand (ﬁnal concentration 5 nM) and a linear dilution of protein (ﬁnal
concentration 0−100 nM) to a ﬁnal volume of 200 μL in 96-well, black,
ﬂat bottom NBS plates (Corning Inc., Corning, NY, USA). After
incubation of the plate for 24 h at rt with gentle shaking, the ﬂuorescence
polarization was measured with the Synergy H1 hybrid multimode
microplate reader (BioTek Instruments Inc., Winooski, VT, USA) with
polarized excitation at 485 nm and emission measured at 528 nm
through polarizing ﬁlters parallel and perpendicularly oriented to the
incident polarized light. KD values were determined by plotting the FP
readout as a function of the protein concentration and applying the
following single-site binding equation (eq 1) that accounts for ligand
depletion:
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where Sobs is the observed signal from the ligand, SF is the signal from
free ligand, SB is the signal from bound ligand, CP is the total
concentration of protein, and CL is the total concentration of ligand.
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KD Determination of FimH Antagonists. The ﬂuorescently labeled
ligand 23was used for the competitive ﬂuorescence polarization assay. A
linear dilution of nonlabeled FimH antagonist with ﬁnal concentrations
ranging from 0 to 10 μM was titrated into 96-well, black, ﬂat-bottom
NBS plates (Corning Inc.) to a ﬁnal volume of 200 μL containing a
constant concentration of protein (ﬁnal concentration 25 nM) and
FITC-labeled ligand which was ﬁxed at a higher concentration in
competitive binding assays than in direct binding experiments to obtain
higher ﬂuorescence intensities (ﬁnal concentration 20 nM). Prior to
measuring the ﬂuorescence polarization, the plates were incubated on a
shaker for 24 h at rt until the reaction reached equilibrium. The IC50
value was determined with Prism (GraphPad Software Inc., La Jolla, CA,
USA) by applying a standard four-parameter IC50 function. The
obtained IC50 values were converted into their corresponding KD values
using the derivation of the Cheng−Prusoﬀ equation.45 This variation of
the Cheng−Prusoﬀ equation is applied to competition assays with tight-
binding inhibitors and includes terms to correct for ligand depletion
eﬀects. However, the KD for antagonists having a higher aﬃnity toward
FimH than the labeled ligand could not be accurately determined.45
Isothermal Titration Calorimetry (ITC). All ITC experiments
were performed with the FimH-CRD-Th-His6 protein using a VP-ITC
instrument from MicroCal, Inc. (Malvern Instruments, Worcestershire,
U.K.) with a sample cell volume of 1.4523 mL. The measurements were
performed with 0−5% DMSO at 25 °C, a stirring speed of 307 rpm, and
10 μcal s−1 reference power. The protein samples were dialyzed in assay
buﬀer prior to all experiments. Because of the high protein consumption
of ITC, only the experiments for the reference compounds (1, 3, and
25) were measured in duplicates. Compounds 1, 3, 9, and 25 were
measured in a direct fashion by titration of ligand (100−2,000 μM) into
protein (8.6−55 μM) with injections of 3−8 μL at intervals of 10 min to
ensure nonoverlapping peaks. The quantity c = Mt(0) KD
−1, where
Mt(0) is the initial macromolecule concentration, is of importance in
titration microcalorimetry. The c-values of the direct titrations were
below 1000 and thus within the reliable range. For the compounds 10b−
e, 10g, and 10j additional competitive ITC experiments were performed
because of their high aﬃnity resulting in c-values above 1000 for direct
titrations. These ligands (600 μM) were titrated into protein (30 μM),
which was preincubated with compound 25 (300 μM) resulting in
sigmoidal titration curves. Because of slow reaction kinetics, titration
intervals of 20 min were used.
Baseline correction and peak integration were performed using the
Origin 7 software (OriginLab, Northampton, MA, USA). An initial 2 μL
injection was excluded from data analysis. Baseline subtraction and
curve-ﬁtting with the three variables N (concentration correction
factor), KD (dissociation constant), andΔH° (change in enthalpy) were
performed with the SEDPHAT software, version 10.40 (National
Institutes of Health).86 A global ﬁtting analysis was performed for the
competition titration (10b−e, 10g, or 10j competing for the protein
binding site with compound 25) and the direct titration of the
competitor (compound 25 binding to protein) to ﬁt for KD.ΔH° andN
were ﬁtted from direct titrations of 10b−e, 10g, or 10j into protein. For
the compounds 3, 9, and 25 binding to protein all variables could be
determined from a global analysis of the direct titration.
The thermodynamic parameters were calculated with the following
equation (eq 2):
Δ ° = Δ ° − Δ ° = = −G H T S RT K RT Kln lnD A (2)
whereΔG°,ΔH°, andΔS° are the changes in free energy, enthalpy, and
entropy of binding, respectively, T is the absolute temperature, and R is
the universal gas constant (8.314 J mol−1 K−1). The 95% conﬁdence
intervals of the measurements were calculated for the two variables KD
and ΔH° with the one-dimensional error surface projection within the
SEDPHAT software.
Calculation of the Free Energy of Desolvation. The three-
dimensional representation for each of the aglycons (4-methoxybi-
phenyl scaﬀold, Figure 8) was built in the Maestro87 modeling
environment, and the global minimum conformation was identiﬁed by
performing 500 iterations of the mixed torsional/low-mode conforma-
tional sampling in combination with the OPLS-2005 force-ﬁeld and the
implicit solvent model (water) as implemented in the Macromodel
Journal of Medicinal Chemistry Article
DOI: 10.1021/jm501524q
J. Med. Chem. 2015, 58, 2221−2239
2233
147
9.9.88 The global minimum structures were used as input for the
AMSOL 7.1 program89 to obtain the free energy of desolvation ΔGdes
(Table 5) with the SM5.4A solvation model90 and the AM191 level of
theory (used keywords “AM1 SM5.4A SOLVNT=WATER TRUES”).
Determination of the MAC90 by Flow Cytometry. The MAC90
was determined in principle as in the previously published ﬂow
cytometry assay79 but with some modiﬁcations. The human epithelial
bladder carcinoma cell line 5637 (DSMZ, Braunschweig, Germany) was
grown in RPMI 1640 medium, supplemented with 10% fetal calf serum
(FCS), 100 U/mL penicillin, and 100 μg/mL streptomycin at 37 °C, 5%
CO2. All solutions were purchased from Invitrogen (Basel, Switzerland).
The cells were subcultured 1:6 twice per week [using trypsin/EDTA
(Sigma-Aldrich) for the detachment]. Two days before infection, 1.8 ×
105 cells were seeded in each well of a 24-well plate in RPMI 1640
containing 10% FCS without antibiotics. The cell density was
approximately (3−5) × 105 cells/well at the assay day.
For infection, the GFP-expressing clinical E. coli isolate UTI8992
(UTI89 wt) and the GFP-expressing FimA-H knockout strain UTI89
Δf imA-Hwere used (strains were provided by Prof. Urs Jenal, Biocenter,
University of Basel, Switzerland).79 Bacteria were cultivated at 37 °C in
10 mL Luria−Bertani (LB) broth (Becton, Dickinson and Company)
overnight, harvested by centrifugation (3800 rpm, 10 min), and washed
three times in phosphate buﬀered saline (PBS, Sigma-Aldrich), and a
bacterial solution of OD600 of 0.75 in RPMI + 10% FCS was prepared.
For the determination of the MAC90 value, the IC90, linear dilutions of
the FimH antagonist were prepared in 5%DMSO and PBS. Bacteria and
antagonists were preincubated for 10 min at 37 °C, before cells were
infected with either only 200 μL of bacterial solution of UTI89 or UTI89
Δf imA-H (positive and negative controls), or 225 μL of the
preincubated bacteria−antagonist mixture. Infection lasted for 1.5 h.
During this time infected cells were incubated at 37 °C. Then, cells were
washed with PBS and detached from wells by the addition of 150 μL of
trypsin and incubation at 37 °C for 10 min, before ﬂushing from wells
PBS containing 2% FCS and transferred to tubes. To dilute the trypsin,
cells were centrifuged at 13 000 rpm, 1 min, 600 μL of the supernatant
was discarded, and the pellet was resuspended in the remaining 300 μL
of PBS containing 2% FCS. Samples were stored on ice until
measurement. Before analysis with the ﬂow cytometer (Becton
Dickinson, FACSCanto II), the samples were gently mixed and ﬁltered
using a 35 μm nylon mesh (Corning Life Sciences) to prevent cellular
aggregation. Cells were gated with linear scaling for side scatter (SSC)
and forward scatter (FSC) and GFP intensity of live cells was evaluated.
IC90 values were determined by plotting the concentration of the
antagonist in a logarithmic mode versus the mean ﬂuorescence intensity
(MFI) of living cells and by ﬁtting a dose−response curve (variable
slope, four parameters) with the Prism software (GraphPad Prism).
X-ray Analysis of the Antagonists 10e and 10j Cocrystallized
with FimH-CRD. FimH-CRD/10e Cocrystallization. Initial FimH-
CRD (18 mg/mL in 20 mM HEPES, pH 7.4) crystals were obtained in
complex with 4-(5-nitroindolin-1-yl)phenyl α-D-mannopyranoside (5
mM).23 Crystals were grown in sitting-drop vapor diﬀusion at 20 °C
with 200 nL of protein−antagonist mixture together with 200 nL of
precipitant solution in well D3 (0.2 M sodium phosphate monobasic
monohydrate, 20% w/v PEG 3,350) of the PEG/Ion HT screen
(Hampton Research, CA, USA). Cubic crystals appeared within 1 week,
which served as cross-seeding crystals. A solution of FimH-CRD (20
mg/mL) and 10e (5 mM) was mixed with 0.2 M sodium phosphate
monobasic monohydrate, 20% w/v PEG 400 with 0.5 μL of each
solution. Streak-seeding was performed after 1 day of incubation. Cubic
FimH-CRD/10e crystals formed within 24 h. Crystals were ﬂash cooled
to 100 K with perﬂuoropolyether cryo oil (Hampton Research, CA,
USA) as cryoprotectant. Data were collected with synchrotron radiation
(λ = 0.999 99 Å) at the PXIII beamline, Swiss Light Source, Switzerland.
FimH-CRD/10j Cocrystallization. Cocrystals were initially grown in
sitting-drop vapor diﬀusion at 20 °C with 0.5 μL of a mixture of FimH-
CRD (20 mg/mL) and 10j (5 mM) together with 0.5 μL of 0.1 M
HEPES, pH 7.5, 2M ammonium sulfate. Platelike crystals formed within
2 weeks and were used as seeds for subsequent crystallization.
Diﬀraction quality crystals were grown by streak-seeding in 0.5 μL of
FimH-CRD (10 mg/mL) with 10j (2.5 mM) and 0.5 μL of 0.1 M
HEPES, pH 7.5, 1.25 M ammonium sulfate. The drops were covered
with perﬂuoropolyether cryo oil prior to ﬂash cooling to 100 K. Data
were collected with synchrotron radiation (λ = 1.000 03 Å) at the PXIII
beamline, Swiss Light Source, Switzerland.
Structure Determination and Reﬁnement. Data were indexed and
integrated with the XDS package93 for the FimH-CRD/10e cocrystal
structure, and with mosﬂm94 for the FimH-CRD/10j cocrystal structure
(Table 6). Scaling was performed with XDS and SCALA included in the
CCP4 suite, respectively.95 Structures were solved by molecular
Figure 8. 4-Methoxybiphenyl scaﬀold of aglycons.
Table 5. Aqueous Free Energy of Desolvation
R ΔGdes [kJ/mol]
neutral
H 15.6
CONHCH3 39.9
COOCH3 23.0
SO2NHCH3 65.5
SO2CH3 56.4
4-morpholineamide 45.3
CN 22.0
deprotonated
COO− 298.2
SO2-N
−-Me 342.0
Table 6. Data Collection and Reﬁnement Statistics for FimH-
CRD/10e and FimH-CRD/10j Cocrystals
FimH-CRD/10e FimH-CRD/10j
PDB code 4CSS 4CST
space group P212121 P212121
no. of molecules in
the asymmetric
unit
1 1
Cell Dimensions
a, b, c (Å) 48.38, 56.23, 61.59 48.84, 55.89, 61.00
α, β, γ (deg) 90, 90, 90 90, 90, 90
Data Collection
beamline Swiss Light Source PXIII Swiss Light Source PXIII
resolution range
(Å)a
30.0−1.07 (1.13−1.07) 23.5−1.10 (1.12−1.10)
unique
observationsa
72000 (9354) 66470 (2500)
average
multiplicitya
10.9 (3.7) 5.4 (2.4)
completeness (%) 96.1 (78.0) 97.2 (76.5)
Rmerge
a 0.056 (0.57) 0.051 (0.305)
mean I/σ(I) a 21.5 (2.22) 15.5 (2.9)
Reﬁnement
resolution range
(Å)
15.7−1.07 23.5−1.10
R, Rfree 11.2, 13.2 11.4, 13.0
rms deviation from
ideal bond length
(Å)
0.010 0.010
rms deviation from
ideal bond angle
(deg)
1.170 1.420
aValues in parentheses are for highest-resolution shell.
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replacement with PHASER96 using the FimH-CRD-butyl α-D-
mannopyranoside complex (PDB code 1UWF) as search model. The
structures were iteratively built using the COOT software97 and reﬁned
with the PHENIX software.98 Geometric restraints for 10e and 10j were
generated with PRODRG.99 The models were validated using
molprobity.100 Residues 113−115 were not modeled in the 10e
structure because of disorder. Furthermore, the ligand was modeled in
two possible conformations. For both ligands, electron density is
reduced on the second aromatic ring because of ﬂexibility of the ligand.
Physicochemical and in Vitro Pharmacokinetic Studies.
Materials. Dimethyl sulfoxide (DMSO), 1-propanol, 1-octanol,
Dulbecco’s modiﬁed Eagle medium (DMEM)−high glucose, L-
glutamine solution, penicillin−streptomycin solution, Dulbecco’s
phosphate buﬀered saline (DPBS), trypsin−EDTA solution, magne-
sium chloride hexahydrate, and reduced nicotinamide adenine
dinucleotide phosphate (NADPH)were purchased from Sigma-Aldrich.
MEM nonessential amino acid (MEM-NEAA) solution, fetal bovine
serum (FBS), and DMEM without sodium pyruvate and phenol red
were bought from Invitrogen (Carlsbad, CA, USA). PRISMA HT
universal buﬀer, GIT-0 Lipid Solution, and Acceptor Sink Buﬀer were
ordered from pIon (Woburn, MA, USA). Human plasma was bought
from Biopredic (Rennes, France), and acetonitrile (MeCN) and
methanol (MeOH) were from Acros Organics (Geel, Belgium). Pooled
male rat liver microsomes were purchased from BD Bioscience
(Franklin Lakes, NJ, USA). Tris(hydroxymethyl)aminomethane
(TRIS) was obtained from AppliChem (Darmstadt, Germany). The
Caco-2 cells were kindly provided by Prof. G. Imanidis, FHNW,
Muttenz, and originated from the American Type Culture Collection
(Rockville, MD, USA).
pKa. The pKa values were determined as described elsewhere.
101 In
brief, the pH of a sample solution was gradually changed and the
chemical shift of protons adjacent to ionizable centers was monitored by
1H nuclear magnetic resonance (NMR) spectroscopy. The shift was
plotted against the pH of the respective sample, and the pKa was read out
from the inﬂection point of the resulting sigmoidal curve.
log D7.4. The in silico prediction tool ALOGPS
102 was used to
estimate log P values of the compounds. Depending on these values, the
compounds were classiﬁed into three categories: hydrophilic com-
pounds (log P below zero), moderately lipophilic compounds (log P
between zero and one), and lipophilic compounds (log P above one).
For each category, two diﬀerent ratios (volume of 1-octanol to volume
of buﬀer) were deﬁned as experimental parameters (Table 7).
Equal amounts of phosphate buﬀer (0.1 M, pH 7.4) and 1-octanol
were mixed and shaken vigorously for 5 min to saturate the phases. The
mixture was left until separation of the two phases occurred, and the
buﬀer was retrieved. Stock solutions of the test compounds were diluted
with buﬀer to a concentration of 1 μM. For each compound, six
determinations, that is, three determinations per 1-octanol/buﬀer ratio,
were performed in diﬀerent wells of a 96-well plate. The respective
volumes of buﬀer containing analyte (1 μM) were pipetted to the wells
and covered by saturated 1-octanol according to the chosen volume
ratio. The plate was sealed with aluminum foil, shaken (1350 rpm, 25 °C,
2 h) on a Heidolph Titramax 1000 plate-shaker (Heidolph Instruments
GmbH & Co. KG, Schwabach, Germany), and centrifuged (2000 rpm,
25 °C, 5 min, 5804 R Eppendorf centrifuge, Hamburg, Germany). The
aqueous phase was transferred to a 96-well plate for analysis by LC−MS.
The logD7.4 coeﬃcient was calculated from the 1-octanol/buﬀer ratio
(o/b), the initial concentration of the analyte in buﬀer (1 μM), and the
concentration of the analyte in buﬀer (cB) with eq 3:
= μ −
⎛
⎝⎜
⎞
⎠⎟D
c
c o b
log log
1 M 1
/7.4
B
B (3)
Aqueous Solubility. Solubility was determined in a 96-well format
using the μSOL Explorer solubility analyzer (pIon, version 3.4.0.5). For
each compound, measurements were performed at pH 3.0 and 7.4 in
triplicate. For this purpose, six wells of a deep well plate, that is, three
wells per pH value, were ﬁlled with 300 μL of PRISMA HT universal
buﬀer, adjusted to pH 3.0 or 7.4 by adding the requested amount of
NaOH (0.5 M). Aliquots (3 μL) of a compound stock solution (10−50
mM in DMSO) were added and thoroughly mixed. The ﬁnal sample
concentration was 0.1−0.5 mM, and the residual DMSO concentration
was 1.0% (v/v) in the buﬀer solutions. After 15 h, the solutions were
ﬁltered (0.2 μm 96-well ﬁlter plates) using a vacuum to collect manifold
(Whatman Ltd., Maidstone, U.K.) to remove the precipitates. Equal
amounts of ﬁltrate and 1-propanol were mixed and transferred to a 96-
well plate for UV/vis detection (190−500 nm, SpectraMax 190). The
amount of material dissolved was calculated by comparison with UV/vis
spectra obtained from reference samples, which were prepared by
dissolving compound stock solution in a 1:1 mixture of buﬀer and 1-
propanol (ﬁnal concentrations 0.017−0.083 mM).
Parallel Artiﬁcial Membrane Permeation Assay (PAMPA). Eﬀective
permeability (log Pe) was determined in a 96-well format with the
PAMPA.60 For each compound, measurements were performed at pH
5.0 and 7.4 in quadruplicates. Eight wells of a deep well plate, that is, four
wells per pH value, were ﬁlled with 650 μL of PRISMA HT universal
buﬀer adjusted to pH 5.0 or 7.4 by adding the requested amount of
NaOH (0.5 M). Samples (150 μL) were withdrawn from each well to
determine the blank spectra by UV/vis spectroscopy (190−500 nm,
SpectraMax 190). Then analyte dissolved in DMSO was added to the
remaining buﬀer to yield 50 μM solutions. To exclude precipitation, the
optical density was measured at 650 nm, with 0.01 being the threshold
value. Solutions exceeding this threshold were ﬁltered. Afterward,
samples (150 μL) were withdrawn to determine the reference spectra.
Further 200 μL was transferred to each well of the donor plate of the
PAMPA sandwich (pIon, P/N 110163). The ﬁlter membranes at the
bottom of the acceptor plate were infused with 5 μL of GIT-0 lipid
solution, and 200 μL of Acceptor Sink Buﬀer was ﬁlled into each
acceptor well. The sandwich was assembled, placed in the GutBox, and
left undisturbed for 16 h. Then it was disassembled and samples (150
μL) were transferred from each donor and acceptor well to UV plates for
determination of the UV/vis spectra. Eﬀective permeability (log Pe) was
calculated from the compound ﬂux deduced from the spectra, the ﬁlter
area, and the initial sample concentration in the donor well with the aid
of the PAMPA Explorer software (pIon, version 3.5).
Colorectal Adenocarcinoma (Caco-2) Cell Permeation Assay.
Caco-2 cells were cultivated in tissue culture ﬂasks (BD Biosciences)
with DMEM high glucose medium, containing L-glutamine (2 mM),
nonessential amino acids (0.1 mM), penicillin (100 U/mL),
streptomycin (100 μg/mL), and fetal bovine serum (10%). The cells
were kept at 37 °C in humidiﬁed air containing 5% CO2, and the
medium was changed every second day. When approximately 90%
conﬂuence was reached, the cells were split in a 1:10 ratio and
distributed to new tissue culture ﬂasks. At passage numbers between 60
and 65, they were seeded at a density of 5.3 × 105 cells per well to
Transwell six-well plates (Corning Inc.) with 2.5 mL of culture medium
in the basolateral and 1.8 mL in the apical compartment. The medium
was renewed on alternate days. Permeation experiments were
performed between days 19 and 21 after seeding. Prior to the
experiment, the integrity of the Caco-2 monolayers was evaluated by
measuring the transepithelial electrical resistance (TEER) with an
Endohm tissue resistance instrument (World Precision Instruments
Inc., Sarasota, FL, USA). Only wells with TEER values higher than 250
Ω cm2 were used. Experiments were performed in the apical-to-
basolateral (absorptive) and basolateral-to-apical (secretory) directions
in triplicate. Transport medium (DMEM without sodium pyruvate and
phenol red) was withdrawn from the donor compartments of three wells
and replaced by the same volume of compound stock solution (10 mM
in DMSO) to reach an initial sample concentration of 62.5 μM. The
Transwell plate was then shaken (600 rpm, 37 °C) on a Heidolph
Table 7. Compound Classiﬁcation Based on Estimated log P
Values
compd type log P ratio (1-octanol/buﬀer)
hydrophilic <0 30:140, 40:130
moderately lipophilic 0−1 70:110, 110:70
lipophilic >1 3:180, 4:180
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Titramax 1000 plate-shaker. Samples (40 μL) were withdrawn from the
donor and acceptor compartments 30 min after initiation of the
experiment, and the compound concentrations were determined by
LC−MS (see below). Apparent permeability (Papp) was calculated
according to eq 4:
=P Q
t Ac
d
d
1
app
0 (4)
where dQ/dt is the compound ﬂux (mol s−1), A is the surface area of the
monolayer (cm2), and c0 is the initial concentration in the donor
compartment (mol cm−3).60 After the experiment, TEER values were
assessed again for each well and results from wells with values below 250
Ω cm2 were discarded.
Plasma Protein Binding (PPB). PPB was determined in a 96-well
format using a high throughput dialysis block (HTD96b; HTDialysis
LCC, Gales Ferry, CT, USA). For each compound, measurements were
performed in triplicate. Dialysis membranes (MWCO 12-14 K;
HTDialysis LCC) were hydrated according to the instructions of the
manufacturer and placed into the dialysis block. Human plasma was
centrifuged (5800 rpm, 5 °C, 10 min), the pH of the supernatant
(without ﬂoating plasma lipids) was adjusted to 7.4 by adding the
requested amount of HCl (4 M), and analyte was added to yield a ﬁnal
concentration of 10 μM. Equal volumes (150 μL) of plasma containing
the analyte or TRIS-HCl buﬀer (0.1 M, pH 7.4) were transferred to the
compartments separated by the dialysis membrane. The block was
covered with a sealing ﬁlm and left undisturbed (5 h, 37 °C). Afterward,
samples (90 μL) were withdrawn from the buﬀer compartments and
diluted with plasma (10 μL). From the plasma compartments, samples
(10 μL) were withdrawn and diluted with TRIS-HCl buﬀer (90 μL).
The solutions were further diluted with ice-cooled MeCN (300 μL) to
precipitate the proteins and centrifuged (3600 rpm, 4 °C, 10 min). The
supernatants (50 μL) were retrieved, and the analyte concentrations
were determined by LC−MS (see below). The fraction bound ( f b) was
calculated as follows (eq 5):
= −f c
c
1b
b
p (5)
where cb is the concentration of the analyte withdrawn from the buﬀer
compartment before dilution and cp is the concentration in the plasma
compartment. The values were accepted if the recovery of analyte was
between 80% and 120% of the initial amount.
Cytochrome P450 Mediated Metabolism. Incubations consisted of
pooledmale rat liver microsomes (0.5 mgmicrosomal protein/mL), test
compound (2 μM), MgCl2 (2 mM), and NADPH (1 mM) in a total
volume of 300 μLTRIS-HCl buﬀer (0.1M, pH 7.4) and were performed
in a 96-well plate on a Thermomixer Comfort (Eppendorf).
Compounds and microsomes were preincubated (37 °C, 700 rpm, 10
min) before NADPH was added. Samples (50 μL) at t = 0 min and after
an incubation time of 5, 10, 20, and 30 min were quenched with 150 μL
of ice-cooled MeOH, centrifuged (3600 rpm, 4 °C, 10 min), and 80 μL
of supernatant was transferred to a 96-well plate for LC−MS analysis
(see below). The metabolic half-life (t1/2) was calculated from the slope
of the linear regression from the log percentage remaining compound
versus incubation time relationship. Control experiments without
NADPH were performed in parallel.
LC−MS Measurements. Analyses were performed using an 1100/
1200 series HPLC system coupled to a 6410 triple quadrupole mass
detector (Agilent Technologies, Inc., Santa Clara, CA, USA) equipped
with electrospray ionization. The system was controlled with the Agilent
MassHunter Workstation Data Acquisition software (version B.01.04).
The column used was an Atlantis T3 C18 column (2.1 mm × 50 mm)
with a 3 μmparticle size (Waters Corp., Milford, MA, USA). Themobile
phase consisted of eluent A (H2O containing 0.1% formic acid (for 10a−
f,h,i), or 10 mM ammonium acetate, pH 5.0 in 95:5, H2O/MeCN (for
10g,j)) and eluent B (MeCN containing 0.1% formic acid). The ﬂow
rate was maintained at 0.6 mL/min. The gradient was ramped from 95%
A/5% B to 5% A/95% B over 1 min and then held at 5% A/95% B for 0.1
min. The system was then brought back to 95% A/5% B, resulting in a
total duration of 4 min. MS parameters such as fragmentor voltage,
collision energy, polarity were optimized individually for each analyte,
and the molecular ion was followed for each compound in the multiple
reaction monitoring mode. The concentrations of the analytes were
quantiﬁed by the Agilent Mass Hunter Quantitative Analysis software
(version B.01.04).
In Vivo Studies. Animals. Female C3H/HeN mice weighing
between 19 and 25 g were obtained from Charles River Laboratories
(Sulzfeld, Germany) or Harlan (Venray, The Netherlands) and were
housed three or four per cage. The mice were kept under speciﬁc
pathogen-free conditions in the Animal House of the Department of
Biomedicine, University Hospital of Basel, and animal experimentation
guidelines according to the regulations of the Swiss veterinary law were
followed. After 7 days of acclimatization, 9- to 10-week-old mice were
used for the studies. Animals had free access to chow and water at any
time and were kept in a 12 h/12 h light/dark cycle. For administration
volumes and sampling the good practice guidelines were followed.103
Pharmacokinetic Studies. The single-dose studies for the ﬁrst
experiment set were performed by intravenous application of FimH
antagonists at a dosage of 50 mg/kg body weight, followed by plasma
and urine sampling. Antagonists were diluted in PBS (Sigma-Aldrich)
for injection into the tail vein. Blood and urine samples (10 μL) were
taken at 6 and 30 min and at 1, 2, 4, 6, and 8 h after injection. For the PK
studies with 10j, the antagonist was dissolved in PBS with 5% DMSO
(Sigma-Aldrich) and injected into the tail vain (0.625 mg/kg) or given
orally (1.25 mg/kg) using a gavage (syringes from BD Micro Fine, U-
100 Insuline, 30 G with BD Microlance 3, 25 G needles, Becton
Dickinson and Soft-Ject, 1 mL syringes from Henke Sass Wolf; gavage
from Fine Science Tools). Blood and urine were sampled (10 μL) after
7, 13, 20, 30, 45min and after 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 24 h. Both blood
and urine samples were directly diluted after sampling with MeOH
(Acros Organics) to precipitate the proteins and centrifuged for 11 min
at 13 000 rpm. The supernatants were transferred to a 96-well plate
(Agilent Technologies, 0.5 mL, polypropylene), and the analyte
concentrations were determined by LC−MS (see above).
Infection Study. For all infection studies, the drinking water of the
mice was replaced by water containing 5% glucose (monohydrate from
AppliChem, BioChemica), 3 days before the start of the experiment. 10j
was dosed at 1.25 mg/kg (in 5% DMSO and PBS) and 10 mg/kg (in 5%
DMSO in PBS containing 1% Tween 80, all purchased from Sigma-
Aldrich) and applied orally via gavage to six and four mice, respectively,
as described in the section Pharmacokinetic Studies, 40 min prior to
infection. Ciproﬂoxacin (Ciproxin solution, 2 mg/mL, Bayer) was dosed
with 8 mg/kg, which would correspond to a human dose of 500 mg,81
subcutaneously 10 min prior to infection with UTI89 to 4 mice. The
values for the control group (PBS, po) resulted from the infection of 11
mice. Four mice were orally treated with the formulation vehicle for 10j
(5% DMSO in PBS containing 1% Tween 80) and termed controls
formulation. Before infection, remaining urine in the bladder was
expelled by gentle pressure on the abdomen. Mice were anesthetized in
2.5 vol % isoﬂurane/oxygen mixture (Attane, Minrad Inc., USA) and
placed on their back. Infection was performed transurethrally using a
polyethylene catheter (Intramedic polyethylene tubing, inner diameter
0.28 mm, outer diameter 0.61 mm, Becton Dickinson), on a syringe
(Hamilton Gastight Syringe 50 μL, removable 30G needle, BGB
Analytik AG, Switzerland). After gentle insertion of the catheter into the
bladder, 50 μL of bacterial suspension of UTI89 (5.5 × 109 to 2.25 ×
1010 CFU/mL) was slowly injected. This corresponded to approx-
imately 107−108 CFU per mouse. Mice were killed by CO2 3 h after
inoculation, and bladder and kidneys were aseptically removed. Organs
were homogenized in 1 mL of PBS using a tissue lyser (Retsch,
Germany). Serial dilutions of bladder and kidneys were plated on Levine
Eosin Methylene Blue Agar plates (Becton Dickinson), and CFUs were
counted after overnight incubation at 37 °C.
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Slaẗtegard, R.; Henalsteens, J.-P.; Wyns, L.; Oscarson, S.; De Greve,
H.; Hultgren, S. J.; Bouckaert, J. Intervening with urinary tract infections
using anti-adhesives based on the crystal structure of the FimH-
oligomannose-3 complex. PLoS One 2008, 3, e2040.
(37) Wellens, A.; Lahmann, M.; Touaibia, M.; Vaucher, J.; Oscarson,
S.; Roy, R.; Remaut, H.; Bouckaert, J. The tyrosine gate as a potential
entropic lever in the receptor-binding site of the bacterial adhesin FimH.
Biochemistry 2012, 51, 4790−4799.
(38) Totsika, M.; Kostakioti, M.; Hannan, T. J.; Upton, M.; Beatson, S.
A.; Janetka, J. W.; Hultgren, S. J.; Schembri, M. A. A FimH inhibitor
prevents acute bladder infection and treats chronic cystitis caused by
multidrug-resistant uropathogenic Escherichia coli ST131. J. Infect. Dis.
2013, 208, 921−928.
(39) Meanwell, M. A. Synopsis of some recent tactical application of
bioisosteres in drug design. J. Med. Chem. 2011, 54, 2529−2591.
(40) Prieto, M.; Zurita, E.; Rosa, E.; Luñoz, L.; Lloyd-Williams, P.;
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Abstract 
Affinity data, such as dissociation constants (KD) or inhibitory concentrations (IC50), are 
widely used in drug discovery. However, these parameters describe an equilibrium state, 
which is often not established in vivo due to pharmacokinetic effects and they are 
therefore not necessarily reliable for evaluating drug efficacy. More accurate indicators 
for pharmacological activity are the kinetics of binding processes, as they shed light on 
the rate of formation of drug-target complexes and their half-life. Nonetheless, although 
highly desirable for medicinal chemistry programs, studies on structure-kinetic 
relationships (SKR) are still rare. With the recently introduced analytical tool kinITC this 
situation may change, since not only thermodynamic but also kinetic information of the 
binding process can be deduced from isothermal titration calorimetry (ITC) experiments. 
Using kinITC, ITC data of 29 mannosides binding to the bacterial adhesin FimH were 
re-analyzed to make their binding kinetics accessible. To validate these kinetic data, 
surface plasmon resonance (SPR) experiments were conducted. The kinetic analysis by 
kinITC revealed that the nanomolar affinities of the FimH antagonists arise from both; (i) 
an optimized interaction between protein and ligand in the bound state (reduced off-rate 
constant, koff), and (ii) a stabilization of the transition state or a destabilization of the 
unbound state (increased on-rate constant, kon). Based on congeneric ligand modifications 
and structural input from co-crystal structures, a strong relationship between the formed 
hydrogen bond network and koff could be concluded, whereas electrostatic interactions 
and conformational restrictions upon binding were found to have mainly an impact on 
kon.  
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Introduction 
Although the theoretical foundation of binding kinetics in drug-target interactions was set 
by Paul Ehrlich more than a century ago (“corpora non agunt nisi fixata”), little attention 
has been paid to this concept until recently.(1,2) Only after Robert A. Copeland introduced 
the drug-target residence time concept in 2006, kinetic considerations gained increasing 
interest.(3) The key message of this model is that residence time (τ = 1/koff)(4) or half-life 
(t1/2 = ln2/koff)(3,5) of a binary drug–target complex, and not the binding affinity (e.g. 
expressed by the dissociation constant KD), controls the in vivo pharmacological activity. 
 
The launch of a new drug is associated with high financial costs and but also with a 
substantial risk of failure, mainly due to insufficient efficacy and unwanted side effects.(6) 
Several studies have shown that kinetic information is more reliable than affinity data to 
predict in vivo potency but also the resistance potential of a drug candidate.(7-9) One of 
many examples is the HIV reverse transcriptase inhibitor efavirenz that exhibits only a 
low affinity for its target (5 µM), but a long dissociation half-life (t1/2 = 2.8 h).(10) 
Furthermore, kinetic studies of Maschera et al. on HIV-1 protease mutants revealed a 
correlation between drug resistance to the HIV protease inhibitor saquinavir and an 
increased dissociation rate of the drug-target complex.(11) Nevertheless, early-phase drug 
discovery still focuses mainly on the optimization of KDs, although it has been recognized 
that kinetic rate constants for association (kon) and dissociation (koff) are a necessary 
precondition for a comprehensive description of the binding process.(12)  
 
Long dissociation half-lives are a crucial feature of many small molecule drugs on the 
market, e.g. for the neuraminidase inhibitor oseltamivir (47 min)(13), the selective COX-2 
inhibitor rofecoxib (9 h)(14) and the HIV-1 protease inhibitor darunavir (> 240 h)(15). 
Generally, a drug-target complex with a long dissociation half-life can compensate for 
unfavorable pharmacokinetics, i.e. a bimolecular complex can still exist while the 
unbound drug molecule is already cleared from the body.(16) This is of particular 
importance for substances with short plasma half-lives.(5) In contrast, in the case of drug 
toxicity fast off-rates are favored as it is the case for antipsychotics that occupy D2 
receptors (t1/2 < 1 min).(17,18) In vivo, fast on-rates play a central role in drug rebinding, 
which can be influenced for example by the local accumulation of the target and spatial 
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characteristics of the binding site.(19) In contrast to off-rates, which are independent of free 
ligand concentration, on-rates can be increased by administration of higher doses. 
However, this requires sufficient oral bioavailability and increases the risk of undesired 
side effects based on an elevated amount of drug in circulation.(20,21) 
 
It is surprising that studies on the correlation of molecular structures and their binding 
kinetics, so-called structure-kinetic relationships (SKRs), are rare.(22) In a rough 
approximation, more rotatable bonds and higher molecular weights correlate with long 
complex half-lives.(23) Moreover, water-shielded hydrogen bonds also tend to improve the 
lifetime of drug-target complexes.(24) On the other hand, the on-rate is limited by diffusion 
and can be influenced by steric and electrostatic factors as well as conformational 
dynamics.(12)  
 
Surface plasmon resonance (SPR) spectroscopy has evolved into the method of choice 
for measuring binding kinetics in drug discovery.(25) It monitors non-covalent interactions 
in real-time by detecting a mass-dependent change in the refractive index close to the 
sensor surface.(26) SPR is also applied to obtain thermodynamic information from affinity 
data as a function of temperature by van’t Hoff analysis. However, since the heat 
capacity (ΔCp) of macromolecular interactions with small molecules is mostly different 
from zero, enthalpy and entropy changes for binding are usually temperature dependent. 
This introduces curvatures in van't Hoff plots and can limit the accuracy of linear 
approximations compared to direct measurements.(27)  
 
Therefore, the method of choice to directly determine the thermodynamics of a 
molecular binding event is isothermal titration calorimetry (ITC). In contrast to SPR, 
where one interaction partner has to be immobilized on the sensor chip surface, ITC 
measures the heat change of a binding interaction in solution. This heat change can be 
converted into a binding isotherm that allows the direct measurement of KD and the 
change in enthalpy (ΔH°), whereas the change in free energy (ΔG°) (ΔG° = RTlnKD, with 
R being the universal gas constant and T the absolute temperature) and the change in 
entropy (ΔS°) (ΔG° = ΔH° – TΔS°) are calculated.(28) Both techniques are the gold-
standard in their field of application, SPR for the determination of kinetic and ITC for 
thermodynamic data.(29) 
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Recent publications from Dumas et al. have the potential to transform the role of ITC in 
drug discovery since it describes an approach to derive binding kinetics from ITC 
experiments (kinITC).(30,31) KinITC extracts kinetic information from the shape of each 
injection peak of an ITC experiment. A simplified version of this kinetic analysis, 
kinITC-ETC (Equilibration Time Curve), was recently implemented into the 
commercially available ITC analysis software AFFINImeter.(30) It determines the time 
necessary for the differential power curve to return to the baseline after the injection of an 
aliquot of ligand solution (equilibration time) as a function of the binding kinetics and the 
intrinsic response time constant of the calorimeter feedback circuit. Narrower peaks at 
the beginning and the end of the titration, as well as wider peaks around the inflection 
point, yield a bell-shaped ETC that can be analyzed in order to determine koff. Obviously, 
kinITC-ETC greatly increases the value of ITC data, allowing the direct determination of 
all relevant biophysical constants describing a binding event within one experiment. 
 
In the present study, the binding kinetics of a series of congeneric mannosides binding to 
the lectin domain of FimH (FimHLD) were determined. FimH is a virulence factor 
located at the tip of type 1 pili of uropathogenic E. coli (UPEC) strains.(32,33) It interacts 
with the highly mannosylated glycoprotein uroplakin Ia, which is part of the urothelial 
mucosa and thereby mediates bacterial adhesion to the bladder epithelium as the initial 
step of urinary tract infection (UTI).(34) An anti-adhesion therapy with FimH antagonists, 
which block the adhesion and thereby prevent the infection, could therefore be beneficial 
for patients suffering from recurrent UTI.(35,36) Reanalyzing data from numerous ITC(37-41) 
and SPR(42) studies we published in the last 5 years, enabled the validation of the 
kinITC-ETC approach and the correlation of kinetic parameters with structural 
properties of a large ligand dataset. The kinetic fingerprints of FimH antagonists offer the 
opportunity to further improve the binding characteristics essential for a clinical 
application.  
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Results and Discussion 
The publication on kinITC by Burnouf et al. in 2012 gained wide interest, but the 
complexity of the analysis hampered a broader application.(31) However, with kinITC-
ETC integrated into the commercially available ITC analysis software AFFINImeter(43) 
this hurdle could be overcome. It uses fully automated data processing to derive kinetic 
and thermodynamic information from ITC raw data avoiding the risk of user bias as can 
arise through manual evaluation of thermograms. We applied kinITC-ETC to deduce 
binding kinetics from ITC data of a large set of structurally diverse FimH antagonists 
(compounds 1-29, see Table S1). This kinetic information proved to be extremely 
valuable as it provided a more detailed insight into the binding process of 
carbohydrate-based antagonists to the adhesin FimHLD. 
 
Validation of kinITC-ETC by SPR. Although Dumas et al. proved the potential of 
kinITC with the evaluation of multi-step kinetic RNA folding,(31) there is, to the best of 
our knowledge, no independent comparison of data obtained by kinITC-ETC and those 
derived from alternative biophysical methods available to date. For this purpose, a subset 
of four mannose-based FimH antagonists (compounds 1-4) was investigated by SPR. For 
the on-rate constants kon, the comparison revealed an excellent correlation with absolute 
values differing by less than a factor of two (Table 1A), whereas up to 6-fold deviation 
was observed for koff values (Table 1B). These differences might be a consequence of 
ligand rebinding on the SPR chip surface.(44) However, when we normalized the koff-
values obtained by SPR and kinITC-ETC to that of n-heptyl α-D-mannopyranoside (1) 
(giving relative koff,  rkoff) differences of less than a factor of 2 arised (Table 1B). In their 
comparison of SPR and kinITC, Dumas et al. reported similar difference for thiamine 
pyrophosphate interacting with mRNA.(31)  
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Table 1. Comparison of kinetic data obtained by kinITC-ETC and SPR for the interaction of FimHLD with 
the mannose-derived FimH antagonists 1-4. Absolute (kon and koff) and relative (rkon and rkoff) kinetic 
parameters are reported for both methods (Table 1A for on-rates & Table 1B for off-rates). Relative values 
are normalized to n-heptyl α-D-mannopyranoside (1), which is set to 1. The discrepancies between kinITC-
ETC and SPR for kon (Table 1A) and koff (Table 1B) values are displayed in the rightmost columns. KD 
values (Table S2), as well as confidence intervals for kon and koff (ITC, Table S4 and SPR, Table S5), are 
part of the supplementary information. 
 
 
 
Table 1A. Association rate constants kon of FimHLD with compound 1 – 4 determined by ITC and SPR 
Compound 
kon
kinITC-ETC kon
SPR kon
kinITC-ETC/kon
SPR 
kon 
[M-1s-1] 
rkon 
kon 
[M-1s-1] 
rkon absolute relative 
1 3.32*104 1.00 2.45*104 1.00 1.35 1.00 
2 9.71*103 0.29 5.57*103 0.23 1.74 1.29 
3 2.31*103 0.07 2.45*103 0.10 0.94 0.70 
4 2.00*103 0.06 2.67*103 0.11 0.75 0.55 
 
Table 1B. Dissociation rate constants koff of FimHLD with compound 1 – 4  determined by ITC and SPR 
Compound 
koff
kinITC-ETC koff
SPR koff
kinITC-ETC/koff
SPR 
koff 
[s-1] 
rkoff 
t1/2 
[min] 
koff 
[s-1] 
rkoff 
t1/2 
[min] 
absolute relative 
1 7.27*10-4 1.00 15.9 1.54*10-4 1.00 75.0 4.72 1.00 
2 1.15*10-3 1.58 10.1 1.89*10-4 1.23 61.1 6.07 1.29 
3 2.86*10-3 3.93 4.1 1.11*10-3 7.21 10.4 2.57 0.54 
4 1.82*10-3 2.50 6.3 6.51*10-4 4.23 17.7 2.80 0.59 
 
 
Kinetics of FimHLD binding. Only recently, when correlations between prolonged drug-
target half-lives and clinical efficacy of drugs were reported, binding kinetics attracted the 
interest of the drug discovery community.(17,45,46) The initial assumption that association 
rate constants are only diffusion controlled and rather constant within a congeneric set of 
ligands for a specific target had to be revised.(22,23,47) Indeed, our test subset clearly 
indicates that the variations of the on-rate constants within the series of congeneric FimH 
antagonists 1-4 are more pronounced (for kinITC ≈ 1 : 16, Table 1A) than of the off-rate 
constants (for kinITC ≈ 1 : 4, Table 1B).  
 
To exclude that the length of the aliphatic aglycone affects the extended hydrogen bond 
network formed by the mannose moieties of compounds 1-4, co-crystal structures of 
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compound 3 (PDB-code: 5JCR) and 4 (PDB-code: 5MUC) were solved and compared 
with published structures of compound 1 (PDB-code: 4XO8)(48) and 2 (PDB-code: 
1UWF)(49) (Table S3). For all four ligands, both protein structure and binding mode were 
found to be identical (Figure 1). Hence, the higher on-rate constants of antagonist 1 and 2 
must be a result of their elongated aglycones. This finding is unexpected since the 
favorable interactions of the elongated aglycones of compound 1 and 2 with Tyr48 and 
Tyr137 (called tyrosine gate) were presumed to primarily lower the off-rate resulting in a 
prolonged complex half-life.  
 
 
Figure 1. Binding mode of compounds 1-4 to FimHLD. The co-crystal structures of 1 (red, PDB-code: 
4XO8), 2 (yellow, PDB-code: 1UWF), 3 (green, PDB-code: 5JCR) and 4 (blue, PDB-code: 5MUC) show 
coinciding binding modes. Their mannose moieties form identical hydrogen bond networks with FimHLD 
and a structural water molecule (W1), whereas only the aglycones of 1 and 2 interact with the two tyrosines 
48 and 137.  
 
A one-step model with ligand and protein in the unbound state (U), in the transition state 
(TS‡), and in the bound state (B) characterized by the kinetic rate constants kon and koff is 
the simplest way to describe a protein-ligand interaction (Figure 2-A). However, more 
common is a multistep binding mechanism with apparent rate constants composed of 
multiple elementary rate constants.(12) Rate constants depend upon the free energy 
difference ΔGTS-U (between TS‡ and U) for kon and the free energy difference ΔGTS-B 
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(between TS‡ and B) for koff, respectively (Figure 2-A). The energy difference between B 
and U represents the equilibrium free energy of binding (ΔGB-U, or ΔG°). Changes in the 
relative stability of these states due to structural differences of the ligand (or the protein as 
a consequence of mutations) provoke changes in one or both rate constants. A 
stabilization of U and B relative to TS‡ (or destabilization of TS‡ relative to U and B) 
decreases the on-rate and the off-rate, respectively. Ligand modifications leading to 
improved or worsened interaction with the target protein, affect the stability of the 
various states. Thus, for example, an additional interaction predominantly formed in B 
and to a lesser extent in TS‡, will increase ΔGTS-B (decrease koff) and to a lesser extent 
decrease ΔGTS-U (increase kon). Concomitantly, the change of ΔG° leads to tighter binding. 
Furthermore, structural modifications that affect long-range electrostatics of the ligand 
and thus its proper orientation can affect the rate constants by altered diffusion, 
significantly impeding an interpretation based only on changes in the relative 
thermodynamic stability of states. 
 
The kinetic data of antagonists 1-4 obtained by both ITC and SPR demonstrate that the 
improvements of on-rates go hand in hand with the elongation of the aglycone, whereas 
off-rates are decreased, however to a lesser extent, leading to an overall improved KD-
value (Table S2). Hence, increased on-rates are related to favorable interactions realized 
in TS‡ or a destabilization of U relative TS‡, whereas decreased off-rates imply an 
additional stabilization of B relative to TS‡. Although structural information regarding 
TS‡ is not available, it seems plausible to speculate that a hydrophobic aglycone first 
establishes a contact with the surface-exposed tyrosine gate of FimHLD. Only then the 
protein-ligand complex relaxes from the TS‡ to the bound state B by a successful 
completion of the hydrogen bond network within the binding site. A similar effect was 
described for the human carbonic anhydrase II (hCAII), where the on-rate increased in 
parallel with the chain length of interacting alkyl benzenesulfonamides.(50,51) In a pre-
binding state, increasing hydrophobicity of the ligand was found to enhance the 
interaction with a hydrophobic patch of the enzymatic cavity.(52) 
 
To investigate the kinetic behavior of FimHLD antagonists in more detail, its binding 
interaction with 29 antagonists (for structural details see supporting information, Table 
S1) covering a broad range of affinities (1 nM to 100 µM) were analyzed by kinITC-ETC. 
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Thermodynamic and kinetic fits (Table S1) and binding parameters (Table S3&S4) are 
listed in the supporting information.  
 
Structure-kinetic relationship (SKR) 
Influence of the site of ligand modification. With the set of 29 carbohydrate-based 
antagonists, we studied how the site of the structural modification affects the correlation 
between binding energies and kinetic binding rates. The ligands were divided into two 
subsets; one subset (n = 17) containing all representatives with varied aglycones 
(compounds 2-4 with alkyl chains of different length; 10-21 with biphenyl aglycones, 22 
with a squaric acid aglycone and 23 with an indolinylphenyl aglycone) and a second 
subset (n = 11) representing compounds with modified mannose moieties (deoxy- and 
deoxy-halogeno derivatives 5-8 and 24-27, septulose derivative 9 and two C-2 branched 
mannose derivatives 28 and 29 (see supporting information, Table S1). For the two 
subsets, significantly different correlations of ΔG° with kon- (Figure 2-B, p < 0.001) and 
koff-values (Figure 2-C, p < 0.001) were obtained. Modifications of the mannose moiety, 
known to form an extended hydrogen bond network in the deep binding pocket of 
FimHLD, affect the koff-values (slope = 0.268, R2 = 0.906) to a greater extent than those of 
the aglycone (slope = 0.133, R2 = 0.801). In contrast, modifications of the aglycone, 
forming beneficial contacts with the tyrosine gate in the bound state,(37) influence kon-
values (slope = -0.270, R2 = 0.943) to a larger degree than those of the mannose moiety 
(slope = -0.135, R2 = 0.710).  
 
Thus, the mannose moiety establishes stronger interactions in the bound state B than in 
the transition state TS‡, resulting in the observed stronger effect on the off-rate constant 
koff (slope = 0.268) than on the on-rate constant kon (slope = -0.135). For structural 
modifications of the aglycone, however, the impact on kon-values (slope = -0.270) is more 
pronounced than on koff- values (slope = 0.133). This suggests that either the TS‡ is 
stabilized relative to the bound state B (e.g. the aglycone establishes stronger interactions 
with the receptor in the TS‡ than in the bound state), or that the unbound state U is 
destabilized relative to the TS‡.  
 
The results observed for compounds 1-4 seamlessly fit into the trend observed for all 
studied FimH antagonists. However, these correlations are based on a rough ligand 
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classification (modifications of the glycan or aglycone), neglecting various factors, e.g. 
electrostatic interactions or flexibility of the ligand. Contributions from these factors can 
only be revealed by a closer look at individual structural details of the various ligands and 
at their interactions with the protein.  
 
 
Figure 2.  A) The energy diagram illustrates a simple one-step binding process with the transition state 
(TS‡) separating the unbound state (U) from the bound state (B). ΔGTS-U is the activation free energy of 
association, ΔGTS-B the activation free energy of dissociation, ΔG° the free energy of binding and kon and koff 
are the kinetic rate constants. B) The correlation of the kinetic parameters kon and C) koff with changes of 
ΔG° depends on the site of a ligand’s modification. Ligands with modified aglycones (2-4; 10-23; for 
structures and binding parameters see supporting information, full symbols, solid regression lines) are 
separated from ligands with modified mannose moieties (5-9; 24-29; for structure and binding parameters 
see supporting information, hollow symbols, dotted regression lines).  
 
 
Hydrogen bonds, electrostatic interactions, and conformational changes. To rationalize the 
trend that mannose modifications have a larger impact on off-rates than on on-rates 
(Figure 2-B & 2-C), interactions of ligands 5-9 with FimHLD were analyzed in more detail 
(Table 2). The 2-hydroxyl of n-heptyl α-D-mannopyranoside (1) forms two hydrogen 
bonds with FimHLD, once as H-bond donor to a structural water molecule (W1) and once 
as H-bond acceptor from the positively charged N-terminal Phe (Figure 1). Substitution 
of the 2-hydroxy group with a fluorine (1 → 5) leads to a loss of hydrogen bonds, while 
the electrostatic interactions are largely preserved as oxygen and fluorine share a 
comparable polarity and a close isosteric relationship. Upon removal of the 2-hydroxy 
group (1 → 8) both the H-bonds and the electrostatic interactions are lost. In terms of 
kinetics, the loss of H-bonds (1 → 5) mainly affects the off-rate. In contrast, decreasing 
electronegativity reduces the electrostatic interaction with the N-terminus from fluorine 
to chlorine to bromine (5 → 6 → 7) and affects the kon-value to a larger extent than the 
koff-value. This complex behavior results from differential contributions: (i) electrostatic 
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guiding during the formation of the TS‡ which enhances on- and off-rates and (ii) the 
formation of more specific interactions in the bound state which decreases off-rates. 
 
Table 2. Kinetic binding parameters for the interaction of FimHLD with mannose derivatives of n-heptyl α-
D-mannopyranoside (1). Confidence intervals of the fitted parameters kon, koff, KD, and the response time of 
the calorimeter feedback circuit are part of the supplementary information (Table S4). Relative changes 
(rkon, rkoff) are compared to n-heptyl α-D-mannopyranoside (1). 
 
 
Compound 
kon 
[M-1s-1] 1/rkon 
koff 
[s-1] rkoff 
t1/2 
[min] 
1 3.32*104 1.0 7.27*10-4 1.0 15.9 
 5 (2-F) 2.04*104 1.6 1.02*10-2 14.0 1.1 
 6 (2-Cl) 8.90*103 3.7 1.19*10-2 16.4 1.0 
 7 (2-Br) 7.90*103 4.2 1.45*10-2 19.9 0.8 
 8 (2-H) 5.35*103 6.2 4.13*10-2 56.8 0.3 
 9 (7-ring) 5.10*103 6.5 1.35*10-3 1.9 8.6 
 
However, mannose modifications may also affect the on-rate constant, as observed for 
the ring extended compound 9.38 Septulose 9 (PDB-code: 5CGB) and pyranoside 1 
(PDB-code: 4XO8) establish an identical H-bond network with FimHLD. Upon binding to 
the lectin, the markedly increased flexibility of septulose 9 in solution leads to an entropy 
penalty due to a loss of conformational freedom upon binding, affecting thermodynamics 
as well as kinetics accordingly. The increase in flexibility of ligand 9 in solution stabilizes 
the U relative to TS‡ and to a lesser extent to B where the flexibility of all ligands is 
largely restricted by binding interactions. This results in a considerably lowered on-rate 
and a relatively small increase in the off-rate (Table 2). 
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Conclusion 
 
Based on ITC measurements, the new analytical tool kinITC-ETC allowed the 
determination of kinetic data for 29 FimH antagonists. To test the reliability of kinITC-
ETC, the kinetic rate constants for a subset of 4 ligands were compared with data 
measured by SPR. The systematically lower dissociation rate constant (koff) obtained by 
SPR may originate from a fundamental difference between the two approaches. ITC 
measures molecular interactions in free solution, whereas SPR requires the 
immobilization of one binding partner on a chip surface. The reduction of the apparent 
koff in SPR measurements may be due to the analyte’s rebinding to the immobilized 
partner. However, our attempts to mitigate this effect by using a low immobilization 
density had only a limited effect. Another rationale for the observed difference in koff may 
arise from errors associated with the kinITC-ETC method, i.e. the observed kinetics of 
heat evolution in ITC experiments includes a contribution from the intrinsic instrumental 
response time (τITC), which can vary between instruments and for the same instrument 
depending on cleanliness. Since we re-analyzed existing data for this study, τITC was 
included as a fitting parameter in the kinITC-ETC analysis and not measured for the 
instrument at the time of the experiment. Nevertheless, it should be noted that the 
systematic disagreement in off-rates between SPR and ITC measurements is still 
relatively small (less than an order of magnitude), and that the relative rate constants 
obtained with kinITC-ETC and SPR are in good agreement. Therefore, kinITC-ETC can 
be regarded as a reliable method to derive kinetic information from ITC experiments. 
 
The insight into the binding kinetics of the 29 mannose-based antagonists strongly 
improved our understanding of their binding characteristics. Their enhanced KD values 
not only stand for prolonged complex half-lives, but also for increased kon-rates indicating 
a stabilization the transition state and destabilization of the unbound state. On a 
structural level, the kinetic contributions of the carbohydrate moiety could be separated 
from that of the aglycone. The structural variations of the sugar moiety, which forms an 
extended hydrogen bond network in the deep binding pocket of FimHLD, mainly 
influence the off-rate constant koff, while modifications on the aglycone establishing 
hydrophobic interactions with the two tyrosines at the entrance to the mannose-binding 
pocket, predominantly affect kon. The latter observation could be an indication that the 
aglycone initially establishes a contact with the tyrosine gate to facilitate the mannose 
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moiety to enter the carbohydrate recognition domain (CRD). This finding is in excellent 
agreement with previous observations from Gaspari et al. for the interaction of hCAII 
with hydrophobic ligands.(52) Initial hydrophobic interactions to stabilize protein-ligand 
interactions before the final binding mode is established might in general facilitate ligand 
recruitment from solution. Furthermore, electrostatic interactions may beneficially 
influence the on-rate as exemplified by the substitution of the 2-hydroxy group of the 
mannose moiety by fluorine, chlorine, bromine or hydrogen. Finally, due to its flexibility 
in solution, the unbound state of septulose derivative 9 is stabilized relative to its 
transition state, resulting in a reduced on-rate. 
 
These kinetic considerations are essential for the success of a therapeutic treatment of 
UTI, because the half-life of the complex formed by a carbohydrate-based antagonist is a 
cardinal parameter. Only an extended half-life of the antagonist/FimH complex, 
prevents bacteria from interacting with the urothelial cells of the host for long enough to 
allow bacterial elimination by urination.  
 
Our kinetic study with FimHLD is the first systematic analysis of a drug-target interaction 
using kinITC-ETC. Additional studies will improve the insight into the effects originating 
from ligand modifications upon binding kinetics and may lead to generally applicable 
rules. For numerous projects over past 20 years ITC data had been acquired and the 
hidden kinetic treasures can now be raised by kinITC-ETC. We therefore expect kinITC-
ETC to become a popular instrument for “data mining.”  
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Supporting Information 
Table S1: Structure, thermodynamic and kinetic fits of FimHLD binding to mannoside ligands 1-29. All 
measurements were performed at 25°C in HEPES buffer adjusted to pH 7.4, containing 150 mM NaCl. 
Data were analyzed using the AFFINImeter software. 
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1 
 
 
  
  
2 
 
  
  
3 
 
  
  
4 
 
  
  
5 
   
OHO
HO
OH
O
HO
OHO
HO
OH
O
HO
OHO
HO
OH
O
HO
OHO
HO
OHHO
OHO
HO
FHO
O
173
Section II. The Bacterial Adhesin FimH – Manuscript 6 
6 
7 
8 
9 
10 
OHO
HO
ClHO
O
OHO
HO
BrHO
O
OHO
HO
HO
O
OHO
HO
HO
OH
O
OHO
HO
OHHO
O
174
Section II. The Bacterial Adhesin FimH – Manuscript 6 
 
11 
 
  
12 
 
  
13 
 
  
14 
 
  
15 
 
  
16 
 
  
17 
 
  
18 
 
  
OHO
HO
OHHO
O
OH
O
OHO
HO
OHHO
O
OH
O
F
OHO
HO
OHHO
O
OH
O
OMe
OHO
HO
OHHO
O
OH
O
Me
OHO
HO
OHHO
O
NHMe
O
OHO
HO
OHHO
O
N
O
O
OHO
HO
OHHO
S
OO
O
Me
OHO
HO
OHHO
S
O
O NH
O
175
Section II. The Bacterial Adhesin FimH – Manuscript 6 
 
19 
 
  
20 
 
  
21 
 
  
22 
 
  
23 
   
24 
 
  
  
25 
 
  
  
OHO
HO
OHHO
O
O
OH
Cl
OHO
HO
OHHO
O
CN
OHO
HO
OHHO
O
CN
Cl
O
Cl
NH
OO
N
NMe
OHO
HO
OHHO
N
NO2
O
OHO
HO
OHHO
OHO
F
OHHO
O
OHO
OHHO
O
176
Section II. The Bacterial Adhesin FimH – Manuscript 6 
26 
27 
28 
29 
OF
HO
OHHO
O
O
HO
OHHO
O
OHO
HO
OH
O
HO
HO
OHO
HO
OH
O
HO
177
Section II. The Bacterial Adhesin FimH – Manuscript 6 
 
Table S2: Comparison of KD-values obtained by kinITC-ETC and SPR for the interaction of FimHLD with 
mannose-derived FimH antagonists. Absolute (KD) and relative (rKD) parameters are shown for both 
methods. Relative values are normalized to n-heptyl α-D-mannopyranoside (1), which is set to 1. The 
discrepancies between kinITC and SPR for KD and rKD is displayed in the right columns.  
 
FimHLD ligand dissociation constants determined by ITC and SPR 
Compound 
KD
kinITC-ETC KD
SPR KD
kinITC-ETC/KD
SPR 
KD [M] rKD KD [M] rKD absolute relative 
1 2.19*10-8 1.00 6.28*10-9 1.00 3.48 1.00 
2 1.18*10-7 5.40 3.39*10-8 5.39 3.49 1.00 
3 1.24*10-6 56.47 4.54*10-7 72.21 2.72 0.78 
4 9.13*10-7 41.71 2.44*10-7 38.78 3.75 1.08 
 
Table S3: Thermodynamic parameters of FimHLD binding to mannoside ligands 1-29. All ITC 
measurements were performed at 25°C in HEPES buffer adjusted to pH 7.4, containing 150 mM NaCl. 
Data were analyzed using the AFFINImeter software. 
Cpd KD [M] 
c.i. KD 
[M] 
ΔG° 
[kJ/mol] 
ΔH° 
[kJ/mol] 
c.i. ΔH° 
[kJ/mol] 
-TΔS° 
[kJ/mol] N c 
1 1.93*10-8 2.45*10-9 -44.0 -48.8 0.2 4.8 0.97 518 
1 2.45*10-8 2.81*10-9 -43.4 -52.1 0.2 8.7 0.98 351 
1 2.19*10-8 2.63*10-9 -43.7 -50.5 0.2 6.7    
2 1.08*10-7 7.38*10-9 -39.8 -42.7 0.3 3.0 0.88 104 
2 1.28*10-7 1.35*10-8 -39.3 -41.1 0.6 1.8 0.94 74 
2 1.18*10-7 1.04*10-8 -39.5 -41.9 0.4 2.4    
3 1.39*10-6 4.87*10-8 -33.4 -36.3 0.2 2.8 0.95 21 
3 1.08*10-6 4.55*10-8 -34.0 -36.7 0.2 2.6 0.92 27 
3 1.24*10-6 4.71*10-8 -33.7 -36.5 0.2 2.8    
4 8.06*10-7 3.69*10-8 -34.8 -41.1 0.2 6.3 1.04 34 
4 1.02*10-6 3.73*10-8 -34.2 -42.3 0.2 8.1 0.97 29 
4 9.13*10-7 3.71*10-8 -34.5 -41.7 0.2 7.2    
5b 5.65*10-7 2.04*10-8 -35.7 -27.5 0.1 -8.2 1.02 41 
5 4.99*10-7 1.30*10-8 -36.0 -28.0 0.1 -8.0 1.04 49 
6 1.68*10-6 3.36*10-8 -33.0 -24.9 0.1 -8.1 1.04 28 
6 9.95*10-7 1.80*10-8 -34.3 -24.1 0.1 -10.1 1.02 40 
6 1.34*10-6 2.58*10-8 -33.5 -24.5 0.1 -9.0     
7 2.14*10-6 3.81*10-8 -32.4 -21.1 0.1 -11.2 1.00 23 
7 1.52*10-6 5.48*10-8 -33.2 -20.5 0.1 -12.7 1.03 21 
7 1.83*10-6 4.65*10-8 -32.7 -20.8 0.1 -11.9   
8b 1.18*10-5 1.16*10-7 -28.1 -20.3 0.0 -7.9 1.01 5.3 
8 7.71*10-6 8.07*10-8 -29.2 -18.4 0.0 -10.7 1.00 5.4 
9 2.59*10-7 8.84*10-9 -37.6 -47.5 0.1 9.9 1.04 110 
9 2.71*10-7 9.85*10-8 -37.5 -48.6 0.1 11.2 0.97 110 
9 2.65*10-7 5.37*10-8 -37.5 -48.0 0.1 10.5     
10 3.62*10-8 3.09*10-9 -42.5 -45.9 0.2 3.4 1.00 290 
10 2.06*10-8 1.33*10-9 -43.9 -43.9 0.1 0.0 1.05 681 
10 2.84*10-8 2.21*10-9 -43.1 -44.9 0.2 1.8    
11 1.21*10-8 9.65*10-9 -45.2 -46.0 0.2 0.8 1.05 802 
12 9.21*10-9 7.20*10-10 -45.9 -49.5 0.1 3.6 1.04 1053 
13 1.35*10-8 9.50*10-10 -44.9 -51.2 0.1 6.3 1.00 717 
14 1.08*10-8 1.24*10-9 -45.5 -56.2 0.3 10.8 1.06 1046 
15a 6.49*10-9 1.13*10-9 -46.7 -52.0 0.5 5.3 1.00 1757 
16a 4.19*10-9 8.47*10-10 -47.8 -56.2 0.2 8.3 0.98 2016 
17a 1.21*10-8 3.49*10-9 -45.2 -49.6 0.1 4.4 0.99 1056 
18a 2.91*10-9 1.01*10-9 -48.7 -50.1 0.3 1.3 1.08 3056 
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19a 4.90*10-9 8.57*10-10 -47.4 -53.9 0.2 6.4 1.04 1980 
20a 4.13*10-9 8.35*10-10 -47.9 -56.1 0.3 8.2 0.98 2544 
21a 1.29*10-9 2.61*10-10 -50.7 -60.8 0.5 10.1 1.05 7737 
22 1.15*10-8 8.48*10-10 -45.3 -60.7 0.2 15.4 1.04 758 
23a 9.74*10-10 3.70*10-10 -51.4 -59.5 0.5 8.0 1.00 5134 
24 9.38*10-7 1.54*10-8 -34.4 -29.3 0.1 -5.1 1.09 33 
24 1.45*10-6 4.40*10-8 -33.3 -33.4 0.2 0.1 1.08 14 
24 1.19*10-6 2.97*10-8 -33.8 -31.4 0.1 -2.4     
25 2.09*10-5 1.52*10-7 -26.7 -25.2 0.1 -1.5 1.00 2.1 
25 1.89*10-5 1.81*10-7 -27.0 -24.4 0.1 -2.6 1.00 3.8 
25 1.99*10-5 1.67*10-7 -26.8 -24.8 0.1 -2.1     
26c 9.19*10-5 1.21*10-6 -23.0 -19.3 0.1 -3.7 1.00 0.5 
26c 1.15*10-4 1.46*10-6 -22.5 -21.7 0.1 -0.8 1.00 0.5 
26 1.03*10-4 1.34*10-6 -22.7 -20.5 0.1 -2.2     
27c 8.57*10-5 5.74*10-7 -23.2 -19.6 0.0 -3.7 1.00 0.5 
27c 9.11*10-5 6.60*10-7 -23.1 -20.1 0.0 -3.0 1.00 0.5 
27 8.84*10-5 6.17*10-7 -23.1 -19.8 0.0 -3.3     
28 1.69*10-7 4.48*10-9 -38.7 -35.0 0.1 -3.7 1.00 164 
28 7.64*10-8 4.27*10-9 -40.6 -33.1 0.1 -7.5 1.00 107 
28 1.22*10-7 4.38*10-9 -39.5 -34.0 0.1 -5.4     
29 5.05*10-8 7.83*10-9 -41.6 -26.1 4.1 -15.5 0.98 77 
29 9.33*10-8 9.66*10-8 -40.1 -28.8 0.3 -11.3 0.99 94 
29 7.19*10-8 5.22*10-8 -40.8 -27.5 2.2 -13.3     
a KD fixed from a competitive experiment evaluated with SEDPHAT due to c-values above 1000. 
b Excluded from data analysis due to large errors of the kinetic fit. 
c Stoichiometry fixed to 1 due to c-values below 1. 
 
Table S4: Kinetic parameters of FimHLD binding to mannoside ligands 1-29. All ITC measurements were 
performed at 25°C in HEPES buffer adjusted to pH 7.4, containing 150 mM NaCl. Data were analyzed 
using AFFINImeter software. kon was calculated from the fitted parameters KD and koff.  
 
Cpd KD [M] ln (KD) 
koff  
[s-1] ln (koff) 
c.i. koff  
[s-1] 
kon  
[M-1s-1] ln (kon) 
t1/2 
[min] 
Response  
time [s] 
1 1.93*10-8 -17.76 7.47*10-4 -7.20 6.10*10-5 3.87*104 10.56 15.46 12.9 
1 2.45*10-8 -17.53 7.06*10-4 -7.26 5.73*10-5 2.88*104 10.27 16.37 12.0 
1 2.19*10-8 -17.64 7.27*10-4 -7.23 5.91*10-5 3.32*104 10.41 15.90  
2 1.08*10-7 -16.04 1.06*10-3 -6.85 5.98*10-5 9.84*103 9.19 10.85 12.1 
2 1.28*10-7 -15.87 1.23*10-3 -6.70 9.32*10-5 9.61*103 9.17 9.39 13.2 
2 1.18*10-7 -15.95 1.15*10-3 -6.77 7.65*10-5 9.71*103 9.18 10.07  
3 1.39*10-6 -13.49 2.92*10-3 -5.84 1.21*10-4 2.10*103 7.65 3.96 11.2 
3 1.08*10-6 -13.74 2.79*10-3 -5.88 1.04*10-4 2.58*103 7.85 4.14 16.3 
3 1.24*10-6 -13.60 2.86*10-3 -5.86 1.12*10-4 2.31*103 7.75 4.05  
4 8.06*10-7 -14.03 1.73*10-3 -6.36 7.43*10-5 2.14*103 7.67 6.69 13.0 
4 1.02*10-6 -13.80 1.92*10-3 -6.26 9.53*10-4 1.88*103 7.54 6.03 11.9 
4 9.13*10-7 -13.91 1.82*10-3 -6.31 5.14*10-4 2.00*103 7.60 6.34  
5b 5.65*10-7 -14.39 5.33*10-2 -2.93 3.13*10-2 9.43*104 11.45 0.22 15.0 
5 4.99*10-7 -14.51 1.02*10-2 -4.59 1.22*10-3 2.04*104 9.92 1.14 13.6 
6 1.68*10-6 -13.30 1.15*10-2 -4.47 1.50*10-3 6.84*103 8.83 1.01 11.8 
6 9.95*10-7 -13.82 1.23*10-2 -4.40 1.42*10-3 1.24*104 9.42 0.94 12.6 
6 1.34*10-6 -13.53 1.19*10-2 -4.43 1.46*10-3 8.90*103 9.09 0.97  
7 2.14*10-6 -13.05 2.19*10-2 -3.82 3.49*10-3 1.02*104 9.23 0.53 13.7 
7 1.52*10-6 -13.40 7.00*10-3 -4.96 5.01*10-4 4.62*103 8.44 1.65 8.9 
7 1.83*10-6 -13.21 1.45*10-2 -4.24 1.99*10-3 7.90*103 8.97 0.80  
8b 1.18*10-5 -11.34 4.98*10-1 -0.70 8.21*10-1 4.21*104 10.65 0.02 14.6 
8 7.71*10-6 -11.77 4.13*10-2 -3.19 1.17*10-2 5.35*103 8.59 0.28 13.1 
9 2.59*10-7 -15.17 1.29*10-3 -6.65 3.88*10-5 4.98*103 8.51 8.95 10.3 
9 2.71*10-7 -15.12 1.41*10-3 -6.56 4.72*10-5 5.20*103 8.56 8.20 12.2 
9 2.65*10-7 -15.14 1.35*10-3 -6.61 4.30*10-5 5.10*103 8.54 8.56  
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10 3.62*10-8 -17.13 1.42*10-3 -6.56 9.98*10-5 3.91*104 10.57 8.16 11.1 
10 2.06*10-8 -17.70 1.31*10-3 -6.64 8.56*10-5 6.36*104 11.06 8.83 12.9 
10 2.84*10-8 -17.38 1.36*10-3 -6.60 9.27*10-5 4.80*104 10.78 8.48 
11 1.21*10-8 -18.23 4.83*10-4 -7.63 2.85*10-5 4.00*104 10.60 23.90 12.2 
12 9.21*10-9 -18.50 5.03*10-4 -7.60 2.94*10-5 5.45*104 10.91 22.99 13.1 
13 1.35*10-8 -18.12 4.40*10-4 -7.73 2.19*10-5 3.25*104 10.39 26.26 12.1 
14 1.08*10-8 -18.34 4.96*10-4 -7.61 4.01*10-5 4.59*104 10.73 23.29 13.3 
15a 6.49*10-9 -18.85 3.31*10-4 -8.01 3.51*10-5 5.10*104 10.84 34.89 12.4 
16a 4.19*10-9 -19.29 3.77*10-4 -7.88 1.07*10-5 9.02*104 11.41 30.61 12.4 
17a 1.21*10-8 -18.23 3.23*10-4 -8.04 1.36*10-5 2.66*104 10.19 35.81 11.1 
18a 2.91*10-9 -19.66 3.08*10-4 -8.08 1.42*10-5 1.06*105 11.57 37.47 12.7 
19a 4.90*10-9 -19.13 4.10*10-4 -7.80 1.56*10-5 8.36*104 11.33 28.20 13.8 
20a 4.13*10-9 -19.31 2.14*10-4 -8.45 9.02*10-6 5.19*104 10.86 53.96 12.8 
21a 1.29*10-9 -20.47 5.14*10-4 -7.57 4.30*10-5 3.98*105 12.89 22.48 12.3 
22 1.15*10-8 -18.28 5.04*10-4 -7.59 2.97*10-5 4.39*104 10.69 22.94 12.8 
23a 9.74*10-10 -20.75 2.10*10-4 -8.47 6.27*10-6 2.16*105 12.28 55.00 13.2 
24 9.38*10-7 -13.88 1.07*10-2 -4.54 8.04*10-4 1.14*104 9.34 1.08 12.8 
24 1.45*10-6 -13.44 2.90*10-2 -3.54 8.16*10-3 2.00*104 9.91 0.40 11.9 
24 1.19*10-6 -13.64 1.98*10-2 -3.92 4.48*10-3 1.66*104 9.72 0.58 
25 2.09*10-5 -10.78 1.85*10-1 -1.69 5.66*10-2 8.85*103 9.09 0.06 13.6 
25 1.89*10-5 -10.88 7.36*10-2 -2.61 1.86*10-2 3.90*103 8.27 0.16 13.4 
25 1.99*10-5 -10.83 1.29*10-1 -2.05 3.76*10-2 6.50*103 8.78 0.09 
26c 9.19*10-5 -9.29 1.03*10-1 -2.27 1.17*10-2 1.12*103 7.02 0.11 13.5 
26c 1.15*10-4 -9.07 1.04*10-1 -2.26 1.48*10-2 9.04*102 6.81 0.11 12.7 
26 1.03*10-4 -9.18 1.03*10-1 -2.27 1.32*10-2 1.00*103 6.91 0.11 
27c 8.57*10-5 -9.36 8.65*10-2 -2.45 8.33*10-3 1.01*103 6.92 0.13 10.9 
27c 9.11*10-5 -9.30 8.25*10-2 -2.50 7.34*10-3 9.05*102 6.81 0.14 10.9 
27 8.84*10-5 -9.33 8.45*10-2 -2.47 7.84*10-3 9.56*102 6.86 0.14 
28 1.69*10-7 -15.60 1.52*10-3 -6.49 6.98*10-5 9.01*103 9.11 7.61 10.8 
28 7.64*10-8 -16.39 8.77*10-4 -7.04 5.35*10-5 1.15*104 9.35 13.18 12.5 
28 1.22*10-7 -15.92 1.20*10-3 -6.73 6.16*10-5 9.78*103 9.19 9.65 
29 5.05*10-8 -16.80 8.93*10-4 -7.02 1.03*10-4 1.77*104 9.78 12.94 16.0 
29 9.33*10-8 -16.19 1.13*10-3 -6.79 9.01*10-5 1.21*104 9.40 10.24 15.0 
29 7.19*10-8 -16.45 1.01*10-3 -6.90 9.67*10-5 1.41*104 9.55 11.43 
a KD fixed from a competitive experiment evaluated with SEDPHAT due to c-values above 1000. 
b Excluded from data analysis due to large errors of the kinetic fit. 
c Stoichiometry fixed to 1 due to c-values below 1. 
Table S5. Kinetic parameters of FimHLD binding to mannoside ligands 1-4. All SPR measurements were 
performed at 25°C in HBS-EP buffer adjusted to pH 7.4, containing 150 mM NaCl, 3 mM EDTA and 
0,005% P20. Two independent measurements were performed and the best fit (Biacore T200 Evaluation 
software version 1) was averaged (bold). Standard deviations are given in parentheses. KD was calculated 
from the fitted parameters kon and koff. 
Cpd KD 
[M] 
koff 
[s-1] 
kon 
[M-1s-1] 
t1/2 
[min] 
Response 
Units 
1 6.10*10-9 1.68*10-4 2.76*104 68.6 5.7 
1 6.53*10-9 1.39*10-4 2.14*104 82.9 5.9 
1 6.28*10-9 (3.05*10-10) 1.54*10-4 (2.05*10-5) 2.45*104 (4.44*103) 75.1 
2 3.04*10-8 1.71*10-4 5.62*103 67.7 4.8 
2 3.75*10-8 2.07*10-4 5.52*103 55.9 4.9 
2 3.39*10-8 (5.05*10-9) 1.89*10-4 (2.56*10-5) 5.57*103 (7.42*101) 61.2 
3 4.57*10-7 1.21*10-3 2.65*103 9.50 5.2 
3 4.50*10-7 1.01*10-3 2.25*103 11.4 4.1 
3 4.54*10-7 (5.23*10-9) 1.11*10-3 (1.44*10-4) 2.45*103 (2.88*102) 10.4 
4 1.77*10-7 4.91*10-4 2.77*103 23.6 3.8 
4 3.16*10-7 8.11*10-4 2.57*103 14.2 3.8 
4 2.44*10-7 (9.82*10-8) 6.51*10-4 (2.27*10-4) 2.67*103 (1.44*102) 17.8 
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Table S6: Data collection and refinement statistics of FimHLD ligand complexes. 
 
 
FimHLD/3 FimHLD/4 
PDB ID 5JCR 5MUC 
Wavelength (Å) 1.00004 1.87287 
Resolution range (Å) 
55.92 - 1.70 
(1.76 - 1.70)* 
49.5 – 2.6 
(2.70 – 2.60)* 
Space group P 21 21 21 P 21 21 21 
Unit cell  63.0 69.0 95.6 62.4 68.6 95.7 
a, β, γ (°) 90 90 90 90 90 90 
Unique reflections 46026 (4525) 12481 (1322) 
Multiplicity 6.5 (6.4) 4.8 (4.8) 
Completeness (%) 99.8 (97.8) 94.9 (96.2) 
Mean I/sigma(I) 12.3 (2.1) 6.0 (2.0) 
Wilson B-factor 14.7 27.8 
R-merge 0.101 (0.505) 0.196 (0.79) 
CC1/2 0.999 (0.959) 0.990 (0.707) 
R-work 0.2114 (0.2542) 0.235 (0.304) 
R-free 0.2330 (0.2729) 0.260 (0.356) 
Number of atoms 5475 5024 
  macromolecules 4732 2392 
  ligands 54 44 
  water 689 266 
Protein residues 316 316 
RMS(bonds) 0.004 0.003 
RMS(angles) 1.10 0.71 
Ramachandran favored 
(%) 
97.1 96.5 
Ramachandran allowed 
(%) 
2.9 3.5 
Clashscore 0.7 0.6 
Average B-factor 19.0 36.0 
*Values in parentheses are for the highest resolution shell. 
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Experimental section 
Protein cloning, expression, purification, and biotinylation. For all ITC experiments FimHLD 
of E.coli K-12 strain was expressed with a C-terminal thrombin cleavage site and a 6His-
tag (FimHLD-Th-6His, 173 residues) following a previously published protocol.(1) For SPR 
experiments a FimHLD-AVITag-6His gene construct was cloned by overlap extension 
PCR using the FimHLD-Th-6His(1) gene construct and an AVITag-6His gene sequence as 
templates and was subsequently ligated into the plasmid pNT.(2) The histidine-tagged 
recombinant protein was expressed in the protease-deficient E. coli strain HM125 and 
purified with Ni-NTA affinity chromatography.(1) AVITag is a specific 15-amino acid 
peptide sequence (GLNDIFEAQKIEWHE) that can be biotinylated by the E. coli biotin 
ligase BirA. To keep the BirA enzyme active, the protein was dialyzed with Slide-A-Lyzer MINI 
Dialysis Units (3,500K MWCO, Thermo Scientific) in 50 mM bicine, pH 8.3. 
Biotinylation was done according to the manufacturer's protocol (Avidity). In order to 
remove excessive biotin the protein sample was dialyzed in HBS-EP, 7.4, overnight. 
 
Surface plasmon resonance (SPR). Surface plasmon resonance-based experiments were 
performed using a Biacore T200 instrument (GE Healthcare). Biotinylated FimHLD (100 
nM) was immobilized on the surface of a streptavidin chip (sensor chip SA) using the 
“aim for immobilized level wizard“ (1300 RU, 5 µL/min). A reference surface with 
Amino PEG biotin (50 µM, Polypure) was prepared (time and flow rate: 60 s and 10 
µL/min, respectively) to correct for unspecific binding events of the glycomimetics with 
streptavidin on the sample surface. Kinetic experiments were run at 25°C using HBS-EP 
(0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% surfactant P20, from GE 
Healthcare) as running buffer at a flow rate of 30 µL/min. Since a convenient 
regeneration condition, which keeps the protein active, was not found, single cycle 
kinetics (SCKs) without regeneration steps was used. Instead of surface regeneration with 
chemical agents after each injection, a complete dissociation of the respective compound 
from the protein was allowed, before a new run was started. Blank injections (HBS-EP 
running buffer) were conducted under equal conditions in order to apply double 
referencing. Binding data was evaluated using Biacore T200 Evaluation software version 1 
(GE Healthcare). 
 
Isothermal titration calorimetry. Standard ITC experiments were performed at 25°C 
using a VP-ITC (Malvern Instruments, Worcestershire, UK) with an injection volume 
between 3 µl and 15 µl, a reference power of 10 µcal/sec, a stirring speed of 307 rpm, in 
high feedback mode and with a filter period of 2 sec. Preceding the measurements, 
FimHLD-Th-His6 was dialyzed against a 10 mM HEPES buffer adjusted to pH 7.4, 
containing 150 mM NaCl. Ligand and protein were dissolved in the same buffer. Protein 
concentration was determined by NanoDrop ND-1000 Spectrophotometer (Thermo 
Scientific, MA, USA) using an extinction coefficient of 24’180 M-1 cm-1. The active 
protein concentration was determined by an ITC experiment with FimHLD binding to 
compound 1.(3) The thermodynamic parameters KA (association constant) and ΔH° 
(change in enthalpy) and the kinetic parameter koff (dissociation rate constant) are 
measured by ITC. All parameters were evaluated using the fully automated analysis 
software package from AFFINImeter (Software for Science Developments, Santiago de 
Compostela, Spain).(4,5) The parameters ΔG° (free energy of binding) and ΔS° (change in 
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entropy) were calculated from equation S1, and kon (association rate constant) was 
calculated according to equation S2: 
ΔG° = ΔH° − TΔS° = −RT lnKA (eq. S1) 
KA = 
kon
koff
=
1
KD
(eq. S2) 
with T being the absolute temperature and R the universal gas constant (8.314 Jmol-1K-1). 
The thermodynamic and kinetic parameters of compounds 1-10 and 24-29 were 
calculated from the average of two independent experiments. The c-values of compounds 
15-21 and 23 were significantly above 1’000 for the direct titrations, therefore additional 
competitive ITC experiments were performed to achieve valid KD-values.(6) These 
compounds were titrated into protein, which was preincubated with excess of the weak 
binding compound 8, resulting in sigmoidal titration curves. The experimental conditions 
and the analysis method with Origin 7.0 (OriginLab, Northampton, MA, USA) and 
SEDPHAT version 10.4 (National Institute of Health)(7) for the competitive experiments 
of compounds 19 and 23 are described in Fiege et al. 2015(8) and for compounds 15-18, 20, 
and 21 in Kleeb et al. 2015.(9) These independently derived KD-values from competitive 
experiments of compounds 15-21 and 23 were manually fixed for the kinetic analysis 
with AFFINImeter. For the low-affinity compounds 26 and 27, the c-value was below 1. 
To extract reliable thermodynamic and kinetic data from low c-value experiments the 
stoichiometry was manually fixed to 1.(10) Correlations of the kinetic parameters kon (B) 
and koff  (C) with the change of free energy of binding (ΔG°), as well as the F-test to check 
if the slopes of the two subgroups (modified mannose moiety vs. modified aglycone 
moiety) are identical or different, were calculated with Prism version 5.0c from 
GraphPad, Inc. (La Jolla, CA, USA).(11) 
Crystallization and structure determination of compound 3 and 4 in complex with 
FimHLD. FimHLD/3 and FimHLD/4 were crystallized by sitting-drop vapor diffusion at 
4°C. FimHLD (residues 1–158) was used at a final concentration of 10 mg/mL
−1 (ca. 0.5 
mM) with a fivefold molar ligand excess in HEPES buffer (pH 7.4, 20 mM). After several 
months, plate like crystals appeared in 1.6 M (NH4)2SO4, 0.1 M Hepes pH 7.5, 1% PEG 
3350 (w/v) and were flash-cooled to 100 K after a quick soak in 2.5 M Li2SO4.(12) Data 
were collected at the PX beamline (X06SA) of the Swiss Light Source (Paul Scherrer 
Institute, Switzerland), indexed, integrated, and scaled with XDS (13). The structures were 
solved by molecular replacement with PHASER (14) with 4X50.pdb (8) as a search model. 
The models were built in COOT (15,16) and refined with the PHENIX software (17,18). 
Geometric ligand restraints were generated with PRODRG (19). The atomic coordinates 
and structure factors are deposited in the Protein Data Bank with PDB code 5JCR (3) 
and 5MUC (4). 
Molecular Modeling. Protein-Ligand complexes of the crystal structures (PDB accession 
codes: 1UWF, 4XO8, 5JCR, 5MUC) were processed with the Protein Preparation 
Wizard.(20) Figures were produced using PyMOL.(21) 
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Synthesis  
General methods. Commercially available reagents were purchased from Aldrich, 
Merck or Alfa Aesar. Methanol was dried by distillation from sodium methoxide. 
Dichloromethane (CH2Cl2) was dried by filtration through Al2O3 (Fluka, basic; 0.05-0.15 
mm). Toluene was dried by distillation from sodium/benzophenone. Optical rotations 
were measured at 20 °C on a Perkin Elmer 341 polarimeter with a path length of 1 dm. 
Concentrations are given in g/100 mL. NMR spectra were obtained on a Bruker Avance 
500 UltraShield spectrometer at 500.13 MHz (1H) or 125.76 MHz (13C). Chemical shifts 
are given in ppm and were calibrated on residual solvent peaks or to tetramethyl silane as 
internal standard. Multiplicities are specified as s (singulet), d (doublet), dd (doublet of a 
doublet), t (triplet), q (quartet), or m (multiplet). Assignment of the 1H and 13C NMR 
spectra was achieved using 2D methods (COSY, HSQC). ESI mass spectra were 
recorded on a Waters micromass ZQ instrument. High resolution mass spectra were 
obtained on an ESI Bruker Daltonics micrOTOF spectrometer equipped with a TOF 
hexapole detector. Reactions were monitored by TLC using glass plates coated with 
silica gel 60 F254 and visualized by using UV light and/or by charring with a molybdate 
solution (a 0.02 M solution of ammonium cerium sulfate dihydrate and ammonium 
molybdate tetrahydrate in aqueous 10% H2SO4) with heating to 140 °C for 5 min. 
Column chromatography was performed on a CombiFlash Companion (ISCO, Inc.) 
using RediSep normal phase disposable flash columns (silica gel). Reversed phase 
chromatography was performed on LiChroprep®RP-18 (Merck, 40- 63 µm). 
 
 
Synthesis of 5 (n-heptyl 2-fluoro-2-deoxy-α-D-mannopyranoside)  
 
 
 
Scheme 1. a) Dibutyltinoxide, MeOH, reflux, 3 h, then BnBr, CsF, DMF, 40°C, overnight, (51%); b) Tf2O, 
2,6-di-tertbutyl-4-methylpyridine, DCM, -15°C-rt, 2.5 h, (50-70%); c) 1M TBAF in THF, 50°C, 2 h, (78%); 
d) i. HOAc/Water (V:V 4:1), 80°C, 1 h, quantitative; ii. Pd/C, MeOH/H2O, catalytic amount HOAc, 4.8 
mbar, hydrogenation, overnight, (91%); e) 4% H2SO4/Ac2O, rt, 3 h, (94%); f) NH2NH2•HOAc, DMF, rt, 3 
h, (77%); g) Cl3CCN, DCM, NaH, 2 h, (60%); h) n-Heptanol, TMSOTf, DCM, rt; i) CH3ONa/MeOH, rt, 
2 h, (two steps 77%).  
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Methyl 3-O-benzyl-4,6-O-benzylidene-β-D-glucopyranoside (31)(22) 
The suspension of 30 (1.998 g, 7.07 mmol), dibutyltinoxide (2.026 g, 8.14 mmol) in dry 
methanol (30 mL) was refluxing at 80°C for 3 h. The solution was then concentrated to 
dryness and CsF (1.181 g, 7.78 mmol) and BnBr (0.923 mL, 7.78 mmol), DMF (17 mL) 
were added. The reaction mixture was stirred at 40°C overnight and then diluted with EE, 
filtered, the filtrate was washed with sat. NaHCO3, brine and dried over Na2SO4. The 
solvent was removed under vacuo and the residue was purified by flash chromatography 
on Silica gel (PE:EA 3:1-3:2) to afford 31 (1.338 g, 51%) as a white fluffy solid. 1H-NMR 
(500 MHz, CDCl3): δ 7.49 (m, 2H), 7.41-7.28 (m, 8H), 5.59 (s, 1H, PhCH), 4.98 (d, J = 
11.5 Hz, 1H, OCH2Ph), 4.79 (d, J = 11.5 Hz, 1H, OCH2Ph), 4.37 (dd, J =10.5, 5.0 Hz, 
1H, H-6a), 4.33 (d, J = 7.5 Hz, 1H, H-1), 3.81 (t, J = 10.5 Hz, 1H, H-6b), 3.72 (t, J = 9.5 
Hz, 1H, H-4), 3.68 (t, J = 9.5 Hz, 1H, H-3), 3.59 (s, 3H, OMe),  3.56 (m, 1H, H-2), 3.46 
(td, J = 9.5, 4.5 Hz, 1H, H-5), 2.47 (dd, J = 7.5, 2.0 Hz, 1H, 2-OH); 13C-NMR (125 MHz, 
CDCl3): δ 138.22, 137.18, 129.00, 128.45, 128.26, 128.05, 127.85, 125.98, 104.17 (C-1), 
101.24 (PhCH), 81.42 (C-4), 80.18 (C-3), 74.62 (OCH2Ph), 74.18 (C-2), 68.69 (C-6), 66.38 
(C-5), 57.44 (OCH3). 
 
Methyl 3-O-Benzyl-4,6-O-benzylidene-2-O-(trifluoromethanefulfony)-β-D-
glucopyranoside (32) 
To a solution of 31 (550 mg, 1.477 mmol), 2,6-Di-tert-butyl-4-methylpyridine (606 mg, 
2.95 mmol) in dry DCM (4.0 mL) was added trifluoromethanesulfonic anhydride (0.294 
mL, 1.77 mmol) slowly at -15°C. The reaction mixture was stirred at -15°C for 0.5 h, 
then removed the cooling bath and stirred for another 1.5 h at rt. The reaction mixture 
was diluted with DCM, washed with 5% NaHCO3, brine and dried over Na2SO4. The 
solvent was removed under vacuo and the residue was purified by flash chromatography 
on silica gel (PE:EA 15:1-10:1) to afford 32 (527 mg, 71%) as a white solid. 1H-NMR 
(500 MHz, CDCl3): δ 7.48 (m, 2H), 7.42-7.29 (m, 8H), 5.58 (s, 1H, PhCH), 4.90 (d, J = 
11.0 Hz, 1H, OCH2Ph), 4.79 (d, J = 10.5 Hz, 1H, OCH2Ph), 4.61 (t, J = 8.5 Hz, 1H, H-2), 
4.52 (d, J = 7.5 Hz, 1H, H-1), 4.40 (dd, J =10.5, 5.0 Hz, 1H, H-6a), 3.88 (t, J = 9.0 Hz, 
1H, H-3), 3.81 (t, J = 10.5 Hz, 1H, H-6b), 3.76 (t, J = 9.5 Hz, 1H, H-4), 3.58 (s, 3H, 
OMe), 3.48 (m, 1H, H-5); 13C-NMR (125 MHz, CDCl3): δ 136.93, 136.71, 129.21,128.45, 
128.35, 128.01, 125.92, 101.38 (PhCH), 101.30 (C-1), 84.59 (C-2), 81.58 (C-4), 77.34  (C-
3), 74.95 (OCH2Ph), 68.36 (C-6), 66.18 (C-5), 57.70 (OCH3); ESI-MS Calcd for [M+H]+, 
505.11, found 505.13, [M+Na]+, 527.10, found 527.05. 
 
Methyl 3-O-Benzyl-4,6-O-benzylidene-2-fluoro-2-deoxy-β-D-mannopyranoside (33)(23) 
A solution of 32 (529 mg, 1.047 mmol) in 1M TBAF/THF (5.4 mL) was stirred at 50°C 
for 2 h. Then concentrated and the residue was purified by flash chromatography on 
silica gel (PE:EA 5:1-3:1) to afford 33 (307 mg, 78%) as a fluffy white solid. 1H-NMR 
(500 MHz, CDCl3): δ 7.51 (m, 2H), 7.42-7.28 (m, 8H), 5.63 (s, 1H, PhCH), 4.87 (d, J = 
12.0 Hz, 1H, OCH2Ph), 4.78 (d, J = 12.0 Hz, 1H, OCH2Ph), 4.80 (dd, J = 50.0, 2.5 Hz, 
1H, H-2), 4.43 (d, J = 19.0 Hz, 1H, H-1), 4.36 (dd, J = 10.5, 5.0 Hz, 1H, H-6a), 4.11 (td, 
J = 12.0, 2.0 Hz, 1H, H-4), 3.92 (t, J = 10.5 Hz, 1H, H-6b), 3.67 (ddd, J = 26.5, 9.5, 2.5 
Hz, 1H, H-3), 3.57 (s, 3H, OMe), 3.39 (td, J = 10.0, 5.0 Hz, 1H, H-5); 13C-NMR (125 
MHz, CDCl3): δ 137.61, 137.20, 129.03, 128.48, 128.26, 127.92, 127.90, 126.01, 101.61 
(PhCH), 100.42 (d, J = 15.75 Hz, C-1), 88.47 (d, J = 188.5 Hz, C-2), 78.32 (d, J = 2.0 Hz, 
C-4), 75.56 (d, J = 16.75 Hz, C-3), 72.69 (OCH2Ph), 68.47 (C-6), 67.07 (C-5), 57.62 
(OCH3); 19F-NMR (470 MHz, CDCl3): -218.677; ESI-MS Calcd for [M+Na]+, 397.14, 
found 397.05. 
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1,3,4,6-Tetra-O-acetyl-2-fluoro-2-deoxy-α-D-mannopyranoside (35)(24) 
A solution of 33 (306 mg, 0.817 mmol) in 80% aqueous HOAc (7.5 mL) was heated at 
80°C for 1 h and then concentrated to dryness. The residue was  hydrogenolyzed in 
methanol/water (V:V 9:1, 10 mL) containing catalytic amount of HOAc in the presence 
of 5-10% Pd/C (150 mg) under 4.8 bar hydrogen at rt overnight. Then filtered the 
reaction suspension, the filtrate was concentrated to dryness to provide 34 (147 mg, two 
steps yield 91%). To a suspension of 34 (147 mg, 0.748 mmol) in acetic anhydride (1.5 
mL) was added H2SO4 (95-97%) (60 µL) at rt. The reaction mixture was stirred at rt for 3 
h. Then diluted with DCM, neutralized carefully with sat. aqueous NaHCO3 at 0°C. The 
aqueous layer was extracted with DCM for two times, the combined organic layers were 
washed with brine and dried over Na2SO4. Solvent was removed under vacuo and the 
residue was purified by flash chromatography on silica gel (PE:EA 3:1-7:3) to afford 35 
(248 mg, 94%) as a white foam. 1H-NMR (500 MHz, CDCl3): δ 6.28 (dd, J = 7.0, 2.0 Hz, 
1H, H-1), 5.41 (t, J = 10.0 Hz, 1H, H-4), 5.26 (ddd, J = 28.0, 10.0, 2.5 Hz, 1H, H-3), 4.75 
(dt, J = 48.5, 2.5 Hz, 1H, H-2), 4.28 (dd, J = 12.5, 4.5 Hz, 1H, H-6a), 4.11 (dd, J = 12.5, 
2.5 Hz, 1H, H-6b), 4.04 (m, 1H, H-5), 2.17, 2.11, 2.09, 2.05 (4xs, 4 COCH3); 13C-NMR 
(125 MHz, CDCl3): δ 170.72, 170.23, 169.28, 168.04 (4xCOCH3), 90.08 (d, J = 30.88 Hz, 
C-1), 85.88 (d, J = 180.88 Hz, C-2), 70.69 (C-5), 69.44 (d, J = 16.88 Hz, C-3), 65.09 (C-
4), 61.69 (C-6), 20.83, 20.70, 20.69, 20.58 (4xC, COCH3).  
 
3,4,6-Tri-O-acetyl-2-fuoro-2-deoxy-α-D-mannopyranosyl trichloroacetimidate (37)(24) 
To a solution of 35 (260 mg, 0.74 mmol) in dry DMF (4.0 mL) was added hydrazine 
acetate (82 mg, 0.89 mmol) and the reaction mixture was stirred at rt for 3 h. Diluted 
with DCM and acetic acid and washed with water, aqueous NaHCO3, brine and dried 
over Na2SO4. Solvent was removed under vacuo and the residue was purified by flash 
chromatography on silica gel (PE:EA 3:2-1:1) to afford 36 (176 mg, 77%). To a solution 
of 36 (176 mg, 0.57 mmol) and trichloroacetonitrile (0.57 mL, 5.7 mmol) in dry DCM 
(5.0 mL) was added NaH (60%) (4 mg) at rt. The reaction mixture was stirred at rt for 2 h, 
then Silica gel was added and the solvent was removed in vacuo. The residue was purified 
by flash chromatography on silica gel (PE:EA 6:1-5:1) to afford the 37 (155 mg, 60%) as 
a colorless syrup. 1H-NMR (500 MHz, CDCl3): δ 8.23 (s, 1H, NHCCCl3), 6.47 (dd, J = 
6.0, 2.0 Hz, 1H, H-1), 5.47 (t, J = 10.0 Hz, 1H, H-4), 5.32 (ddd, J = 27.5, 10.0, 2.5 Hz, 
1H, H-3), 4.97 (dt, J = 48.5, 2.5 Hz, 1H, H-2), 4.28 (dd, J = 12.5, 4.5 Hz, 1H, H-6a), 
4.20-4.16 (m, 2H, H-6b, H-5), 2.12, 2.08, 2.07 (3xs, 3 COCH3); 13C-NMR (125 MHz, 
CDCl3): δ 170.65, 170.08, 169.36 (3xCOCH3), 159.75 (NHCCCl3), 93.92 (d, J = 31.38 
Hz, C-1), 85.34 (d, J = 181 Hz, C-2), 71.21 (C-5), 69.56 (d, J = 16.75 Hz, C-3), 64.92 (C-
4), 61.63 (C-6), 20.70, 20.68, 20.61 (3xC, COCH3); ESI-MS Calcd for [M+Na]+, 473.99, 
found 473.96. 
 
n-Heptyl 3,4,6-tri-O-acetyl-2-fluoro-2-deoxy-α-D-mannopyranoside (38) 
A mixture of 37 (150 mg, 0.33 mmol), 4Å MS and n-heptanol (94 µL, 0.66 mmol) in dry 
DCM (4 mL) was stirred at rt for 0.5 h before the addition of TMSOTf (9.0 µL, 0.0495 
mmol) at rt under Argon. The reaction mixture was stirred under these conditions for 2 h, 
then neutralized with Et3N, and concentrated to dryness. The residue was purified by 
flash chromatography on silica gel (PE:EA 5:1) to afford 38 (quantitative yield due to 
containing some n-heptanol) as a colorless oil. 1H-NMR (500 MHz, CDCl3): δ 5.31 (t, J = 
10.0 Hz, 1H, H-4), 5.25 (ddd, J = 28.0, 10.0, 2.5 Hz, 1H, H-3), 4.98 (dd, J = 7.0, 1.5 Hz, 
1H, H-1), 4.73 (dt, J = 50.0, 2.5 Hz, 1H, H-2), 4.27 (dd, J = 12.0, 5.0 Hz, 1H, H-6a), 4.12 
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(dd, J = 12.0, 2.0 Hz, 1H, H-6b), 3.97 (ddd, J = 9.5, 4.5, 2.0 Hz, 1H, H-5), 3.71 (dt, J = 
9.5, 6.5 Hz, 1H, H-OCH2C6H13), 3.47 (dt, J = 9.5, 6.5 Hz, 1H, H-OCH2C6H13), 2.10, 2.09, 
2.04 (3xs, 3 COCH3), 1.58 (m, 2H), 1.31 (m, 8H), 0.87 (m, 3H, CH3); 13C-NMR (125 
MHz, CDCl3): δ 170.75, 170.17, 169.53 (3xCOCH3), 97.12 (d, J = 28.63 Hz, C-1), 87.05 
(d, J = 178.25 Hz, C-2), 69.99 (d, J = 16.5 Hz, C-3), 68.67 (OCH2C6H13), 68.41 (C-5), 
65.91 (C-4), 62.18 (C-6), 32.79, 31.71, 28.98, 25.99, 22.58, 14.06 (OCH2C6H13), 20.78, 
20.74, 20.65 (3xC, COCH3); HR-MS Calcd. for C19H31FO8 [M+Na]+, 429.1901, found 
429.1905.   
 
n-Heptyl 2-deoxy-2-fluoro-α-D-mannopyranoside (5) 
To a soultion of 38 (134 mg, 0.33 mmol) in dry methanol (4.0 mL) was added 0.5 M 
CH3ONa/MeOH solution (99 µL) at rt. The reaction mixture was stirred for 2 h and then 
neutralized with Amberlyst 15, fitered and the filtrate was concentrated under vacuo. The 
residue was purified by flash chromatography on silica gel (DCM:MeOH 20:1-16:1) to 
afford 5 (71.3 mg, two steps yield 77%) as colorless oil. [α]D20  +75.4 (c 0.4, DCM); 1H-
NMR (500 MHz, CDCl3): δ 4.93 (dd, J = 7.5, 1.5 Hz, 1H, H-1), 4.66 (d, J = 50.0 Hz, 1H, 
H-2), 3.92-3.82 (m, 4H, H-6a, H-6b, H-4, H-3), 3.68 (dt, J = 9.5, 6.5 Hz, 1H, H-
OCH2C6H13), 3.59 (m, 1H, H-5), 3.41 (dt, J = 9.5, 6.5 Hz, 1H, H-OCH2C6H13), 4.21, 3.03, 
2.10 (3,4,6-OH), 1.56 (m, 2H), 1.27 (m, 8H), 0.88 (t, J = 7.0 Hz, 3H, CH3); 13C-NMR 
(125 MHz, CDCl3): δ 97.41 (d, J = 29.13 Hz, C-1), 89.71 (d, J = 172.63 Hz, C-2), 71.91 
(C-5), 70.82 (d, J = 17. 5 Hz, C-3), 68.22 (OCH2C6H13), 67.66 (C-4), 61.73 (C-6), 31.73, 
29.30, 29.02, 25.98, 22.59, 14.06 (OCH2C6H13); HR-MS Calcd for C13H25FO5 [M+Na]+, 
303.1584, found 303.1585.   
 
Synthesis of 6 (n-heptyl 2-chloro-2-deoxy-α-D-mannopyranoside) and 7 (n-heptyl 2- 
bromo-2-deoxy-α-D-mannopyranoside) 
 
 
 
Scheme 2. a) PhCH(OMe)2, camphorsulfonic acid, CH3CN, 50°C, overnight (81%); b) i. nBu2SnO, 
toluene, reflux, 3h; ii. BnBr, CsF, DMF, rt, overnight (50%); c) i. Tf2O, pyridine, DCM, -20°C, 2h; ii. LiCl, 
NMP, rt, 2 days for 42a; TBAB, DMF, 60°C, 2 days for 42b; d) i. 80% AcOH/H2O, 60°C; ii. 10% Pd/C, 
H2 (g), MeOH/EtOAc/DCM (3:1:1), rt, 1h, 43a-b (90-94%); e) conc. H2SO4, Ac2O, rt, 3h, 44a-b (98% to 
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quant.); f) i. NH4OAc, DMF, rt, overnight; ii. NaH, trichloroacetonitrile, DCM, rt, 2h; iii. n-heptanol, 
TMSOTf, DCM, 0°C to rt, 6h, 45a-b (70-80%); g) NaOMe, MeOH, rt, 4h, 6 and 7 (67-70%). 
 
General procedure A for the preparation of mannosides 45a-b:  
To a solution of 44a-b (1.0 equiv) in DMF (2 mL), NH4OAc (2.0 equiv) was added. The 
mixture was stirred at RT overnight. The reaction mixture was extracted with EtOAc (10 
mL) and washed with water (10 mL). The organic layer was dried over Na2SO4 and 
concentrated in vacuo. The residue was dissolved with DCM (2 mL), and added with 
60% NaH in mineral oil (0.15 equiv) and trichloroacetonitrile (10 equiv) at RT. The 
reaction mixture was stirred at RT for 1.5h. The mixture was concentrated and dried in 
vacuo to give the crude trichloroacetimidate donor. To a suspension of the crude 
trichloroacetimidate, n-heptanol (2 equiv), and molecular sieves (4 Å, 600 mg) in dry 
DCM (5 mL), TMSOTf (0.15 equiv) was added dropwise under argon. The mixture was 
stirred at RT for 5h, then filtered over Celite and concentrated. The residue was purified 
by MPLC on silica gel (PE/EtOAc) to yield 45a-b. 
 
General procedure B for deacetylation:  
To a solution of 45a-b, (1.0 equiv) in dry MeOH (5 mL) was added freshly prepared 1M 
NaOMe/MeOH (0.1 equiv) under argon. The mixture was stirred at RT until the 
reaction was complete (monitored by TLC), then neutralized with Amberlyst-15 (H+) 
ion-exchange resin, filtered and concentrated in vacuo. The residue was purified by 
MPLC on silica gel (DCM/MeOH 10:1-8:1) to affored 6 and 7. 
 
Methyl 4,6-O-benzylidene-α-D-glucopyranoside (40).  
Prepared according to the similar procedure as described in literature. 1H NMR (500 
MHz, CDCl3): δ 7.49 (d, J = 5.6 Hz, 2H, Ph), 7.37 (d, J = 4.7 Hz, 3H, Ph), 5.53 (s, 1H, 
PhCHO2), 4.79 (d, J = 2.9 Hz, 1H, H-1), 4.29 (dd, J = 9.8, 4.3 Hz, 1H, H-6a), 3.93 (t, J = 
9.2 Hz, 1H, H-3), 3.86 - 3.77 (m, 2H, H-5 and H-6b), 3.74 (t, J = 10.2 Hz, 1H, H-4), 3.63 
(t, J = 7.5 Hz, 1H, H-2), 3.53 - 3.43 (m, 4H, H-4, -OCH3), 2.77 (s, 1H, OH), 2.31 (d, J = 
9.4 Hz, 1H, OH). The proton NMR was consistent with literature data.(25) 
 
Methyl 3-O-benzyl-4,6-O-benzylidene-α-D-glucopyranoside (41).  
Prepared according to the similar procedure as described in literature. 1H NMR (500 
MHz, CDCl3): δ 7.49 (d, J = 5.8 Hz, 2H, Ph), 7.42 - 7.28 (m, 8H, Ph), 5.51 (s, 1H, 
PhCHO2), 4.78 (d, J = 12.2 Hz, 1H, PhCHH), 4.70 (d, J = 12.2 Hz, 1H, PhCHH), 4.61 
(d, J = 3.3 Hz, 1H, H-1), 4.26 (dd, J = 10.1, 4.8 Hz, 1H, H-6a), 4.15 (t, J = 9.3 Hz, 1H, 
H-3), 3.81 (td, J = 9.9, 4.8 Hz, 1H, H-5), 3.70 (t, J = 10.3 Hz, 1H, H-6b), 3.54 - 3.44 (m, 
2H, H-2, H-4), 3.37 (s, 3H, OCH3). The proton NMR was consistent with literature 
data.(26) 
 
Methyl 2-deoxy-2-chloro-α-D-mannopyranoside (43a):  
According to the similar procedure for the preparation of 33, 42a was prepared by 
treatment of the triflate intermediate (478 mg, 0.95 mmol) with LiCl (201 mg, 4.75 
mmol) in N-methyl-2-pyrrolidone (2 mL) at RT overnight. The reaction mixture was then 
diluted with EtOAc (20 mL), and washed with water (20 mL) and brine (20 mL). The 
organic layer was dried over Na2SO4, concentrated and purified by MPLC (PE/EtOAc 
8:1) to give crude 42a (393 mg). The crude 42a was treated with 80% AcOH in water (5 
mL) at 60°C for 1h, and then concentrated in vacuo. The residue was dissolved in a 
mixed solvent of MeOH/EtOAc/DCM (3:1:1), added with 10% Pd/C (60 mg), and 
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stirred under hydrogen atmosphere at RT for 1h. The reaction mixture was filtered and 
concentrated. The residue was purified by MPLC (DCM/MeOH 9:1) to yield 43a (60 
mg, 32% over two steps) as colorless oil. [α]D = +80.22 (c = 1.5, MeOH); 1H NMR (500 
MHz, MeOD): δ 4.85 (s, 1H, H-1), 4.22 (d, J = 2.0 Hz, 1H, H-2), 3.99 (dd, J = 9.1, 3.3 
Hz, 1H, H-3), 3.87 (d, J = 11.8 Hz, 1H, H-6a), 3.71 (dd, J = 11.8, 6.1 Hz, 1H, H-6b), 
3.66 (t, J = 9.5 Hz, 1H, H-4), 3.60 - 3.53 (m, 1H, H-5), 3.42 (s, 3H); 13C NMR (126 MHz, 
MeOD): δ 102.43(C-1), 75.22 (C-5), 71.00 (C-3), 68.30 (C-4), 63.00 (C-2), 62.84 (C-6), 
55.58 (OCH3); ESI-MS: m/z: calcd for C7H13ClNaO5 [M+Na]+: 235.03, found: 234.76. 
 
Methyl 2-deoxy-2-bromo-α-D-mannopyranoside (43b):  
According to the similar procedure for the preparation of 33, 42b was prepared by 
treatment of the triflate intermediate (540 mg, 1.07 mmol) with nBu4NBr (700 mg, 2.14 
mmol) in DMF (5 mL) at 60°C for 48h. The reaction mixture was then diluted with 
EtOAc (50 mL), and washed with water (50 mL) and brine (50 mL). The organic layer 
was dried over Na2SO4, concentrated and purified by MPLC (PE/EtOAc 5:1) to give the 
crude 42b (280 mg). The crude product 42b was treated with 80% AcOH in water (5 mL) 
at 60°C for 1h, and then concentrated in vacuo. The residue was dissolved in a mixed 
solvent of MeOH/EtOAc/DCM (3:1:1), added with 10% Pd/C (150 mg), and stirred 
under hydrogen atmosphere at RT for 1h. The reaction mixture was filtered and 
concentrated. The residue was purified by MPLC (DCM/MeOH 10:1) to yield 43b (150 
mg, 55% over two steps) as colorless oil. [α]D = + 53.47 (c = 0.8, EtOAc); 1H NMR (500 
MHz, MeOD): δ 4.96 (s, 1H), 4.31 (dd, J = 3.8, 1.3 Hz, 1H, H-2), 3.87 (dd, J = 11.8, 2.3 
Hz, 1H, H-6a), 3.82 (dd, J = 9.0, 3.9 Hz, 1H, H-3), 3.71 (dd, J = 11.8, 6.1 Hz, 1H, H-6b), 
3.66 (t, J = 9.4 Hz, 1H, H-4), 3.62 - 3.57 (m, 1H, H-5), 3.42 (s, 3H, CH3); 13C NMR (126 
MHz, MeOD): δ 102.65 (C-1), 75.35 (C-5), 70.44 (C-3), 69.12 (C-4), 62.88 (C-6), 56.37 
(C-6), 55.60 (C-2); ESI-MS: m/z: calcd for C7H13BrNaO5 [M+Na]+: 278.98, found 278.79. 
 
2-Deoxy-2-chloro-1,3,4,6-tetra-O-acetyl-α-D-mannopyranoside (44a):  
43a (20 mg, 0.09 mmol) was mixed with acetic anhydride (0.25 mL) and conc. H2SO4 
(7.5 µl, 0.14 mmol). The reaction mixture was stirred at RT overnight, and then diluted 
with DCM (10 mL). After being washed with sat. NaHCO3 aq. solution (10 mL) and 
brine (10 mL), the organic layer was dried over Na2SO4 and concentrated in vacuo. The 
residue was purified by MPLC (PE/EtOAc 2:1) to yield 44a (34 mg, 99%) as colorless 
oil. [α]D = + 27.51 (c = 1.7, EtOAc); 1H NMR (500 MHz, CDCl3): δ 6.24 (s, 1H, H-1), 
5.48 (t, J = 9.9 Hz, 1H, H-4), 5.36 (dd, J = 9.8, 3.1 Hz, 1H, H-3), 4.40 (s, 1H, H-2), 4.25 
(dd, J = 12.4, 4.3 Hz, 1H, H-6a), 4.14 (d, J = 12.7 Hz, 1H, H-6b), 4.09 (d, J = 10.0 Hz, 
1H, H-5), 2.18, 2.11, 2.10, 2.07 (4 s, 12H, 4 COOCH3); 13C NMR (126 MHz, CDCl3): δ 
170.68, 170.12, 169.27, 168.10 (4 CO), 92.91 (C-1), 71.19 (C-5), 69.24 (C-3), 64.91 (C-4), 
61.88 (C-6), 56.36 (C-2), 20.87, 20.71, 20.69, 20.61 (4C, COCH3). ESI-MS: m/z: calcd for 
C14H19ClNaO9 [M+Na]+: 389.06, found: 388.97. 
 
2-Deoxy-2-bromo-1,3,4,6-tetra-O-acetyl-α-D-mannopyranoside (44b):  
Prepared according to the similar procedure of 44a from 43b (100mg, 0.39 mmol). Yield: 
136 mg (85%). [α]D = + 20.13 (c = 0.9, EtOAc); 1H NMR (500 MHz, CDCl3): δ 6.32 (d, J 
= 1.7 Hz, 1H, H-1), 5.49 (t, J = 9.9 Hz, 1H, H-4), 5.20 (dd, J = 9.7, 4.0 Hz, 1H, H-3), 
4.44 (dd, J = 4.0, 1.7 Hz, 1H, H-2), 4.24 (dd, J = 12.4, 4.6 Hz, 1H, H-6a), 4.16 (dd, J = 
12.4, 2.4 Hz, 1H, H-6b), 4.10 (ddd, J = 10.0, 4.5, 2.6 Hz, 1H, H-5), 2.17, 2.11, 2.11, 2.07 
(4 s, 12H, 4 COOCH3); 13C NMR (126 MHz, CDCl3): δ 170.70, 170.07, 169.28, 168.12 
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(4 CO), 93.19 (C-1), 71.33 (C-5), 68.82 (C-3), 65.63 (C-4), 61.89 (C-6), 47.82 (C-2), 20.88, 
20.77, 20.71, 20.62 (4C, COCH3). ESI-MS: m/z: calcd for C14H19BrNaO9 [M+Na]+: 
433.01, found: 432.91. 
Heptyl 2-deoxy-2-chloro-3,4,6-tetra-O-acetyl-α-D-mannopyranoside (45a):  
Prepared according to general procedure A from 44a (60 mg, 0.28mmol). Yield: 42 mg 
(35%) as colorless oil. [α]D = +35.0 (c = 1.3, EtOAc); 1H NMR (500 MHz, CDCl3): δ 
5.43 - 5.34 (m, 2H, H-3, H-4), 4.96 (s, 1H, H-1), 4.38 (s, 1H, H-2), 4.25 (dd, J = 12.2, 4.9 
Hz, 1H, H-6a), 4.14 (d, J = 12.1 Hz, 1H, H-6b), 3.99 (s, 1H, H-5), 3.68 (dd, J = 16.3, 6.9 
Hz, 1H, -OCH- of heptyl), 3.48 (dd, J = 16.1, 6.7 Hz, 1H, -OCH- of heptyl), 2.10, 2.09, 
2.05 (3 s, 9H, 3COOCH3), 1.67 - 1.55 (m, 2H, CH2), 1.30 (d, J = 12.6 Hz, 8H, 4 CH2), 
0.89 (d, J = 6.9 Hz, 3H, CH3); 13C NMR (126 MHz, CDCl3): δ 170.72, 170.07, 169.50 (3 
CO), 99.72 (C-1), 69.77 (C-3), 68.88 (CH2), 68.83 (C-5), 65.60 (C-4), 62.34 (C-6), 57.70 
(C-2), 31.74, 29.28, 29.00, 26.03, 22.60 (5C, CH2), 20.79, 20.73, 20.67 (3C, COCH3), 
14.07 (CH3); ESI-MS: m/z: calcd for C19H31ClNaO8 [M+Na]+: 445.16, found: 445.12. 
Heptyl 2-deoxy-2-bromo-3,4,6-tetra-O-acetyl-α-D-mannopyranoside (45b):  
Prepared according to general procedure A from 44b (207 mg, 0.52 mmol). Yield: 60 mg 
(26%) as colorless oil. [α]D = + 38.2 (c = 0.4, EtOAc); 1H NMR (500 MHz, CDCl3): δ 
5.40 (t, J = 9.9 Hz, 1H, H-4), 5.23 (dd, J = 9.7, 4.0 Hz, 1H, H-3), 5.06 (s, 1H, H-1), 4.44 
(dd, J = 4.0, 1.3 Hz, 1H, H-2), 4.24 (dd, J = 12.2, 5.0 Hz, 1H, H-6a), 4.14 (dd, J = 12.2, 
2.4 Hz, 1H, H-6b), 4.00 (ddd, J = 10.0, 4.9, 2.4 Hz, 1H, H-5), 3.68 (dt, J = 9.6, 6.8 Hz, 
1H, -OCH-), 3.47 (dt, J = 9.6, 6.6 Hz, 1H, -OCH-), 2.11, 2.09, 2.05 (3 s, 9H, 3 
COOCH3), 1.60 (dd, J = 14.1, 6.9 Hz, 2H, CH2), 1.37 - 1.27 (m, 8H, 4 CH2), 0.89 (t, J = 
6.9 Hz, 3H, CH3); 13C NMR (126 MHz, CDCl3): δ 170.72, 170.01, 169.50 (3 CO), 99.95 
(J = 9.43 Hz, C-1), 69.34 (C-3), 68.98 (C-5), 68.87 (OCH2), 66.28 (C-4), 62.34 (C-6), 
49.71 (C-2), 31.74, 29.31, 29.01, 26.04, 22.60 (5C, 5 CH2), 20.83, 20.74, 20.67 (3C, 
COCH3), 14.07 (CH3); ESI-MS: m/z: calcd for C19H31BrNaO8 [M+Na]+: 489.11, found: 
489.04. 
Heptyl 2-deoxy-2-chloro-α-D-mannopyranoside (6):  
Prepared according to general prodedure B from 45a (30 mg, 0.07 mmol). Yiled: 14 mg 
(67%) as a white solid. [α]D = + 60.9 (c = 0.6, MeOH); 1H NMR (500 MHz, MeOD): δ 
4.94 (s, 1H, H-1), 4.22 (s, 1H, H-2), 4.02 (dd, J = 8.9, 2.9 Hz, 1H, H-3), 3.85 (d, J = 11.7 
Hz, 1H, H-6a), 3.77 (dd, J = 15.8, 6.9 Hz, 1H, -OCH- of heptyl), 3.74 - 3.63 (m, 2H, H-4, 
H-6b), 3.63 - 3.56 (m, 1H, H-5), 3.47 (dd, J = 15.6, 6.5 Hz, 1H, -OCH- of heptyl), 1.62 
(d, J = 6.7 Hz, 2H, CH2), 1.45 - 1.28 (m, 8H, 4 CH2), 0.93 (t, J = 6.3 Hz, 3H, CH3); 13C 
NMR (126 MHz, MeOD): δ 101.31 (C-1), 75.33 (C-5), 71.09 (C-3), 69.10 (CH2), 68.35 
(C-4), 63.24 (C-6), 62.86 (C-2), 32.99, 30.62, 30.25, 27.30, 23.70 (5 CH2), 14.44 (CH3); 
HR-MS: m/z: calcd for C13H25ClNaO5 [M+Na]+: 319.1283, found: 319.1285. 
Heptyl 2-deoxy-2-bromo-α-D-mannopyranoside (7): 
Prepared according to general prodedure B from 45b (60 mg, 0.13 mmol). Yiled: 26 mg 
(60 %) as a white solid. [α]D = +67.5 (c = 0.8, MeOH); 1H NMR (500 MHz, MeOD): δ 
5.05 (s, 1H, H-1), 4.31 (dd, J = 3.8, 1.3 Hz, 1H, H-2), 3.88 - 3.82 (m, 2H, H-3, H-6a), 
3.76 (dt, J = 9.5, 6.7 Hz, 1H, -OCH-), 3.73 - 3.60 (m, 3H, H-4, H-5, H-6b), 3.47 (dt, J = 
9.5, 6.4 Hz, 1H, -OCH-), 1.67 - 1.58 (m, 2H, CH2), 1.44 - 1.30 (m, 8H, 4 CH4), 0.93 (t, J 
= 7.0 Hz, 3H, CH3); 13C NMR (126 MHz, MeOD): δ 101.54 (C-1), 75.46 (C-5), 70.53 (C-
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3), 69.18 (C-4), 69.15 (OCH2), 62.90 (C-6), 56.66 (C-2), 33.00, 30.66, 30.25, 27.30, 23.70 
(5 CH2), 14.45 (CH3); HR-MS: m/z: calcd for C13H25BrNaO5 [M+Na]+:  363.0778, found: 
363.0780. 
Synthesis of 24 (n-heptyl 3-deoxy-3-fluoro-α-D-mannopyranoside) 
Scheme 3. a) DAST, DCM, pyr, (46-53%); b) acetyl chloride, MeOH-benezene, reflux, quantitative; c) 
benzaldehyde dimethylacetal, p-TsOH, CH3CN, reflux, 1 h, (69%); d) Tf2O, pyr, DCM, -15°C-rt, 1.5 h, 
(96%); e) CsOAc, 18-crown-6, toluene, reflux, 2 h, (92%); f) H2SO4 /Ac2O, (92%); g) CH3ONa/CH3OH, rt, 
quantitative; h) BzCl, pyr, DMAP, (94%); i) HBr/HOAc, DCM, (58-81%); j) HgBr2, Hg(CN)2, n-heptanol, 
DCM, (27%); k) CH3ONa/CH3OH, rt, (86%). 
3-Deoxy-3-fluoro-1,2:5,6-di-O-isopropylidene-α-D-glucofuranose (47) 
To a solution of 1,2:5,6-di-O-isopropylidene-α-D-allofuranose 46 (1 g, 3.84 mmol) and 
pyridine (1 mL, 12.29 mmol) in dry DCM (7 mL) was added DAST (95%) (0.79 mL, 
6.14 mmol) dropwise at 0°C under argon. The reaction mixture was stirred at 0°C for 0.5 
h and stirred at rt overnight. Then diluted with DCM, quenched with NaHCO3 carefully 
at 0°C, the aqueous layer was extracted with DCM for 2 times, the combined organic 
layers were washed with water, brine and dried over Na2SO4. The solvent was removed 
under vacuo and the residue was purified by flash chromatography on silica gel (PE:EA 
10:1-9:1) to afford 47 (532 mg, 53%) as a colorless oil.1H-NMR (500 MHz, CDCl3): δ 
5.94 (d, J = 4.0 Hz, 1H, H-1), 5.0 (dd, J = 49.5, 2.0 Hz, 1H, H-3), 4.69 (dd, J = 11.0, 4.0 
Hz, 1H, H-2), 4.28 (m, 1H, H-5), 4.14-4.06 (m, 2H, H-6a, H-4), 4.03 (dd, J = 9.0, 5.0 Hz, 
1H, H-6b), 1.49, 1.44, 1.36, 1.32 (4xs, 4CH3); 13C-NMR (125 MHz, CDCl3): δ 112.35, 
109.49 (2xacetal), 105.16 (C-1), 93.79 (d, J = 182.75 Hz, C-3), 82.51 (d, J = 32.63 Hz, C-
2), 80.62 (d, J = 18.88 Hz, C-4), 71.86 (d, J = 7.13 Hz, C-5), 67.15 (d, J = 0.75 Hz, C-6), 
26.83, 26.67, 26.15, 25.13 (4xC, CH3); 19F-NMR (470 MHz, CDCl3): δ -207.60. 
Methyl 3-deoxy-3-fluoro-D-glucoside (48) 
Acetyl chloride (6.5 mL) was added to a solution of 3-deoxy-3-fluoro-1,2:5,6-di-O-
isopropylidene-α-D-glucofuranose (1.28 g) in a mixture of MeOH (45 mL) and benzene 
(18 mL) at 0°C. The solution was heated overnight under reflux with the exclusion of 
atmospheric moisture. Solvent was removed under vacuo and the residue was purified by 
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flash chromatography on Silica gel (DCM:MeOH 10:1-8:1) to afford 48 as unseparated 
α/β anomers in quantitative yield. ESI-MS Calcd for [M+Na]+, 219.06, found 218.63. 
Methyl 3-deoxy-3-fluoro-4,6-O-benzylidene-D-glucopyranoside (49) 
A mixture of 48 (1.04 g, 5.3 mmol) and benzaldehyde dimethyl acetal (3.17 mL, 21.2 
mmoL) in dry acetonitrile (10 mL) was heated to reflux and p-toluenesulfonic acid (60 
mg) was added. The reaction mixture was refluxed for 1 h and then neutralized with 
triethylamine. The reaction mixture was then concentrated to dryness and the residue 
was purified by flash chromatography on Silica gel (PE:EE 3:1-3:2) to afford 49 (1.04 g, 
69%) (α:β = 2.2:1, by NMR)  as a white solid. α isomer: 1H-NMR (500 MHz, CDCl3): δ 
7.51 (m, 2H), 7.37 (m, 3H), 5.55 (s, 1H, PhCH), 4.83 (t, J = 3.5 Hz, 1H, H-1), 4.69 (dt, J 
= 54.5, 9.0 Hz, 1H, H-3), 4.32 (m, 1H, H-6a), 3.87-3.69 (m, 4H, H-2, H-4, H-6b, H-5), 
3.45 (s, 3H, OMe), 2.51 (m, 1H, 2-OH); 13C-NMR (125 MHz, CDCl3): δ 136.70, 129.18, 
128.25, 126.17, 101.54 (PhCH), 99.99 (d, J = 9.88 Hz, C-1), 91.66 (d, J = 185.5 Hz, C-3), 
79.12 (d, J = 16.88 Hz, C-4), 71.42 (d, J = 17.88 Hz, C-2), 68.69 (d, J = 0.63 Hz, C-6), 
55.61 (OCH3); β isomer: 1H-NMR (500 MHz, CDCl3): δ 7.51 (m, 2H), 7.37 (m, 3H), 5.56 
(s, 1H, PhCH), 4.62 (dt, J = 54.5, 9.0 Hz, 1H, H-3), 4.39 (ddd, J = 10.5, 5.0, 2.0 Hz, 1H, 
H-6a), 4.32 (m, 1H, H-1), 3.87-3.69 (m, 3H, H-2, H-4, H-6b), 3.59 (s, 3H, OMe), 3.43 (m, 
1H, H-5), 2.88 (m, 1H, 2-OH); 13C-NMR (125 MHz, CDCl3): δ 136.60, 129.21, 128.26, 
126.14, 103.75 (d, J = 10.75 Hz, C-1), 101.58 (PhCH), 92.10 (d, J = 186.5 Hz, C-3), 78.80 
(d, J = 16.88 Hz, C-4), 73.34 (d, J = 17.88 Hz, C-2), 68.42 (d, J = 1.38 Hz, C-6), 57.63 
(OCH3); ESI-MS Calcd for C14H17FO5 [M+Na]+, 307.0958, found 307.0957. 
Methyl 3-deoxy-3-fluoro-4,6-O-benzylidene-2-O-(trifluoromethanesulfonyl)-D-
glucopyranoside (50) 
To a solution of 49 (970 mg, 3.41 mmol) and pyridine (0.55 mL, 6.82 mmol) in dry 
DCM (10 mL) was added trifluoromethanesulfonic anhydride (0.68 mL, 4.09 mmol) 
slowly at -15°C. The reaction mixture was stirred at -15°C for 0.5 h, then removed the 
cooling bath and stirred for another 1.5 h at rt. The reaction mixture was diluted with 
DCM, washed with 5% NaHCO3, brine and dried over Na2SO4. Solvent was removed 
under vacuo and the residue was purified by flash chromatography on silica gel (PE:EA 
15:1-10:1) to afford 50 (α, β isomers, 1.37 g, 96%) as a pale yellow solid.1H-NMR (500 
MHz, CDCl3): δ 7.49 (m, 2H), 7.39 (m, 3H), 5.57 (s, 1H, PhCH), 5.02 (t, J = 3.5 Hz, 1H, 
H-1), 5.00 (dt, J = 54.0, 9.0 Hz, 1H, H-3), 4.82 (ddd, J = 12.5, 9.0, 3.5 Hz, 1H, H-2), 4.35 
(ddd, J = 10.5, 4.5, 2.0 Hz, 1H, H-6a), 3.90 (m, 1H, H-5), 3.81 (m, 2H, H-6b, H-4), 3.49 
(s, 3H, OMe); 13C-NMR (125 MHz, CDCl3): δ 136.27 129.42, 128.37, 126.14, 101.83 
(PhCH), 97.90 (d, J = 7.88 Hz, C-1), 87.05 (d, J = 192.13 Hz, C-3), 82.07 (d, J = 17.38 
Hz, C-2), 79.10 (d, J = 16.88 Hz, C-4), 68.46 (C-6), 61.53 (d, J = 7.0 Hz, C-5), 56.05 
(OCH3); ESI-MS Calcd for [M+Na]+, 439.0, found 438.85, Calcd for [M+H]+, 417.06, 
found 416.98. 
Methyl 2-O-acetyl-3-deoxy-3-fluoro-4,6-O-benzylidene-D-mannopyranoside (51) 
A mixture of 50 (1.327 g, 3.187 mmol), cesium acetate (918 mg, 4.78 mmol) and 18-
crown-6 (1.263 g, 4.78 mmol) in dry toluene (20 mL) was refluxing for 2.5 h. After 
cooling down to rt, toluene was removed under vacuo and the residue was redissolved in 
DCM and washed with water, brine and dried over Na2SO4. Solvent was removed in 
vacuo and the residue was purified by flash chromatography on silica gel (PE:EA 5:1-4:1) 
to afford 51 (α, β isomers, 0.955 g, 92%) as  white solid. α isomer: 1H-NMR (500 MHz, 
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CDCl3): δ 7.51 (m, 2H), 7.37 (m, 3H), 5.64 (s, 1H, PhCH), 5.19 (ddd, J = 5.5, 4.0, 1.5 
Hz, 1H, H-2), 4.98 (ddd, J = 49.5, 10.0, 4.0 Hz, 1H, H-3), 4.74 (dd, J = 4.0, 1.5 Hz, 1H, 
H-1), 4.32 (m, 1H, H-6a), 4.18 (q, J = 10.0 Hz, 1H, H-4), 3.89 (t, J = 10.0 Hz, 1H, H-6b), 
3.84 (m, 1H, H-5), 3.40 (s, 3H, OMe), 2.18 (s, 3H, COCH3); 13C-NMR (125 MHz, 
CDCl3): δ 169.89 (COCH3), 136.85, 129.22, 128.32, 126.17, 101.91 (PhCH), 99.74 (d, J = 
6.38 Hz, C-1), 86.18 (d, J = 191.75 Hz, C-3), 77.02 (d, J = 22.5 Hz, C-4), 70.05 (d, J = 
15.75 Hz, C-2), 68.58 (d, J = 1.3 Hz, C-6), 62.88 (d, J = 7.5 Hz, C-5), 55.32 (OCH3), 
20.88 (COCH3); 19F-NMR (470 MHz, CDCl3): δ -205.93; HR-MS Calcd for C16H19FO6 
[M+Na]+, 349.1063, found 349.1060; β isomer: 1H-NMR (500 MHz, CDCl3): δ 7.50 (m, 
2H), 7.37 (m, 3H), 5.71 (m, 1H, H-2),  5.62 (s, 1H, PhCH), 4.76 (ddd, J = 48.5, 10.0, 4.0 
Hz, 1H, H-3), 4.56 (m, 1H, H-1), 4.40 (ddd, J = 10.5, 5.0, 2.0 Hz, 1H, H-6a), 4.14 (q, J = 
9.5 Hz, 1H, H-4), 3.94 (t, J = 10.5 Hz, 1H, H-6b), 3.55 (s, 3H, OMe), 3.41 (m, 1H, H-5), 
2.20 (s, 3H, COCH3); 13C-NMR (125 MHz, CDCl3): δ 169.91 (COCH3), 136.70, 129.26, 
128.33, 126.11, 101.79 (PhCH), 100.09 (d, J = 8.38 Hz, C-1), 87.64 (d, J = 194 Hz, C-3), 
76.86 (C-4), 68.90 (d, J = 16.63 Hz, C-2), 68.29 (d, J = 1.75 Hz, C-6), 65.79 (d, J = 8.0 
Hz, C-5), 57.68 (OCH3), 20.79 (COCH3); 19F-NMR (470 MHz, CDCl3): δ -201.82. ESI-
MS Calcd for [M+Na]+, 349.11, found 348.92. 
1,2,4,6-Tetra-O-acetyl-3-deoxy-3-fluoro-D-mannopyranoside (52) 
To a mixture of 51 (780 mg, 2.387 mmol) in acetic anhydride (9.9 mL) was added H2SO4 
(95-97%) (397 µL) at rt. The reaction mixture was stirred at rt for 3 h. Then diluted with 
DCM, neutralized carefully with Sat. aqueous NaHCO3 at 0°C. The aqueous layer was 
extracted with DCM for two times, the combined organic layers were washed with brine 
and dried over Na2SO4. Solvent was removed under vacuo and the residue was purified by 
flash chromatography on silica gel (PE:EA 3:1-7:3) to afford 52 (770 mg, 92%) as a white 
foam as unseparated α/β anomers. 
3-Deoxy-3-fluoro-D-mannose (53) 
To a solution of 52 (296 mg, 0.845 mmol) in dry methanol (5 mL) was added 0.5 M 
CH3ONa/MeOH (0.34 mL). The reaction mixture was stirred at rt for 3 h. Then 
neutralized with Amberlyst 15, filtered, concentrated to dryness to afford 3-deoxy-3-
fluoro-D-mannose as a mixture of unseparated α/β anomers 53 in quantitative yield 
which was used for next step without further purification. 
1,2,4,6-Tetra-O-benzoyl-3-deoxy-3-fluoro-α-D-mannopyranoside (54) 
To a suspension 53 (153 mg, 0.845 mmol) in pyridine (4.0 mL) was added DMAP (5 mg) 
and benzoyl chloride (0.59 mL) dropwise at 0°C. The reaction mixture was stirred at rt 
overnight and then diluted with DCM, washed with ice-water, Sat. NaHCO3 and brine, 
dried over Na2SO4. Solvent was removed under vacuo and the residue was purified by 
flash chromatography on silica gel (PE:EA 5:1-4:1) to afford 54 (500 mg, 98%) as a white 
foam. 1H-NMR (500 MHz, CDCl3): δ 8.14-8.05 (m, 8H), 7.69-7.35 (m, 12H), 6.61 (dd, J 
= 4.5, 2.0 Hz, 1H, H-1), 6.20 (q, J = 10.0 Hz, 1H, H-4), 5.87 (ddd, J = 5.5, 3.5, 2.0 Hz, 
1H, H-2), 5.40 (ddd, J = 48.0, 9.5, 3.5 Hz, 1H, H-3), 4.69 (dd, J = 10.0, 2.0 Hz, 1H, H-
6a), 4.47-4.41 (m, 2H, H-6b, H-5); 13C-NMR (125 MHz, CDCl3): δ 166.00, 165.15, 
165.10, 163.56 (4xCOPh), 148.86, 136.81, 134.11, 133.72, 133.67, 133.26, 133.07, 
130.03, 130.01, 129.97, 129.90, 129.72, 128.78, 128.61, 128.52, 128.18, 128.16 (Ar-C), 
91.41 (d, J = 6.75 Hz, C-1), 87.49 (d, J = 193.38 Hz, C-3), 70.60 (d, J = 6.5 Hz, C-5), 
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69.09 (d, J = 16.25 Hz, C-2), 67.03 (d, J = 19.38 Hz, C-4), 62.11 (C-6); HR-MS Calcd for 
C34H27FO9 [M+Na]+, 621.1537, found 621.1537.  
2,4,6-Tri-O-benzoyl-3-deoxy-3-fluoro-α-D-mannopyranosyl bromide (55) 
To a solution of 54 (766 mg, 1.28 mmol) in dry DCM (2.0 mL) was added 33% 
HBr/HOAc (2.5 mL) at 0°C and then reaction mixture was stirred at rt overnight. The 
reaction mixture was diluted with DCM, washed with ice-water, Sat. NaHCO3 and brine, 
dried over Na2SO4. Solvent was removed under vacuo and the residue was purified by 
flash chromatography on silica gel (PE:EA 8:1-6:1) to afford 55 (580 mg, 81%) as a white 
foam. 1H-NMR (500 MHz, CDCl3): δ 8.07 (m, 6H), 7.59 (m, 3H), 7.48 (t, J = 7.5 Hz, 
2H), 7.40 (t, J = 7.5 Hz, 4H), 6.55 (dd, J = 5.0, 1.5 Hz, 1H, H-1), 6.26 (m, 1H, H-4), 5.85 
(ddd, J = 5.0, 3.5, 1.5 Hz, 1H, H-2), 5.62 (ddd, J = 48.0, 9.5, 3.5 Hz, 1H, H-3), 4.73 (dt, J 
= 12.0, 1.5 Hz, 1H, H-6a), 4.51-4.44 (m, 2H, H-5, H-6b); 13C-NMR (125 MHz, CDCl3): δ 
165.90, 165.08, 165.07 (3xCOPh), 133.86, 133.80, 133.21, 129.98, 129.97, 129.77, 
129.50, 128.72, 128.65, 128.60, 128.53, 128.46 (Ar-C), 86.55 (d, J = 192.88 Hz, C-3), 
82.97 (d, J = 6.75 Hz, C-1), 72.73 (d, J = 6.87 Hz, C-5), 72.58 (d, J = 17.13 Hz, C-2), 
66.68 (d, J = 19.75 Hz, C-4), 61.53 (C-6); 19F-NMR (470 MHz, CDCl3): δ -204.34. 
n-Heptyl 2,4,6-tri-O-benzoyl-3-deoxy-3-fluoro-α-D-mannopyranoside (56) 
To a suspension of 55 (425 mg, 0.76 mmol), n-Heptanol (0.212 mL, 1.52 mmol) and 4Å 
MS in dry DCM (7 mL) was added Hg(CN)2 (232 mg, 0.918 mmol), HgBr2 (331 mg, 
0.918 mmol) and was stirred at rt for 5 h under argon. The reaction mixture was filtered 
through a pad of celite, the celite was washed with DCM thoroughly and the filtrate was 
washed with NaHCO3, brine, dried over Na2SO4. Solvent was removed under vacuo and 
the residue was purified by flash chromatography on silica gel (PE:EA 15:1) to 56 (123 
mg, 27%) as colorless syrup. [α]D20 +9.65 (c 1.54, CHCl3); 1H-NMR (500 MHz, CDCl3): δ 
8.08 (m, 6H), 7.58 (m, 3H), 7.47-7.38 (m, 6H), 6.02 (m, 1H, H-4), 5.64 (ddd, J = 6.0, 4.5, 
2.0 Hz, 1H, H-2), 5.23 (ddd, J = 48.0, 9.5, 4.0 Hz, 1H, H-3), 5.08 (dd, J = 4.5, 2.0 Hz, 
1H, H-1), 4.69 (ddd, J = 12.0, 2.0, 1.5 Hz, 1H, H-6a), 4.44 (dd, J = 12.0, 4.5 Hz, 1H, H-
6b), 4.25 (ddd, J = 10.0, 4.5, 2.5 Hz, 1H, H-5), 3.76 (dt, J = 10.0, 7.0 Hz, 1H, H-
OCH2C6H13), 3.52 (dt, J = 10.0, 7.0 Hz, 1H, H-OCH2C6H13), 1.67 (m, 2H), 1.34 (m, 8H), 
0.91 (t, J = 7.0 Hz, 3H, CH3); 13C-NMR (125 MHz, CDCl3): δ 166.10, 165.51, 165.32 
(3xCOPh), 133.53, 133.48, 133.06, 129.89, 129.74, 129.68, 129.16, 129.10, 128.51, 
128.48, 128.38 (Ar-C), 97.63 (d, J = 7.13 Hz, C-1), 87.70 (d, J = 191.25 Hz, C-3), 70.33 
(d, J = 15.5 Hz, C-2), 68.76 (OCH2C6H13), 68.31 (d, J = 6.75 Hz, C-5), 67.76 (d, J = 19.13 
Hz, C-4), 62.74 (d, J = 0.88 Hz, C-6), 31.74, 29.29, 28.98, 25.99, 22.57, 14.08 
(OCH2C6H13); 19F-NMR (470 MHz, CDCl3): δ -203.69; HR-MS Calcd for C34H37FO8 
[M+Na]+, 615.2370, found 615.2360. 
n-Heptyl 3-deoxy-3-fluoro-α-D-mannopyranoside (24) 
To a solution of 56 (68.8 mg, 0.116 mmol) in dry methanol (3.0 mL) was added 0.5 M 
CH3ONa/MeOH (30 µL) at rt. The reaction mixture was stirred for 4 h, then neutralized 
with Amberlyst 15, filtered, concentrated to dryness. The residue was purified by flash 
chromatography on silica gel (PE:EA 1:1 to 1:2) to afford 24 (28 mg, 86%) as a colorless 
syrup. [α]D20 = +66.51 (c = 0.78, DCM); 1H-NMR (500 MHz, CDCl3): δ 4.86 (d, J = 3.0 
Hz, 1H, H-1), 4.71 (ddd, J = 49.5, 9.5, 3.0 Hz, 1H, H-3), 4.60 (d, J = 5.0 Hz, 1H, 2-OH), 
4.41 (d, J = 4.0 Hz, 1H, 4-OH), 4.24 (m, 1H, H-4), 4.13 (m, 1H, H-2), 4.06 (m, 1H, 6-
OH), 3.97 (m, 1H, H-6a), 3.82 (m, 1H, H-6b), 3.56 (m, 1H, H-5), 3.63 (dt, J = 9.5, 6.5 
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Hz, 1H, H-OCH2C6H13), 3.38 (dt, J = 9.5, 6.5 Hz, 1H, H-OCH2C6H13), 1.54 (m, 2H), 1.28 
(m, 8H), 0.88 (t, J = 7.0 Hz, 3H, CH3); 13C-NMR (125 MHz, CDCl3): δ 99.88 (d, J = 8.13 
Hz, C-1), 93.18 (d, J = 180.25 Hz, C-3), 71.17 (d, J = 7.13 Hz, C-5), 69.50 (d, J = 16.13 
Hz, C-2), 68.11 (OCH2C6H13), 64.61 (d, J = 18.5 Hz, C-4), 60.85 (C-6), 31.72, 29.29, 
29.02, 26.00, 22.59, 14.06 (OCH2C6H13); 19F-NMR (470 MHz, CDCl3): δ -203.25; HR-MS 
Calcd for C13H25FO5 [M+Na]+, 303.1584, found 303.1582. 
Synthesis of 25 (n-heptyl 3-deoxy-α-D-mannopyranoside) 
Scheme 4. a) i. Dibutyltin oxide, toluene, TBAB, BnBr, reflux, (44%); ii. Benzoyl chloride, pyr, DMAP, 
(68%); b) Pd(OH)2/H2, dioxane, rt, 3 bar, (80%); c) TCDI, DCE, reflux, (94%); d) Bu3SnH/toluene, reflux, 
overnight, (99%); e) CH3ONa/CH3OH, rt, 6 h, (83%). 
n-Heptyl 2,4,6-O-tribenzoyl-3-O-benzyl-α-D-mannopyranoside (58) 
The mixtures of 57 (380 mg, 1.365 mmol) and dibutyltin oxide (374 mg, 1.5 mmol) were 
dissolved in dry MeOH (10 mL). The reaction mixture was refluxed for 4 h, concentrated 
to dryness under reduced pressure. To a solution of the product generated above in dry 
toluene (10 mL) was added tetrabutylammonium bromide (TBAB) (484 mg, 1.5 mmol) 
and benzyl bromide (194 µL, 1.638 mmol). The mixture was stirred at 80°C overnight, 
concentrated to dryness, and purified by chromatography on silica gel (PE-EA 3:1-7:3) to 
give heptyl 3-O-benzyl-α-D-mannopyranoside (220 mg, 44%) as colorless oil. The above 
product was dissolved in pyridine (5.0 mL) and benzoyl chloride (0.42 mL, 3.58 mmol), 
DMAP (3.6 mg) was added to the solution at rt. The reaction mixture was stirred at rt for 
2 h, then diluted with ethyl acetate, washed with 5% NaHCO3, brine and the organic 
layer was dried over Na2SO4. The solvent was removed in vacuo and the residue was 
purified by flash chromatography on silica gel (PE-EA 9:1-4:1) to provide 58 (277 mg, 
68%) as colorless syrup. 1H NMR (CDCl3, 500 MHz): δ 8.08 (m, 4H), 7.99 (m, 2H), 7.60-
7.54 (m, 3H), 7.45 -7.16 (m, 6H), 7.17-7.06 (m, 5H), 5.86 (t, J = 10.0 Hz, 1H, H-4), 5.65 
(m, 1H, H-2), 5.01 (s, 1H, H-1), 4.69 (d, J = 12.5 Hz, 1H, OCH2Ph), 4.66 (dd, J = 12.0, 
2.5 Hz, 1H, H-6a), 4.51 (d, J = 12.5 Hz, 1H, OCH2Ph), 4.39 (dd, J = 12.0, 5.0 Hz,1H, H-
6b), 4.21 (ddd, J = 10.0, 4.5, 2.0 Hz, 1H, H-5), 4.16 (dd, J = 10.0, 3.5 Hz, 1H, H-3), 3.73 
(m, 1H, OCH2C6H13), 3.49 (dt, J = 9.5, 6.5 Hz, 1H, OCH2C6H13), 1.62 (m, 2H, 
OCH2CH2C5H11), 1.30 (m, 8H, OC2H4C4H8CH3), 0.90 (t, J = 7.0 Hz, 3H, 
OC2H4C4H8CH3); 13C NMR (CDCl3, 125 MHz) δ 166.25, 165.83, 165.45 (3xC=O), 
137.53, 133.28, 133.26, 132.99, 129.97, 129.95, 129.76, 128.47, 128.39, 128.21, 127.86, 
127.57 (Ar-C), 97.86 (C-1), 74.38 (C-3), 71.04 (OCH2Ph), 68.87 (C-5), 68.80 (C-2), 68.49 
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(OCH2C6H13), 68.30 (C-4), 63.27 (C-6), 31.81, 29.35, 29.04, 26.04, 22.62, 14.15 
(OCH2C6H13); ESI-MS Calcd for C41H44O9 [M+Na]+, 703.29, found 703.33. 
n-Heptyl 2,4,6-O-tribenzoyl-α-D-mannopyranoside (59) 
Hydrogenolysis of 58 (266 mg, 0.39 mmol) in dioxane (6.0 mL) in the presence of 10% 
Pd(OH)2 (20 mg) and catalytic aomount of HOAc under hydrogen (3 bar) at rt overnight. 
Then filtered the reaction suspension through celite, the filtrate was concentrated under 
vacuo. The residue was purified by flash chromatography on silica gel (PE-EA 9:1-5:1) to 
provide 59 (184 mg, 80%) as colorless syrup. 1H NMR (CDCl3, 500 MHz): δ 8.09-8.05 
(m, 6H), 7.61-7.55 (m, 3H), 7.46 (t, J = 8.0 Hz, 2H), 7.40 (m, 4H), 5.69 (t, J = 10.0 Hz, 
1H, H-4), 5.42 (dd, J = 3.0, 1.5 Hz, 1H, H-2), 5.04 (d, J = 1.5 Hz, 1H, H-1), 4.68 (dd, J = 
12.0, 2.0 Hz, 1H, H-6a), 4.46 (dd, J = 12.0, 4.5 Hz, 1H, H-6b), 4.41 (m, 1H, H-3), 4.30 
(ddd, J = 10.0, 4.5, 2.5 Hz, 1H, H-5), 3.77 (dt, J = 9.5, 6.5 Hz, 1H, OCH2C6H13), 3.52 (dt, 
J = 9.5, 6.5 Hz, 1H, OCH2C6H13), 2.47 (d, J = 8.0 Hz, 1H, OH), 1.64 (m, 2H, 
OCH2CH2C5H11), 1.31 (m, 8H, OC2H4C4H8CH3), 0.90 (t, J = 7.0 Hz, 3H, 
OC2H4C4H8CH3); 13C NMR (CDCl3, 125 MHz): δ 166.80, 166.14, 165.92 (3xC=O), 
133.59, 133.49, 133.06, 129.91, 129.83, 129.80, 129.68, 129.31, 129.16, 128.54, 128.51, 
128.39 (Ar-C), 97.36 (C-1), 73.01 (C-2), 70.43 (C-4), 69.11 (C-3), 68.58  (OCH2C6H13), 
68.42 (C-5), 63.10 (C-6), 31.77, 29.37, 29.01, 26.03, 22.59, 14.10 (OCH2C6H13); ESI-MS 
Calcd for C34H38O9 [M+Na]+, 613.24, found 613.17. 
n-Heptyl 2,4,6-O-tribenzoyl-3-O-thiocarbonylimidazoyl-α-D-mannopyranoside (60) 
A mixture of 59 (168 mg, 0.286 mmol) and N,N’-thiocarbonyldiimidazole (153 mg, 0.86 
mmol) in 1,2-dichloroethane (5.0 mL) was refluxed overnight. The solution was 
concentrated in vacuo and the residue was diluted with DCM, washed with 1N HCl and 
brine. The organic layer was dried over Na2SO4 and the solvent was removed in vacuo, 
the residue was purified by chromatography on silica gel (PE-EA 4:1-3:1) to afford 60 
(188 mg, 94%) as pale yellow viscous solid.1H NMR (CDCl3, 500 MHz): δ 8.17 (s, 1H), 
8.08 (d, J = 7.0 Hz, 2H), 8.02 (d, J = 7.0 Hz, 2H), 7.97 (d, J = 7.0 Hz, 2H), 7.62-7.54 (m, 
3H), 7.44-7.37 (m, 7H), 6.87 (s, 1H), 6.34 (dd, J = 10.0, 3.0 Hz, 1H, H-3), 6.19 (t, J = 
10.0 Hz, 1H, H-4), 5.84 (dd, J = 3.0, 2.0 Hz, 1H, H-2), 5.11 (s, 1H, H-1), 4.74 (m, 1H, H-
6a), 4.50-4.46 (m, 2H, H-6b, H-5), 3.84 (dt, J = 9.5, 6.5 Hz, 1H, OCH2C6H13), 3.60 (dt, J 
= 9.5, 6.5 Hz, 1H, OCH2C6H13), 1.72 (m, 2H, OCH2CH2C5H11), 1.41-1.33 (m, 8H, 
OC2H4C4H8CH3), 0.91 (t, J = 7.0 Hz, 3H, OC2H4C4H8CH3); 13C NMR (CDCl3, 125 
MHz): δ 182.54 (C=S), 166.07, 165.32, 165.28 (3xC=O), 137.05, 133.77, 133.17, 130.88, 
129.89, 129.71, 129.68, 128.78, 128.72, 128.58, 128.48, 117.82 (Ar-C), 97.54 (C-1), 78.24 
(C-3), 69.38 (C-2), 68.99 (OCH2C6H13), 68.74 (C-5), 66.35 (C-4), 62.60 (C-6), 31.78, 
29.29, 29.01, 25.99, 22.60, 14.11 (OCH2C6H13); ESI-MS Calcd for C38H40N2O9S [M+H]+, 
701.25, found 701.28, Calcd for [M+Na]+, 723.24, found 723.26. 
n-Heptyl 2,4,6-O-tribenzoyl-3-deoxy-α-D-mannopyranoside (61) 
A solution of 60 (178 mg, 0.254 mmol) in dry toluene (2 mL) was added dropwise over 
10 min to a stirred solution of refluxing toluene (3 mL) and tributylstanne (0.103 mL, 
0.381 mmol) under argon. After the reaction mixture was refluxed overnight, the solvent 
was removed in vacuo and the residue was purified by chromatography on silica gel (PE-
EA 10:1) to afford 61 (145 mg, 99%) as colorless oil. 1H NMR (CDCl3, 500 MHz): δ 
8.10- 8.02 (m, 6H), 7.60-7.54 (m, 3H), 7.46-7.37 (m, 6H), 5.57 (td, J = 10.5, 4.5 Hz, 1H, 
H-4), 5.24 (d, J = 1.0 Hz, 1H, H-2), 4.92 (s, 1H, H-1), 4.65 (dd, J = 12.0, 2.5 Hz, 1H, H-
6a), 4.46 (dd, J = 12.0, 5.5 Hz, 1H, H-6b), 4.34 (ddd, J = 10.0, 5.5, 2.5 Hz, 1H, H-5), 
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3.80 (dt, J = 9.5, 7.0 Hz, 1H, OCH2C6H13), 3.54 (dt, J = 9.5, 6.5 Hz, 1H, OCH2C6H13), 
2.54 (dt, J = 13.0, 3.5 Hz, 1H, H-3a), 2.30 (m, 1H, H-3e), 1.66 (m, 2H, OCH2CH2C5H11), 
1.30 (m, 8H, OC2H4C4H8CH3), 0.92 (t, J = 7.0 Hz, 3H, OC2H4C4H8CH3); 13C NMR 
(CDCl3, 125 MHz): δ 166.26, 165.56, 165.39 (3xC=O), 133.33, 133.28, 132.99, 129.91, 
129.81, 129.72, 129.68, 129.65, 129.59, 128.46, 128.34 (Ar-C), 96.27 (C-1), 70.05 (C-2), 
68.83 (C-5), 68.16 (OCH2C6H13), 65.46 (C-4), 63.68 (C-6), 29.04 (C-3), 31.78, 29.48, 
29.43, 26.08, 22.59, 14.10 (OCH2C6H13); ESI-MS Calcd for C34H38O8 [M+Na]+, 597.25, 
found 597.21. 
n-Heptyl 3-deoxy-α-D-mannopyranoside (25) 
To a solution of 61 (138 mg, 0.24 mmol) in methanol (4 mL) was added 0.5 M 
CH3ONa/MeOH (96 µL) at rt. The reaction mixture was stirred at rt for 6 h, then 
neutralized with amberlyst 15, filtered and the solvent was concentrated to dryness. The 
residue was purified by flash chromatography on silica gel with (DCM-MeOH 11:1) to 
give 25 (52 mg, 83%) as colorless oil. [α]D20 +90.24 (c 0.34, DCM); 1H NMR (CD3OD, 
500 MHz): δ 4.57 (s, 1H, H-1),  3.81 (dd, J = 11.5, 2.0 Hz, 1H, H-6a), 3.78-3.74 (m, 3H, 
H-2, H-4, OCH2C6H13), 3.67 (dd, J = 11.5, 6.0 Hz, 1H, H-6b), 3.52 (ddd, J = 9.0, 6.0, 2.0 
Hz, 1H, H-5), 3.42 (dt, J = 9.5, 6.5 Hz, 1H, OCH2C6H13), 1.98 (dt, J = 13.0, 3.5 Hz, 1H, 
H-3a), 1.82 (m, 1H, H-3e), 1.58 (m, 2H, OCH2CH2C5H11), 1.40-1.32 (m, 8H, 
OC2H4C4H8CH3), 0.91 (t, J = 7.0 Hz, 3H, OC2H4C4H8CH3); 13C NMR (CD3OD, 125 
MHz): δ 100.17 (C-1), 75.50 (C-5), 69.23 (C-2), 68.34 (OCH2C6H13), 63.13 (C-4), 62.89 
(C-6), 35.93 (C-3), 33.02, 30.69, 30.29, 27.38, 23.70, 14.43 (OCH2C6H13); HR-MS Calcd 
for C13H26NaO5 [M+Na]+ 285.1678, found 285.1682. 
Synthesis of 27 (4-H) (n-heptyl 4-deoxy-α-D-mannopyranoside) 
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Scheme 5. a) DMP, acetone, p-toluenesulfonic acid, water, rt, 3 h, (69%); b) DCM, benzoyl chloride, 
<15°C, 10 min, (87%); c) TCDI, DCE, reflux, (96%); d) Bu3SnH/toluene, reflux, overnight, (95%); e) 
HOAc/H2O (4:1), 70°C, 0.5 h, quantitative; f) (Ac)2O/pyr, DMAP, 4 h, (96%); g) CAN, CH3CN/H2O 
(4:1), 2 h, (91%); h) Cl3CCN, DCM, NaH, (71%); i) TMSOTf, toluene, (52%); j) CH3ONa/CH3OH, rt, 
(61%). 
4-Methoxyphenyl α-D-mannopyranoside (62) 
To a mixture of 1,2,3,4,6-penta-O-acetyl-α-D-mannopyranoside (3.3 g, 8.45 mmol) and 
4-methoxyphenol (1.57 g, 12.68 mmol) in 1,2-dichloroethane (30 mL) was added 
TMSOTf (0.18 mL, 1.01 mmol) at 0°C. The reaction mixture was stirred at 0°C for 1 h 
and then stirred at rt overnight. Diluted with EtOAc, washed with NaHCO3, water and 
brine. The organic layer was dried over Na2SO4, filtered and concentrated. The residue 
was purified by flash chromatography on silica gel (PE-EA 4:1-2:1) to give the desired 
compound (3.14 g, 82%) as a white solid.1H NMR (500 MHz, CDCl3): δ 7.02 (d, J = 9.0 
Hz, 2H), 6.82 (d, J = 9.0 Hz, 2H), 5.55 (dd, J = 10.0, 3.5 Hz, 1H, H-3), 5.43 (m, 1H, H-
2), 5.41 (s, 1H, H-1), 5.36 (t, J = 10.0 Hz, 1H, H-4), 4.28 (dd, J = 12.5 Hz, 5.0 Hz, 1H, 
H-6a), 4.14 (ddd, J = 10.0, 5.5, 1.0 Hz, 1H, H-5), 4.11 (dd, J = 12.5, 2.0 Hz, 1H, H-6b), 
3.77 (s, 3H, OCH3), 2.10, 2.06, 2.05, 2.03 (4xs, 12H, 4xCOCH3).To a solution of 4-
methoxyphenyl 2,3,4,6-tetra-O-acetyl-α-D-mannopyranoside (2.7 g, 5.94 mmol) in 
MeOH (25mL) was added 0.5 M CH3ONa/MeOH (1.2 mL) at rt. The reaction mixture 
was stirred at rt overnight, then neutralized Amberlyst 15. The reaction mixture was 
filtered and the residue was washed thoroughly with MeOH. The filtrate was 
concentrated in vacuo to give compound 62 (1.7 g, quantitative) as a white solid, which 
was used for next step without further purification. 1H NMR (500 MHz, CD3OD): δ 7.04 
(d, J = 9.0 Hz, 2H), 6.83 (d, J = 9.0 Hz, 2H), 5.33 (d, J = 1.5 Hz, 1H, H-1), 3.99 (dd, J = 
3.5, 1.5 Hz, 1H, H-2), 3.88 (dd, J = 9.5, 3.5 Hz, 1H, H-3), 3.78 (dd, J = 12.0, 2.5 Hz, 1H, 
H-6a), 3.74 (s, 3H, OCH3), 3.74-3.70 (m, 2H, H-4, H-6b), 3.65 (m, 1H, H-5); 13C NMR 
(CD3OD, 125 MHz): δ 156.60, 152.04, 119.20, 115.60, 101.17 (C-1), 75.23 (C-5), 72.45 
(C-3), 72.13 (C-2), 68.44 (C-4), 62.72 (C-6), 56.04 (OCH3).  
Methoxyphenyl 2,3-isopropylidene-α-D-mannopyranoside (63) 
Compound 62 (1 g), acetone (10 mL), DMP (10 mL), and p-toluenesulfonic acid (0.2 g) 
were stirred together until the solid dissolved (about 15 minutens). Water (20 mL) was 
added and stirring was continued for 3 h. The reaction mixture was diluted with DCM, 
the aqueous layer was extracted with DCM for 3 times, the combined organic layers 
were washed with water, brine and dried over Na2SO4. Concentrated and the residue was 
purified with (PE-EA 2:1-1:1) to afford 63 (790 mg, 69%) as a white solid. 1H NMR (500 
MHz, CD3OD): δ 7.05 (d, J = 9.0 Hz, 2H), 6.85 (d, J = 9.0 Hz, 2H), 5.60 (s, 1H, H-1), 
4.36 (dd, J = 5.5, 0.5 Hz, 1H, H-2), 4.18 (m, 1H, H-3), 3.75 (s, 3H, OCH3), 3.72 (m, 1H, 
H-6a), 3.69 (m, 1H, H-5), 3.66 (m, 2H, H-4, H-6b), 1.52, 1.38 (2xs, 6H, CH3CCH3); 13C 
NMR (125 MHz, CD3OD): δ 156.70, 151.76, 119.46, 115.56, 110.65, 98.21 (C-1), 80.16 
(C-3), 77.19 (C-2), 72.53 (C-5), 69.79 (C-4), 62.16 (C-6), 56.01 (OCH3), 28.37, 26.64 
(CH3CCH3).  
Methoxyphenyl 6-O-benzoyl-2,3-isopropylidene-α-D-mannopyranoside (64) 
A solution of 63 (990 mg, 3.04 mmol) in DCM (7 mL) and pyridine (0.7 mL) was stirred 
at < 15°C while benzoyl chloride (0.37 mL, 3.188 mmol) was added. After 10 minutes, 
TLC shows no 64 left. Then methanol was added to quench the BzCl, the reaction 
mixture was diluted with DCM and then washed with 1N HCl, brine. The organic layer 
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was dried over Na2SO4, concentrated and the residue was purified by chromatography on 
silica gel (PE-EA 4:1-3:2) to afford 64 (1.14g, 87%) as a white solid. [α]D20 = +38.95 (c = 
0.44, DCM); 1H NMR (CDCl3, 500 MHz): δ 7.88 (dd, J = 8.5, 1.5 Hz, 1H), 7.56 (t, J = 
7.5 Hz, 1H), 7.38 (t, J = 8.0 Hz, 2H), 7.02 (d, J = 9.0 Hz, 2H), 6.76 (d, J = 9.0 Hz, 2H), 
5.71 (s, 1H, H-1), 4.60 (dd, J = 12.0, 6.0 Hz, 1H, H-6a), 4.50 (dd, J = 12.0, 2.0 Hz, 1H, 
H-6b), 4.39 (d, J = 6.0 Hz, 1H, H-2), 4.33 (t, J = 6.0 Hz, 1H, H-3), 4.03 (ddd, J = 10.0, 
6.0, 2.0 Hz, 1H, H-5), 3.73 (s, 3H, OCH3), 3.69 (ddd, J = 11.0, 7.0, 4.0 Hz,  1H, H-4), 
3.04 (d, J = 4.5 Hz, 1H, 4-OH), 1.52, 1.40 (2xs, 6H, CH3CCH3); 13C NMR (CDCl3, 125 
MHz): δ 169.93, 154.96, 149.67, 133.13, 129.78, 129.52, 128.26, 117.65, 114.56, 109.94, 
95.98 (C-1), 78.27 (C-3), 75.59 (C-2), 69.42 (C-4), 68.94 (C-5), 63.88 (C-6), 55.50 (OCH3), 
28.01, 26.21 (CH3CCH3); ESI-MS Calcd for C23H26O8 [M+Na]+, 453.15, found 453.14. 
Methoxyphenyl 6-O-benzoyl-2, 3-isopropylidene-4-O-thiocarbonylimidazoyl-α-D-
mannopyranoside (65) 
A mixture of 64 (570 mg, 1.324 mmol) and N,N’-thiocarbonyldiimidazole (708 mg, 3.97 
mmol) in 1,2-dichloroethane (6.0 mL) was refluxed for 5 h. The solution was 
concentrated in vacuo and the residue was diluted with DCM, washed with 1N HCl and 
brine. The organic layer was dried over Na2SO4 and the solvent was removed in vacuo, 
the residue was purified by chromatography on silica gel (PE-EA 3:1-1:1) to afford 65 
(693 mg, 97%) as an off-white solid. [α]D20 = +75.4 (c = 0.615, MeOH); 1H NMR 
(CDCl3, 500 MHz): δ 8.35 (s, 1H), 7.79 (d, J = 7.5 Hz, 2H), 7.63 (s, 1H), 7.52 (t, J = 7.5 
Hz, 1H), 7.35 (t, J = 10.5 Hz, 2H), 7.02 (m, 3H), 6.73 (d, J = 9.5 Hz, 2H), 6.04 (t, J = 7.5 
Hz, 1H, H-4), 5.75 (s, 1H, H-1), 4.64 (t, J = 6.5 Hz, 1H, H-3), 4.48 (d, J = 5.5 Hz, 1H, H-
2), 4.46-4.38 (m, 3H, H-6a, H-5, H-6b), 3.71 (s, 3H, OCH3), 1.66, 1.42 (2xs, 6H, 
CH3CCH3); 13C NMR (CDCl3, 125 MHz): δ 183.46 (C=S), 165.98 (C=O), 155.24, 149.53, 
136.98, 133.09, 131.16, 129.63, 129.42, 128.23, 118.12, 117.60, 114.67, 110.90, 95.82 (C-
1), 78.40 (C-4), 75.75 (C-2), 75.17 (C-3), 66.91 (C-5), 63.20 (C-6), 55.49 (OCH3), 27.53, 
26.29 (CH3CCH3); HR-MS Calcd for C27H28N2O8S [M+Na]+, 563.1461, found 563.1462. 
Methoxyphenyl 6-O-benzoyl-4-deoxy-2,3-isopropylidene-α-D-mannopyranoside (66) 
A solution of 65 (1.378 g, 2.55 mmol) in dry toluene (20 mL) was added dropwise over 
30 min to a stirred solution of refluxing toluene (60 mL) and tributylstanne (1.05 mL, 
3.83 mmol) under argon. After the reaction mixture was refluxed for 6 h, the solvent was 
removed in vacuo and the residue was purified by chromatography on silica gel (PE-EA 
9:1-4:1) to afford 66 (1.046 g, 99%) as a pale yellow solid. [α]D20 = +95.0 (c = 0.502, 
CHCl3); 1H NMR (CDCl3, 500 MHz): δ 7.85 (m, 2H), 7.52 (m, 1H), 7.38 (t, J = 8.0 Hz, 
2H), 7.01 (d, J = 9.0 Hz, 2H), 6.72 (d, J = 9.0 Hz, 2H), 5.71 (s, 1H, H-1), 4.56 (m, 1H, H-
3), 4.33 (m, 2H, H-6a, 6b), 4.21 (m, 2H, H-2, H-5), 3.71 (s, 3H, OCH3), 2.04 (ddd, J = 
13.0, 6.5, 2.5 Hz, 1H, H-4a), 1.69 (ddd, J = 13.0, 10.5, 9.0 Hz, 1H, H-4b), 1.57, 1.40 
(2xs, 6H, CH3CCH3); 13C NMR (CDCl3, 125 MHz): δ 166.20 (C=O), 154.87, 150.03, 
132.94, 129.83, 129.69, 128.21, 117.77, 114.51, 109.35, 96.61 (C-1), 73.01 (C-2), 70.43 
(C-3), 66.74 (C-6), 65.27 (C-5), 55.49 (OCH3), 29.98 (C-4), 28.09, 26.25 (CH3CCH3); HR-
MS Calcd for C23H26O7 [M+Na]+, 437.1576, found 437.1576. 
Methoxyphenyl 6-O-benzoyl-4-deoxy-α-D-mannopyranoside (67) 
A solution of 66 (322 mg) in 80% aqueous HOAc (5.0 mL) was heated at 75°C for 0.5 h 
and then concentrated to afford 67 as a white solid in quantitative yield. It was used for 
next step without further purification. 1H NMR (CD3OD, 500 MHz): δ 7.87 (dd, J = 8.0, 
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1.0 Hz, 2H), 7.58 (m, 1H), 7.43 (t, J = 8.0 Hz, 2H), 7.00 (d, J = 9.0 Hz, 2H), 6.71 (d, J = 
9.5 Hz, 2H), 5.43 (d, J = 1.0 Hz, 1H, H-1), 4.35-4.22 (m, 3H, H-6a, H-6b, H-5), 4.17 (m, 
1H, H-3), 3.89 (m, 1H, H-2), 3.69 (s, 3H, OCH3), 1.84 (q, J = 12.0 Hz, 1H, H-4a), 1.74 
(m, 1H, H-4b). 
Methoxyphenyl 6-O-benzoyl-4-deoxy-2,3-O-acetyl-α-D-mannopyranoside (68) 
To a solution of 67 (290 mg, 0.77 mmol) in dry pyridine (2.0 mL) was added acetic 
anhydride (1.5 mL) and DMAP (15 mg) at rt. The reaction mixture was stirred at rt for 4 
h then concentrated to dryness. The residue was purified by flash chromatography on 
silica gel (PE-EA 6:1-3:1) to afford 68 (340 mg, 96%) as a white solid. [α]D20 = +66.7 (c = 
0.8, CHCl3); 1H NMR (CDCl3, 500 MHz): δ 7.95 (dd, J = 8.5, 1.0 Hz, 2H), 7.56 (t, J = 
7.5 Hz, 1H), 7.41 (t, J = 8.0 Hz, 2H), 7.01 (d, J = 9.0 Hz, 2H), 6.73 (d, J = 9.0 Hz, 2H), 
5.53 (ddd, J = 12.0, 5.5, 3.5 Hz, 1H, H-5), 5.46 (d, J = 1.5 Hz, 1H, H-1), 5.30 (m, 1H, H-
2), 4.38 (m, 3H, H-3, H-6a, H-6b), 3.73 (s, 3H, OCH3), 2.16, 2.06 (2xs, 6H, 2xCOCH3), 
1.97 (m, 2H, H-4); 13C NMR (CDCl3, 125 MHz): δ 170.07, 169.96, 166.13 (3xC=O), 
155.16, 149.86, 133.09, 129.76, 129.70, 128.29, 117.99, 114.52, 97.22 (C-1), 67.71 (C-2), 
66.91 (C-3), 66.30 (C-5), 66.16 (C-6), 55.54 (OCH3), 27.84 (C-4), 20.96, 20.88 (CH3CO); 
HR-MS Calcd. for C24H26O9 [M+Na]+, 481.1475, found 481.1447. 
6-O-Benzoyl-2,3-di-O-acetyl-4-deoxy-α-D-mannopyranosyl trichloroacetimidate (70) 
To a solution of 68 (151 mg, 0.328 mmol) in CH3CN/H2O (v:v = 4:1, 20.0 mL) was 
added CAN (539 mg, 0.983 mmol) in portions at 0°C. The mixture was stirred at 0°C for 
0.5 h, continuously stirred at rt for additional 1 h. Then diluted with EA, the organic 
layers were washed with water, brine and dried over Na2SO4 and concentrated in 
vacuum, the residue was purified by chromatography on silica gel (PE-EA 6:1-3:1) to 
afford a mixture of 69 (106 mg, 91%). To a solution of this mixture in dry DCM (6.0 mL) 
was added NaH (60%) (1.2 mg) at rt. The mixture was stirred at rt for 4 h, then added 
silica gel and concentrated, the residue was purified by chromatography on silica gel (PE-
EA 9:1-4:1) to afford 70 (106 mg, 71%) as a white solid. [α]D20 = +54.02 (c = 0.81, 
CHCl3); 1H NMR (CDCl3, 500 MHz): δ 8.71 (s, 1H, NH), 8.03 (dd, J = 8.5, 1.0 Hz, 2H), 
7.57 (t, J = 7.5 Hz, 1H), 7.44 (t, J = 7.5 Hz, 2H), 6.32 (d, J = 1.5 Hz, 1H, H-1), 5.41 (m, 
1H, H-5), 5.32 (m, 1H, H-2), 4.46 (m, 1H, H-3), 4.43 (m, 2H, H-6a, H-6b), 2.17, 2.06 
(2xs, 6H, 2xCOCH3), 2.08 (m, 2H, H-4); 13C NMR (CDCl3, 125 MHz): δ 169.84, 169.77, 
166.13 (3xC=O),159.97 (NHCCCl3), 133.19, 129.75, 129.68, 128.37, 95.46 (C-1), 69.17 
(C-3), 66.12, 66.09, 65.85 (C-2, C-5, C-6), 27.73 (C-4), 20.87, 20.76 (2xCOCH3); HR-MS 
Calcd. for C19H20Cl3NO6 [M+Na]+, 518.0152, found 518.0156. 
n-Heptyl 6-O-benzoyl-4-deoxy-2,3-O-acetyl-α-D-mannopyranoside (71) 
To a solution of 70 (100 mg, 0.2 mmol) and n-heptanol (85 µL) in dry toluene (4 mL) 
was added a solution of TMSOTf/toluene (20 µL/480 µL) (50 µL) at rt. The reaction 
mixture was stirred at rt for 3 h, then diluted with EtOAc, washed with 5% NaHCO3, 
brine and dried over Na2SO4 and the solvent was removed in vacuo, the residue was 
purified by chromatography on silica gel (PE-EA 9:1-6:1) to afford 71 (47 mg, 52%) as 
colorless oil. [α]D20 = +41.15 (c = 0.88, CHCl3); 1H NMR (CDCl3, 500 MHz): δ 8.06 (d, J 
= 7.5, 1.0 Hz, 2H), 7.57 (t, J = 7.0 Hz, 1H), 7.44 (t, J = 7.5 Hz, 2H), 5.32 (m,  1H, H-3), 
5.09 (s, 1H, H-2), 4.84 (d, J = 1.0 Hz, 1H, H-1), 4.40 (m, 2H, H-6), 4.23 (m, 1H, H-5), 
3.67 (dt, J = 9.5, 6.5 Hz, 1H, OCH2C6H13), 3.42 (dt, J = 9.5, 6.5 Hz, 1H, OCH2C6H13), 
2.14, 2.02 (2xs, 6H, 2xCOCH3), 1.92 (m, 2H, H-4), 1.57 (m, 2H), 1.28 (m, 8H), 0.88 (t, J 
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= 7.0 Hz, 3H); 13C NMR (CDCl3, 125 MHz): δ 170.21, 169.99, 166.24 (3xCO), 133.14, 
129.85, 129.64, 128.37, 98.08 (C-1), 68.13 (OCH2C6H13), 68.04 (C-2), 66.60 (C-3), 66.43 
(C-6), 66.16 (C-5), 28.09 (C-4), 32.79, 31.80, 29.08, 25.68, 22.59, 14.07 (OCH2C6H13), 
21.00, 20.96 (2xCH3CO); HR-MS Calcd. for C24H34O8 [M+Na]+, 473.2151, found 
473.2149. 
n-Heptyl 4-deoxy α-D-mannopyranoside (27) 
To a solution of 71 (47 mg, 0.1 mmol) in methanol (4 mL) was added 0.5 M 
CH3ONa/MeOH (40 µL) at rt. The reaction mixture was stirred at rt overnight, then 
neutralized with HOAc. The solvent was concentrated to dryness and the residue was 
purified by flash chromatography on silica gel (PE-EA 1:1-0:1) to 27 (16 mg, 61%) as a 
white solid. [α]D20 = +86.14 (c = 0.19, CHCl3); 1H NMR (CDCl3, 500 MHz): δ 4.89 (s, 
1H, H-1), 4.05 (m, 1H, H-3), 3.84 (m, 1H, H-5), 3.77 (m, 1H, H-2), 3.71-3.64 (m, 2H, H-
6a, H-OCH2C6H13), 3.60 (m, 1H, H-6b), 3.39 (dt, J = 9.5, 6.5 Hz, 1H, OCH2C6H13),  2.59 
(d, J = 5.5 Hz, 1H, 2-OH), 2.30 (m, 2H, 3-OH, 6-OH), 1.68 (m, 2H, H-4), 1.55 (m, 2H), 
1.28 (m, 8H), 0.88 (t, J = 7.0 Hz, 3H); 13C NMR (CDCl3, 125 MHz): δ 100.12 (C-1), 
69.20 (C-2), 68.36 (C-5), 67.80 (OCH2C6H13), 65.59 (C-3), 65.32 (C-6), 30.08 (C-4), 31.76, 
29.42, 29.06, 26.09, 22.59, 14.07 (OCH2C6H13); HR-MS Calcd for C13H26O5 [M+Na]+ 
285.1678, found 285.1676. 
Synthesis of compounds previously published 
Compound 1 and 2 by Bouckaert et al. 2005(27); compound 10 by Han et al. 2010(28);
compound 11 and 20 by Klein et al. 2010(2); compound 12 - 14 by Pang et al. 2012(29);
compound 15 by Scharenberg et al. 2012(30); compound 16 - 19 and 21 - 22 by Kleeb et al.
2015(9); compound 23 by Jiang et al. 2012(31); compound 8 and 26 by Fiege et al. 2015(8);
compound 9 by Sager et al. 2018(32) and compound 28 and 29 by Schönemann et al.
2018(33). Compound 4 was purchased from TRC Canada (Toronto, Canada) and
compound 3 was obtained from Sigma Aldrich (Buchs, Switzerland).  
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1. Introduction
1.1. A brief overview of the selectin family members 
The selectin family consists of E-, P-, and L-selectin, three structurally closely related 
carbohydrate binding cell-adhesion molecules (CAMs) belonging to the C-type lectins. 
All selectins are transmembrane proteins, expressed on the surface of vascular endothelial 
cells (E-selectin, P-selectin), leukocytes (L-selectin) and platelets (P-selectin).(1) They play 
an important role in the initiation of an inflammation by mediating tethering and rolling 
of leukocytes on vascular endothelial cells.(2) Table 1 gives an overview of the most 
important characteristics of E-, P-, and L-selectin. 
Table 1. Characteristics of the three selectin family members L-, E-, and P-selectin. Historical 
nomenclature, structural traits, features of expression, and binding targets.  
L-Selectin E-Selectin P-Selectin 
Historical synonyms CD62L, LAM-1, 
LECAM-1 
CD62E, ELAM-1, 
LECAM-2 
CD62P, GMP-140, 
LECAM-3 
Molecular weight (protein) 42 kDa 64 kDa 86 kDa 
Molecular weight (glycosylated) 90 kDa(3) 115 kDa(4) 140 kDa(5) 
Number glycosylation sites 7 11 12 
Number of consensus repeats 2 6 9 
Expressing cells Leukocytes Endothelial cells Endothelial cells, 
Thrombocytes 
Activating molecules Constitutively 
expressed 
LPS, TNF-α, IL-1 Histamine, Thrombin 
Activation time - 4-6 hrs 10 mins 
Target cells Endothelial cells Leukocytes Leukocytes 
Target structures Various Sialomucins, 
PSGL-1 
ESL-1, PSGL-1 PSGL-1 
1.2. Structural features 
Selectins are heavily glycosylated and share an overall sequence identity of approx. 50% 
with a higher similarity in the domains relevant for ligand binding. Furthermore, 
selectins share a similar overall architecture (Figure 1): An N-terminal lectin domain 
(~120 amino acids) points into the vascular lumen where it is responsible for binding 
interactions. It harbors a structural Ca2+ ion, which stabilizes the protein conformation 
and coordinates with the carbohydrate ligand.(6) Although not in direct contact with the 
ligand, the EGF-like domain (~40 amino acids) C-terminally connected to the lectin 
domain is essential for ligand binding.(7,8) A major structural difference between the 
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members of the selectin family is the number of short consensus repeat (SCR) domains 
(~60 amino acids) connecting the EGF-like domain to the transmembrane domain.(9) 
SCR domains are thought to act as spacers between the binding interface and the 
endothelial surface(10), but they were furthermore found to influence binding affinity and 
specificity.(11,12) However, some publications did not confirm these findings, which are 
therefore still debatable.(13) Selectins are anchored to the cell by a short α-helical 
transmembrane region (23 amino acids). A C-terminal cytoplasmic tail (17-35 amino 
acids) is involved in signal transduction(14,15) and interacts with the cytoskeleton.(16)  
Figure 1. The structure of selectins and their natural ligands. The overall architecture of the selectins is 
conserved. A lectin domain is followed by an epidermal growth factor (EGF)-like domain, a variable 
number of short consensus repeats, a transmembrane anchor, and a C-terminal cytosolic tail. L-selectin 
ligands are sulfated sialomucins and PSGL-1 that binds to all selectins. ESL-1 binds to E-selectin. (Picture 
modified from Vestweber and Blanks (1999)).(9) 
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1.3. Selectin ligands 
The natural ligands of selectins are expressed on the surface of vascular endothelial cells, 
leukocytes, and thrombocytes (Figure 1). They are heavily glycosylated proteins which 
bear sialylated and fucosylated terminal glycan epitopes.(17) The common minimal 
binding motif for all selectins is the tetrasaccharide sialyl Lewisx (sLex) and its 
regioisomer sialyl Lewisa (sLea) (Figure 2).(18,19)  
 Figure 2. Minimal carbohydrate epitopes binding to E-, P-, and L-selectin. Sialyl Lewisx (Neu5Ac(α2-
3)Gal(β1-4)[Fuc(α1-3)]GlcNAc) and its regioisomer sialyl Lewisa (Neu5Ac(α2-3)Gal(β1-3)[Fuc(α1-
4)]GlcNAc). R is the linkage site to the glycan structure of a glycoprotein. 
The interaction between the selectins and this minimal binding epitope is very specific 
but exhibits a rather weak affinity: sLex binds with an affinity of 0.8 ± 0.1 mM to 
E-selectin, 7.8 ± 1.0 mM to P-selectin and 3.9 ± 0.6 mM to L-selectin.(20,21) As an 
exception for a much higher affinity, P-selectin glycoprotein ligand-1 (PSGL-1) presented on 
leukocytes and thrombocytes and P-selectin show an affinity of in the nanomolar range 
(320 nM(22); 826 nM(23); 80 nM(24)). Because PSGL-1 harbors multiple glycans presenting 
sLex the avidity of binding might be increased due to multivalency.(25) However, PSGL-1 
additionally contains sulfated tyrosines that form interactions to a secondary binding site 
on P-selectin.(23,26) Like P-selectin, L-selectin requires sulfation on its counterreceptors, 
while for E-selectin the minimal binding epitope sLex is sufficient for binding.(27,28) 
PSGL-1 is, therefore, a ligand of all selectins,(20) but the affinity to E-selectin is weaker as 
it lacks the secondary binding site for sulfated tyrosines.(29) The 150 kDa glycoprotein 
ligand E-selectin ligand-1 (ESL-1) is not sulfated and consequently binds only to E-selectin 
with an affinity of 60 µM.(20,30) E-selectin is furthermore reported to bind 
glycosphingolipids on human neutrophils(31) and P- and L-selectin are reported to bind to 
the anticoagulant heparin, which is a heterogeneous mixture of sulfated 
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glycosaminoglycan.(32) For L-selectin currently nine confirmed ligands are known: 
glycosylation-dependent cell adhesion molecule-1 (GlyCAM-1), mucosal vascular 
addressin cell adhesion molecule-1 (MAdCAM-1), CD34, podocalyxin, nepmucin, 
Sgp200, endomucin, endoglycan, and PSGL-1.(33) Most of these ligands are sialo-mucins 
expressed by high endothelial venule (HEV) cells that mediate the homing of 
lymphocytes to lymph nodes. 
1.4. The Role of Selectins in Inflammation 
1.4.1. Inflammatory cascade 
The inflammatory cascade is a response of the body to cell injuries or infections. An infection 
triggers the inflammatory response by pathogen-associated molecular patterns (PAMPs) 
(e.g. bacterial LPS, viral dsRNA).(34) Damage-associated molecular patterns (DAMPs) 
are molecules located inside the cell in healthy tissue that are released upon injury (e.g. 
DNA, RNA, ATP).(35) PAMPs and DAMPs are recognized by pattern recognition 
receptors (PRR) on sentinel cells such as macrophages or dendritic cells.(36) Activated 
sentinel cells release proinflammatory cytokines(37) that cause the five classical signs of an 
acute inflammation, namely redness, swelling, heat, pain, and loss of function by 
vasodilatation, increased permeability of the vascular endothelium, and hyperalgesia. 
Furthermore, these cytokines initiate the inflammatory cascade as a part of the non-specific 
(innate) immune response (Figure 3).(1)  
Figure 3. The role of selectins in the inflammatory cascade. Selectins are exposed on the surface upon an 
inflammatory stimulus. By initiating the tethering and rolling of leukocytes along vascular endothelial cells 
they allow leukocytes to reduce their velocity in the bloodstream. Finally, integrins provide firm adhesion 
of decelerated leukocytes and enable extravasation to the site of inflammation. (Picture from A. Vögtli) 
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Leukocytes, which circulate in the bloodstream, are cells of the immune system with 
executing functions (e.g. phagocytosis, release of reactive oxygen species) to defend the 
body against infections. However, to do so they have to extravasate from the 
bloodstream to the site of inflammation. As a response to the proinflammatory cytokines 
cell adhesion molecules (CAMs) such as proteins of the selectin and the integrin family 
are expressed that mediate the process of extravasation.(38,39) Initially, P-selectin, stored in 
Weibel-Palade bodies within the vascular endothelial cells, is rapidly transported to the 
cell surface as a response to the proinflammatory mediators thrombin and histamine.(40-42) 
This process is completed within a few minutes. The expression of E-selectin is regulated 
on the transcription level by the NFκB-pathway and has to be expressed de novo. It is 
induced by lipopolysaccharides (LPS), tumor necrosis factor-α (TNF-α), and 
interleukin-1β (IL-1β).(43,44) The highest expression level of E-selectin on vascular 
endothelial cells is reached 4-6 hours after the stimulus.(45,46) In contrast, L-selectin is 
constitutively expressed on leukocytes.(47) It interacts with a broad variety of sialomucins 
on endothelial cells and furthermore with PSGL-1. This allows leukocytes to interact 
with other leukocytes (secondary tethering)(33,48) and to form clusters with thrombocytes.(49-51) 
Interactions between the selectins and their carbohydrate ligands are characterized by fast 
association and dissociation kinetics to allow leukocytes rolling along the vascular 
endothelium.(30) While L- and P-selectin redundantly mediate rolling at high velocities, 
E-selectin decelerates to slow motions.(52) Together, the selectins decelerate the mobility 
of the leukocytes from 1-10 mm/s down to 5 µm/s.(52) However, it is the integrin mediated 
interaction that finally provides firm adhesion and enables diapedesis.(53,54) The interplay 
between selectins and integrins is crucial since knockout mice of either system suffer from 
an impaired leukocyte extravasation.(46) Leukocytes either transmigrate via a paracellular 
(cell junctions) or transcellular pathway through the endothelial cell layer to the site of 
inflammation where they execute their protective function.(55,56) 
1.4.2. Role of selectins in disease 
The proper reaction of the body to an injury or infection is an acute inflammation that 
leads to a complete cure. An acute inflammation has to be distinguished from a chronic 
inflammation, which is established in case defense mechanisms are insufficient to 
eradicate the causative stimulus or an acute inflammation is not downregulated after 
resolution of the initial trauma. In both forms of inflammation, acute and chronic, 
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excessive leukocyte extravasation may lead to the destruction of healthy tissue.(57) 
Although selectins are not the cause, their dysregulation during immune reactions can be 
correlated with a broad variety of diseases: Selectins play a major role in cardiovascular 
diseases like atherosclerosis,(58) myocardial infarction,(59) hypertension,(60) and reperfusion 
injury.(61) Furthermore, they are relevant for immune diseases like rheumatoid arthritis(62) 
and asthma bronchiale(63) and they are associated with graft rejection,(64,65) sickle cell 
disease,(66) and carcinoma cell metastasis.(67,68) Therefore, the carbohydrate epitopes sLex 
and sLea binding selectins are tumor-associated antigens and can be used as predictive 
biomarkers for the diagnosis of breast and colon cancer.(57,69) Selectin-deficient mice have 
no developmental defects, but they show impaired inflammatory responses.(70,71) Similar 
symptoms could be reproduced by blocking the selectins with antibodies in mice and 
rats.(72,73) Hence, their key role as initiators of leukocyte extravasation make the selectins 
target of utmost importance for drug discovery.(74) 
1.5. Structural binding properties 
Since Graves et al. published the first structure of apo E-selectin in 1994(75), many more 
selectin structures were solved and provided information of inestimable value for 
numerous drug discovery programs (Table 2). The selectins share a high sequence 
identity (61-65% for the lectin and EGF-like domain) and consequently a similar 3-D 
architecture (Figure 4A). However, upon ligand binding the co-crystallized structures of 
P- and E-selectin (4CSY, 4C16, and 1G1S) unveil a conformational change of great 
importance for the biological function of selectins (Figures 4B and 4C), as well as for the 
rational design of selectin antagonists.   
Table 2. Overview of the selectin structures deposited in the Protein Data Bank (PDB). Resolution for 
X-ray structures is given in Ångström (Å). 
PDB-Code Construct Ligand Resolution Remarks Ref 
1ESL E-selectin (LecEGF) none 2.0 apo (75)
1G1T E-selectin (LecEGF) sLex 1.5 soaked (23)
4CSY E-selectin (LecEGF SCR2) sLex 2.4 co-crystal (76)
4C16 E-selectin (LecEGF SCR2) DS04-115 1.9 co-crystal (76)
1G1Q P-selectin (LecEGF) none 2.4 apo (23)
1G1R P-selectin (LecEGF) sLex 3.4 soaked (23)
1G1S P-selectin (LecEGF) SGP-3 (glycosylated 
PSGL-1 fragment) 
1.9 co-crystal (23)
3CFW L-selectin (LecEGF) none 2.2 apo 
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Figure 4. Superimposed selectin structures. (A) Apo structures of E-selectin (green, PDB-Code: 1ESL),(75) 
P-selectin (purple, PDB-Code: 1G1Q),(23) and L-selectin (yellow, PDB-Code: 3CFW) share a high 
structural similarity to the selectins soaked with sLex [E-selectin (light blue, PDB-Code: 1G1T)(77) and 
P-selectin (orange, PDB-Code: 1G1R)](77). (B) The co-crystalized structures of E-selectin with sLex (dark 
blue, PDB-Code: 4CSY)(76) and P-selectin with SGP-3 (C) (red, PDB-Code: 1G1S)(23) exhibit major 
structural changes in the binding site and the relative orientation between the lectin domain and the EGF-
like domain compared to their soaked analogue. Ligands are shown in grey and the calcium ion in white. 
Two consensus repeats of 4CSY were removed.  
1.5.1. E-selectin 
Before the first crystal structure of E-selectin in complex with sLex was published, 
pharmacophores had to be elucidated by systematic structure-activity relationship (SAR) 
studies. Hence, all hydroxyl groups of L-fucose (L-Fuc) were identified as crucial for 
binding.(78,79) On the D-galactose (D-Gal) only the hydroxyl groups in position C-4 and 
C-6 (4-OH and 6-OH), but not the 2-OH was found to interact with the protein.(80) From 
the sialic acid moiety (Neu5Ac) solely the carboxylate group appeared essential for 
binding.(18,79) Finally, N-acetylglucosamin (D-GlcNAc) does not interact with the protein, 
but rather serve as a spacer to keep the pharmacophores of D-Gal and L-Fuc in the 
correct spatial orientation.(81,82)  
The crystal structure of E-selectin soaked with sLex published by Somers et al. in 2000(23) was 
very similar to the apo structure previously published by Graves et al. six years earlier.(75) 
The bound crystal structure could largely confirm previous findings of the 
pharmacophores of sLex (Figure 5A):(83)  
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o Ca2+ coordinates with 3-OH and 4-OH of L-Fuc, and 4-OH furthermore
forms hydrogen bonds with Glu80 and Asn82.
o A salt bridge is formed between Arg97 and the carboxylic acid of
Neu5Ac, which additionally forms a hydrogen bond with Tyr48.
o 4-OH and 6-OH of D-Gal each are involved in one hydrogen bond each.
o D-GlcNAc does not interact with the protein, but pre-organizes D-Gal
and L-Fuc in their bioactive conformation.
o The oxygen in the glycosidic bond between Neu5Ac and D-Gal accepts
a hydrogen bond from Arg97.
o The bioactive conformation of sLex observed in the crystal structure is
nearly identical to its conformation in solution.(84-86)
Figure 5. Schematic representation of the interaction between sLex and E-selectin. Differences between 
ligand soaking (A) (PDB-Code 1G1T) and co-crystallization (B) (PDB-code 4CSY) are shown in red. 
Pharmacophores are highlighted in blue. (Picture modified from R. Preston). 
Surprisingly, the hydroxyl group in 2-position of L-Fuc that was found to be crucial for 
binding by SAR studies, is not involved in a direct interaction with the protein. This 
discrepancy could only recently be solved when Preston et al. (2015)(76) published a 
co-crystal structure of E-selectin in complex with sLex, disclosing substantial conformational 
changes compared to the soaked crystal structure from Somers et al. (Figures 4B and 5B). 
The changes were not only restricted to the binding site, but furthermore the relative 
position between the lectin domain and the EGF-like domain altered significantly:  
o Loop 81-89 in the binding site moves up to 10 Å towards the binding
site. Glu88 displaces Asn83 and coordinates with Ca2+ and forms a
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hydrogen bond with 2-OH of L-Fuc. Furthermore, Gln85 and Glu107 
shift into hydrogen bonding distance of 2-OH and 3-OH of L-Fuc, 
respectively. 
o The angle between the lectin and the EGF-like domain around the pivot
residue Trp1 is 154° and therefore more stretched (‘extended
conformation’) than in the unbound structure, where the angle between
the domains is 120° (‘bent conformation’).
o Two loops (residues 52-72) bridge the loop movements between the
binding site and the pivot region extending the overall alterations to a
total distance of 35 Å.
It is known that this induced fit is part of a catch-bond mechanism, which is described in 
section 1.5.3. The conformational change could not be observed in the soaked X-ray 
structure as the protein in a grown crystal is locked due to close protein contacts. 
1.5.2. P-selectin 
The binding sites of E- and P-selectin resemble each other but exhibit some important 
differences (Figure 6A). Compared to E-selectin, P-selectin has a 10-fold reduced affinity 
towards sLex.(21) However, three sulfated tyrosines on the natural ligand PSGL-1 
significantly improve the affinity. Somers et al. (2000)(23) therefore expressed an 
O-glycosylated peptide fragment (SGP-3) of PSGL-1 containing the sulfotyrosine 
sequence (Tys5, Tys7, Tys10). SGP-3 showed a similar affinity to P-selectin as PSGL-1. 
Furthermore, both, SGP-3 containing no sulfated tyrosines and SGP-3 containing no 
glycan revealed a massive drop in affinity. SGP-3 could be co-crystallized with P-selectin 
(Figures 6B and 6C) and induced a conformational change in a similar manner as 
observed with E-selectin (Figure 4C):(83) 
o Arg97 forming a salt bridge to the carboxylic acid of Neu5Ac in
E-selectin is substituted by Ser97 in P-selectin and there forms a water-
mediated hydrogen bond.
o Lys99 that points away from the binding site in E-selectin is substituted
by Ser99, which builds a hydrogen bond to 4-OH of Neu5Ac.
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o Glu88 swings in and simultaneously coordinates with Ca2+ and forms a
hydrogen bond to 2-OH of L-Fuc.
o 13 of totally 19 amino acids of the peptide fragment SGP-3 interact with
the protein.
o All three oxygen atoms of the Tys7 sulfate group form direct or water-
mediated hydrogen bonds to P-selectin (Figure 6B).
Figure 6. Schematic representation of the interaction between SGP-3 and P-selectin. (A) The terminal 
sLex motif of O-glycosylated SGP-3 is interacting with the binding site of P-selectin (PDB-Code: 1G1S). A 
difference to the binding site interacting with soaked sLex (PDB-Code: 1G1R) is highlighted in red, and 
differences to E-selectin co-crystalized with sLex (PDB-Code: 4CSY) are highlighted in green. The 
interactions of the sulfated tyrosines Tys7 (B) and Tys10 (C) of the protein backbone of SGP-3 contribute 
beneficially to the binding affinity to P-selectin. (Picture 6B and 6C modified after Somers et al. (2000)(23); 
reprinted with permission from Elsevier)  
The different amino acids in position 97 (Arg97 vs. Ser97) are mainly responsible for the 
reduced affinity of sLex to P-selectin, compared to E-selectin. Additional contacts of 
Pro98 and Ser99 formed to P-selectin cannot compensate for the salt bridge formed in 
case of E-selectin. Instead, a large cluster of positive electrostatic potential adjacent to the 
sLex binding site supports the binding of anionic molecules to P-selectin, such as the 
sulfotyrosines of PSGL-1. This cluster might also promote the binding of heparin, which 
was reported to bind P-selectin but not E-selectin.(32) 
1.5.3. Catch-bond mechanism 
Like FimH, selectins show an increased bond lifetime under tensile force conditions.(87) 
This catch-bond behavior could be demonstrated first for P-selectin(88), later for 
L-selectin(89) and E-selectin(90) with atomic force microscopy and by performing binding 
experiments in flow chambers. The sliding-rebinding model is an attempt to link the catch-
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bond behavior to the existence of a bent and extended selectin conformation observed in 
crystal structures (Figure 4): Mechanical force is thought to induce the extended 
conformation aligning the bound selectins along the direction of flow. This allows 
leukocytes to slide on the endothelial surface by continuously forming transient new 
contacts with unbound selectins in bent conformation before completely unbinding.(91) 
Other models assume an allosteric regulation by the EGF-like domain.(87,92) Indeed, the 
removal of the EGF-like domain prevents P-selectin from binding PSGL-1.(93) Moreover, 
stabilizing the extended conformation of P-selectin increases the affinity to PSGL-1 at 
low force, but impairs the ability to mediate leukocyte rolling.(94) On the basis of allosteric 
regulation and observations in crystal structures, a two-state-two-pathway model was 
suggested.(76,95) It assumes the bent and extended conformation in equilibrium and the 
ligand able to bind to both of them, although with different rates. Tensile force shifts the 
equilibrium towards the extended conformation and increases the average bond lifetime. 
1.6. Selectin Antagonists 
A pan-selectin antagonist is the aim of many drug development programs for more than 
20 years. However, this is a very ambitious aim, since tight binding of ligands seems 
against the nature of selectins. Nevertheless, some considerable achievements were made 
and three candidates are currently in clinical evaluation (Figure 7). The preclinical and 
clinical selectin antagonists were recently reviewed by Ernst and Magnani.(74)  
Most approaches started with sLex as lead structure, but other leads (e.g glycyrrhizin(96), 
efomycin M(97), quinic salicylic acid(98)) have been explored as well. Quinic salicylic acid 
was discovered by a high throughput ELISA screen at Wyeth and was suggested as a 
non-carbohydrate sLex mimic due to hydroxyl groups similarly oriented as on L-Fuc.(77,98) 
The affinity towards P-selectin was determined to be in the millimolar range.(77) 
Subsequent optimization led to the clinical candidate PSI-697 with an improved affinity 
of 125 µM and drug-like properties allowing oral application.(98) It completed clinical 
phase II in 2008 but the successful reduction of platelet-monocyte aggregates ex vivo(99) 
could not be confirmed in vivo.(100) An approach to mimic sialyl di-Lewisx by biphenyl 
substituted D-mannose resulted in the divalent molecule Bimosiamose (TBC1269) 
developed by Revotar Biopharmaceuticals AG (Hennigsdorf, DE).(101) It was successfully 
215
Section III. E-selectin – Introduction 
Figure 7. Chemical structures of selectin antagonists in clinical trials and glycomimetics of sLex. 
TBC1269 (Bimosiamose), PSI-697 and GMI-1070 (Rivipansel) are currently in clinical evaluation. 
Rivipansel is a glycomimetic of sLex and was rationally designed. GCP69669A, DS04-115, and DS04-139 
are important intermediate steps towards a low micromolar E-selectin antagonist (beneficial modifications 
are shown in brown). Linking sulfonated naphthalene to a glycomimetic of sLex leads to Rivipansel.   
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tested for the treatment of patients with chronic obstructive pulmonary disease (COPD) 
by inhalation in phase II clinical trials.(102) So far the most successful approach was the 
systematic reduction and substitution of hydrophilic parts of sLex not directly involved in 
binding interactions. The GlcNAc spacer of sLex between L-Fuc and D-Gal was 
substituted by cyclohexane-1,2-diol and the highly polar sialic acid was replaced by 
S-cyclohexylactic acid resulting in GCP69669 with a 10 fold improved affinity towards 
E-selectin (IC50 = 80 µM).(103) A further increase in affinity was achieved by stabilizing the 
core conformation of sLex. Steric repulsion between L-Fuc and the 3’-methyl substituent 
of the adjacent cyclohexane-1,2-diol (DS04-115), as well as an improved pre-
organization of the acid orientation by 2’-benzoylation on D-Gal (DS04-139) improved 
the affinity towards E-selectin by a factor of 15.(104,105) These findings finally led to the 
rationally designed pan-selectin antagonist GMI-1070 (Rivipansel, GlycoMimetics Inc.), 
where the sLex mimetic was linked to a threefold sulfated naphthalene fragment that is 
required to increase the affinity towards P- and L-selectin.(106) It was successfully tested 
for the reduction in time to resolution of a vaso-occlusive crisis in patients with sickle cell 
disease in phase II clinical trials(107) and recently entered phase III.  
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Abstract 
Carbohydrate-lectin interactions are generally of rather low affinity. As a consequence, 
high ligand concentrations are required to saturate a lectin and to accurately determine 
the dissociation constants (KD). Probably the most prominent lectin targets in drug 
discovery are the selectins. These cell-adhesion macromolecules play an important role in 
early stages of inflammation by mediating tethering and rolling of leukocytes on vascular 
endothelial cells and are therefore correlated with a broad spectrum of diseases. Their 
minimally required binding epitope is the tetrasaccharide sialyl Lewisx (sLex) with an 
affinity in the millimolar range. Nevertheless, it was selected as a lead structure for the 
development of therapeutic antagonists because extensive random screens did not reveal 
acceptable hits.  
To reduce the amounts of required protein and ligand for the determination of KD values 
an assay using microscale thermophoresis (MST) was developed. The method is based 
on the phenomenon that bound molecules move with different velocity along a 
temperature gradient than unbound molecules. Here, we compare KD values determined 
by MST and isothermal titration calorimetry (ITC), which is the gold standard method 
for the evaluation of molecular interactions. Both methods were found to be in good 
agreement. Furthermore, the effect of DMSO – a frequently used co-solvent for solubility 
reasons - on the binding properties of E-selectin was investigated. Surprisingly, DMSO 
was found to improve the affinity of E-selectin ligands.  
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Introduction 
In recent years, lectins, such as selectins, siglecs or DC-SIGN have received increasing 
attention as drug targets.(1) They play important roles in biological processes like cell 
adhesion,(2) signal transduction,(3) cell recognition,(4,5) or inflammation(2). Among the 
lectins, selectins are the most extensively studied family. As a response to an injury, pro-
inflammatory cytokines initiate the presentation of selectins on the surface of endothelial 
cells (E- and P-selectin) and leukocytes (L-selectin).(6) Selectins have been found to 
recognize the carbohydrate motifs sialyl Lewisx (sLex) and sialyl Lewisa (sLea) as part of 
the glycan of their physiological glycoprotein ligands.(7,8) This rather weak interaction 
mediates the initial tethering and rolling of leukocytes on endothelial surfaces, which is 
followed by firm adhesion and transmigration to the injured tissue.(9) Dysregulation of 
selectins by immune reactions could be correlated with a variety of cardiovascular 
diseases (e.g. atherosclerosis,(10) myocardial infarction,(11) reperfusion injury(12)), immune 
diseases (e.g. rheumatoid arthritis,(13) psoriasis,(14) asthma bronchiale(15)), metastasis(16) and 
sickle cell disease.(17) Hence, its role as an initial mediator of the inflammatory cascade 
makes E-selectin a valuable target for drug discovery.(18,19)  
Lectin-carbohydrate interactions are characterized by complex hydrogen bond networks 
formed by the hydroxyl groups on the carbohydrate residues.(20) The polar hydroxyl 
groups establish strong interactions with water molecules. Hence, the interaction of a 
carbohydrate with its lectin target is accompanied by a high enthalpic penalty for water 
displacement.(21) As a consequence, carbohydrate-lectin interactions tend to be highly 
specific but at the same time in average weaker than biomolecular interactions are in 
general.(22) Because the determination of affinities of weak interactions requires high 
sample concentrations it is important to run the binding experiment at the lowest possible 
volume. Microscale thermophoresis (MST) is a new method with low sample 
consumption and short measurement time, allowing the determination of the 
dissociation constants (KD).(23) Therefore, the movement of molecules along a 
temperature gradient is monitored. An infrared laser induces this temperature gradient 
within capillaries containing the interacting molecules. Their movement is monitored by 
a change in fluorescence requiring labeling or intrinsic fluorescence of one of the 
interaction partners. The velocity of the molecule moving in the temperature gradient 
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depends on its size, charge, and solvation.(24) Upon a binding interaction of a ligand and a 
protein these parameters are changed. 
In this study, we evaluated MST as a new method for lead optimization of E-selectin 
antagonists by a comparison with results achieved by isothermal titration calorimetry 
(ITC). Thereby, we additionally found the widely used co-solvent dimethylsulfoxide 
(DMSO) to have a significant influence on the KD. Several groups reported the influences 
of DMSO on proteins, but to our knowledge, only two publications are examining the 
influence on affinity.(25,26) Both reported a decrease in affinity considering DMSO to act 
as a competing ligand. Here, we report the first protein-ligand interaction with an 
improved affinity in the presence of DMSO. 
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Results 
Measurements of reference compounds with ITC. The four reference compounds 
(Figure 1) represent a typical carbohydrate lead optimization process in drug discovery 
starting from the natural binding epitope sLex (1) with a binding affinity in the millimolar 
range. Rational substitution of the polar non-binding parts of the molecule leads to 
compound 2 with a more than 10 fold improved affinity (Table 1).(27) A further increase 
in affinity is achieved by stabilizing the core conformation of sLex. Steric repulsion 
between L-Fuc and the 3’-methyl substituent of the adjacent cyclohexane-1,2-diol (3),(28) 
as well as a hydrophobic collapse between the cyclohexane on the S-cyclohexylactic acid 
site and the-benzoate in the 2’-position of the D-Gal moiety (4)(29,30) pre-organizes the acid 
in its bioactive conformation and improves the affinity towards E-selectin by a factor of 
15 (Table 1). Compounds 1-3 were previously studied by ITC and these data are already 
published.(31) Since ITC is the “gold standard” for the evaluation of molecular interaction, 
we used it to validate the results obtained by MST.(32) 
Figure 1. Structures of the reference compounds tested with ITC and MST for their affinity to E-
selectin. Sialyl Lewisx (1) is the natural binding epitope, while ligands 2-4 represent rationally designed 
antagonists with improved binding affinity to E-selectin.  
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Table 1. Comparison of dissociation constants achieved by ITC and MST in the presence or absence of 
DMSO. Standard errors and 95% confidence intervals are reported in Table S1 (MST) and Table S2 (ITC). 
ITC (0% DMSO) MST (0% DMSO) MST (10% DMSO) 
Compound 
KD 
[μM] rKD 
KD app 
[μM] 
rKD app
Fluorescence 
change [%] 
KD app 
[μM] 
rKD app
Fluorescence 
change [%] 
1 778 1.000 695 1.000 5.14 392 1.000 9.71 
2 60.7 0.078 57.1 0.082 5.58 35.7 0.091 11.1 
3 17.8 0.022 12.9 0.019 5.59 8.69 0.022 11.2 
4 3.99 0.005 3.93 0.006 5.19 2.65 0.007 8.34 
Construct. Attempts to perform MST experiments with a full-length construct of 
E-selectin containing the lectin domain, the EGF-like domain, six short consensus 
repeats, and the Fc part of an IgG (E-selectinLEC6-IgGFc, previously used for the ITC 
measurements) failed, presumably due to the high molecular weight. This construct is 
heavily glycosylated and forms dimers resulting in a molecular weight of approx. 
300 kDa. Hence, it could not be sufficiently mobilized in the temperature gradient of the 
MST device. We therefore expressed a smaller construct consisting of the lectin domain, 
the EGF-like domain, and two short consensus repeats (E-selectinLEC2). This construct is 
monomeric and has a molecular weight of approx. 60 kDa.(33) Performing ITC 
measurements revealed that antagonist 4 binds to both constructs with the same affinity 
(Table 2), but the smaller E-selectinLEC2 construct has an improved thermophoresis 
compared to E-selectinLEC6-IgGFc. 
Labeling procedure. Following the standard labeling procedure recommended for the 
amine reactive protein labeling kit resulted in a strongly fluorescent protein. However, 
affinities of compounds 2 and 4 measured by MST differed by a constant factor of 3 
compared to the ITC measurements (Table 2). Although not directly interacting with the 
ligand, three lysines (Lys99, Lys111, Lys113) are located in close proximity to the 
binding site (PDB: 4C16) (Figure 2). Labeling of one of these lysines could influence the 
lectin-carbohydrate interaction. To prevent labeling of lysines close to the binding site, 
E-selectin was pre-incubated with antagonist 4 prior to the labeling procedure. After the 
labeling reaction, free dye and ligand were removed by dialysis. As a result, labeled 
E-selectin was obtained delivering comparable affinity data by MST and ITC (Table 2).  
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Figure 2. Crystal structure of E-selectin bound to compound 1. Lys99, Lys111, and Lys113 (highlighted 
in red) are pointing towards the binding site and potentially influence the binding affinity when labeled. 
Compound 1 is shown in purple, the Ca2+ ion is depicted by a black sphere, and the short consensus repeats 
were removed for clarity (PDB-Code: 4CSY).(33) 
Table 2. Comparison of different protein constructs used for ITC and MST. Both, the 
E-selectinLEC6-IgGFc and the E-selectinLEC2, show comparable affinity to reference compound 4. The protein 
labeling method is crucial for the validity of the MST assay. Standard errors and 95% confidence intervals 
are reported in Table S2 (ITC) and Table S3 (MST). 
Measuring 
technique 
E-selectin 
construct 
Labeling procedure 
KD [μM] 
Compound 2 
KD [μM] 
Compound 4
ITC LEC6-IgGFc Unlabeled 60.7 3.99 
ITC LEC2 Unlabeled n.d. 3.58 
MST LEC2 Unblocked binding site 166 12.2 
MST LEC2 Blocked binding site 57.1 3.93 
Laser power. Laser power is an adjustable parameter in the setting of MST 
measurements and defines the temperature gradient established in the capillaries 
containing the interacting molecules. Evaluating the optimal laser power for the 
Lys111 
Lys113 
Lys99 
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interaction of antagonist 2 with E-selectin revealed a strong dependence of the apparent 
KD (KD, app) on the temperature gradient (Figure 3A). Most likely, this dependence is 
caused by a combination of convection and thermal diffusion leading to local 
accumulations of ligand. The effect is comparable to the ‘Clusius tube’ effect, which was 
described by Baaske et al. (2007).(34) Suitable measuring conditions are encountered using 
lower laser powers as the accumulation grows exponentially with an increasing 
temperature difference (Table S4). The conditions at a laser power of 50% are a good 
trade-off between a reduced accumulation effect (lower laser power) and an improved 
signal to noise ratio (higher laser power). 
Figure 3. Apparent binding constants (KD,app) of E-selectinLEC2 interacting with compound 2 in 
dependence of the laser power and the presence of DMSO. (A) A temperature dependent accumulation 
effect is observed at laser power ≥ 40%. (B) The presence of 10% DMSO improves the binding affinity for 
all four antagonists (1 in red, 2 in green, 3 in yellow, and 4 in blue). Best-fit values are reported in Table S4 
(Laser power) and Table S1 (DMSO). 
Validation of MST results. With the E-selectinLEC2 construct applying a laser power of 
50%, highly reliable affinity data characterized by a small standard deviation were 
obtained by MST (Table S1). For validation, the KD, app values determined by MST were 
compared to those determined by ITC (Table 1). In the absence of DMSO, the absolute 
values of both methods are in very good agreement. In the presence of DMSO, the KD 
values varied significantly, however, the relative affinities (rKD) correspond well.  
DMSO improves the signal to noise ratio and the binding affinity. The influence of 
DMSO was of interest since it is frequently used as a co-solvent for substances with low 
solubility. Thereby two notable effects were observed. First, the fluorescence change 
(signal to noise ratio) was beneficially increased in the presence of DMSO (Table 1). 
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Second, the affinity of E-selectinLEC2 to all tested ligands was significantly increased (by a 
factor of about 1.5 to 1.8) in the presence of 10% DMSO (Table 1, Figure 3B). 
Furthermore, up to 20% DMSO the affinities for compound 2 are constantly increasing 
(Table S5). To exclude an MST specific effect due to unspecific changes in the solvation 
shell of the protein, an ITC measurement was performed to confirm and furthermore 
revealed a dramatic change in the thermodynamic fingerprint (Table 3, Figure 4): The 
former mainly entropy driven interaction becomes enthalpy driven in the presence of 
DMSO.  
Figure 4. Thermodynamic fingerprint for antagonist 2 binding to E-selectin LEC6-IgGFc in presence or 
absence of DMSO. (A) Enthalpograms of antagonist 2 in the absence (left) and presence of 10% (right) 
DMSO. (B) The thermodynamic fingerprint reveals a dramatic change in enthalpy and entropy. 
Table 3. Thermodynamic parameters of compound 2 binding to E-Selectin in presence or absence of 
DMSO. A substantial enthalpy-entropy compensation leads only a minor effect on the free energy of 
binding. 95% confidence intervals are reported in parentheses.   
KD [μM] ∆G° [kJ/mol] ∆H° [kJ/mol] -T∆S° [kJ/mol K] 
0% DMSO 60.7 (43.4 – 84.8) -24.1 -5.3 (-4.5 - -6.5) -18.8 
10% DMSO 20.7 (18.8 – 22.8) -26.7 -15.9 (-15.3 - -16.5) -10.9 
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Discussion 
Although sialyl Lewisx (1) binds to all selectins(35) with affinities in the millimolar range, 
it was selected as lead structure for the search of glycomimetic antagonists.(36) Knowledge 
of its pharmacophores allowed glycomimetics with largely improved affinities in the low 
micromolar range.(29,30,37) Still, for ITC measurements in this affinity range, high ligand 
and protein concentrations are required. This can be problematic and expensive for 
synthetically cumbersome ligands and/or protein production. Since for obtaining an 
accurate KD ligand concentrations cannot be reduced, the total volume used in a binding 
assay has to be diminished.  
Therefore, MST became the preferred assay format in our research group for several 
reasons. First, only low amounts of protein and ligand are required. Compared to ITC, 
ligand consumption could be reduced by a factor of ten and protein consumption was 
even lowered by more than 10’000 times. Second, high reliability of this assay format 
allows the comparison of very small changes, which is often decisive in lead 
optimization. Third, short measuring times and the straightforward measuring procedure 
enable a more project orientated approach enabling immediate feedback on activities of 
newly synthesized compounds.  
However, drawbacks such as ligand accumulation at higher laser powers and the 
requirement for protein labeling must not be ignored and have to be solved in advance. 
Furthermore, MST seems limited for macromolecules with high molecular weights. For 
E-selectinLEC2, approaches like label-free MST, specific N-terminal labeling, or labeling of 
a free cysteine were explored but not suitable. We could demonstrate that blocking the 
binding site with a competitive ligand is a simple and efficient way to prevent labeling 
next to the binding site.  
Since DMSO is often used for solubility reasons, its influence on affinities was studied. 
We discovered that DMSO increases the affinity of E-selectin-ligand interactions for all 
tested cases by a constant factor. Nevertheless, relative affinities did not differ in the 
presence or absence of DMSO and therefore KD values of related ligands can still be used 
for ranking compounds in cases the use of DMSO cannot be avoided. However, the fact 
that DMSO increases the affinity of E-selectin ligands is remarkable and requires further 
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investigation, especially since to our knowledge no publication reports an improved KD in 
the presence of DMSO. Tjenberg et al. (2006)(25) and Cubrilovic & Zenobi (2013)(26) 
investigated the influence of DMSO on protein-ligand interactions, but both reported a 
decrease in affinity. They speculated that DMSO may act as a competitive binder and 
furthermore considered a protein destabilization and a thereof resulting destruction of the 
binding pocket as possible explanations. Yet, none of these explanations is consistent 
with our observations. To rule out an MST method specific effect, an insight into the 
thermodynamics of the binding reaction in the presence of DMSO was gained by ITC 
measurements. A spectacular change of the thermodynamic fingerprint was observed. In 
the presence of DMSO, the enthalpy term became much more beneficial and the gain in 
entropy decreased significantly. We speculate, that DMSO alters the hydrogen bond 
network of water molecules in the binding site of unbound E-selectin or around the 
ligands. Hence, binding becomes enthalpically more favorable as a consequence of the 
decreased desolvation penalty. On the other hand, displacing fewer water molecules to 
the bulk is associated with a reduced gain in entropy. This example demonstrates the 
interplay of ITC and MST where MST was used as a fast standard method to determine 
the KD of an interaction and the more laborious ITC was used as a reference method to 
answer questions, which require in-depth information. 
In summary, we have shown the application of MST to the lectin E-selectin, established 
a simple way to overcome the obstacle of labeled lysines in the vicinity of the binding site 
and report a functional E-selectin construct that is suitable for MST. By comparing the 
KD of four reference compounds with the affinities determined by ITC the MST assay 
was validated. Furthermore, we demonstrated that a combination of MST and ITC 
might help to overcome drawbacks of both individual methods, which entails valuable 
synergies and guarantees opportunity for carbohydrate-based drug discovery.   
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Experimental Section 
Reagents, devices and compounds. VP-ITC apparatus was purchased from MicroCal 
Inc. (Uppsala, Sweden). MonolithTM NT.115, Protein Labeling Kit BLUE-NHS (Amine 
Reactive), and Standard Treated Capillaries were purchased from Nanotemper 
Technologies GmbH (Munich, Germany). HEPES, NaOH, NaCl, CaCl2· 2H2O, DMSO 
and Tween 20 were purchased from Sigma-Aldrich Chemie GmbH (Steinheim, 
Germany). Slide-A-Lyzer cassettes (10 kDa MWCO) and bovine serum albumin (BSA) 
standard ampules were obtained from Thermo Fisher Scientific (Rockford, IL, USA) 
Compound 1 was obtained from Carbosynth (San Diego, CA, USA) and compounds 2-4 
were synthetized as according to Schwizer et al.(1) 
E-selectin production. Cloning, transfection, expression and purification were 
previously described for the E-selectinLEC6-IgGFc construct by Jahnke et al.(1997)(2) and for 
the E-selectinLEC2 construct by Preston et al. (2015).(3)  
Labeling. E-selectinLEC2 was labeled using the amine reactive protein labeling kit BLUE-
NHS. Buffer exchange and labeling were performed according to the manufacturer’s 
protocol. To protect the 1ysines in the binding site from being labeled, the protein was 
saturated with 600 µM of compound 4. The labeled protein was dialyzed over night 
against assay buffer (10mM HEPES pH 7.4, 150 mM NaCl, 1 mM CaCl2) using Slide-A-
Lyzer dialysis cassettes (10 kDa MWCO). Protein concentration was determined by 
HPLC-UV against a BSA standard.(4,5) Figure 2 was illustrated with Maestro software 
version 9.7 (Schrödinger, LLC, NY, USA). 
Microscale Thermophoresis. MST experiments were carried out at 25° C with 100% 
LED power, 10-100% laser power (standard condition 50% laser power), a laser on time 
of 30 sec, and a laser off time of 5 sec using standard treated capillaries. Ligands were 
dissolved in assay buffer supplemented with 0.05% v/v Tween 20 (and 0-20% v/v 
DMSO) at a concentration of 88 mM (1), 10 mM (2), 4 mM (3), and 1 mM (4). Titration 
series were generated diluting the ligand stocks 15 times 1:1 with the corresponding 
buffer. The dilution series of ligand was 1:1 mixed with a solution of 0.2 to 0.25 µM E-
SelectinLEC2 and incubated for 10 mins at room temperature. The protein concentration 
was determined by HPLC-UV against a BSA standard.(4,5) Except the measurements with 
varying laser power, all experiments were independently performed three times. 
Datapoints were normalized using the bound and unbound borders achieved by 
NanoTemper Analysis 1.2.205 software (NanoTemper Technologies GmbH, Munich, 
Germany) and analyzed/illustrated with GraphPad Prism 5.0 (GraphPad Software, La 
Jolla, CA, USA). The measurements were globally fitted using equation 1 for single site 
binding.(6) 
PL =
(CP+ CL+KD) - (CP+CL+KD) - 4CPCL
2CP
(eq. 1) 
where [PL] is the protein-ligand complex concentration and KD is the dissociation 
constant. CP represents the total concentration of protein and CL the total concentration of 
ligand. 
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Isothermal Titration Calorimetry. Measurements were performed at 25° C with a 
reference power of 10 µcal/sec., a stirring speed of 307 rpm, high feedback, a spacing 
time of 600 sec., and a filter period of 2 sec. Preceding the measurements, E-selectin was 
dialyzed against assay buffer. Ligands were dissolved in the same buffer. For the 
measurement of compound 2 in the presence of dimethylsulfoxide, 10% v/v DMSO was 
added to both, protein and ligand. 5 – 15 µL ligand solution were injected into the sample 
cell (1.4523 mL) containing the protein. The protein concentration was determined by 
HPLC-UV against a BSA standard.(4,5) Ligand and protein concentrations of all 
experiments are reported in Table S2. The first injection was always excluded from data 
analysis. Baseline adjustment and peak integration were carried out using Origin 7.0 as 
described by the manufacturer (OriginLab, Northampton, MA, USA). A global three-
parameter data fitting was processed to determine N (stoichiometry), KA (association 
constant) and ∆H° (change in standard enthalpy) using SEDPHAT software.(7) Previously 
published data from Binder et al. (2012)(8) (compounds 1-3 binding to E-selectinLEC6-IgGFc) 
were reanalyzed in a similar manner, although for 1 and 2 the stoichiometry had to be 
fixed to 1 due to low c-values. This allowed a reliable determination of KA and ∆H°.(9,10) 
Thermodynamic parameters were calculated from equation 2:  
∆G° = ∆H°-T∆S° = RTlnKD = -RTlnKA (eq. 2) 
where ΔG° is the change in standard free energy of binding and ΔS° is the change in 
standard entropy, T is the absolute temperature, and R is the universal gas constant 
(8.314 J/mol K).  
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Abstract 
Microscale thermophoresis (MST) is a time-efficient method to determine affinities 
consuming only small amounts of ligand and receptor with a constantly growing field of 
applications. In the present work, we introduce MST as a primary screening method for 
the identification of fragments. The assay performance was demonstrated with E-selectin, 
a lectin that plays an important role in the early stage of inflammation. The screening 
was performed competitively against a reference ligand, a derivative of the natural 
carbohydrate binding motif. This allowed screening in cocktails and restricting the 
detected binding fragments to the ones binding in the natural binding site. The assay 
format was validated by the competitive displacement of a compound representing a sub-
structure of the natural binding motif, which is known to bind with a weak affinity. By 
deconvoluting the active cocktails several hits could be identified. Using nuclear 
magnetic resonance (NMR) as an orthogonal method, the validation of fragments 
binding in the binding site could be achieved, confirming the reliability of the assay for a 
primary screening of fragment libraries. 
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Introduction 
E-selectin is a C-type lectin that plays a major role in the initial phase of inflammation.(1) 
Upon an inflammatory stimulus, macrophages activate vascular endothelial cells via 
proinflammatory cytokines. The endothelial cells subsequently express E-selectin and 
present it on their luminal cell surface.(2) Once presented, E-selectin mediates the initial 
contact between the vascular endothelium and leukocytes at the site of inflammation.(3) 
This first weak interaction slows down the leukocytes enabling stronger interactions 
between members of the immunoglobulin superfamily and integrins.(4) Ultimately, the 
tethering, rolling, and firm adhesion results in the extravasation of the leukocytes. 
Besides its physiological function, E-selectin is also involved in the pathology of several 
diseases. Even though E-selectin is not the causative molecule, the cell-adhesive 
properties of E-selectin are a promoting factor in a variety of diseases. These are 
cardiovascular diseases like atherosclerosis,(5) myocardial infarction,(6) reperfusion 
injury,(7) and hypertension.(8) Furthermore, E-selectin plays a role in immune diseases 
such as asthma bronchiale(9) or rheumatoid arthritis(10) due to facilitated neutrophil 
extravasation. Finally, E-selectin is also associated with sickle cell adhesion(11) and 
metastasis of breast and colon cancer.(12) To treat these types of diseases, E-selectin is a 
valuable drug target.(13)  
With GMI-1070 (Rivipansel), the first intravenously applied E-selectin antagonist 
recently entered clinical trial phase 3 for the treatment of acute sickle cell crisis.(14) The 
lead structure for the development was the natural ligand of E-selectin, the 
tetrasaccharide sialyl Lewisx (sLex).(15,16) As for all lectins, E-selectin binds its natural 
carbohydrate ligand with high specificity, which is achieved by the formation of a 
complex network of hydrogen bonds and salt bridges. A total of eleven interactions are 
formed between E-selectin and sLex as determined from a recently published crystal 
structure (PDB code 4CSY).(17) However, the lead optimization is highly challenging as 
the removal of a single hydroxyl or carboxyl group leads to a dramatic loss in affinity due 
to their direct involvement in binding. The oral availability, on the other hand, is 
decreased by these groups due to lowered membrane permeability.(18) As most of the 
E-selectin related diseases are chronic or recurrent in nature requesting frequent 
applications, oral availability is a prerequisite for a therapeutic success. A possible 
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approach to this challenge is a non-carbohydrate replacement of the sLex mimetic based 
on a fragment-based approach. 
A fragment-based approach starts with a library of small drug-like fragments. Screening 
of fragments for binding to a specific target usually yields hits with affinities in the 
millimolar range. In a second step, hits are further characterized regarding their mode of 
binding. Different hits are either chemically linked together,(19) grown,(20) or serve for 
fragment-assisted drug design.(21) Since 2013, a single drug emerged from a fragment-
based approach and eleven drug candidates have surpassed clinical phase 1.(22) A 
challenging step of a fragment-based approach is the initial screen. Due to their small 
size, solubility limits, and generally weak affinities, many of the standard assay methods 
to reliably determine KD values are unsuccessful because they reach their detection limits. 
A method for robust, sensitive, and rapid KD determination for weakly binding and small 
ligands is therefore highly desirable. 
The recently introduced assay technique termed microscale thermophoresis (MST) works 
with small sample volumes and allows for the determination of weak affinities without 
the need for immobilization of either interaction partner. MST is based on the 
observation that different molecules exhibit individual thermophoretic properties, i.e. the 
mobility of molecules along temperature gradients. Thermophoresis is sensitive to 
changes in size, charge, and the solvation shell of a molecule.(23) Upon complex 
formation of ligand and protein, the thermophoretic parameters usually differ from the 
unbound state of the protein. Therefore a change of the thermophoresis of a protein is a 
function of its bound state. In recent studies, MST has been demonstrated to measure 
high-affinity ligands with low molecular weight(24) and it has furthermore been used to 
confirm hits found in a primary screen with other methods.(25) 
In this study, we present an MST-based method for screening fragments for E-selectin 
binding. To the best of our knowledge, no MST-based fragment screening method has 
been published to date. Our method is based on competitive binding to an sLex mimetic 
and provides fast screening with low sample consumption to detect fragments in the 
millimolar affinity range. As a result, we could successfully identify four site-specifically 
binding fragments. 
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Results 
Assay Validation. The principle of the applied assay format is to pre-incubate E-selectin 
with a titrated reference compound and a constant fragment concentration. The reference 
compound has a known binding affinity and binding mode analog to PDB entry 4C16. A 
fragment binding to the binding site competes with the reference compound, observable 
in a shift of the binding curve. 
For the development of the competitive assay, we selected 1-methyl α-L-fucopyranoside 
(MeFuc), a weakly binding fragment of both the reference compound as well as sLex. 
With a direct MST experiment, we determined the affinity of MeFuc to be 
50.9 ± 3.4 mM. Indeed, the competing effect of 15 mM MeFuc decreased the binding 
affinity of the reference compound from 22.6 µM to 33.5 µM (Figure 1). Using 
equation 2, this shift corresponds to the affinity of 31.1 mM for MeFuc. Therefore, the 
competitive assay is in good agreement with the direct titration. 
Figure 1. Shift of the normalized binding curve of E-selectin when binding the reference compound alone 
(●) and when binding the reference compound competing against MeFuc (○). 
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Considering the maximal DMSO-d6 tolerance of E-selectin of 20% (v/v) and the fact that 
the fragments from the Maybridge library are prepared as 100 mM stock solutions, we 
decided to use cocktails of 12 fragments, each at a concentration of 1.66 mM. This allows 
the detection of fragments binding with an affinity in the low millimolar range. 
Fragment Screening with MST. In an initial screen, we tested 480 fragments in 40 
cocktails (Figure 2). To ensure comparability, we prepared a stock dilution series of the 
reference compound to preincubate with E-selectin before the cocktails (1 - 40) were 
added. In cocktails 3, 8, 18, and 27 one or more fragments were present with a self-
fluorescence that shifted the baseline over the detection limit of the device. Furthermore, 
cocktail 4 contained a quenching substance and cocktail 23 contained turbid residues that 
prevented the cocktail from being properly measured. 
Figure 2. Overview of the competitive binding experiments of the reference compound competing against 
fragment cocktails (1 - 40) for binding to E-selectin. The affinity shifts are given relative to the reference 
compound. The dashed line represents the affinity of the reference compound in the absence of competitor. 
The dotted lines (1 mM, 2.5 mM) indicate the theoretical binding affinity of a fragment when only one 
fragment in the cocktail accounted for the KD shift of the reference compound. 
Out of the 40 cocktails the lower confidence interval border was shifted over the 
reference value of the reference compound in a total of 14 cocktails (5, 6, 9, 10, 15, 21, 
22, 26, 29, 30, 31, 33, 36, 37). As we are interested only in the best binding fragments we 
selected the best three cocktails (10, 21, 26) considering KD shift and the according 
confidence interval for more in depth-analysis. Therefore, we measured each fragment of 
these three cocktails individually applying the same assay procedures. Figure 3 depicts 
the results of the resolved cocktails 10, 21, and 26. In all three, multiple fragments 
introduced KD shift. With 10-6, 10-8, 21-5, 21-6, 21-7, 26-11, and 26-12, a total of seven 
possible hit fragments were identified. 
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Figure 3. Overview of the competitive binding experiments of the reference compound competing with one 
fragment for the binding to E-selectin. The affinity shifts are given relative to the reference compound. The 
dashed line represents the reference affinity of the reference compound in the absence of competitor. The 
dotted lines visualize the theoretical shift of the binding curve in the presence of a competitor with an 
affinity of 1 mM and 2.5 mM, respectively.  
To evaluate the possibilities of a direct measurement, we measured all hits again non-
competitively at three different laser powers (50 %, 75 %, and 100 %). Except for 
fragment 10-1, none of the hits showed a clear change in thermophoresis that would 
unambiguously identify it as a binder. In three cases (fragments 21-5, 21-6, 26-11) there 
was an indication for binding at the highest ligand concentrations (10 - 20 mM). 
However, only a marginal signal change was achieved and a binding curve could not be 
fitted. Fragments 21-7 and 26-12 showed no change in thermophoresis at all. A special 
case was observed for the binding of fragment 10-8 for which the fluorescence decreased 
from the moment the LED was turned on.  
Hit Validation by NMR. To validate fragments identified by the competitive MST assay 
with a second orthogonal method, we performed T1ρ NMR experiments, a label-free and 
well-established technique. Based on T1ρ NMR experiments, discriminating between a 
bound and an unbound fragment is possible as the relaxation of fragment protons in the 
close proximity of a protein is faster (Figure 4). Each fragment has an individual 
relaxation behavior in the absence of protein. Furthermore, the fragments bind to 
different sub-pockets providing a unique chemical environment for each proton affecting 
the relaxation in a distinct manner. This makes a cross-comparison between the 
fragments difficult and a ranking of the fragments affinity would not be reliable based on 
the T1ρ NMR results alone. However, T1ρ NMR is a valuable experiment to distinguish 
binders from non-binders. 
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Figure 4. Comparison of the relaxation of fragment 10-6 after 20 ms (red) and 200 ms (green) in the 
absence (left) and presence (right) of E-selectin in a T1ρ NMR experiment. In the presence of E-selectin fast 
relaxation can be observed, whereas in the absence of protein only slow relaxation occurs. 
A foregoing COSY NMR confirmed the identity of all hit fragments except for fragment 
21-6, which was therefore excluded from further experiments. A random fragment from 
each hit cocktail that did not show a change in KD in the competitive MST assay was 
selected as negative control (10-1, 21-1, 26-8). For the confirmed binders, two additional 
T1ρ NMR experiments were conducted. First, a competitive measurement against 
MeFuc was performed to answer the question whether the fragment occupies the same 
part of the binding site as MeFuc. The aim of the second experiment, namely the 
subsequent addition of the reference compound to the same sample, was to confirm that 
the fragment is binding in the binding pocket of interest. 
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Table 1. IX depicts the percentage intensity change of the NMR signal after 200 ms compared to the 
intensity after 20 ms. Shown are the differences between the sole fragment (F) and the relaxation after 
adding protein (P), MeFuc and reference compound (Ref). Per fragment, a distinct aromatic peak was 
chosen for evaluation. The difference is given in percentage points. 
Fragment IF - IF+P IF - IF+P+MeFuc IF - IF+P+MeFuc+Ref Classification 
10-6 23.5 24.9 2.8 competitive binder  
10-8 3.4 n.d. n.d. non binder 
21-5 26.6 20.4 15.2 competitive binder  
21-7 1.8 n.d. n.d. non binder 
26-11 18.2 11.9 8.1 competitive binder  
26-12 14.6 10.5 4.5 competitive binder  
10-1 1.0 n.d. n.d. non binder (negative control) 
21-1 1.9 n.d. n.d. non binder (negative control) 
26-8 28.37 n.d. 29.6 non-competitive binder (negative control) 
n.d.: The competitive measurements were not conducted for the non-binding fragments.
A change in relaxation greater than 5 percentage points was defined as lower limit due to 
the signal to noise ratio. From the six hits, only four (10-6, 21-5, 26-11, and 26-12) could 
be confirmed as binders. The competitive measurements showed that fragment 10-6 is 
only competitive to the reference compound but does not occupy the binding site of 
MeFuc. Fragments 21-5, 26-11, and 26-12 are competitive against MeFuc and the 
reference compound. Because MeFuc at a 50 mM concentration does not completely 
saturate the binding sites, the reference compound can further increase the competitive 
effect. The two negative controls 10-1 and 21-1 did not bind. However, the third negative 
control 26-8 was a binder. However, since binding was observed after addition of the 
reference compound, this fragment likely does not bind in the binding site and could 
therefore not be detected in the competitive MST screen. 
To get more precise KD values and to test the reproducibility of the competitive MST 
assay we then remeasured the four confirmed binders. The values presented in Table 2 
are in good agreement with the initial values depicted in Figure 3. 
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Table 2. The KD values and structures of the hit fragments from the competitive measurements 
Fragment KD [mM] Structure 
10-6 3.3 ± 0.9 
21-5 1.8 ± 0.5 
26-11 1.7 ± 0.4 
26-12 2.7 ± 0.6 
Discussion 
Four fragments with millimolar affinities to E-selectin were identified by modifying the 
previously introduced MST assay.(26) Again, MST was shown to be a robust and fast 
method with only low consumption of ligand and protein.  
In our project aimed to identify fragments binding to E-selectin, two major problems had 
to be solved. First, the determination of binders at a single fragment concentration, as 
practiced in established fragment screens with Differential Scanning Fluorimetry(27) or 
Surface Plasmon Resonance,(28) was not applicable with MST. For the evaluation of the 
MST experiment, the unbound, as well as the bound state of the protein, has to be 
distinguishable, which demands a dilution series. Hence, reaching the bound state for 
molecules with binding affinities in the low millimolar range requires high starting 
concentrations of the dilution series. This inevitably leads to problems regarding 
compound solubility and self-fluorescence of a substantial number of fragments. Second, 
OH
O
N
N
OO
F
F
F
NH2+ S
H
N
O O
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not all fragments are capable to significantly alter the hydration shell, a prerequisite to 
obtaining a measurable signal. Conformingly, except for fragment 10-6, none of the hits 
identified by a competitive MST screen would have been detected by a direct titration of 
the fragment. Furthermore, the laser power optimal to observe the thermophoretic 
behavior of a protein-ligand complex is not predictable. Therefore, each fragment should 
be measured with different laser power intensities. 
Nevertheless, these problems could be solved by performing a competitive experiment 
with a serial dilution of the reference compound and the addition of the competing 
fragment at a constant concentration. The preliminary experiment with MeFuc showed 
that a competitive MST measurement with small molecular weight compounds causes a 
distinct KD shift of the titrated reference compound. In addition, the competitive 
experiment provides further advantages. Most importantly it is possible to screen 
fragment cocktails, which drastically reduces measurement time and protein 
consumption. Also, the applied low fragment concentrations decreased the risk of 
reaching the solubility limits, diminishes the problem of self-fluorescence and reduces the 
fragment consumption. Furthermore, the competition with a mimetic of the natural 
binding epitope (reference compound) allows identifying fragments binding in the 
binding site of interest. In addition, stable and well-known screening conditions with an 
unambiguous fluorescence change of 15% allowed detecting also small shifts of the 
binding curves. 
We used cocktails that were a compromise between the DMSO-d6 tolerance of 
E-selectin, the assumed druggability representing the number of hits expected, and the 
desired fragment affinity. However, several weakly binding fragments added up their 
effect leading us to believe in an apparent large KD shift. Therefore, the deconvolution of 
a cocktail might not lead to a hit with expected high affinity. Also, too strong self-
fluorescence or quenching properties of a specific fragment might mask a binding 
fragment and not every apparent hit can be confirmed. Furthermore, an interaction of the 
fragment with the fluorescent label covalently attached to the protein may falsify the 
result. An interaction with the label of the protein or the competitor (reference 
compound) might also explain the false positive result obtained with fragment 21-7. In 
our case, a total of 13 out of 48 cocktails showed a significantly shift in KD and thereof 
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seven over the 4 mM and three over the 2.5 mM mark. As lectins are generally regarded 
to have a low druggability,(29) this amount of hits was surprising. In future projects, we 
should work with smaller cocktails to decrease the number of hits in one cocktail.  
The competitive NMR experiments gave a first indication for future project strategies. As 
fragment 10-1 is not competing the MeFuc, a linking strategy between the two fragments 
is at hand. However, the linking of fragments 21-5, 26-11, and 26-12 to MeFuc is not 
advised as they are competing for the same binding site. Here, a fragment growing 
approach, i.e. regarding the fragment as scaffold has to be considered. However, before 
any further experiments are initiated, fragments of interest should be co-crystallized to 
gain solid information regarding their binding mode. 
In conclusion, our approach proved to be eligible to fragments with low millimolar 
affinities within short period of time and with low material consumption. Especially 
when the MST assay for high-affinity binders is already established, no changes to the 
existing protocol have to be made, except for adding constant amounts of fragments. This 
makes it an easily applicable method for an initial fast screen in a fragment-based 
approach.
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Experimental Section 
Reagents and Compounds.  HEPES and 1-methyl α-L-fucopyranoside were purchased 
from Sigma-Aldrich Chemie GmbH (Steinheim, Germany). D2O, TSP-d4, and DMSO-
d6 were purchased from Armar Chemicals (Döttingen, Switzerland) and HEPES-d18 was 
purchased from Cambridge Isotope Laboratories Inc. (Andover, MA, USA). Vivaspin® 
20 centrifugal concentration tubes for membrane filtration were purchased from 
Sartorius-Stedim (Göttingen, Germany). Protein Labeling Kit BLUE-NHS (Amine 
Reactive) and Standard Treated Capillaries were purchased from Nanotemper 
Technologies GmbH (Munich, Germany). The Maybridge Ro3 Diversity Fragment 
Library Core Set was purchased from Fisher Scientific AG (Wohlen, Switzerland). SLex 
methyl glycoside was obtained from Carbosynth (San Diego, CA, USA). The reference 
compound CGP69669A(30) was synthetized according to Kolb and Ernst.(31) 
Microscale Thermophoresis 
Protein Preparation. The E-selectinLEC2 construct was expressed and purified according 
to Preston et al.(17) The labeling procedure was performed according to Zihlmann et al.(26) 
Briefly, the E-selectinLEC2 binding site was blocked and then labeled using the amine 
reactive protein labeling kit BLUE-NHS according to the protocol of the manufacturer. 
Unreacted dye was removed by dialysis against buffer A (10 mM HEPES, 150 mM 
NaCl, 1 mM CaCl2, pH 7.4). 
Measurements. All experiments were carried out using a Monolith™ NT.115 device 
(Nanotemper Technologies GmbH, Munich, Germany) at 298 K with 100% LED power, 
50% laser power, laser on time of 30 s, and laser off time of 5 s with standard treated 
capillaries. Throughout all experiments, the E-selectinLEC2 concentration was 0.1 μM. For 
the competitive measurements, a stock dilution series of the reference compound was 
prepared. The reference compound was diluted 1:1 starting at a concentration of 5 mM 
with buffer A supplemented with 0.1% (v/v) Tween 20. For the cocktail measurements 
cocktails of 12 fragments at a concentration of 3.33 mM in buffer A with 40% (v/v) 
DMSO-d6 were prepared. For the single compound measurements, the 1-methyl α-L-
fucopyranoside concentration was 30 mM and the fragment concentration was 3.33 mM 
in buffer A with 40% (v/v) DMSO-d6. The E-selectinLEC2 was preincubated with the stock 
dilution series. Subsequently, the preincubated protein was mixed 1:1 with either a 
cocktail or single compound. For the direct measurements, three runs with the same 
sample at a laser power of 50%, 75%, and 100% were conducted. The fragments were 
diluted 1:1 with buffer A supplemented with 0.1% (v/v) Tween 20 and 40% (v/v) 
DMSO-d6. The highest concentrations were 1 M for the 1-methyl α-L-fucopyranoside, 
40 mM for the fragments 10-8, 21-5, 21-6, 21-7, 26-11, and 26-12, and due to solubility 
problems 4 mM for fragment 10-6. The dilution series were mixed 1:1 with 0.2 μM of the 
E-selectinLEC2 protein. 
Data Analysis. Every measurement was conducted once except for the four hit 
fragments and the 1-methyl α-L-fucopyranoside measurements, which were measured in 
triplicate. Data points were normalized using the bound and unbound borders calculated 
by NanoTemper Analysis 1.2.205 software (NanoTemper Technologies GmbH, Munich, 
Germany) and analyzed with GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA, 
USA). To evaluate the KD shift of the reference compound the measurements were 
globally fitted using equation (1) for single site binding.(32) 
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where [PL] is the protein-ligand complex concentration and KD is the dissociation 
constant. CP represents the total concentration of protein and CL the total concentration 
of ligand. To obtain the affinity constant of the fragment, the measurements were first 
globally fitted using Wang formula for competitive single site binding.(33) As the same 
results were obtained with the simplified Schild formula(34) (equation 2) this equation was 
used instead.  
!! = !!!!,!1+ !!!!,! + !!!!,! (2) 
where pS is the fraction of binding sites occupied by the fragment. KD,F is the dissociation 
of the fragment, CF is the fragment concentration, KD,S is the dissociation constant of the 
reference compound and CS is the concentration of the reference compound. 
Nuclear Magnetic Resonance 
Protein Preparation. Buffer B (10 mM HEPES-d18, 150 mM NaCl, pH 7.4) was 
prepared by adjusting the pH in water with correction for deuterium effect, subsequent 
three times lyophilization, and resolvation in D2O. The E-selectinLEC6-IgGFc construct was 
expressed and purified according to Jahnke et al.(31) After purification the protein was 
transferred to buffer B by membrane filtration (10 kDa MWCO). 
T1ρ Measurements. A sample with 1 mM fragment in D2O with 10% (v/v) DMSO-d6 
with 0.1 mM TSP-d4 added as internal reference was prepared to evaluate the signal 
reduction of the unbound fragment. For the measurements combined with protein a 
sample of 0.5 mM fragment, 20 μM E-selectinLEC6-IgGFc, 0.1 mM TSP-d4, and 1 mM 
CaCl2 in buffer B with 10% (v/v) DMSO-d6 was prepared. For the competitive 
measurements first 1-methyl α-L-fucopyranoside and second the reference compound 
were added to the sample protein sample to reach a final concentration of 50 mM and 
5 mM, respectively. All experiments were measured on a Bruker Avance III 500 MHz 
NMR spectrometer equipped with a 5 mm BBO room temperature probe head at a 
temperature of 298 K. The measurements are based on a reference Bruker pulse sequence 
with excitation sculpting for suppression of residual water signals, with a relaxation delay 
of 10 s, an acquisition time of 2.73 s, and with 256 to 512 scans and 4 dummy scans. For 
analysis of the transversal relaxation in absence and presence of protein, spinlock pulses 
of 20 ms and 200 ms were used at a power level of 2.6 kHz. Spectra were acquired, 
processed and analyzed with Topspin 2.1 (Bruker, Fällanden, Switzerland). 
Data Analysis. Data were evaluated according to Hajduk et al.(35) With data evaluation 
software Bruker Topspin v2.1 the percentaged signal reduction per proton signal of the 
fragment with 200 ms spinlock compared to 20 ms spinlock were obtained. Subsequently, 
the percentaged signal reduction of a proton signal was compared to the percentaged 
signal reduction in presence of protein and competitor. A difference of 5 percentage 
points was defined as the cut-off for binding. 
!" = (!! + !! + !! − !! + !! + !! ! − 4!!!!2!! (1) 
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Abstract 
E-selectin is a cell-adhesion lectin expressed on the surface of vascular endothelial cells 
involved in the recruitment of leukocytes to the site of inflammation. By interacting with 
the tetrasaccharide sialyl Lewisx ([Neu5Ac(α2-3)Galβ(1-4)[Fucα(1-3)]GlcNAc, sLex, 1) in 
the glycan of glycoproteins on leukocytes, E-selectins mediates the initial contact and 
enable them rolling along the endothelial vessel. This process is useful to defend the body 
against infections, but excessive extravasation of leukocytes can harm the tissue and is 
associated with a broad variety of diseases. Hence, blocking this interaction is a 
promising strategy to suppress an inflammation at the beginning of the cascade.  
Our approach to develop a potent E-selectin antagonist is to optimize the natural ligand 
sLex.  We have been able to improve the affinity 15 fold by the replacement of D-Neu5Ac 
by (S)-cyclohexyl lactic acid and D-GlcNAc by (R,R)-cyclohexane-1,2-diol (2). Further 
improvement by a factor of 20 was achieved by methyl substitution in 3’-position of the 
1,2-cyclohexyldiol (3) and by benzoylation in 2’-position of D-Gal (4).  
Here, we demonstrate by X-ray crystallography, NMR spectroscopy and in silico 
molecular modeling that benzoylation in 2’-position of D-Gal rather stabilizes the 
bioactive conformation of 4 in solution than mediating new interactions with the protein. 
An intramolecular hydrophobic clash between the benzoate and (S)-cyclohexyl lactic 
acid was considered as cause for the improved pre-organization. Therefore we 
synthesized a series of antagonists to further explore the hydrophobic clash and used 
microscale thermophoresis to evaluate their affinities. The hydrophobic interaction 
between the benzoate and the (S)-cyclohexyl lactic acid was found support the 
pre-organization of the core conformation of sLex mimics. 
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Introduction 
Lectins, such as selectins,(1-3) galectins(4,5) or siglecs(6) are subject of numerous studies as 
potential drug targets. Most notably, recent research has focused on selectins, a class of 
three cell-adhesion molecules (E-, P- and L-selectin), as they play a crucial role in the 
early stage of inflammation. They mediate tethering and rolling of leukocytes on 
endothelial cells near damaged tissue, which consequently allows for tighter integrin 
binding and leukocyte extravasation from blood circulation into the diseased or infected 
tissue.(7,8) However, exceedingly high number of leukocytes in the adjacent tissue can be 
destructive, leading to a range of acute and chronic diseases such as psoriasis,(9) 
asthma,(10) reperfusion injury(11) and rheumatoid arthritis(12). Moreover, selectins are 
involved in the development of certain tumors, as they enable the migration process of 
tumor cells to metastasize.(13) These findings further underline the importance of selectins 
as a therapeutical target.    
Scheme 1. Schematic presentation of the development of E-selectin antagonists 2-4 from sLex, 1. a) 
Replacement of D-Neu5Ac and D-GlcNAc in ligand 1 by (S)-cyclohexyl lactic acid and (R,R)-cyclohexane-
1,2-diol, respectively, leading to a 15 fold increase in activity. b) An equatorial methyl group in position 3 
of the d-GlcNAc mimic ((R,R)-cyclohexane-1,2-diol → (1R,2R,3S)-3-methylcyclohexane-1,2-diol) helps to 
stabilize the core conformation of 3, which further improves the affinity by a factor of 3-6. c) A 
benzoylation of the 2-hydroxyl position of D-Gal residue additionally increases the potency of ligand 4 by a 
factor of 3.6. KD values from isothermal titration calorimetry (KD ITC) for compounds 1-3 are taken from 
Binder et al.(14) Steady-state KD values from surface plasmon resonance (KD SPR) data for compounds 2-4 are 
taken from Schwizer et al.(15)  
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Sialyl Lewis X (sLex, 1) is the common tetrasaccharide epitope of all natural selectin 
ligands. Since sLex has only weak affinity to selectins, it is presented in multivalent forms 
in nature.(16,17) To develop a sLex-based antagonist with drug like properties(1), ligand 1 
had to undergo certain structural changes. Studies employing transferred nuclear 
overhauser enhancement NMR spectroscopy (trNOE-NMR)(18-21), saturation transfer 
difference NMR spectroscopy (STD-NMR)(22), elucidation of the structure activity 
relationship (SAR)(23-26), X-ray crystallography(27,28), mutation studies(29), in-silico molecular 
modeling(30) and finally isothermal titration calorimetry (ITC)(14) yielded a profound 
understanding of the interaction between sLex and E-selectin on an atomic level. The 
main pharmacophores of 1 are the hydroxyls of the fucose moiety, the 4-OH and 6-OH 
of the galactose residue as well as the COOH group of the sialic acid moiety. 
Conformational studies revealed that the molecule contains a rigid core represented by 
the Galβ(1-4)[Fucα(1-3)]GlcNAc (Lex-core) trisaccharide. This rigid motif is stabilized by 
the exo-anomeric effect(31), hydrophobic interactions(32), steric effects(2,3,15) and by a 
non-conventional hydrogen bond (33), consequently its conformation in solution and 
bound state is almost identical. Structural elucidations revealed, that the GlcNAc residue 
has only weak interaction with the protein and acts rather as a unique restrained linker 
between fucose and galactose to ensure the bioactive conformation of sLex. The 
replacement of non-binding elements in molecule 1 by carefully selected hydrophobic 
residues yielded ligand 2, a potent sLex mimetic with improved drug-like properties. The 
KD values determined by isothermal titration calorimetry(14) and surface plasmon 
resonance(15) showed a 15 fold higher activity for 2 over its natural counterpart 1. An 
additional methyl group in position 3 of the 1,2-cyclohexyldiol spacer in mimic 3 
stabilizes the sLex core which leads to a 3-6 fold improvement over ligand 2. 
Furthermore, benzoylation in 2’-position of D-galactose increased the affinity by an 
additional factor of 3.6 (3→4). This effect was previously observed by Thoma et al.(34), and 
it was presumed that the 2’ benzoylation has a stabilizing effect on the Lex mimic core, 
however, this reasoning was not further investigated.  
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Scheme 2. E-selectin ligands designed and synthesized in this paper. a) the lactic acid moiety is 
functionalized with neutral (5a, 6a), electron rich (5b, 6b) and electron poor (5c, 6c) phenyl rings. The 
hydroxyl group in position 2 of D-Gal is either un-substituted (6a-c) or functionalized with a benzyl group 
(5a-c) or an acetyl function (7) b) The benzoyl group in ligand 4 is replaced by a smaller acetyl function (8). 
In this study, we elucidate the role of the benzoyl function on the 2’ position of D-Gal in 
ligand 4. By using co-crystallization X-ray experiments, NMR spectroscopy, and in silico 
molecular modeling the conformation of 4 in both solution and bound state was 
determined. To further investigate the influence of the substituents on C2-OH of D-Gal 
on the binding, a set of antagonists 5a-c, 6a-c, 7 and 8 was synthesized and evaluated 
using microscale thermophoresis for affinity (KD) determination. In the designed 
glycomimetic antagonists the lactic acid moiety is functionalized with either neutral, 
electron rich or electron poor phenyl rings, whereas the OH on the C2 position of D-Gal 
is either unprotected or functionalized with a benzoyl or an acetyl moiety. In ligand 8, 
position 2 of D-Gal is protected with and acetyl group instead of the benzoyl function.  
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Results & Discussion 
To describe the spatial arrangement of the pharmacophores of sLex (1), two dihedral 
angles have previously been identified.(35) The core conformation describes the spatial 
arrangement of L-Fuc and D-Gal, while the acid orientation describes the orientation of the 
carboxylic acid group relative to the Lex core (Figure 2).(36) These two torsion angles were 
previously determined for sLex (1) in its protein-bound state by transferred nuclear 
overhauser-NMR (trNOE-NMR), and were later confirmed in the bound state where 
E-selectin crystals were soaked with sLex (1). (18,27,37,38) In its bioactive conformation, the 
core conformation of sLex (1) ranges between -30° and -55°, and the acid orientation between 
105° and 130°.(20,22,39) Using molecular dynamic (MD) simulations, we calculated the two 
torsion angles in a solvated environment for sLex (1) and for the three E-selectin 
antagonists (2-4). As shown in Figure 1, the angles for sLex (1), describing the core 
conformation and the acid orientation, are highly populated within the experimental 
window. The replacement of D-GlcNAc and D-NeuNAc by smaller, hydrophobic and 
unsubstituted residues in compound 2, lead to a small offset in the core conformation(15), 
whereas the carboxylic acid gained more flexibility. The introduction of a methyl group 
in the 3-position of the cyclohexane-diol aided to rigidify the core conformation in 
compound 3. The additional benzoate in the 2’-position of D-Gal in compound 4 restored 
the preorganization of the acid orientation to the position as determined for sLex (1).  
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Figure 1. The acid orientation is a measurement of the carboxylic acid position relative to the Lex core. The 
core conformation describes the spatial arrangement of the core itself. These torsion angles were calculated in 
solution for the ligands 1–4 in absence of protein with 9.6 ns MD simulations. A darker shading correlates 
with higher population in the respective conformation. The red rectangle encloses experimental trNOE-
NMR data of sLex (1) bound to E-selectin.(18,37,38) The measured angles from crystallographic structures for 
E-selectin soaked with sLex (1, cyan, PDB code 1G1T), (27) and the co-crystallized compounds (1, magenta; 
2, orange; 3, green; 4, yellow) are given. The blue arrow indicates the small offset in core-conformation of 
antagonist 2. 
In a co-crystallization study with sLex (1) and antagonist 3 we recently demonstrated that 
the overall conformation of the protein is altered.(40) While the binding mode and the 
general orientation of the pharmacophores of sLex (1) and antagonist 3 remained similar 
to the soaked structure, the protein undergoes significant alterations.(40) We demonstrated 
that small-molecule ligand interaction lead to a ligand-induced fit of the protein in 
solution and an overall extension of the protein, which involves rearrangements over the 
entire length of the lectin domain to the EGF-like domain interface.  
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Figure 2. E-selectin co-crystallized with the flexible antagonists 3 (green), and the pre-organized antagonist 
4  (yellow). a) Comparison of binding site residues in direct or water-mediated (Pro46) contact to the 
ligands (semi-transparent). All residues are in identical orientations, except for Glu89 and Lys99 side-
chains. The water mediating an interaction to Pro46 is shown as green or yellow sphere. The Ca2+ ion is 
depicted as a purple sphere. b) Comparison of crystallographic b-values in blue (below average low b-
value), white (average), and red (above average). For the Glu98 and Lys99 side-chains, the b-values were 
normalized against their backbone atoms. For the ligands, the b-values of the (S)-cyclohexyl lactic acid was 
normalized against the modified Lex core. The arrow indicates the shift of the cyclohexane ring orientation. 
For further insights into the E-selectin-ligand interactions, we herein report a co-crystal 
structure of compound 4 with E-selectin consisting of the four N-terminal domains (lectin 
domain, EGF-like domain, and first two short consensus repeats). While the binding site 
residues which directly interact with the L-Fuc and D-Gal moieties have identical 
orientations as previously observed in the co-crystal E-Selectin-ligand 3 (Figure 2a), the 
side-chain rotamers of Glu98 and Lys99 surrounding the (S)-cyclohexyl lactic acid 
moiety shows significant alterations. The benzoate on D-Gal in antagonist 4 can 
potentially create both hydrophobic and σ–π interactions with the cyclohexane moiety. 
These intra-molecular stabilizations shifts the cyclohexane residue into a well-defined 
orientation compared to antagonists 3. This re-orientation helps to accommodate the 
cyclohexyl unit between the side-chain residues of Glu98 and Lys99 causing an overall 
rigidification. Indeed, crystallographic b-factor analysis of the cyclohexyl moiety 
(normalized to the Lex core) reveals a significantly higher thermal motion in antagonist 3 
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in comparison to antagonist 4 (Figure 2b). This suggests a stabilization of the cyclohexyl 
moiety in antagonist 4, which in turn constrains the orientation of carboxylic 
pharmacophore and adopts a more rigid pre-organized conformation. This is reflected in 
the b-values for the carboxylic acid that are decreased in compound 4. 
Compound 4 is pre-organized in the bioactive conformation in solution. To prove our 
hypothesis that the acid pharmacophore of compound 4 is pre-organized in the bioactive 
conformation by an interaction between the benzoate and the cyclohexyl lactic acid, we 
solved the conformation in solution. Recently, it was demonstrated that NOESY NMR 
spectroscopy is an effective tool to analyze the conformation of oligosaccharides at ~277 
K at 900 MHz high field in solution.(41) 
Figure 3. a) Schematic overview of interresidual NOEs between cyclohexane moieties and H2-benzoate 
(red arrows) protons; b) Ensemble of 20 lowest energy conformations of 4 at 277 K in solution, calculated 
and refined using experimental NOE restraints; c) Crystal structure of 4.  
The chemical shift assignment of the resonances of compound 4 was achieved by homo- 
and heteronuclear 2D spectra recorded in D2O (Figures S1 and S2). Using a 2D NOESY 
spectrum, we could extract 56 unambiguous NOE cross-peaks (36 intraresidual and 20 
interresidual) between various non-exchangeable protons (Table S1 and statistics in 
Table S2). Specifically 10 interresidual NOEs between the benzoate and the two 
cyclohexane residues could be extracted (Figure 3a and Table S1). With 57 NOE derived 
distance restraints we were able to calculate a well-defined structural ensemble of 
compound 4 using Cyana(42) and subsequent refinement with AMBER 9(43) GAFF force 
field (Figure 3b). A comparison of this ensemble of solution conformations and the 
crystal structure of 4 displays an obvious similarity (Figure 3b and 3c). Furthermore, the 
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dihedral angles of conformations of 4 observed in solution, crystal and by molecular 
dynamic calculations showed values in a narrow range in the core conformation/acid 
orientation plot (Figure S3; statistics in Table S2). Another confirmation for the 
interactions between the cyclohexyl lactic acid and the benzoate are the pronounced 
upfield shifts of cyclohexane protons with spatial proximity to the aromatic ring in 4 
compared to 3 (Figure S4). The results propose that the stabilization of the cyclohexyl 
lactic acid by the benzoate in 4 is established already in solution, which guarantees a pre-
organization of the acid pharmacophore before the binding event. 
Synthesis of the ligands. The structural data obtained from the NMR and x-ray studies 
of ligand 4 suggest, that by tuning the intra-molecular interactions between the residue on 
position 3 of the lactic acid moiety and the substituent on position 2 of D-Gal, the pre-
organization of the carboxylic pharmacophore could be improved.  
Scheme 3. E-Selectin antagonists synthesized in this study. In order to achieve better pre-organization of 
the acid pharmacophore, the lactic acid moiety and the hydroxyl group in position 2 of D-Gal were 
functionalized with different substituents. The used moieties can potentially exhibit various intra-molecular 
interactions what should be reflected in the activity of the ligand. 
We propose a small library of E-selectin antagonists 5a-c, in which we replace the 
cyclohexyl residue of lactic acid moiety in ligand 4 by phenyl groups with different 
substituents. The two aromatic functions could potentially create intra-molecular pi-pi or 
sigma-pi interactions and affect the orientation of the acid pharmacophore. For 
comparison, we also prepared the analogues without the benzoate on the D-Gal unit (6a-
c). Furthermore, we replaced the benzoyl function in ligand 4 and 5a by an acetyl group 
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(8, 7 resp.) to study the effect of smaller substituents in position 2 of D-Gal on the 
activity. 
Scheme 4. Schematic presentation of the main building blocks (9a-c, 10 and 11) used for the preparation of 
the desired ligands 5a-c, 6a-c, 7, 8. 
The synthesis of the designed ligands starts with the preparation of building blocks 9a-c, 
10 and 11. We recently reported the synthesis of the Fucα(1-3)GlcNAc mimic 11(15) and 
herein we describe a faster and more efficient approach to prepare 7 from commercially 
available racemic seudenol 3-methyl-2-cyclohexenol, 12. Using optimized conditions for 
the butanoylation of racemic seudenol with immobilized Candida antarctica lipase C 
(Novozym 435),(44) we could isolate (R)-seudenolester 13. Subsequent saponification with 
NaOH afforded (R)-seudenol 14 in 84% yield and 97.5% enantiomeric excess (ee). Since 
the protection group of the hydroxy group in 16 has to be stable under strongly basic and 
acidic conditions, should not hamper fucosylation by steric bulk, and finally allow 
cleavage under mild conditions orthogonal to benzyl protecting groups, a tert-
butyldimethylsilyl (TBS) ether 15 was synthesized. Hydroboration followed by oxidation 
yielded all-trans 16 in 81% over two steps. Fucosylation of 16 under in situ anomerisation 
conditions(45,46) gave 18, which was smoothly deprotected with tetrabutylammonium 
fluoride, affording pseudodisaccharide 11(15) in good yield over two steps. Starting from 
racemic seudenol, this short sequence allowed the gram scale synthesis of 11 in 27% 
overall yield, requiring only four chromatographic purifications.  
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Scheme 5. Synthesis of disaccharide mimic 11: a) Novozyme 435, vinylbutyrate, heptane; b) aqueous 
NaOH, MeOH, 84%; c) TBSCl, imidazol, DMAP, CH2Cl2; d) (i) BH3⋅THF, THF; (ii) H2O2, aqueous 
NaOH, 81% from 10; e) CuBr2, DTBMP, TBAB, CH2Cl2, DMF, MS 4 Å, 87%; f) TBAF, THF, quant. 
The preparation of building blocks 9a-c and 10 starts with the synthesis of lactic acid 
derivatives 19a-c, which can be generated from the corresponding D-amino acids (SI 
scheme S1 and S2). Tin mediated alkylation of position 3 of the D-galactose derivative 
20(47) with triflate 19a-c, gave a mixture of 22a-c and its lactonisation by-product 21a-c, 
whereas 21a-c was converted back to 22a-c using neat benzyl alcohol and DMAP in 
catalytic amount. Benzoylation of the hydroxyl in 22a-c afforded glycosyl donors 9a-c, 
whereas the acetylation of 18a resulted in donor 10.  
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Scheme 6. Synthesis of galatoside derivatives 9a-c and 10: a) (i) Bu2SnO, MeOH; (ii) CsF, DME, (lactone - 
17a: 16%, 17b: 25%, 17c: 25%; benzylester - 18a: 25%, 18b: 0%, 18c: 5%); b) BnOH, DMAP (cat.) (17a: 
73%, 17b: 80%, 17c: 65%); c) BzCl, py, DMAP (cat.) (8a: 87%, 8b: 72%, 8c: 64%); d) Ac2O, pyridine, 9: 
78%. 
In the following step disaccharide mimic 11 was glycosylated with the corresponding 
galactoside donor (9a-c and 10) using dimethyl(methylthio)sulfonium triflate (DMTST) 
as promoter, what gave product 23a-c and 24 respectively, in good yields. In order to 
remove the benzyl protecting groups as well as the benzylyden acetal function, 
compound 23a-c was hydrogenated under heterogeneous conditions using Pd(OH)2/C as 
catalyst resulting in final ligands 5a-c with a benzoyl moiety on position 2 of the 
galactose unit, whereas hydrogenation of 24 generated ligand 7 with an acetyl function. 
To obtain the fully deprotected antagonist 6a-c, compound 23a-c was additionally 
treated with LiOH after the hydrogenation step. 
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Scheme 7. Synthesis of E-selectin ligands 5a-c, 6a-c and 7: a) DMTST, DCM, mol. sieves (4Å) (19a: 79%, 
19b: 80%, 19c: 83%, 20: 78%); b) H2, Pd(OH)2/C, MeOH or THF (5a: 42%, 5b: 37%, 5c: 63%, 7: 33%) c) 
(i) H2, Pd(OH)2/C, MeOH;  (ii) LiOH, MeOH/H2O (6a: 12%, 6b: 41%, 6c: 59%). 
In order to generate ligand 8 with a cyclohexylactic acid residue on position 3 and an 
acetyl group on position 2 of the galactoside unit, molecule 24 was additionally 
hydrogenated in the presence of Rh/Al2O3 after the removal of benzyl and benzylydine 
acetal protecting groups.  
Scheme 8. Synthesis of sLex mimic 8, a) i) H2, Pd(OH)2/C, THF; ii) H2, Rh/Al2O3, H2O/dioxane/AcOH : 
2/1/0.5 (10%) 
Benzoylation in 2’-position of the D-galactose residue effects affinity in lactic acid 
derivatives. The prepared ligands 5a-c, 6a-c, 7 and 8 were tested using microscale 
thermophoresis (MST) along with the previously reported antagonists 3 and 4. MST is a 
new method to determine the dissociation constant (KD) of a binding reaction that was 
recently applied to E-selectin.(48) The technique is based on the phenomenon that proteins 
move different along a temperature gradient if they undergo a change in size, charge or 
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hydration shell.(49) If binding a ligand changes one of these parameters the amount of 
bound protein can be monitored by a change in fluorescence. Measuring the 
thermophoresis of the protein with different amounts of ligand allows deducing the 
binding affinity. MST turned out to be a highly valid and reliable method to determine 
binding affinities of E-selectin – ligand interactions. The results are summarized in 
table 1: 
entry R1 R2 Ligand KD rKD 
1 H 3 13.69 ± 0.93 3.28 
2 Bz 4 4.18  ± 0.47 1.00 
3 Ac 8 4.85 ± 0.41 1.16 
4 H 5a 38.99 ± 1.69 9.34 
5 Bz 6a 7.81 ± 0.49 1.87 
6 Ac 7 9.97 ± 0.54 2.39 
7 H 5b 35.16 ± 1.66 8.42 
8 Bz 6b 5.75 ± 0.36 1.38 
9 H 5c 34.90 ± 1.65 8.36 
10 Bz 6c 5.42 ± 0.37 1.30 
Table 1. Affinity data of E-Selectin antagonists 3, 4, 5a-c, 6a-c, 7 and 8 determined by microscale 
thermophoresis (MST) assay.  
Ligands, which contain the phenyl lactic acid derivatives and lack the benzoyl group on 
position 2’ of D-Gal (5a-c) showed lower activity in comparison to the cyclohexyl lactic 
acid analogue 3 by a factor of 2.5.  However, an additional benzoylation of ligands 6a-c 
improved the potency up to a factor of 6.5 (5c→6c), whereas the difference between 3 
and 4 is only 3.2 fold. This suggests, that the benzoate in position 2 of D-Gal helps to 
stabilize the acid orientation in a similar fashion as in ligand 4, and sets the KD values of 
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6a-c and 4 in the same range. The substitution on the phenyl rings had only a small effect 
on the potency of the ligands. Interestingly, ligands with electron donating (6b) and 
electron withdrawing (6c) substituents on the phenyl groups exhibited higher potency in 
comparison to the un-functionalized derivative (6a).  
Scheme 9. Substitution in position 2’ of D-Gal in E-selectin ligand 3 improves the affinity by a factor of 3.2 
whereas the increase in the phenyl lactic acid derivatives is up to 6.5 fold. 5c→6c 
An acetyl group in position 2’ of D-Gal in ligands 7 and 8 had similar effect on the 
activity as the benzoyl function in 4 and 6a, respectively. Activity evaluation of the 
prepared antagonists showed that substitution in position 2’ of the galactose unit 
improves the activity of the ligands in the same manner as in inhibitor 4, what further 
underlines the importance of the substitution in this position. This effect can be achieved 
by a benzoyl function as well as an acetyl moiety, a functional group with a much 
smaller molecular weight. Ligand 8 revealed, that no aromatic group is required to 
achieve the desired acid pre-organization.  
O
HO
OH
OH
O
HO
OH
OH
O
OO
COONa
O
HO
OH
OH
O
HO
OH
OH
O
OO
COONa
rKD MST = 7.8
O
HO
OH
O
O
HO
OH
OH
O
OO
COONa
O
rKD MST = 1.2
5c 6c
6.5 fold
O
HO
OH
O
O
HO
OH
OH
O
OO
COONa
3.2 fold
O
F
F
F
F
rKD MST = 3.2 rKD MST = 1.0
3 4
3
4
34.9 µM 5 4 µM 
13.7 µM 4 2 µM 
279
Section III. E-selectin – Manuscript 9 
In summary, we could demonstrate with by NMR spectroscopy, X-ray crystallography 
and in silico modeling that pre-organization rather than additional interactions are 
responsible for the improved affinity of 4. Using NOE derived distance restraints we were 
able to calculate solution structures of 4 that are highly comparable to the bound 
conformation in the co-crystal structure. The crystal structure furthermore confirmed that 
the lactic acid substituents and the benzoate in position 2’ of D-Gal are pointing to the 
solvent and interact with each other by hydrophobic effects. An MD-simulation could 
show that the acid pre-organization of 4 is improved. Additionally, a b-factor analysis 
revealed lower thermal motion on the (S)-cyclohexyl lactic acid site of 4 compared to 3, 
which presumably constrains the orientation of carboxylic pharmacophore. However, 
substituting the benzoyl by a non-aromatic acetyl group in position 2’ of D-Gal (7, 8) had 
a comparable effect, while having a much smaller molecular weight. It remains an issue 
of further investigation to study the impact of smaller substituents in position 2’ of 
D-Gal. 
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Figure S1. 13C-1H HSQC of 4 recorded at 750 MHz and 275 K with assignments. The aliphatic region is 
shown on top, the carbohydrate region at the bottom. 
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Figure S2. Chemical shift assignment of cyclohexane resonances using a 13C-1H HMQC-COSY. The small 
unassigned signals originating from two-bond scalar couplings 2JCH are ideally suited to assign the 
cyclohexane resonances by following the dotted lines. Resonances from axial protons were distinguished 
from equatorial ones by their strength of 3JHH scalar coupling constants and NOE signal intensities (data 
not shown). As is typical the axial resonances are more upfield than the equatorial ones. 
Figure S3. a) Acid orientation / core conformation blot of GMI1077: crystal structure of sLex (black cross), 
(Lit: Somers et al. sLex crystal) molecular dynamics simulations (blue) and the ensemble of 20 solution 
conformations determined by NMR at 277 K at 900 MHz high field (red crosses). b) Schematic overview of 
core conformation (= relative orientation of D-galactose and L-fucose) and acid orientation (= tilting angle 
of the carboxylic acid relative to the core). 
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Figure S4. Confirmation of the three-dimensional solution structure by chemical shift deviations caused by 
the benzoyl group. a) Overlay of HSQC spectra of compound 4 (red) and compound 3 (blue). The region 
with signals of the methyl-cyclohexane diol mimic and the (S)-cyclohexane lactic acid are shown. 
Corresponding signals are connected by dotted lines. The benzoyl group causes a large variety of upfield 
chemical shift changes, which are typically caused by ring current effects on protons perpendicular to the 
aromatic ring plane. b) Histogram of the chemical shift deviations of cyclohexane protons caused by the 
benzoyl group. c) Representative of the obtained structural ensemble by solution NMR spectroscopy. 
Relevant protons in the proximity of the aromatic ring are labeled. The closest protons perpendicular to the 
aromatic plane are expected to experience the largest ring current effect and indeed they show the largest 
chemical shift perturbation. 
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Figure S5. 13C-1H HSQC of 3 recorded at 750 MHz and 275 K with assignments. The aliphatic region is 
shown on top, the carbohydrate region at the bottom. 
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Table S1. Intra and interresidual NOEs of 4 at 275K with the corresponding calculated 1H-1H distances. 
proton pair 
S/N of 
NOEs 
cross 
peaks 
Corresponding 
1H-1H 
distanceb
proton pair 
S/N of 
NOEs 
cross peaks 
Corresponding 
1H-1H 
distanceb
Intra Intra 
Lac H2-H3ax 476 2.6 Cyc H3eq-H5ax 167 3.1 
Lac H2-H3eq 943 2.3 Cyc H3ax-H4eq 848 2.4 
Lac H2-H4eq 187 3.0 Cyc H5ax-H7 303f 2.8 
Lac H3ax-H4eq 441 2.6 Fuc H1-H2 798 2.4 
Lac H4-H6ax 268a 2.9 Fuc H1-H3 113a 3.3 
Lac H4-H8ax 231a 2.9 Fuc H3-H5 962 2.3 
Lac H3ax-H5ax 312 2.8 Fuc H4-H5 1494 2.1 
Lac H3eq-H5ax 407 2.7 Inter 
Lac H5ax-H6ax 341 2.7 Lac H9eq-Gal H3 223 2.9 
Lac H7ax-H8eq 413a 2.7 Lac H4-Bz H2 88a,e 3.4 
Lac H2-H9eq 1012 2.3 Lac H6ax-Bz H2 56a,e 3.7 
Lac H2-H9ax 261 2.9 Lac H8eq-Bz H2 84a,e 3.5 
Lac H3ax-H9ax 102 3.4 Lac H8ax-Bz H2 114a,e 3.3 
Lac H7ax-H9ax 335 2.7 Lac H9eq-Bz H2 80a,e 3.5 
Gal H1-H5 1271 2.2 Gal H1-Cyc H2 1221 2.2 
Gal H1-H2 277 2.8 Gal H1-Cyc H3a 969 2.3 
Gal H1-H3 541 2.5 Gal H1-Cyc H3b 167 3.1 
Gal H2-H3 198a 3.0 Gal H2-Fuc H5 387 2.7 
Gal H4-H5 1568a 2.1 Gal H2-Fuc H6 241f 2.9 
Cyc H1-H2 290 2.8 Gal H6-Fuc H6 62 e,f 3.6 
Cyc H1-H3eq 146 3.2 Gal H1-Bz H2 57a,e 3.7 
Cyc H1-H3ax 712 2.4 Bz H2-Cyc H3eq 157e 3.1 
Cyc H1-H5ax 612 2.5 Bz H2-Cyc H3ax 123a,e 3.2 
Cyc H1-H7 424f 2.6 Fuc H1-Cyc H1 1576 2.1 
Cyc H2-H3 929 2.3 Fuc H1-Cyc H6 173 3.1 
Cyc H2-H4ax 625a 2.5 Fuc H1-Cyc H7 777f 2.4 
Cyc H3eq-H3ax 4648d 1.77 Fuc H5-Cyc H1 173a 3.1 
Cyc H3eq-H4eq 894 2.3 Fuc H5-Cyc H2 140 3.2 
Cyc H3eq-H4ax 742 2.4 
a 
Only one cross-peak was used because of artifacts or overlap. 
b The 1H-1H distances were calculated from experimentally obtained NOE intensities using the H3a-H3b 
cross-peak of Cyc as a reference with a distance of 1.77 Å assuming a r-6 dependence of the NOE 
intensities. 
d Reference restraints for the 13C-filtered-filtered NOESY. 
e,f Signal to noise ratios from cross-peaks involving methyl- or methylene protons with coinciding 
frequencies were divided by 3 or 2, respectively 
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Table S2. NMR structure determination statistics of 4 in solution. 
Compound 4 
NMR distance and dihedral restraints 
Total NOE restraints 56 
Intra-residue 36 
Inter-residue 20 
Sequential (|i – j| = 1) 10 
Nonsequential (|i – j| > 1 ) 10 
Structure statistics * 
Violations (mean and s.d.) 
Number of distance constraint violations > 0.1 
Å 
0±0 
Max. distance constraint violation [Å] 0.10±0.01 
Deviations from idealized geometry 
Bond lengths [Å] 0.0125±0.0002 
Bond angles [º] 1.54±0.03 
Heavy atom RMSD to mean [Å] 0.79±0.30 
Glycosidic linkage phi / psi angles ** 
Fuca(1,1)CycMe -68.9±0.8/-100.5±0.4 
 (crystal: -78.0/-101.4) 
Galb(1,2)CycMe -75.1±4.8/151.3±2.3 
 (crystal: -99.8/142.4) 
Acid Orientation 82.0±6.4 
(crystal: 120.5) 
Core -37.8±3.6 
(crystal: -41.6) 
* for an ensemble of 20 refined structures
** phi is defined as O5-C1-Ox-C'x and psi as C1-Ox-C'x-C'x-1 
† extracted by XtalView 
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Experimental Section 
NMR spectroscopy for three-dimensional structure determination 
Unless indicated otherwise spectra were measured at a 750 MHz Bruker Avance III 
spectrometer equipped with a TXI triple-resonance probe at 275 K. For complete 
chemical shift assignment of compounds 3 and 4 they were dissolved in D2O at 
concentrations of 6.6 mM 4 and 7.6 mM 3, respectively. Assignment was achieved using 
the following 2D spectra:  13C-1H HSQC, 13C-1H HMBC, 13C-1H HMQC-COSY(4) and 
TOCSY 1H-1H TOCSY (mixing times 13 ms and 120 ms). The 13C-1H HMQC-COSY 
spectrum was especially useful for assigning the cyclohexane resonances, see 
Supplementary Figure S2. Complete chemical shift assignments for compounds 3 and 4 
can be found in Supplementary Figures S1 and S5. A 2D NOESY spectrum of 
compound 3 was recorded at 900 MHz with a mixing time of 150ms, 96 transients and 
2,048×530 points. Spectra were processed using Topspin 2.1 and analyzed by Sparky (5). 
All spectra were referenced to DSS according to Markley et al.(6)  
Structure Calculation and Refinement 
Initial structures were calculated using CYANA 3.0 (7). Signal to noise (S/N) ratios of all 
NOE signals were extracted using the program Sparky(5) and converted to distances using 
the r−6 dependence and the Cyc H3a−H3b cross-peaks (1.77 Å) as reference. S/N ratios of
signals involving CH2 and CH3 groups with coinciding 1H resonances were divided by a 
factor of 2 or 3, respectively. Upper limit restraints with an additional tolerance of 0.5 Å 
were applied. Out of 200 structures, the 30 structures with the lowest target function were 
further refined in AMBER 9 (8) applying the general AMBER force field (GAFF)(9). A 
generalized Born model (10) was used to mimic solvent. Initial charge parameters were 
generated by Antechamber for the GAFF force field. 
Microscale Thermophoresis 
MST experiments were carried out at 25° C with 100% LED power, 10-100% laser power 
(standard condition 50% laser power), a laser on time of 30 sec, and a laser off time of 
5 sec using standard treated capillaries. Ligands were dissolved in assay buffer 
supplemented with 0.05% (v/v) Tween 20 at a concentration of 10 mM (reference 
substance, 5a-c and 7), 4 mM (3) 1 mM (6a-c and 8) and 0.66 mM (4). Titration series 
were generated diluting the ligand stocks 15 times 1:1 with assay buffer. E-Selectin was 
purified and labeled according to Zihlmann et al. 2014.(2) The protein concentration was 
determined by HPLC-UV against a BSA standard.(11,12) The dilution series of ligand was 
1:1 mixed with a solution of 0.1 to 0.25 µM E-Selectin and incubated for 10 mins at room 
temperature. All experiments were independently performed three times. Datapoints 
were normalized using the bound and unbound borders achieved by NanoTemper 
Analysis 1.2.205 software (NanoTemper Technologies GmbH, Munich, Germany) and 
analyzed/illustrated with GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA, 
USA). The measurements were globally fitted using equation 1 for single site binding.(13) 
PL   = (CP+ CL+KD − CP+CL+KD 2- 4CPCL
2CP
(eq. 1) 
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where [PL] is the protein-ligand complex concentration and KD is the dissociation 
constant. CP represents the total concentration of protein and CL the total concentration of 
ligand. Batch variations were normalized according to a measurement with a reference 
substance (GCP69669A)(1) to an absolute KD which was determined by isothermal 
titration calorimetry.(2,3)  
Synthesis 
General Methods: NMR spectra were recorded on a Bruker Avance DMX-500 (500 
MHz) spectrometer. Assignment of 1H and 13C NMR spectra was achieved using 2D 
methods (COSY, HSQC). Chemical shifts are expressed in ppm using residual TMS, 
CHCl3, CHD2OD and HDO as references. For complex molecules, the following prefixes 
for substructures are used: Cy (cyclohexyl), Fuc (fucose), Gal (galactose) and Lac 
(lactate). Optical rotations were measured on a Perkin-Elmer Polarimeter 341. Electron 
spray ionization mass spectra (ESI-MS) were obtained on a Waters micromass ZQ. 
HRMS analysis was carried out using a Bruker Daltonics micrOTOF spectrometer 
equipped with a TOF hexapole detector. Reactions were monitored by TLC using glass 
plates coated with silica gel 60 F254 (Merck) and visualized by using UV light and/or by 
heating to 140°C for 5 min with aq. KMnO4 solution or a molybdate solution (a 0.02 M 
solution of ammonium cerium sulfate dihydrate and ammonium molybdate tetrahydrate 
in aq. 10% H2SO4). Column chromatography was performed on a CombiFlash 
Companion (Teledyne-ISCO, Inc.) using RediSep® normal phase disposable flash 
columns (silica gel). Reversed phase chromatography was performed on LiChroprep® 
RP-18 (Merck, 40-63 μm). Hydrogenation reactions were performed in a shaking 
apparatus (Parr Instruments Company, Moline, Illinois, USA) in 250 mL or 500 mL 
bottles. Methanol (MeOH), dichloromethane (DCM), dimethoxyethane (DME) were 
dried by filtration through Al2O3 (Fluka, type 5016 A basic) and stored on activated 
molecular sieves. Dioxane, were dried by distillation from sodium/benzophenone. DMF 
was dried by distillation from calcium hydride. 
(R)-3-Methylcyclohex-2-en-1-yl butyrate (13) 
Immobilized Novozyme 435 (222 mg, 444 U, EC 232-619-9) was added to a solution of 
12 (10.0 g, 89 mmol) and vinyl butyrate (22.6 mL, 20.3 g, 178 mmol) in heptane (90 mL). 
The mixture was stirred at 23°C and 200 rpm. After 2 h 25 min the mixture was filtered 
and volatiles were evaporated at 60°C and 10 mbar to give 12 g of a clear oil. Column 
chromatography on silica (CH2Cl2) yielded pure 13 (7.50 g, 41 mmol, 46%). [α]D22 
+168.7 (c 9.28, CHCl3); 1H NMR (500.1 MHz, CDCl3): δ = 5.44 (m, 1H, H-2), 5.23 (m, 
1H, H-1), 2.24 (t, J = 7.4 Hz, 2H, COCH2CH2CH3), 2.02-1.84 (m, 2H, H-4, H-4’), 1.81-
1.56 (m, 9H, H-5, H-5’, H-6, H-6’, -CH3, COCH2CH2CH3), 0.92 (t, J = 7.4 Hz, 3H, 
O
O
13
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COCH2CH2CH3); 13C NMR (125.8 MHz, CDCl3): δ 173.5 (COCH2CH2CH3), 141.0 (C-
3), 120.2 (C-2), 68.6 (C-1), 36.7 (COCH2CH2CH3), 30.0 (C-4), 28.1 (C-6), 23.8 (-CH3), 
19.1, 18.7 (2C, C-5, COCH2CH2CH3), 13.7 (COCH2CH2CH3); MS (ESI) m/z: Calcd for 
C11H18NaO2+ [M+Na]+: 205.12; found: 204.83; elemental analysis calcd (%) for C11H18O2 
(182.26): C 72.49, H 9.95; found: C 72.87, H 9.65. 
(R)-seudenol (14)(14) 
A solution of NaOH in H2O (10.3 mL, 4N) was slowly added to a solution of seudenol 
butyrate 13 (3.50 g, 19 mmol) in MeOH (30 mL) at 0°C and stirred at 0°C for 5 h. The 
mixture was diluted with H2O (25 mL) and extracted with CH2Cl2 (3 x 20 mL). The 
combined organic layers were washed with brine (25 mL) and dried over Na2SO4. 
Filtration and evaporation of volatiles (200 mbar, 40°C) gave spectroscopically pure (R)-
seudenol (14) (1.81 g, 16.0 mmol, 84%) as a clear oil, which was directly used in the next 
step. [α]D +91.7 (c 0.74, CHCl3); HPLC: 97.5% ee, 98% purity; NMR data were in 
accordance with literature.(14) 
(1R,2R,3S)-1-[(tert-butyldimethylsilyl)oxy]-3-methylcyclohexan-2-ol (16) 
Imidazol (4.40 g, 65 mmol) was added to a solution of (R)-seudenol 14 (3.50 g, 31 
mmol), DMAP (cat.), and TBSCl (7.31 g, 48 mmol) in anhydrous CH2Cl2 (65 mL) at r.t. 
under argon. After stirring for 15 h, the reaction mixture was quenched with satd. aq. 
NaHCO3 (50 mL) and extracted with CH2Cl2 (20 mL). The organic layer was washed 
with aq. HCl (20 mL, 0.01 N), satd. aq. NaHCO3 (20 mL), and brine (20 mL) and dried 
over Na2SO4. Filtration and evaporation of volatiles (200 mbar, 40°C) gave the TBS ether 
15 as clear oil. A solution of BH3⋅THF (60 mL, 1M in THF) was slowly added to a 
solution of the crude TBS ether (15) in anhydrous THF (60 mL) under argon at 0°C. 
After stirring for 2 h at rt, the reaction mixture was cooled to 0°C again and aq. NaOH 
(180 mL, 3N) followed by aq. H2O2 (180 mL, 30%) were slowly added via dropping 
funnel (CAUTION: strong gas development). The mixture was stirred at 0°C for 1 h, 
subsequently acidified to pH 3 by slow addition of 10% aq. HCl via dropping funnel 
(CAUTION: strong gas development) and extracted with DCM (2 x 300 mL). The 
extracts were dried over Na2SO4, filtered, concentrated (100 mbar, 40°C) and purified by 
column chromatography (petroleum ether/Et2O 98.5/1.5) to yield pure 16 (6.20 g, 25 
OH
14
OTBDMS
OH
16
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mmol, 81%) as clear oil. [α]D22 - 13.7 (c 3.14, CHCl3); 1H NMR (500.1 MHz, CDCl3): δ = 
3.34 (m, 1H, H-1), 2.92 (dd, J = 8.5 , 10.0 Hz, 1H, H-2), 2.47 (s, 1H, OH), 1.81 (m, 1H, 
H-6), 1.63-1.56 (m, 2H, H-4, H-5), 1.41 (m, 1H, H-3), 1.34-1.99 (m, 2H, H-5’, H-6’), 
1.04-0.92 (m, 4H, H-4’, Me), 0.91-0.83 (m, 9H, SiC(CH3)3), 0.07 (s, 3H, SiCH3), 0.05 (s, 
3H, SiCH3); 13C NMR (125.8 MHz, CDCl3): δ = 81.0 (C-2), 77.0 (C-1), 37.0 (C-3), 33.4, 
33.9 (2C, C-4, C-6), 25.9 (3C, SiC(CH3)3), 23.6 (C-5), 18.5 (-CH3), 18.1 (SiC(CH3)3), -3.9, -
4.6 (SiCH3); HR-MS (ESI) m/z: calcd for C13H28NaO2Si+ [M+Na]+: 267.1751; found: 
267.1752. 
[(1R,2R,3S)-1-(tert-Butyldimethylsilyl)oxy)-3-methyl-cyclohex-2-yl] 2,3,4-tri-O-
benzyl-6-deoxy-α-L- galactopyranoside (18) 
Ethylthio fucoside 17(15) (3.90 g, 8.15 mmol) and TBAB (4.00 g, 12.4 mmol) were dried at 
high vacuum overnight. Powdered activated molecular sieves 4 Å (5.0 g), compound 16 
(1.00 g, 4.09 mmol), 2,6-di-tert-butyl-4-methylpyridine (2.50 g, 12.2 mmol), anhydrous 
DCM (35 ml) and DMF (5 ml) were added and the mixture was stirred for 4 h at rt under 
argon. CuBr2 (2.70 g, 12.1 mmol), dried under high vacuum overnight at 70°C, was 
added and the resulting dark mixture was stirred at rt under argon. After completion of 
the reaction (17 h), the solution was filtered through a pad of celite and the filtrate was 
washed with a solution of satd. aq. NH4Cl and aqueous NH3 (9/1 (v/v), 2 x 200 mL) and 
brine (100 mL). The aqueous layers were extracted with DCM (2 x 200 mL) and the 
combined organic layers were dried (Na2SO4) and concentrated. Column 
chromatography on silica (petroleum ether/EtOAc 98/2 to 97/3) gave the 
pseudodisaccharide 18 as clear oil (2.34 g, 3.54 mmol, 87%). [α]D - 53.7 (c 2.1, CHCl3); 
1H NMR (500.1 MHz, CDCl3): δ  = 7.47-7.27 (m, 15H, 3 C6H5), 5.16 (d, 3J = 3.4 Hz, 1H, 
Fuc H-1), 5.03 (A of AB, 2J = 11.6Hz, 1H, CH2Ph), 4.89, 4.85, 4.78, 4.76 (4d, 2J = 
11.8Hz, 4H, CH2Ph), 4.70 (B of AB, 2J = 11.6Hz, 1H, CH2Ph), 4.26 (q, 3J = 6.4 Hz, 1H, 
Fuc H-5), 4.10 (dd, 3J = 3.4, 10.2 Hz, 1H, Fuc H-2), 4.05 (dd, 3J = 2.6, 10.2 Hz, 1H, Fuc 
H-3), 3.75 (m, 1H, H-1), 3.70 (m, 1H, Fuc H-4), 3.36 (t, 3J = 6.4 Hz, H-2), 1.88-1.77 (m, 
2H, H-3, H-6a), 1.76-1.68 (m, 2H, H-4a, H-5a), 1.43 (m, 1H, H-6b), 1.34-1.11 (m, 8H, 
Fuc-H6, -CH3, H-4b, H-5b), 0.93 (s, 9H, SiC(CH3)3), 0.09 (s, 3H, SiCH3), 0.06 (s, 3H, 
SiCH3); 13C NMR (125.8 MHz, CDCl3): δ 139.1, 138.9, 138.8, 128.4, 128.3, 128.2, 127.6, 
127.5 (18C, 3 C6H5), 96.8 (Fuc C-1), 81.5 (C-2), 79.3 (Fuc C-3), 78.2 (Fuc C-4), 76.7 (Fuc 
C-2), 74.9 (CH2Ph), 73.6 (CH2Ph), 73.3 (C-1), 73.0 (CH2Ph), 66.4 (Fuc C-5), 35.6 (C-3), 
33.2 (C-6), 31.1 (C-5), 26.1 (3C, SiC(CH3)3), 19.8 (C-4), 18.9 (Fuc C-6), 18.2 (SiC(CH3)3), 
17.0 (CH3), -3.9, -5.0 (2C, SiCH3); HR-MS (ESI) m/z: Calcd for C40H56NaO6Si+ [M+Na]+: 
683.3738; found: 683.3740. 
O
O
BnO OBn
OBn
TBDMSO
18
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[(1R,2R,3S)-1-Hydroxy-3-methyl-cyclohex-2-yl] 2,3,4-tri-O-benzyl-6-deoxy-α-L- 
galactopyranoside (11)(16)
Compound 18 (2.10 g, 3.18 mmol) was dissolved in a solution of TBAF in THF (20 mL, 
1M) and stirred for 24 h at rt. The solution was diluted with DCM (50 mL) and washed 
with H2O (100 mL). The aq. layer was extracted with DCM (2 x 50 mL) and the 
combined organic layers were dried (Na2SO4) and concentrated. Column 
chromatography on silica (petroleum ether/EtOAc 80/20) gave 11 as white solid (1.74 g, 
3.18 mmol, quant.); [α]D - 42.0 (c 0.45, CHCl3); NMR data were in accordance with 
literature.(16)
Scheme S1: Synthesis of triflate derivative 19a a) BnOH, TsOH, benzene (88%); b) Tf2O, 
lutidine, DCM (98%).  
Scheme S2. Synthesis of triflate derivatives 19b-c a) (i) NaNO2, H2SO4, H2O (ii) BnOH, 
TsOH, benzene (b: 57%, c: 50%); b) Tf2O, lutidine, DCM (b: 97%, c: 95%). 
O
O
BnO OBn
OBn
HO
11
CO2H
OH
CO2Bn
OH
CO2Bn
OTfa b
S1a S2a 19a
a
CO2H
NH2
R1
R2
CO2Bn
OH
R1
R2
CO2Bn
OTf
R1
R2
c
b: R1=Me; R2=H
c: R1=R2=F
SXb-c SXb-c SXb-c1 -­‐c S2b-­‐c 19b-­‐c
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(R)-Benzyl 2-hydroxy-3-phenylpropanoate (S2a)(17) 
To a solution of 2-hydroxy-3-phenyl-2-(R)-propanoic acid (S1a) (1.94 g, 11.6 mmol) in 
benzene (25 mL) benzyl alcohol (1.62 mL, 15.6 mmol) and p-toluenesulfonic acid (200 
mg, 1.2 mmol) were added. The solution was refluxed at 80°C until completion of the 
reaction (3 h, TLC: DCM/MeOH, 19:1 and petroleum ether/EtOAc, 4:1). The reaction 
mixture was allowed to cool down to rt, diluted with EtOAc (50 mL) and washed with 
satd. aq. NaHCO3 (20 mL), water (20 mL) and brine (10 mL). The organic layer was 
dried over Na2SO4, filtered and solvent was removed in vacuo. The crude product was 
purified by flash chromatography (petroleum ether/EtOAc, gradient 0-25%) to afford 
(S2a)(17) as colorless wax (2.62 g, 10.2 mmol, 88%). Rf = (petroleum ether/EtOAc, 4:1) 
0.50; [α]D22 +53.5 (c 0.69, CHCl3); 1H NMR (500.1 MHz, CDCl3): δ = 7.54 - 7.06 (m, 
10H, Ar-H), 5.18 (s, 2H, Ar-CH2), 4.50 (br s, 1H, H-2,), 3.22 - 3.06 (m, 1H, H-3), 3.09 - 
2.90 (m, 1H, H-3’); 13C NMR (125.8 MHz, CDCl3): δ = 174.0 (C-1), 136.1, 135.0, 129.5, 
128.7, 128.7, 128.6, 128.4 (8C, Ar-C); 71.3 (C-2); 67.5 (Ar-CH2); 40.5 (C-3); ESI-MS: 
m/z: Calcd for C16H16NaO3 [M+Na]+: 279.3, found: 278.9. 
(R)-Benzyl 2-hydroxy-3-(4-methylphenyl)-propanoate (S2b) 
A solution of sodium nitrite (11.7 g, 0.17 mol) in water (40 mL) was added dropwise to a 
stirred and ice-cooled solution of p-methyl-D-phenylalanine (S1b) (5.10 g, 28.4 mmol) in 
1 M H2SO4 (50 mL) over 1 h, and the resulting mixture was stirred for 24 h at rt. The 
reaction mixture was extracted with Et2O (3 x 150 mL), the combined organic phases 
were washed with brine (30 mL), dried over Na2SO4, filtered and concentrated in vacuo. 
The crude product (4.85 g) was dissolved in benzene (30 mL) and the resulting solution 
was treated with benzyl alcohol (3.63 mL, 35.0 mmol, 1.3 eq) and p-toluenesulfonic acid 
(463 mg, 2.70 mmol, 0.1 eq). The solution was refluxed until completion of the reaction 
(5 h, TLC: DCM/MeOH, 19:1 and petroleum ether/EtOAc, 4:1). The reaction mixture 
was allowed to cool down to rt, diluted with EtOAc (150 mL) and washed with satd. aq. 
NaHCO3 (30 mL), water (30 mL) and brine (20 mL). The organic layer was dried over 
Na2SO4, filtered and concentrated in vacuo. The crude product was purified by flash 
CO2Bn
OH
S2a
CO2Bn
OH
S2b
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chromatography (petroleum ether/EtOAc, gradient 0-25%) to afford (S2b) as colorless 
wax (4.2 g, 15.16 mmol, 53% over two steps). Rf = (petroleum ether/EtOAc, 4:1) 0.52; 
[α]D22 -46.5 (c 0.63, CHCl3); 1H NMR (500.1 MHz, CDCl3): δ = 7.40 - 7.30 (m, 5H, Ar-
H), 7.05 (dd, J = 8.1 Hz, 4H, Ar-H); 5.15 - 5.02 (m, 2H, Ar-CH2), 4.47 (dd, J = 4.7, 6.4 
Hz, 1H, H-2), 3.09 (dd, J = 4.7, 13.9 Hz, 1H, H-3), 2.95 (dd, J = 6.4, 13.9 Hz, 1H, H-3’), 
2.31 (s, 3H, Ar-Me); 13C NMR (125.8 MHz, CDCl3): δ = 174.2 (C-1), 136.6, 135.2, 133.0, 
129.5, 129.3, 128.8, 128.7 (8C, Ar-C), 71.5 (C-2), 67.5 (Ar-CH2), 40.2 (C-3), 21.2 (Ar-
Me); ESI-MS: m/z: Calcd for C17H18NaO3 [M+Na]+: 293.3, found: 292.9. 
(R)-Benzyl 2-hydroxy-3-(3,4-difluorophenyl)-propanoate (S2c) 
A solution of sodium nitrite (2.05 g, 39.8 mmol) in water (10 mL) was added dropwise to 
a stirred and ice-cooled solution of 3,4-difluoro-D-phenylalanine (S1c) (1.00 g, 4.97 
mmol) in 1 M H2SO4 (10 mL) over 30 min, and the resulting mixture was stirred for 2 d 
at rt. The reaction mixture was extracted with Et2O (3 x 50 mL), the combined organic 
phases were washed with brine (20 mL), dried over Na2SO4, filtered and concentrated in 
vacuo. The crude product (790 mg) was dissolved in benzene (10 mL) and the resulting 
solution was treated with benzyl alcohol (0.55 mL, 5.08 mmol) and p-toluenesulfonic 
acid (62 mg, 0.39 mmol). The solution was refluxed at 80°C until completion of the 
reaction (4 h, TLC: DCM/MeOH, 19:1 and petroleum ether/EtOAc, 4:1). The reaction 
mixture was allowed to cool down to rt, diluted with EtOAc (50 mL) and washed with 
satd. aq. NaHCO3 solution (20 mL), water (20 mL) and brine (10 mL). The organic layer 
was dried over Na2SO4, filtered and concentrated in vacuo. The crude product was 
purified by flash chromatography (Tol/EtOAc, gradient 0-10%) to afford (S2c) as 
colorless wax (720 mg, 2.46 mmol, 50% over two steps). Rf = (petroleum ether/EtOAc, 
4:1) 0.38; [α]D22 +61.9 (c 0.76, CHCl3); 1H NMR (500.1 MHz, CDCl3): δ = 7.43 - 7.21 
(m, 6H, Ar-H), 7.03 - 6.91 (m, 2H, Ar-H), 6.87 - 6.77 (m, 1H, Ar-H), 5.26 - 5.11 (m, 2H, 
Ar-CH2), 4.45 (q, J = 5.3 Hz, 1H, H-2,), 3.07 (dd, J = 4.0, 14.1 Hz, 1H, H-3), 2.91 (dd, J 
= 6.2, 14.1 Hz, 1H, H-3’); 13C NMR (125.8 MHz, CDCl3): δ = 173.7 (C-1), 151.3 – 148.2 
(m, 2C, ArF-C), 134.8 (Ar-C) 133.1 (m, Ar-C), 128.9, 128.8 (2C, Ar-C), 125.5 (m, Ar-C), 
118.4 (d, J = 17.1 Hz, Ar-C), 116.9 (d, J = 17.1 Hz, Ar-C), 70.8 (C-2); 67.7 (Ar-CH2); 
39.3 (C-3). ESI-MS: m/z: Calcd for C16H14F2NaO3 [M+Na]+: 315.3, found: 314.6. 
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(R)-Benzyl 3-phenyl-2-(trifluoromethyl)sulfonyloxy-propanoate (19a) 
To a stirred solution of (S2a) (2.44 g, 8.35 mmol) and lutidine (1.16 mL, 10.8 mmol) in 
dry DCM (30 mL) Tf2O (1.68 mL, 10.0 mmol) was added dropwise at -60°C under 
argon. The reaction was stirred at -60°C for 20 min, then at -5°C for 40 min. TLC 
(petroleum ether/EtOAc, 9:1) indicated completion of the reaction and the mixture was 
quenched by addition of water (10 mL) at 0°C. The organic phase was separated and the 
water phase was extracted with DCM (50 mL). The combined organic phases were 
washed with water (20 mL), dried over Na2SO4, filtered and concentrated in vacuo. The 
crude product was purified by flash chromatography using a short silica pad 
(DCM/petroleum ether, 1:1) to afford (19a) as pale orange oil. (3.17 g, 8.17 mmol, 98%). 
Rf = (petroleum ether/EtOAc, 9:1) 0.50; [α]D22 +29.5 (c 1.33, CHCl3); 1H NMR (500.1 
MHz, CDCl3): δ  = 7.41 - 7.12 (m, 10H, Ar-H), 5.30 - 5.20 (m, 1H, H-2), 5.24 (s, 2H, Ar-
CH2), 3.34 (dd, J = 3.6, 14.6 Hz, 1H, H-3), 3.21 (dd, J = 8.5, 14.6 Hz, 1H, H-3’); 13C 
NMR (126 MHz, CDCl3): δ = 166.5 (C-1), 134.2, 133.2, 129.5, 128.9, 128.8, 128.7, 
128.9, 127.8 (8C, Ar-C), 83.8 (C-2), 68.4 (Ar-CH2), 38.2 (C-3). 
(R)-Benzyl 3-(4-methylphenyl)-2-(trifluoromethyl)sulfonyloxy-propanoate (19b) 
To a stirred solution of (S2b) (4.10 g, 15.2 mmol) and lutidine (2.29 mL, 19.7 mmol) in 
dry DCM (30 mL) a solution of Tf2O in dry DCM (1 M, 18.2 mL, 18.2 mmol) was added 
at -80°C under argon. The reaction was allowed to warm up to -20°C (2 h) and stirred at 
that temperature for an additional 1 h. TLC (petroleum ether/EtOAc, 9:1) indicated 
completion of the reaction and the mixture was quenched by addition of water (10 mL) 
at 0°C. The organic phase was separated and the water phase was extracted with DCM 
(2 x 50 mL). The combined organic phases were washed with water (20 mL), dried over 
Na2SO4, filtered and concentrated in vacuo. The crude product was purified by flash 
chromatography using a short silica pad (DCM/petroleum ether, 1:1) to afford (19b) as 
pale grey oil (5.90 g, 14.7 mmol, 97%). Rf = (petroleum ether/EtOAc, 9:1) 0.45; [α]D22 -
26.1 (c 1.22, CHCl3); 1H NMR (500 MHz, CDCl3): δ = 7.39 - 7.27 (m, 5H, Ar-H), 7.09 
(d, J = 7.9 Hz, 2H, Ar-H), 7.04 (d, J = 7.9 Hz, 2H, Ar-H), 5.26 (dd, J = 4.5, 8.1 Hz, 1H, 
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H-2), 5.23 (s, 2H, Ar-CH2), 3.29 (dd, J = 4.5, 14.6 Hz, 1H, H-3), 3.18 (dd, J = 8.1, 14.6 
Hz, 1H, H-3’), 2.32 (s, 3H, Ar-Me); 13C NMR (126 MHz, CDCl3): δ = 166.6 (C-1), 137.7, 
134.4, 130.1, 129.6, 129.5, 129.0, 128.8, 128.8 (8C, Ar-C), 84.0 (C-2), 68.5 (Ar-CH2), 38.0 
(C-3), 21.2 (Ar-Me). 
(R)-Benzyl 3-(3,4-difluorophenyl)-2-(trifluoromethyl)sulfonyloxy-propanoate (19c) 
To a stirred solution of (S2c) (670 mg, 2.29 mmol) and lutidine (0.35 mL, 2.97 mmol) in 
dry DCM (10 mL) a solution of Tf2O in dry DCM (1 M, 2.75 mL, 2.75 mmol) was added 
at -80°C under argon. The reaction was allowed to warm up to -20°C (1 h) and stirred at 
this temperature for an additional 1 h. TLC (petroleum ether/EtOAc, 9:1) indicated 
completion of the reaction and the mixture was quenched by addition of water (10 mL) 
at 0°C. The organic phase was separated and the water phase was extracted with DCM 
(2 x 30 mL). The combined organic phases were washed with water (10 mL), dried over 
Na2SO4, filtered and concentrated in vacuo. The crude product was purified by flash 
chromatography using a short silica pad (DCM/petroleum ether, 1:1) to afford (19c) as 
colorless oil (900 mg, 2.12 mmol, 93%). Rf = (petroleum ether/EtOAc, 9:1) 0.40; [α]D22 
+31.1 (c 0.62, CHCl3); 1H NMR (500 MHz, CDCl3): δ = 7.41 - 7.22 (m, 5H, Ar-H), 7.09 - 
7.00 (m, 1H, Ar-H), 7.00 - 6.92 (m, 1H, Ar-H), 6.89 - 6.83 (m, 1H, Ar-H), 5.32 - 5.14 (m, 
3H, H-2, Ar-CH2), 3.28 (dd, J = 3.6, 14.8 Hz, 1H, H-3), 3.18 (dd, J = 7.9, 14.8 Hz, 1H, 
H-3’); 13C NMR (126 MHz, CDCl3): δ = 166.0 (C-1); 151.5 - 148.8 (m, 2C, ArF-C), 134.1 
(Ar-C) 130.0 (m, Ar-C), 129.1, 128.8 (2C, Ar-C), 125.7 (m, Ar-C), 118.6 (d, J = 17.6 Hz, 
Ar-C), 117.6 (d, J = 17.4 Hz, Ar-C), 82.9 (C-2), 68.6 (Ar-CH2), 37.3 (C-3). 
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Scheme S3. Synthesis of galatoside derivatives 9a-c: a) (i) Bu2SnO, MeOH; (ii) CsF, DME, (lactone - 21a: 
16%, 21b: 25%, 21c: 25%; benzylester - 22a: 25%, 22b: 0%, 22c: 5%); b) BnOH, DMAP (cat.) (21a: 73%, 
21b: 80%, 21c: 65%); c) BzCl, py, DMAP (cat.) (9a: 87%, 9b: 72%, 9c: 64%,); d) Ac2O, pyridine, 10: 78%. 
Ethyl 4,6-O-benzylidene-3-O-[(S)-1-(benzyloxy)-1-oxo-3-phenylpropan-2-yl]-1-thio-β-
D-galactopyranoside (22a) 
Thiogalactoside (20) (482 mg, 1.544 mmol, 1 eq) and n-Bu2SnO (575 mg, 2.31 mmol 
were dissolved in dry MeOH (15 mL) and refluxed at 65°C under argon for 4 h. The 
solvent was removed under reduced pressure and the crude product was dried in high 
vacuum for 16 h. The residue was dissolved in dry DME (10 mL) under argon and a 
solution of triflate (19a) (2 g, 5.14 mmol) in dry DME (10 mL) was added followed by 
the addition of CsF (700 mg, 4.62 mmol, dried in high vacuum at 100°C for 16 h). The 
turbid solution was stirred for 5 h after which TLC (petroleum ether/EtOAc, 9:1, 
DCM/MeOH, 19:1) indicated still presence of starting material (20) but no triflate (19a) 
so another portion of (19a) (1 g, 2.57 mmol) was added and the mixture was stirred for 
additional 16 h. A solution of KF (10%) in aq. KH2PO4 (1 N, 10 mL) was added, and 
after stirring for 1 h, the reaction was extracted with DCM (3 x 70 mL). The combined 
organic phases were washed with brine (20 mL) dried over Na2SO4 and the solvents were 
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removed in vacuo. The crude product was purified by flash chromatography (petroleum 
ether/EtOAc, gradient 0-50%) to afford a 1:1.6 mixture of 21a (lactone) and 22a (open) 
(330 mg, 41%), which was used in the following reaction without further purification. 
ESI-MS: m/z: Calcd for (21a) (lactone) C24H26NaO6S [M+Na]+: 465.5, found: 465.2; 
Calcd for (22a) (open) C31H34NaO7S [M+Na]+: 573.7, found: 573.1. To a solution of the 
mixture (330 mg) obtained in the previous reaction, benzyl alcohol (2mL) and DMAP 
(cat.) were added. The reaction was heated up to 60°C for 4 h, then the reaction mixture 
was purified by flash chromatography (petroleum ether/EtOAc, gradient 0-50%) to 
afford pure (22a) as white foam (260 mg, 0.47 mmol, 30% starting from 20). Rf = 
(petroleum ether/EtOAc, 7:3) 0.33; [α]D22 -44.9 (c 0.31, CHCl3); 1H NMR (500.1 MHz, 
CDCl3): δ = 7.52 - 7.47 (m, 2H, Ar-H), 7.41 - 7.31 (m, 5H, Ar-H), 7.28 - 7.20 (m, 8H, Ar-
H), 5.34 (s, 1H, Ph-CH), 5.10 (d, J = 12.1 Hz, 1H, Ar-CH2), 5.04 (d, J = 12.1 Hz, 1H, Ar-
CH2), 4.62 (dd, J = 4.8, 8.4 Hz, 1H, Lac-H2), 4.26 - 4.16 (m, 3H, Gal-H1, Gal-H4, Gal-
H6), 3.88 - 3.82 (m, 2H, Gal-H2, Gal-H6’), 3.37 (dd, J = 3.4, 9.2 Hz, 1H, Gal-H3), 3.29 
(br s, 1H, Gal-H5), 3.14 - 3.03 (m, 2H, Lac-H3), 2.80 - 2.62 (m, 2H, SCH2CH3), 2.09 (d, J 
= 1.9 Hz, 1H, OH), 1.28 (t, J = 7.5 Hz, 3H, SCH2CH3); 13C NMR (125.8 MHz, CDCl3): 
δ = 172.3 (Lac-C1), 138.0, 137.0, 135.4, 129.6, 128.9, 128.6, 128.5, 128.5, 128.5, 128.3, 
128.1, 126.9, 126.4 (12C, Ar-C), 100.9 (Ph-CH), 85.2 (Gal-C1), 81.8 (Gal-C3), 80.4 (Lac-
C2), 75.2 (Gal-C4), 70.2 (Gal-C5), 69.2 (Gal-C6), 68.7 (Gal-C2), 66.8 (Ph-CH2), 39.2 
(Lac-C3), 23.0 (SCH2CH3), 21.1 (Ar-Me), 15.2 (SCH2CH3); ESI-MS: m/z: Calcd for 
C31H34NaO7S [M+Na]+: 573.7, found: 573.1. 
Ethyl 4,6-O-benzylidene-3-O-[(R)-1-(benzyloxy)-1-oxo-3-(4-methylphenyl)-propan-2-
yl]-1-thio-β-D-galactopyranoside (22b) 
Thiogalactoside (20) (50 mg, 0.16 mmol) and n-Bu2SnO (60 mg, 0.24 mmol) were 
dissolved in dry MeOH (3 mL) and refluxed at 65°C under argon for 4 h. The solvent 
was removed under reduced pressure and the crude product was dried in high vacuum 
for 16 h. The residue was dissolved in dry DME (3 mL) under argon and a solution of 
triflate (19b) (193 mg, 0.48 mmol) in dry DME (2 mL) was added followed by the 
addition of CsF (73 mg, 0.48 mmol, dried in high vacuum at 100°C for 16 h). The turbid 
solution was stirred for 3 h after which TLC (petroleum ether/EtOAc, 9:1, DCM/MeOH, 
19:1) indicated still presence of starting material (20) but no triflate (19b) so another 
portion of (19b) (128 mg, 0.32 mmol) was added and the mixture was stirred for 
additional 3 h. A solution of KF (10%) in aq. KH2PO4 (1 N, 10 mL) was added, and after 
stirring for 1 h, the reaction was extracted with DCM (3 x 20 mL). The combined organic 
phases were washed with brine (10 mL) dried over Na2SO4 and the solvents were 
removed in vacuo. The crude product was purified by flash chromatography (petroleum 
ether/EtOAc, gradient 0-40%) to afford (21b) as colorless wax (22.6 mg). ESI-MS: m/z: 
Calcd for C25H28NaO6S [M+Na]+: 479.5, found: 479.1. To a solution of 21b (22.6 mg, 
0.050 mmol) in benzyl alcohol (0.5 mL) DMAP (cat.) was added. The reaction was 
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heated to 60°C for 4 h, then the reaction mixture was purified by flash chromatography 
(petroleum ether/EtOAc, gradient 0-50%) to afford (22b) as colorless wax (18.2 mg, 
0.032 mmol, 20% after two steps). Rf = (petroleum ether/EtOAc, 7:3) 0.30; [α]D22 -79.3 (c 
0.25, CHCl3); 1H NMR (500 MHz, CDCl3): δ = 7.53 - 7.45 (m, 2H, Ar-H), 7.41 - 7.30 
(m, 6H, Ar-H), 7.12 (d, J = 7.4 Hz, 2H, Ar-H), 7.04 (d, J = 7.4 Hz, 2H, Ar-H), 5.34 (s, 
1H, Ph-CH), 5.09 (d, J = 12.1 Hz, 1H, Ar-CH2), 5.03 (d, J = 12.1 Hz, 1H, Ar-CH2), 4.66 - 
4.54 (m, 1H, Lac-H2), 4.26 - 4.20 (m, 2H, Gal-H1, Gal-H6), 4.18 (s, 1H, Gal-H4), 3.91 - 
3.82 (m, 2H, Gal-H2, Gal-H6’), 3.32 (d, J = 9.2 Hz, 1H, Gal-H3), 3.29 (s 1H, Gal-H5), 
3.10 - 2.98 (m, 2H, Lac-H3), 2.81 - 2.71 (m, 2H, SCH2CH3), 2.30 (s, 3H, Ar-Me), 1.28 (t, 
J = 7.5 Hz, 3H, SCH2CH3); 13C NMR (125.8 MHz, CDCl3): δ = 172.4 (Lac-C1), 138.3, 
136.3, 135.4, 133.8, 129.5, 129.1, 128.9, 128.6, 128.5, 128.5, 128.1, 126.4 (12C, Ar-C), 
100.3 (Ph-CH), 85.1 (Gal-C1), 81.9 (Gal-C3), 80.6 (Lac-C2), 75.1 (Gal-C4), 70.2 (Gal-
C5), 69.2 (Gal-C6), 68.6 (Gal-C2), 66.8 (Ph-CH2), 38.8 (Lac-C3), 23.0 (SCH2CH3), 21.1 
(Ar-Me), 15.2 (SCH2CH3); ESI-MS: m/z: Calcd for C32H36NaO7S [M+Na]+: 587.7, found: 
587.2. 
Ethyl 4,6-O-benzylidene-3-O-[(R)-1-(benzyloxy)-1-oxo-3-(3,4-difluorophenyl)-propan-
2-yl]-1-thio-β-D-galactopyranoside (22c) 
Thiogalactoside derivative (20) (208 mg, 0.66 mmol) and n-Bu2SnO (247 mg, 1.00 
mmolwere dissolved in dry MeOH (10 mL) and refluxed at 65°C under argon for 4 h. 
The solvent was removed under reduced pressure and the crude product was dried in 
high vacuum for 16 h. This residue was dissolved in dry DME (4 mL) under argon and a 
solution of triflate (19c) (533 mg, 1.33 mmol) in dry DME (6 mL) was added followed by 
the addition of CsF (302 mg, 2.00 mmol, dried in high vacuum at 100°C for 16 h). The 
turbid solution was stirred for 3 h after which TLC (petroleum ether/EtOAc, 9:1, 
DCM/MeOH, 19:1) indicated still presence of starting material (20) but no triflate (19c) 
so another portion of (19c) (266 mg, 0.66 mmol) was added and the mixture was stirred 
for additional 16 h. A solution of KF (10%) in aq. KH2PO4 (1 N, 10 mL) was added, and 
after stirring for 1 h, the reaction was extracted with DCM (3 x 50 mL). The combined 
organic phases were washed with brine (10 mL), dried over Na2SO4 and the solvents 
were removed in vacuo. The crude product was purified by flash chromatography 
(petroleum ether/EtOAc, gradient 0-50%) to afford a 5:1 mixture of 21c (lactone) and 
22c (benzylester), which was used in the following reaction without further purification. 
(94 mg). ESI-MS: m/z: Calcd for 21c (lactone) C24H24F2NaO6S [M+Na]+: 501.5, found: 
501.1, found: Calcd for 22c (open) C31H32F2NaO7S [M+Na]+: 609.6, found: 609.1. To a 
solution of 21c (90.0 mg, 0.188 mmol) in benzyl alcohol (1 mL) DMAP (cat.) was added. 
The reaction was heated to 60°C for 3 h, then the reaction mixture was purified by flash 
chromatography (petroleum ether/EtOAc, gradient 0-50%) to afford (22c) as colorless 
wax (88 mg, 0.15 mmol, 22% after two steps). Rf = (petroleum ether/EtOAc, 3:2) 0.32; 
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[α]D22 -35.8 (c 0.35, CHCl3); 1H NMR (500.1 MHz, CDCl3): δ = 7.52 - 7.47 (m, 2H, Ar-
H), 7.40 - 7.32 (m, 6H, Ar-H), 7.31 - 7.24 (m, 2H, Ar-H), 7.12 - 7.05 (m, 1H, Ar-H), 6.92 
- 6.82 (m, 2H, Ar-H), 5.42 (s, 1H, Ph-CH), 5.11 (d, J = 12.0 Hz, 1H, Ar-CH2), 5.05 (d, J 
= 12.0 Hz, 1H, Ar-CH2), 4.75 (t, J = 5.7 Hz, 1H, Lac-H2), 4.29 - 4.18 (m, 3H, Gal-H1, 
Gal-H4, Gal-H6a), 3.93 - 3.87 (m, 2H, Gal-H2, Gal-H6b), 3.47 (d, J = 9.3 Hz, 1H, Gal-
H3), 3.34 (s 1H, Gal-H5), 3.10 - 2.95 (m, 2H, Lac-H3), 2.82 - 2.64 (m, 2H, SCH2CH3), 
2.31 (br s, 1H, OH), 1.30 (t, J = 7.4 Hz, 3H, SCH2CH3); 13C NMR (125.8 MHz, CDCl3): 
δ = 172.0 (Lac-C1), 153.5 - 148.1 (m, 2C, ArF-C), 130.0, 135.3, 128.9, 128.7, 128.6, 
128.1 (6C, Ar-C), 126.3 (Ar-C), 125.5 (m, Ar-C), 118.8 (d, J = 17.7 Hz, Ar-C), 116.6 (d, J 
= 17.0 Hz, Ar-C), 100.9 (Ph-CH), 85.7 (Gal-C1), 80.5 (Gal-C3), 79.3 (Lac-C2), 75.6 
(Gal-C4), 70.4 (Gal-C5), 69.2 (Gal-C6), 69.1 (Gal-C2), 66.8 (Ph-CH2), 38.2 (Lac-C3), 
23.0 (SCH2CH3), 15.4 (SCH2CH3); ESI-MS: m/z: Calcd for C31H32F2NaO7S [M+Na]+: 
609.6, found: 609.11. 
Ethyl 2-O-acetyl-4,6-O-benzylidene-3-O-[(R)-1-(benzyloxy)-1-oxo-3-phenylpropan-2-
yl]-1-thio-β-D-galactopyranoside (9a) 
To a solution of (22a) (60 mg, 0.109 mmol) in pyridine (1 mL) Ac2O (1 ml) was added. 
The reaction was stirred at rt for 18 h. The solvent was removed in vacuo, and the crude 
product was purified by flash chromatography (petroleum ether/EtOAc, gradient 0-60%) 
to afford (10) as white solid (60 mg, 0.087 mmol, 80%). Rf = (petroleum ether/EtOAc, 
7:3) 0.40; [α]D22 -14.1 (c 1.0, CHCl3); 1H NMR (500.1 MHz, CDCl3): δ = 7.51 (dd, J = 
7.7, 1.5 Hz, 2H, Ar-H), 7.42 – 7.33 (m, 6H, Ar-H), 7.31 - 7.14 (m, 7H, Ar-H), 5.36 (m,  
2H, Gal-H2, Ph-CH), 5.07 (q, J = 12.0 Hz, 2H, Ar-CH2), 4.35 (dd, J = 5.0, 7.2 Hz, 1H, 
Lac-H2), 4.28 – 4.20 (m, 3H, Gal-H1, Gal-H4, Gal-H6), 3.85 (dd, J = 1.4, 12.3 Hz, Gal-
H6’), 3.50 (dd, J = 3.3, 9.7 Hz, 1H, Gal-H3), 3.28 (s, 1H, Gal-H5), 3.05 - 2.96 (m, 2H, 
Lac-H3), 2.86 – 2.78 (m, 1H, SCH2CH3), 2.70 – 2.62 (m, 1H, SCH2’CH3), 1.78 (s, 3H, 
CO-CH3), 1.22 (t, J = 7.5 Hz, 3H, SCH2CH3); 13C NMR (126 MHz, CDCl3): δ = 172.1 
(Lac-C1), 169.1 (Ac-CO), 137.9, 136.0, 135.3, 129.6, 128.9, 128.7, 128.6, 128.6, 128.3, 
128.1, 126.7, 126.4 (12C, Ar-C), 100.9 (Ph-CH), 82.8 (Gal-C1), 81.3 (Lac-C2), 79.6 (Gal-
C3), 75.3 (Gal-C4), 70.2 (Gal-C5), 69.1 (Gal-C6), 68.7 (Gal-C2),, 66.8 (Ph-CH2), 39.3 
(Lac-C3), 22.5 (SCH2CH3), 20.7 (CO-CH3), 14.6 (SCH2CH3); ESI-MS: m/z: Calcd for 
C33H36NaO8S [M+Na]+: 615.7, found: 615.2. 
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Ethyl 2-O-benzoyl-4,6-O-benzylidene-3-O-[(R)-1-(benzyloxy)-1-oxo-3-phenylpropan-
2-yl]-1-thio-β-D-galactopyranoside (9a) 
To a solution of (22a) (250 mg, 0.45 mmol, 1 eq) in pyridine (2 mL) DMAP (6 mg, 0.05 
mmol, 0.1 eq) and benzoyl chloride (0.16 mL, 1.36 mmol, 3 eq) were added at 0°C. The 
reaction was stirred at rt for 3h after which TLC (petroleum ether/EtOAc, 3:2) indicated 
completion of the reaction. The solvent was removed in vacuo, the crude residue was 
taken up in DCM (100 mL), washed with 0.5 M aq. HCl (20 mL), satd aq. NaHCO3 (20 
mL) and brine (20 mL), dried over Na2SO4 and concentrated in vacuo. The crude product 
was purified by flash chromatography (petroleum ether/EtOAc, gradient 0-50%) to 
afford (9a) as white solid (260 mg, 0.40 mmol, 87%). Rf = (petroleum ether/EtOAc, 7:3) 
0.45; [α]D22 -22.5 (c 2.0, CHCl3); 1H NMR (500 MHz, CDCl3): δ = 7.95 (d, J = 7.3 Hz, 
2H, Ar-H), 7.62 - 7.51 (m, 3H, Ar-H), 7.46 - 7.28 (m, 10H, Ar-H), 7.02 (t, J = 7.3 Hz, 
1H, Ar-H), 6.98 - 6.90 (m, 2H, Ar-H), 7.02 (d, J = 7.2 Hz, 2H, Ar-H), 5.67 (t, J = 9.7 Hz, 
1H, Gal-H2), 5.39 (s, 1H, Ph-CH), 5.05 - 4.95 (m, 2H, Ar-CH2), 4.44 (d, J = 9.7 Hz, 1H, 
Gal-H1), 4.34 (t, J = 6.2 Hz, 1H, Lac-H2), 4.30 - 4.24 (m, 2H, Gal-H6a, Gal-H4), 3.88 
(d, J = 12.2 Hz, Gal-H6b), 3.68 (d, J = 7.6 Hz, 1H, Gal-H3), 3.34 (s, 1H, Gal-H5), 2.92 - 
2.82 (m, 3H, Lac-H3, SCH2CH3), 2.77 - 2.66 (m, 1H, SCH2CH3), 1.22 (t, J = 7.5 Hz, 3H, 
SCH2CH3); 13C NMR (126 MHz, CDCl3): δ = 172.0 (Lac-C1), 164.8 (Bz-CO), 137.9, 
136.0, 135.3, 133.1, 129.9, 129.8 129.4, 128.9, 128.7, 128.6, 128.4, 128.2, 128.1, 126.5, 
126.4 (16C, Ar-C), 100.9 (Ph-CH), 82.9 (Gal-C1), 81.3 (Lac-C2), 79.9 (Gal-C3), 75.3 
(Gal-C4), 70.3 (Gal-C5), 69.6 (Gal-C2), 69.2 (Gal-C6), 66.7 (Ph-CH2), 39.2 (Lac-C3), 
22.7 (SCH2CH3), 14.8 (SCH2CH3); ESI-MS: m/z: Calcd for C38H38O8S [M+Na]+: 577.8, 
found: 577.2. 
Ethyl 2-O-benzoyl-4,6-O-benzylidene-3-O-[(R)-1-(benzyloxy)-1-oxo-3-(4-
methylphenyl)-propan-2-yl]-1-thio-β-D-galactopyranoside (9b) 
To a solution of (22b) (195 mg, 0.34 mmol) in pyridine (2 mL) DMAP (4 mg, 0.03 
mmol) and benzoyl chloride (0.12 mL, 1.04 mmol) were added at 0°C. The reaction was 
stirred at rt for 16 h after which TLC (petroleum ether/EtOAc, 3:2) indicated completion 
of the reaction. The solvent was removed in vacuo, the crude residue was taken up in 
DCM (100 mL), washed with 0.5 M aq. HCl (20 mL), satd aq. NaHCO3 (20 mL) and 
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brine (20 mL), dried over Na2SO4 and concentrated in vacuo. The crude product was 
purified by flash chromatography (petroleum ether/EtOAc, gradient 0-50%) to afford 
(9b) as white solid (166 mg, 0.25 mmol, 72%). Rf = (petroleum ether/EtOAc, 7:3) 0.48; 
[α]D22 -26.3 (c 0.45, CHCl3); 1H NMR (500.1 MHz, CDCl3): δ  = 7.94 (d, J = 7.7 Hz, 2H, 
Ar-H), 7.64 - 7.50 (m, 3H, Ar-H), 7.49 - 7.29 (m, 8H, Ar-H), 7.25 - 7.17 (m, 2H, Ar-H), 
6.81 - 6.68 (m, 4H, Ar-H), 5.67 (t, J = 9.7 Hz, 1H, Gal-H2), 5.39 (s, 1H, Ph-CH), 5.01 (s, 
2H, Ar-CH2), 4.43 (d, J = 9.6 Hz, 1H, Gal-H1), 4.35 - 4.23 (m, 3H, Gal-H6, Lac-H2, Gal-
H4), 3.88 (d, J = 12.2 Hz, Gal-H6’), 3.67 (d, J = 9.6 Hz, 1H, Gal-H3), 3.35 (s 1H, Gal-
H5), 2.93 - 2.66 (m, 4H, Lac-H3, SCH2CH3), 2.18 (s, 3H, Ar-Me), 1.23 (t, J = 7.7 Hz, 3H, 
SCH2CH3); 13C NMR (125.8 MHz, CDCl3): δ = 172.1 (Lac-C1), 164.8 (Bz-CO), 137.9, 
135.8, 135.3, 133.0, 132.9, 129.9, 129.8 129.3, 128.9, 128.8, 128.6, 128.6, 128.5, 128.3, 
128.2, 126.5 (16C, Ar-C), 101.0 (Ph-CH), 82.9 (Gal-C1), 81.7 (Lac-C2), 79.9 (Gal-C3), 
75.3 (Gal-C4), 70.3 (Gal-C5), 69.5 (Gal-C2), 69.2 (Gal-C6), 66.7 (Ph-CH2), 38.8 (Lac-
C3), 22.7 (SCH2CH3), 21.0 (Ar-Me), 14.7 (SCH2CH3); ESI-MS: m/z: Calcd for 
C39H40NaO8S [M+Na]+: 691.8, found: 691.2. 
Ethyl 2-O-benzoyl-4,6-O-benzylidene-3-O-[(R)-1-(benzyloxy)-1-oxo-3-(3,4-
difluorophenyl)-propan-2-yl]-1-thio-β-D-galactopyranoside (9c) 
To a solution of (22c) (73 mg, 0.2 mmol) in pyridine (2 mL) DMAP (1.5 mg, 0.01 mmol) 
and benzoyl chloride (0.045 mL, 0.37 mmol) were added at 0°C. The reaction was stirred 
at rt for 16 h after which TLC (petroleum ether/EtOAc, 3:2) indicated completion of the 
reaction. The solvent was removed in vacuo, the crude residue was taken up in DCM (100 
mL), washed with 0.5 M aq. HCl (20 mL), sat. NaHCO3 (20 mL) and brine (20 mL), 
dried over Na2SO4 and concentrated in vacuo. The crude product was purified by flash 
chromatography (petroleum ether/EtOAc, gradient 0-50%) to afford (9c) as white solid 
(55 mg, 0.08 mmol, 64%). Rf = (petroleum ether/EtOAc, 7:3) 0.40; [α]D22 -35.3 (c 0.28, 
CHCl3); 1H NMR (500.1 MHz, CDCl3): δ = 7.92 (d, J = 7.7 Hz, 2H, Ar-H), 7.65 - 7.51 
(m, 3H, Ar-H), 7.50 - 7.32 (m, 8H, Ar-H), 7.32 - 7.22 (m, 2H, Ar-H), 6.77 - 6.53 (m, 3H, 
Ar-H), 5.65 (t, J = 9.6 Hz, 1H, Gal-H2), 5.42 (s, 1H, Ph-CH), 5.13 (d, J = 11.9 Hz, 1H, 
Ar-CH2), 5.02 (d, J = 11.9 Hz, 1H, Ar-CH2), 4.43 (d, J = 9.7 Hz, 1H, Gal-H1), 4.38 - 4.23 
(m, 3H, Lac-H2, Gal-H6a, Gal-H4), 3.89 (d, J = 12.3 Hz, Gal-H6b), 3.69 (d, J = 9.5 Hz, 
1H, Gal-H3), 3.36 (s, 1H, Gal-H5), 2.93 - 2.66 (m, 4H, Lac-H3, SCH2CH3), 1.22 (t, J = 
7.5 Hz, 3H, SCH2CH3); 13C NMR (125.8 MHz, CDCl3): δ = 171.6 (Lac-C1), 164.7 (Bz-
CO), 160.8 - 140.9 (m, 2C, Ar-C), 137.9, 135.1, 133.7, 133.3 (4C, Ar-C), 133.0 (m, Ar-C), 
130.2, 129.7, 129.0, 128.8, 128.8, 128.8, 128.5, 128.5, 128.2, 126.4 (10C, Ar-C), 125.7 - 
125.4 (m, Ar-C), 118.4 (d, J = 17.2 Hz, Ar-C), 116.6 (d, J = 17.0 Hz, Ar-C), 101.0 (Ph-
CH), 82.9 (Gal-C1), 80.8 (Lac-C2), 79.8 (Gal-C3), 75.5 (Gal-C4), 70.3 (Gal-C5), 69.6 
(Gal-C2), 69.1 (Gal-C6), 67.0 (Ph-CH2), 38.2 (Lac-C3), 22.7 (SCH2CH3), 14.7 
(SCH2CH3); ESI-MS: m/z: Calcd for C38H36F2NaO8S [M+Na]+: 713.7, found: 713.1. 
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(1R,2R,3S)-2-[(2,3,4-Tri-O-benzyl-6-deoxy-α-L-galactopyranosyl)oxy]-3-methyl- 
cyclo-hex-1-yl 2-O-benzoyl-4,6-O-benzylidene-3-O-[(R)-1-(benzyloxy)-1-oxo-3-
phenylpropan-2-yl]-β-D-galactopyranoside (24) 
A solution of donor (10) (45 mg, 0.076 mmol) and acceptor (11) (62 mg, 0.113 mmol) in 
dry DCM (5 mL) was added via syringe to activated 4Å molecular sieves (0.5 g) under 
argon. A suspension of dimethyl(methylthio)sulfonium triflate (DMTST, 97 mg, 0.395 
mmol) and activated 4Å molecular sieves (0.5 g) in DCM (5 mL) was prepared in a 
second flask under argon. Both suspensions were stirred at rt for 4 h, then the DMTST 
suspension was added via syringe to the other suspension. The reaction was stopped after 
18 h, filtered through celite and the celite was washed with DCM (20 mL). The filtrate 
was successively washed with satd. aq. NaHCO3 (25 mL) and water (25 mL), dried over 
Na2SO4, filtered and concentrated. The crude product was purified by flash 
chromatography (petroleum ether/EtOAc, gradient 0-50%) to afford (24) as white solid 
(64 mg, 0.059 mmol, 78%). Rf = (petroleum ether/EtOAc, 3:2) 0.30; [α]D22 -66.0 (c 0.48, 
CHCl3); 1H NMR (500.1 MHz, CDCl3): δ = 7.60 (d, J = 7.4 Hz, 2H, Ar-H), 7.36 - 7.13 
(m, 28H, Ar-H), 5.39 (s, 1H, Ph-CH), 5.25 (dd, J = 8.2, 10.0 Hz, 1H, Gal-H2), 5.07 - 4.99 
(m, 2H, Ph-CH2), 4.94 (d, J = 3.1 Hz, 1H, Fuc-H1), 4.88 (q, J = 6.5 Hz, 1H, Fuc-H5), 
4.80 (d, J = 7.4 Hz, 1H, Ph-CH2), 4.70 (d, J = 11.7 Hz, 1H, Ph-CH2), 4.59 (q, J = 11.5 Hz, 
2H, Ph-CH2), 4.37 (t, J = 6.0 Hz, 1H, Lac-H2), 4.29 (d, J = 8.0 Hz, 1H, Gal-H1), 4.25 (d, 
J = 11.5 Hz, 1H, Gal-H6), 4.22 – 4.17 (m, 2H, Gal-H4, Ph-CH2), 3.96 - 3.86 (m, 3H, Gal-
H6’, Fuc-H2, Fuc-H3), 3.60 (d, J = 11.4 Hz, 1H, Ph-CH2), 3.52 (dd, J = 3.3, 10.1 Hz, 1H, 
Gal-H3), 3.49 – 3.41 (m, 2H, MeCy-H1), 3.23 (s, 1H, Fuc-H4), 3.21 – 3.14 (m, 2H, 
MeCy-H2, Gal-H5), 3.07 - 3.04 (m, 2H, Lac-H3), 1.87 - 1.85 (m, 1H, MeCy-H3), 1.85 (s, 
3H, CO-CH3), 1.63 - 1.50 (m, 3H, MeCy-H6, MeCy-H4), 1.16 (d, J = 6.4 Hz, 3H, Fuc-
H6), 1.05 (d, J = 6.4 Hz, 3H, MeCy-Me), 1.16 - 0.81 (m, 3H, MeCy-H4’, MeCy-H5); 13C 
NMR (125.8 MHz, CDCl3): δ = 171.9 (Lac-C1), 168.6 (Ac-CO), 139.8, 139.6, 138.7, 
138.1, 136.5, 135.2, 129.6, 128.6, 128.6, 128.6, 128.5, 128.3, 128.1, 128.0, 127.8, 127.5, 
127.4, 127.3, 127.0, 126.7, 126.7, 125.9 (Ar-C), 99.9 (Gal-C1), 99.5 (Ph-CH), 98.2 (Fuc-
C1), 81.3 (MeCy-C2), 81.0 (Lac-C2), 80.7 (MeCy-C1), 79.7 (Fuc-C3), 79.0 (Fuc-C4), 
78.6 (Gal-C3), 75.6 (Fuc-C3), 74.9, 74.8 (2C, Gal-C4, Ph-CH2), 74.4 (Ph-CH2), 71.1 (Ph-
CH2), 70.9 (Gal-C2),  69.1 (Gal-C6), 66.8 (Ph-CH2), 66.3, 66.2 (2C, Fuc-C5, Gal-C5), 
39.5 (MeCy-C6), 39.3 (Lac-C3), 33.6 (MeCy-C4), 31.3 (MeCy-C3), 23.3 (MeCy-C5), 
20.8 (CO-CH3), 18.7 (MeCy-Me), 16.0 (Fuc-C6); ESI-MS: m/z: Calcd for C65H72NaO14 
[M+Na]+: 1100.27, found: 1099.43. 
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(1R,2R,3S)-2-[(2,3,4-Tri-O-benzyl-6-deoxy-α-L-galactopyranosyl)oxy]-3-methyl- 
cyclo-hex-1-yl 2-O-benzoyl-4,6-O-benzylidene-3-O-[(R)-1-(benzyloxy)-1-oxo-3-
phenylpropan-2-yl]-β-D-galactopyranoside (23a) 
A solution of donor (9a) (101 mg, 0.159 mmol) and acceptor (11) (101 mg, 0.185 mmol) 
in dry DCM (5 mL) was added via syringe to activated 4Å molecular sieves (0.5 g) under 
argon. A suspension of dimethyl(methylthio)sulfonium triflate (DMTST, 119 mg, 0.462 
mmol) and activated 4Å molecular sieves (0.5 g) in DCM (5 mL) was prepared in a 
second flask under argon. Both suspensions were stirred at rt for 4 h, then the DMTST 
suspension was added via syringe to the other suspension. The reaction was stopped after 
18 h, filtered through celite and the celite was washed with DCM (20 mL). The filtrate 
was successively washed with satd. aq. NaHCO3 (25 mL) and water (25 mL), dried over 
Na2SO4, filtered and concentrated. The crude product was purified by flash 
chromatography (petroleum ether/EtOAc, gradient 0-50%) to afford (23a) as white solid 
(138 mg, 0.12 mmol, 79%). Rf = (petroleum ether/EtOAc, 3:2) 0.35; [α]D22 -78.6 (c 0.39, 
CHCl3); 1H NMR (500.1 MHz, CDCl3): δ = 7.99 (d, J = 7.7 Hz, 2H, Ar-H), 7.63 (d, J = 
7.5 Hz, 2H, Ar-H), 7.59 (t, J = 7.2 Hz, 1H, Ar-H), 7.45 (t, J = 7.4 Hz, 2H, Ar-H), 7.35 - 
7.14 (m, 23H, Ar-H), 7.07 - 6.93 (m, 5H, Ar-H), 5.57 (t, J = 8.8 Hz, 1H, Gal-H2), 5.42 (s, 
1H, Ph-CH), 5.02 - 4.85 (m, 5H, 2 Ph-CH2, Fuc-H1), 4.80 (d, J = 11.7 Hz, 1H, Ph-CH2), 
4.69 (d, J = 11.7 Hz, 1H, Ph-CH2), 4.63 (d, J = 11.5 Hz, 1H, Ph-CH2), 4.58 d, J = 11.3 
Hz, 1H, Ph-CH2), 4.51 (d, J = 7.9 Hz, 1H, Gal-H1), 4.36 - 4.16 (m, 4H, Lac-H2, Gal-H6, 
Gal-H4, Fuc-H2), 4.00 - 3.87 (m, 3H, Gal-H6’, Fuc-H3, Fuc-H5), 3.71 - 3.57 (m, 2H, 
Gal-H3, Fuc-H4), 3.51 (t, J = 9.5 Hz, 1H, MeCy-H2), 3.33 - 3.22 (m, 2H, Gal-H5, Fuc-
H4), 3.13 (t, J = 9.5 Hz, 1H, MeCy-H1), 2.98 - 2.85 (m, 2H, Lac-H3), 1.85 - 1.77 (m, 1H, 
MeCy-H3), 1.58 - 1.41 (m, 3H, MeCy-H6, MeCy-H4), 1.25 (d, J = 6.3 Hz, 3H, Fuc-H6), 
1.01 (d, J = 6.0 Hz, 3H, MeCy-Me), 1.16 - 0.81 (m, 3H, MeCy-H4’, MeCy-H5); 13C 
NMR (125.8 MHz, CDCl3): δ = 171.8 (Lac-C1), 164.5 (Bz-CO), 139.8, 139.6, 138.8, 
138,2, 136.0, 135.2, 133.0, 130.1, 129.7, 129.5, 128.7, 128.6, 128.6, 128.5, 128.5, 128.4, 
128.1, 128.0, 128.0, 127.8, 127.5, 127.4, 127.3, 127.0, 126.8, 126.5, 126.0  (28C, Ar-C), 
99.7 (Gal-C1), 99.5 (Ph-CH), 98.3 (Fuc-C1), 81.3 (MeCy-C1), 81.1 (Lac-C2), 80.7 
(MeCy-C2), 79.7 (Fuc-C3), 79.1 (Fuc-C4), 89.9 (Gal-C3), 75.7 (Fuc-C5), 74.9 (2C, Gal-
C4, Fuc-C4), 74.5 (Ph-CH2), 71.6 (Gal-C2), 71.2 (Ph-CH2), 69.2 (Gal-C6), 66.7 (Ph-CH2), 
66.4 (Ph-CH2), 66.3 (Gal-C5), 39.5 (MeCy-C6), 39.2 (Lac-C3), 33.5 (MeCy-C4), 31.1 
(MeCy-C3), 23.3 (MeCy-C5), 18.7 (MeCy-Me), 16.2 (Fuc-C6); ESI-MS: m/z: Calcd for 
C70H74NaO14[M+Na]+: 1162.3, found: 1161.4. 
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(1R,2R,3S)-2-[(2,3,4-Tri-O-benzyl-6-deoxy-α-L-galactopyranosyl)oxy]-3-methyl- 
cyclohex-1-yl 2-O-benzoyl-4,6-O-benzylidene-3-O-[(R)-1-(benzyloxy)-1-oxo-3-(4-
methylphenyl)-propan-2-yl]-β-D-galactopyranoside (23b) 
A solution of donor (9b) (30 mg, 0.044 mmol, 1 eq) and acceptor (11) (30 mg, 0.058 
mmol) in dry DCM (1.5 mL) was added via syringe to activated 4Å molecular sieves (0.2 
g) under argon. A suspension of dimethyl(methylthio)sulfonium triflate (DMTST, 35 mg,
0.134 mmol) and activated 4Å molecular sieves (0.2 g) in DCM (1.5 mL) was prepared in 
a second flask under argon. Both suspensions were stirred at rt for 4 h, then the DMTST 
suspension was added via syringe to the other suspension. The reaction was stopped after 
18 h, filtered through celite and the celite was washed with DCM (10 mL). The filtrate 
was successively washed with satd. aq. NaHCO3 (15 mL) and water (15 mL), dried over 
Na2SO4, filtered and concentrated. The crude product was purified by flash 
chromatography (petroleum ether/EtOAc, gradient 0-50%) to afford (23b) as white solid 
(41 mg, 0.035 mmol, 80%). Rf = (petroleum ether/EtOAc, 3:2) 0.33; [α]D22 -79.3 (c 0.25, 
CHCl3); 1H NMR (500.1 MHz, CDCl3): δ = 7.98 (d, J = 7.7 Hz, 2H, Ar-H), 7.64 (d, J = 
7.4 Hz, 2H, Ar-H), 7.59 (t, J = 7.2 Hz, 1H, Ar-H), 7.39 - 7.12 (m, 27H, Ar-H), 6.87 (d, J 
= 7.5 Hz, 2H, Ar-H), 6.26 (d, J = 7.5 Hz, 2H, Ar-H), 5.56 (t, J = 9.6 Hz, 1H, Gal-H2), 
5.43 (s, 1H, Ph-CH), 5.04 - 4.90 (m, 5H, 2 Ph-CH2, Fuc-H1), 4.80 (d, J = 11.7 Hz, 1H, 
Ph-CH2), 4.68 (d, J = 11.7 Hz, 1H, Ph-CH2), 4.63 (d, J = 11.3 Hz, 1H, Ph-CH2), 4.58 (d, J 
= 11.3 Hz, 1H, Ph-CH2), 4.51 (d, J = 9.7 Hz, 1H, Gal-H1), 4.30 - 4.15 (m, 4H, Lac-H2, 
Gal-H6, Gal-H4, Fuc-H2), 4.00 - 3.86 (m, 3H, Gal-H6’, Fuc-H3, Fuc-H5), 3.71 - 3.57 (m, 
2H, Gal-H3, Fuc-H4), 3.55 (t, J = 9.5 Hz, 1H, MeCy-H2), 3.30 - 3.21 (m, 2H, Gal-H5, 
Fuc-H4), 3.13 (t, J = 9.5 Hz, 1H, MeCy-H1), 2.93 - 2.85 (m, 2H, Lac-H3), 2.18 (s, 3H, 
Ar-Me), 1.86 - 1.74 (m, 1H, MeCy-H3), 1.55 - 1.40 (m, 3H, MeCy-H6, MeCy-H4), 1.25 
(d, J = 6.0 Hz, 3H, Fuc-H6), 1.01 (d, J = 6.1 Hz, 3H, MeCy-Me), 1.16 - 0.81 (m, 3H, 
MeCy-H4’, MeCy-H5); 13C NMR (125.8 MHz, CDCl3): δ = 172.0 (Lac-C1), 164.5 (Bz-
CO), 139.8, 139.6, 138.8, 138,2, 135.9, 135.3, 132.9, 132.9, 130.1, 129.7, 129,4, 128.8, 
128.7, 128.6, 128.6, 128.5, 128.5, 128.4, 128.1, 128.0, 128.0, 127.8, 127.6, 127.5, 127.3, 
127.0, 126.8, 126.0  (28C, Ar-C), 99.7 (Gal-C1), 99.5 (Ph-CH), 98.3 (Fuc-C1), 81.4 (Lac-
C2, MeCy-C1), 80.7 (MeCy-C2), 79.7 (Fuc-C3), 79.1 (Fuc-C4), 79.0 (Gal-C3), 75.7 (Fuc-
C5), 74.9 (2C, Gal-C4, Fuc-C4), 74.5 (Ph-CH2), 71.6 (Gal-C2), 71.2 (Ph-CH2), 69.2 (Gal-
C6), 66.7 (Ph-CH2), 66.4 (Ph-CH2), 66.3 (Gal-C5), 39.5 (MeCy-C6), 38.8 (Lac-C3), 33.5 
(MeCy-C4), 31.1 (MeCy-C3), 23.3 (MeCy-C5), 18.7 (MeCy-Me), 16.2 (Fuc-C6); ESI-MS: 
m/z: Calcd for C71H76NaO14 [M+Na]+: 1176.3, found: 1175.6. 
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(1R,2R,3S)-2-[(2,3,4-Tri-O-benzyl-6-deoxy-α-L-galactopyranosyl)oxy]-3-methyl- 
cyclohex-1-yl 2-O-benzoyl-4,6-O-benzylidene-3-O-[(R)-1-(benzyloxy)-1-oxo-3-(3,4-
difluorophenyl)-propan-2-yl]-β-D-galactopyranoside (23c) 
A solution of donor (9c) (53 mg, 0.076 mmol) and acceptor (11) (50 mg, 0.092 mmol) in 
dry DCM (1.5 mL) was added via syringe to activated 4Å molecular sieves (0.25 g) under 
argon. A suspension of dimethyl(methylthio)sulfonium triflate (DMTST, 60 mg, 0.230 
mmol) and activated 4Å molecular sieves (0.25 g) in DCM (1.5 mL) was prepared in a 
second flask under argon. Both suspensions were stirred at rt for 4 h, then the DMTST 
suspension was added via syringe to the other suspension. The reaction was stopped after 
18 h, filtered through celite and the celite was washed with DCM (10 mL). The filtrate 
was successively washed with satd. aq. NaHCO3 (20 mL) and water (20 mL), dried over 
Na2SO4, filtered and concentrated. The crude product was purified by flash 
chromatography (petroleum ether/EtOAc, gradient 0-50%) to afford (23c) as colorless 
wax (41 mg, 0.035 mmol, 80%). Rf = (petroleum ether/EtOAc, 3:2) 0.28; [α]D22 -84.6 (c 
0.60, CHCl3); 1H NMR (500.1 MHz, CDCl3): δ = 7.96 (d, J = 7.5 Hz, 2H, Ar-H), 7.66 - 
7.55 (m, 3H, Ar-H), 7.45 (t, J = 7.6 Hz, 2H, Ar-H), 7.40 - 7.14 (m, 23H, Ar-H), 6.89 - 
6.81 (m, 1H, Ar-H), 6.74 - 6.60 (m, 2H, Ar-H), 5.56 (t, J = 9.0 Hz, 1H, Gal-H2), 5.47 (s, 
1H, Ph-CH), 5.09  (d, J = 12.0 Hz, 1H, Ph-CH2), 4.98 (d, J = 12.0 Hz, 1H, Ph-CH2), 4.95 - 
4.90 (m, 2H, Fuc-H1, Fuc-H2), 4.80 (d, J = 11.7 Hz, 1H, Ph-CH2), 4.69 (d, J = 11.7 Hz, 
1H, Ph-CH2), 4.63 (d, J = 11.5 Hz, 1H, Ph-CH2), 4.58 (d, J = 11.3 Hz, 1H, Ph-CH2), 4.51 
(d, J = 7.9 Hz, 1H, Gal-H1), 4.34 - 4.24 (m, 3H, Lac-H2, Gal-H6, Gal-H4), 4.20 (d, J = 
11.3 Hz, 1H, Ph-CH2), 4.00 - 3.88 (m, 3H, Gal-H6’, Fuc-H2, Fuc-H3), 3.68 (d, J = 8.2 
Hz, 1H, Gal-H3), 3.63 (d, J = 11.3 Hz, 1H, Ph-CH2), 3.57 - 3.46 (m, 1H, MeCy-H2), 3.33 
- 3.23 (m, 2H, Gal-H5, Fuc-H4), 3.13 (t, J = 9.5 Hz, 1H, MeCy-H1), 2.94 - 2.80 (m, 2H, 
Lac-H3), 1.85 - 1.77 (m, 1H, MeCy-H3), 1.56 - 1.40 (m, 3H, MeCy-H6, MeCy-H4), 1.25 
(d, J = 6.3 Hz, 3H, Fuc-H6), 1.01 (d, J = 6.4 Hz, 3H, MeCy-Me), 1.16 - 0.81 (m, 3H, 
MeCy-H4’, MeCy-H5); 13C NMR (126 MHz, CDCl3): δ = 171.5 (Lac-C1), 164.4 (Bz-
CO), 150.9 - 145.1 (m, 2C, ArF-C), 139.8, 139.6, 138.8, 138.1, 135.0, 133.1, 132.9, 130.1, 
129.8, 129.6, 129.0, 128.8, 128.7, 128.6, 128.5, 128.2, 128.1, 128.1, 128.0, 127.8, 127.6, 
127.4, 127.3, 127.0, 126.8, 125.9, 125.5  (26C, Ar-C), 118.5 (d, J = 17.3 Hz, Ar-C), 116.9 
(d, J = 17.3 Hz, Ar-C), 99.6, 99.6 (2C, Gal-C1, Ph-CH), 98.3 (Fuc-C1), 81.3 (MeCy-C1), 
80.7 (Lac-C2), 80.5 (MeCy-C2), 79.7 (Fuc-C3), 79.1 (Fuc-C4), 79.9 (Gal-C3), 75.7 (Fuc-
C2), 75.1 (Gal-C4), 74.9 (Ph-CH2), 74.5 (Ph-CH2), 71.8 (Gal-C2), 71.2 (Ph-CH2), 69.2 
(Gal-C6), 66.7 (Ph-CH2), 66.4, 66.3 (2C, Gal-C5, Fuc-C5), 39.5 (MeCy-C6), 38.2 (Lac-
C3), 33.5 (MeCy-C4), 31.1 (MeCy-C3), 23.3 (MeCy-C5), 18.7 (MeCy-Me), 16.2 (Fuc-
C6); ESI-MS: m/z: Calcd for C70H72F2NaO14 [M+Na]+: 1198.3, found: 1198.9. 
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(1R,2R,3S)-2-[(α-L-Fucopyranosyl)oxy]-3-methyl-cyclohex-1-yl 2-O-acetyl-3-O-
[sodium (S)-1-carboxy-2-phenylethyl]-ß-D-galactopyranoside (7) 
A suspension of (24) (15 mg, 0.014 mmol) and Pd(OH)2/C (50 mg, 10% Pd) in THF (2 
mL) was hydrogenated (2 bar H2) at rt. After 1 h TLC (silica: petroleum ether/EtOAc, 
3:2; C-18: H2O/MeOH, 1:1) indicated completion of the reaction. The reaction mixture 
was filtered and concentrated in vacuo. The crude product was purified by reversed phase 
column chromatography (C-18, H2O/MeOH, gradient 0-100%) followed by a Dowex 50 
(Na+ form) ion exchange column, a Sephadex G15 column, and lyophilization from 
water to yield the product (7) as white foam (3 mg, 0.0046 mmol, 33%). Rf = (C-18, 
H2O/MeOH, 1:1) 0.55; [α]D22 -97.6 (c 0.35, MeOH); 1H NMR (500 MHz, CDCl3): δ = 
7.42 - 7.36 (m, 2H, Ar-H), 7.34 – 7.28 (m, 3H, Ar-H), 5.06 (d, J = 4.0 Hz, 1H, Fuc-H1), 
4.92 - 4.84 (m, 2H, Fuc-H5, Gal-H2), 4.52 (d, J = 8.1 Hz, 1H, Gal-H1), 4.16 (dd, J = 3.3, 
9.8 Hz, 1H, Lac-H2), 3.99 (d, J = 2.6 Hz, 1H, Gal-H4), 3.89 (dd, J = 3.3, 10.5 Hz, 1H, 
Fuc-H3), 3.84 - 3.77 (m, 2H, Fuc-H2, Fuc-H4), 3.74 (d, J = 5.9 Hz, 2H, Gal-H6), 3.61 - 
3.54 (m, 2H, Gal-H5, MeCy-H1), 3.51 (dd, J = 3.1, 9.8 Hz, 1H, Gal-H3), 3.18 – 3.01 (m, 
2H, MeCy-H2, Lac-H3), 2.84 (dd, J = 9.8, 14.3 Hz, 1H, Lac-H3’), 2.04 - 1.92 (m, 1H, 
MeCy-H6), 1.83 (s, 3H, CO-CH3), 1.65 - 1.51 (m, 3H, MeCy-H3, MeCy-H4a, MeCy-
H5), 1.21 (d, J = 6.6 Hz, 3H, Fuc-H6), 1.17 – 1.09 (m, 1H, MeCy-H5’), 1.07 (d, J = 6.4 
Hz, 3H, MeCy-Me), 1.09 - 0.97 (m, 2H, MeCy-H4’, MeCy-H6’); 13C NMR (126 MHz, 
D2O): δ = 180.9 (Lac-C1), 173.4 (Me-CO), 138.3, 129.0, 128.6, 126.6 (4C, Ar-C), 98.7, 
98.6 (2C, Gal-C1, Fuc-C1), 83.5 (MeCy-C2), 82.1 (Lac-C2), 80.6 (Gal-C3), 79.8 (MeCy-
C1), 74.1 (Gal-C5), 72.0 (Fuc-C4), 71.6 (Gal-C2), 69.3 (Fuc-C3), 68.2 (Fuc-C2), 66.5 
(Fuc-C5), 66.4 (Gal-C4), 61.7 (Gal-C6), 39.6 (Lac-C3), 38.6 (MeCy-C3), 33.0 (MeCy-
C4), 30.7 (MeCy-C6), 22.4 (MeCy-C5), 20.6 (CO-CH3), 18.1 (MeCy-C6), 15.3 (Fuc-C6); 
HR-MS: m/z:  Calcd for C30H43Na2O14  [M+Na]+: 673.2448, found: 673.2451. 
(1R,2R,3S)-2-[(α-L-Fucopyranosyl)oxy]-3-methyl-cyclohex-1-yl 2-O-benzoyl-3-O-
[sodium (S)-1-carboxy-2-phenylethyl]-ß-D-galactopyranoside (5a) 
A suspension of (23a) (76 mg, 0.068 mmol) and Pd(OH)2/C (50 mg, 10% Pd) in MeOH 
(5 mL) was hydrogenated (2 bar H2) at rt. After 1 h TLC (silica: petroleum ether/EtOAc, 
3:2; C-18: H2O/MeOH, 1:1) indicated completion of the reaction. The reaction mixture 
was filtered through celite and concentrated in vacuo. The crude product was purified by 
O
O
OAc
COONa
HO
OH
O
O
HO
OH
OH
O
7
O
O
HO OH
OH
O
O
OBz
O
HO
HO
CO2Na
5a 5a
Section III. E-selectin – Manuscript 9 
 
310
reversed phase column chromatography (C-18, H2O/MeOH, gradient 0-100%) followed 
by a Dowex 50 (Na+ form) ion exchange column, a Sephadex G15 column, and 
lyophilization from water to yield the product (5a) as white foam (20.3 mg, 0.028 mmol, 
42%). Rf = (C-18, H2O/MeOH, 1:1) 0.48; [α]D22 -97.6 (c 0.35, MeOH); 1H NMR (500 
MHz, CDCl3): δ = 7.92 (d, J = 8.1 Hz, 2H, Ar-H), 7.76 (t, J = 7.5 Hz, 1H, Ar-H), 7.57 (t, 
J = 7.9 Hz, 2H, Ar-H), 7.04 - 7.96 (m, 2H, Ar-H), 6.87 - 6.75 (m, 2H, Ar-H), 5.19 (m, 
1H, Gal-H2), 5.04 (d, J = 4.0 Hz, 1H, Fuc-H1), 4.90 (q, J = 6.6 Hz, 1H, Fuc-H5), 4.70 
(d, J = 8.1 Hz, 1H, Gal-H1), 4.12 (dd, J = 3.2, 9.7 Hz, 1H, Lac-H2), 4.04 (d, J = 2.5 Hz, 
1H, Gal-H4), 3.91 - 3.75 (m, 5H, Gal-H6, Fuc-H2, Fuc-H3, Fuc-H4), 3.69 - 3.62 (m, 2H, 
Gal-H3, Gal-H5), 3.57 (m, 1H, MeCy-H1), 3.06 (t, J = 9.4 Hz, 1H, MeCy-H2), 3.00 (dd, 
J = 3.1, 14.3 Hz, 1H, Lac-H3), 2.74 (dd, J = 9.7, 14.3 Hz, 1H, Lac-H3’), 1.95 (s, 1H, Ar-
Me), 1.97 - 1.88 (m, 1H, MeCy-H6), 1.55 - 1.39 (m, 3H, MeCy-H3, MeCy-H4a, MeCy-
H5), 1.30 (d, J = 8.1 Hz, 3H, Fuc-H6), 1.14 (m, 1H, MeCy-H5’), 1.01 (d, J = 6.4 Hz, 3H, 
MeCy-Me), 1.82 - 0.76 (m, 2H, MeCy-H4’, MeCy-H6’); 13C NMR (126 MHz, D2O): δ = 
181.1 (Lac-C1), 167.8 (Bz-CO), 137.9, 134.0, 129.9, 129.0, 128.7, 128.6, 128.1, 126.2 
(8C, Ar-C), 98.7, 98.7 (2C, Gal-C1, Fuc-C1), 83.5 (MeCy-C2), 82.4 (Lac-C2), 80.9 
(MeCy-C2), 79.8 (Gal-C3), 74.2 (MeCy-C1), 72.1, 72.0 (2C, Gal-C5, Gal-C2), 69.3 (Fuc-
C4), 68.2 (Fuc-C2), 66.5 (Fuc-C5), 66.4 (Gal-C4), 61.7 (Gal-C6), 39.6 (Lac-C3), 38.5 
(MeCy-C3), 32.9 (MeCy-C4), 30.8 (MeCy-C6), 22.3 (MeCy-C5), 20.0 (Ar-Me), 18.0 
(MeCy-C6), 15.4 (Fuc-C6); HR-MS: m/z:  Calcd for C35H45Na2O14 [M+Na]+: 735.2605, 
found: 735.2607. 
(1R,2R,3S)-2-[(α-L-Fucopyranosyl)oxy]-3-methyl-cyclohex-1-yl 2-O-benzoyl-3-O-
[sodium (S)-1-carboxy-2-(4-methylphenyl)-ethyl]-ß-D-galactopyranoside (5b) 
A suspension of (23b) (40 mg, 0.035 mmol) and Pd(OH)2/C (50 mg, 10% Pd) in MeOH 
(5 mL) was hydrogenated (2 bar H2) at rt. After 3 h TLC (silica: petroleum ether/EtOAc, 
3:2; C-18: H2O/MeOH, 1:1) indicated completion of the reaction. The reaction mixture 
was filtered through celite and concentrated in vacuo. The crude product was purified by 
reversed phase column chromatography (C-18, H2O/MeOH, gradient 0-100%) followed 
by a Dowex 50 (Na+ form) ion exchange column, a Sephadex G15 column, and 
lyophilization from water to yield the product (5b) as colorless foam (9.4 mg, 0.013 
mmol, 37%). Rf = (C-18, H2O/MeOH, 1:1) 0.42; [α]D22 -64.5 (c 0.23, MeOH); 1H NMR 
(500.1 MHz, CDCl3): δ = 7.92 (d, J = 7.9 Hz, 2H, Ar-H), 7.77 (t, J = 7.2 Hz, 1H, Ar-H), 
7.59 (t, J = 7.7 Hz, 2H, Ar-H), 6.92 (d, J = 7.5 Hz, 2H, Ar-H), 6.59 (d, J = 7.5 Hz, 2H, 
Ar-H), 5.19 (t, J = 8.7 Hz, 1H, Gal-H2), 5.03 (d, J = 2.8 Hz, 1H, Fuc-H1), 4.90 (dd, J = 
6.5, 13.0 Hz, 1H, Fuc-H5), 4.71 (d, J = 8.1 Hz, 1H, Gal-H1), 4.08 (d, J = 10.4 Hz, 1H, 
Lac-H2), 4.03 (s, 1H, Gal-H4), 3.91 – 3.73 (m, 5H, Gal-H6, Fuc-H2, Fuc-H3, Fuc-H4), 
3.69 - 3.60 (m, 2H, Gal-H3, Gal-H5), 3.57 (t, J = 13.2 Hz, 1H, MeCy-H1), 3.08 (t, J = 
9.3 Hz, 1H, MeCy-H2), 2.96 (d, J = 13.7 Hz, 1H, Lac-H3a), 2.69 (m, 1H, Lac-H3b), 1.95 
(s, 1H, Ar-Me), 1.93 (m, 1H, MeCy-H6), 1.58 - 1.40 (m, 3H, MeCy-H3, MeCy-H4, 
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MeCy-H5), 1.30 (d, J = 6.5 Hz, 3H, Fuc-H6), 1.14 (m, 1H, MeCy-H5’), 1.01 (d, J = 6.4 
Hz, 3H, MeCy-Me), 1.93 - 0.76 (m, 2H, MeCy-H4’,  MeCy-H6’); 13C NMR (125.8 MHz, 
D2O): δ = 181.2 (Lac-C1), 167.8 (Bz-CO), 136.0, 134.9, 134.0, 129.7, 129.1, 128.8, 128.8, 
128.6 (8C, Ar-C), 98.7, 98.7 (2C, Gal-C1, Fuc-C1), 83.6 (MeCy-C2), 82.6 (Lac-C2), 80.5 
(MeCy-C2), 80.9 (Gal-C3), 79.7 (MeCy-C1), 74.2 (Gal-C5), 72.1 (2C, Gal-C2, Fuc-C3), 
69.3 (Fuc-C4), 68.2 (Fuc-C2), 66.5 (Fuc-C5), 66.4 (Gal-C4), 61.7 (Gal-C6), 39.2 (Lac-
C3), 38.5 (MeCy-C3), 32.9 (MeCy-C4), 30.8 (MeCy-C6), 22.3 (MeCy-C5), 20.0 (MeCy-
Me), 18.0 (MeCy-C6), 15.0 (Fuc-C6); HR-MS: m/z: Calcd for C36H47Na2O14 [M+Na]+: 
749.2761, found: 749.2760. 
(1R,2R,3S)-2-[(α-L-Fucopyranosyl)oxy]-3-methyl-cyclohex-1-yl 2-O-benzoyl-3-O-
[sodium (S)-1-carboxy-2-(3,4-difluorophenyl)-ethyl]-ß-D-galactopyranoside (5c) 
A suspension of (23c) (48 mg, 0.040 mmol) and Pd(OH)2/C (50 mg, 10% Pd) in MeOH 
(5 mL) was hydrogenated (2 bar H2) at rt. After 1 h TLC (silica: petroleum ether/EtOAc, 
3:2; C-18: H2O/MeOH, 1:1) indicated completion of the reaction. The reaction mixture 
was filtered through celite and concentrated in vacuo. The crude product was purified by 
reversed phase column chromatography (C-18, H2O/MeOH, gradient 0-100%) followed 
by a Dowex 50 (Na+ form) ion exchange column, a Sephadex G15 column, and 
lyophilization from water to yield the product (5c) as colorless foam (18.8 mg, 0.025 
mmol, 63%). Rf = (C-18, H2O/MeOH, 1:1) 0.45; [α]D22 -80.7 (c 0.24, MeOH); 1H NMR 
(500.1 MHz, CDCl3): δ = 7.86 (d, J = 7.7 Hz, 2H, Ar-H), 7.72 (t, J = 7.2 Hz, 1H, Ar-H), 
7.54 (t, J = 7.7 Hz, 2H, Ar-H), 6.95 (m, 1H, Ar-H), 6.77 (m, 1H, Ar-H), 6.58 (m, 1H, Ar-
H), 5.16 (t, J = 8.8 Hz, 1H, Gal-H2), 5.03 (br s, 1H, Fuc-H1), 4.89 (dd, J = 6.6, 13.0 Hz, 
1H, Fuc-H5), 4.70 (d, J = 8.1 Hz, 1H, Gal-H1), 4.16 (d, J = 10.8 Hz, 1H, Lac-H2), 4.08 
(br s, 1H, Gal-H4), 3.90 - 3.65 (m, 7H, Gal-H6, Gal-H5, Fuc-H2, Fuc-H3, Fuc-H4, Gal-
H3), 3.56 (t, J = 11.6 Hz, 1H, MeCy-H1), 3.05 (t, J = 9.3 Hz, 1H, MeCy-H2), 2.97 (d, J 
= 14.1 Hz, 1H, Lac-H3), 2.72 (m, 1H, Lac-H3b), 1.90 (m, 1H, MeCy-H6), 1.57 - 1.34 (m, 
3H, MeCy-H3, MeCy-H4, MeCy-H5), 1.30 (d, J = 6.2 Hz, 3H, Fuc-H6), 1.14 (m, 1H, 
MeCy-H5’), 1.01 (d, J = 6.2 Hz, 3H, MeCy-Me), 1.96 - 0.70 (m, 2H, MeCy-H4’,  MeCy-
H6’); 13C NMR (125.8 MHz, D2O): δ = 180.7 (Lac-C1), 167.4 (Bz-CO), 150.2 - 146.4 (m, 
2C, ArF-C), 135.1, 134.0, 129.5, 128.6, 128.5, 124.8 (8C, Ar-C), 117.1 (d, J = 17.2 Hz, 
Ar-C), 116.6 (d, J = 17.3 Hz, Ar-C), 98.8, 98.7 (2C, Gal-C1, Fuc-C1), 83.6 (MeCy-C2), 
82.2 (Lac-C2), 80.9 (MeCy-C2), 80.9 (Gal-C3), 79.8 (MeCy-C1), 74.3 (Gal-C5), 72.1, 
72.0 (2C, Gal-C2, Fuc-C3), 69.3 (Fuc-C4), 68.2 (Fuc-C2), 66.6, 66.5 (Fuc-C5, Gal-C4), 
61.7 (Gal-C6), 38.7 (Lac-C3), 38.5 (MeCy-C3), 32.9 (MeCy-C4), 30.7 (MeCy-C6), 22.3 
(MeCy-C5), 18.0 (MeCy-Me), 15.4 (Fuc-C6); HR-MS: m/z:  Calcd for C35H43F2NaO14 
[M+Na]+: 771.2416, found: 771.2415. 
O
O
HO OH
OH
O
O
OBz
O
HO
HO
CO2Na
F
F
5c 
5c
Section III. E-selectin – Manuscript 9 
 
312
(1R,2R,3S)-2-[(α-L-Fucopyranosyl)oxy]-3-methyl-cyclohex-1-yl 3-O-[sodium (S)-1-
carboxy-2-phenylethyl]-ß-D-galactopyranoside (6a) 
A suspension of (23a) (15 mg, 0.013 mmol) and Pd(OH)2/C (50 mg, 10% Pd) in MeOH 
(5 mL) was hydrogenated (1 bar H2) at rt. After 2 h TLC (silica: petroleum ether/EtOAc, 
3:2; C-18: H2O/MeOH, 1:1) indicated completion of the reaction. The reaction mixture 
was filtered through celite and concentrated in vacuo. The residue was dissolved in 
MeOH/H2O (4:1, 1 mL) and treated with LiOH (16 mg, 0.65 mmol) for 7 days. The 
mixture was neutralized with Dowex 50X8 (H+ form), filtered through a Dowex 50 (Na+ 
form) ion exchange column and concentrated. The residue was purified by reversed 
phase column chromatography (C-18, H2O/MeOH, gradient 0-100%) followed by a 
Sephadex G15 column, and lyophilization from water to yield the product (6a) as white 
foam (1.5 mg, 0.0024 mmol, 18%).  Rf = (C-18, H2O/MeOH, 1:1) 0.25; [α]D22 -76.6 (c 
0.26, MeOH); 1H NMR (500.1 MHz, CDCl3): δ = 7.43 – 7.36 (m, 4H, Ar-H), 7.35 – 7.30 
(m, 1H, Ar-H), 5.10 (d, J = 4.0 Hz, 1H, Fuc-H1), 4.86 – 4.80 (m, 1H, Fuc-H5), 4.40 (d, J 
= 8.0 Hz, 1H, Gal-H1), 4.18 (dd, J = 4.7, 8.7 Hz, 1H, Lac-H2), 3.92 (d, J = 2.8 Hz, 1H, 
Gal-H4), 3.89 (dd, J = 3.2, 10.6 Hz, 1H, Fuc-H3), 3.87 - 3.78 (m, 2H, Fuc-H2. Fuc-H4), 
3.76 - 3.65 (m, 3H, MeCy-H1, Gal-H6), 3.58 – 3.51 (m, 2H, Gal-H2, Gal-H5), 3.30 (dd, J 
= 3.2, 9.5 Hz, 1H, Gal-H3), 3.22 (t, J = 9.6 Hz, 1H, MeCy-H2), 3.15 (dd, J = 4.6, 14.0 
Hz, 1H, Lac-H3), 2.98 (dd, J = 8.8, 14.0 Hz, 1H, Lac-H3’), 2.12 - 2.05 (m, 1H, MeCy-
H6), 1.70 - 1.53 (m, 3H, MeCy-H3, MeCy-H5), 1.37 - 1.21 (m, 2H, MeCy-H6’, MeCy-
H4), 1.18 (d, J = 6.6 Hz, 3H, Fuc-H6), 1.01 (d, J = 6.3 Hz, 3H, MeCy-Me), 1.14 – 1.04 
(m, 1H, MCy-H4’); 13C NMR (125.8 MHz, D2O): δ = 181.0 (Lac-C1), 138.2, 129.4, 
128.6, 126.7 (4C, Ar-C), 99.4 (Gal-C1), 98.9 (Fuc-C1), 84.1 (MeCy-C2), 82.7 (Gal-C3), 
82.0 (Lac-C2),  78.6 (MeCy-C1), 74.2 (Gal-C2), 72.0 (Fuc-C2), 69.8 (Gal-C5), 69.3 (Fuc-
C3), 68.2 (Fuc-C4), 66.5 (Fuc-C5), 66.2 (Gal-C4), 61.6 (Gal-C6), 39.3 (Lac-C3), 38.7 
(MeCy-C3), 33.1 (MeCy-C4), 30.2 (MeCy-C6), 22.6 (MeCy-C5), 18.1 (MeCy-Me), 15.5 
(Fuc-C6); HR-MS: m/z: Calcd for C28H42NaO13+ [M+H]+: 609.2518, found: 609.2521. 
(1R,2R,3S)-2-[(α-L-Fucopyranosyl)oxy]-3-methyl-cyclohex-1-yl 3-O-[sodium (S)-1-
carboxy-2-(4-methylphenyl)-ethyl]-ß-D-galactopyranoside (6b) 
A suspension of (23b) (40 mg, 0.035 mmol) and Pd(OH)2/C (50 mg, 10% Pd) in MeOH 
(5 mL) was hydrogenated (2 bar H2) at rt. After 2 h TLC (silica: petroleum ether/EtOAc, 
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3:2; C-18: H2O/MeOH, 1:1) indicated completion of the reaction. The reaction mixture 
was filtered through celite and concentrated in vacuo. The residue was dissolved in 
MeOH/H2O (4:1, 1 mL) and treated with LiOH (41 mg, 1.73 mmol) for 32 h. The 
mixture was neutralized with Dowex 50X8 (H+ form), filtered through a Dowex 50 (Na+ 
form) ion exchange column and concentrated. The residue was purified by reversed 
phase column chromatography (C-18, H2O/MeOH, gradient 0-100%) followed by a 
Dowex 50 (Na+ form) ion exchange column, a Sephadex G15 column, and 
lyophilization from water to yield the product (6b) as colorless foam (8.9 mg, 0.014 
mmol, 41%). Rf = (C-18, H2O/MeOH, 1:1) 0.31; [α]D22 -76.6 (c 0.26, MeOH); 1H NMR 
(500.1 MHz, CDCl3): δ = 7.28 (d, J = 8.0 Hz, 2H, Ar-H), 7.23 (d, J = 8.0 Hz, 2H, Ar-H), 
5.10 (d, J = 4.0 Hz, 1H, Fuc-H1), 4.86 – 4.80 (m, 1H, Fuc-H5), 4.39 (d, J = 8.0 Hz, 1H, 
Gal-H1), 4.15 (dd, J = 4.6, 8.9 Hz, 1H, Lac-H2), 3.92 – 3.86 (m, 2H, Gal-H4, Fuc-H3), 
3.83 - 3.78 (m, 2H, Fuc-H2. Fuc-H4), 3.74 - 3.65 (m, 3H, MeCy-H1, Gal-H6), 3.56 – 
3.49 (m, 2H, Gal-H2, Gal-H5), 3.28 (dd, J = 3.2, 9.3 Hz, 1H, Gal-H3), 3.22 (t, J = 9.6 
Hz, 1H, MeCy-H2), 3.12 (dd, J = 4.5, 14.0 Hz, 1H, Lac-H3), 2.93 (dd, J = 8.9, 14.0 Hz, 
1H, Lac-H3’), 2.33 (s, 3H, Ar-CH3), 2.13 - 2.05 (m, 1H, MeCy-H6), 1.70 - 1.53 (m, 3H, 
MeCy-H3, MeCy-H5), 1.30 - 1.21 (m, 2H, MeCy-H6’, MeCy-H4), 1.18 (d, J = 6.6 Hz, 
3H, Fuc-H6), 1.14 – 1.04 (m, 1H, MCy-H4’), 1.01 (d, J = 6.3 Hz, 3H, MeCy-Me); 13C 
NMR (125.8 MHz, D2O): δ = 180.6 (Lac-C1), 136.7, 135.1, 129.4, 129.1 (4C, Ar-C), 99.4 
(Gal-C1), 98.9 (Fuc-C1), 84.1 (MeCy-C2), 82.7 (Gal-C3), 82.1 (Lac-C2), 78.6 (MeCy-
C1), 74.2 (Gal-C2), 72.0 (Fuc-C2), 69.8 (Gal-C5), 69.3 (Fuc-C3), 68.2 (Fuc-C4), 66.5 
(Fuc-C5), 66.2 (Gal-C4), 61.6 (Gal-C6), 38.9 (Lac-C3), 38.8 (MeCy-C3), 33.2 (MeCy-
C4), 30.2 (MeCy-C6), 22.6 (MeCy-C5), 20.1 (Ar-CH3), 18.1 (MeCy-Me), 15.5 (Fuc-C6); 
HR-MS: m/z: Calcd for C35H43F2Na2O14 [M+Na]+: 645.2499, found: 645.2496. 
(1R,2R,3S)-2-[(α-L-Fucopyranosyl)oxy]-3-methyl-cyclohex-1-yl 3-O-[sodium (S)-1-
carboxy-2-(3,4-difluorophenyl)-ethyl]-ß-D-galactopyranoside (6c) 
A suspension of (23c) (12 mg, 0.010 mmol) and Pd(OH)2/C (50 mg, 10% Pd) in MeOH 
(5 mL) was hydrogenated (2 bar H2) at rt. After 3 h TLC (silica: petroleum ether/EtOAc, 
3:2; C-18: H2O/MeOH, 1:1) indicated completion of the reaction. The reaction mixture 
was filtered through celite and concentrated in vacuo. The residue was dissolved in 
MeOH/H2O (4:1, 1 mL) and treated with LiOH (12 mg, 0.51 mmol) for 7 days. The 
mixture was neutralized with Dowex 50X8 (H+ form), filtered through a Dowex 50 (Na+ 
form) ion exchange column and concentrated. The residue was purified by reversed 
phase column chromatography (C-18, H2O/MeOH, gradient 0-100%) followed by a 
Sephadex G15 column, and lyophilization from water to yield the product (6c) as white 
foam (3.5 mg, 0.0054 mmol, 59%).  Rf = (C-18, H2O/MeOH, 1:1) 0.25; [α]D22 -76.6 (c 
0.26, MeOH); 1H NMR (500.1 MHz, CDCl3): δ = 7.33 – 7.25 (m, 1H, Ar-H), 7.24 – 7.15 
(m, 1H, Ar-H), 7.15 – 7.03 (m, 1H, Ar-H), 5.11 (d, J = 4.0 Hz, 1H, Fuc-H1), 4.90 – 4.80 
(m, 1H, Fuc-H5), 4.43 (d, J = 8.0 Hz, 1H, Gal-H1), 4.15 (dd, J = 4.8, 8.2 Hz, 1H, Lac-
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H2), 3.93 (d, J = 2.9 Hz, 1H, Gal-H4), 3.90 (dd, J = 3.2, 10.6 Hz, 1H, Fuc-H3), 3.87 - 
3.78 (m, 2H, Fuc-H2. Fuc-H4), 3.76 - 3.66 (m, 3H, MeCy-H1, Gal-H6), 3.59 – 3.53 (m, 
2H, Gal-H2, Gal-H5), 3.33 (dd, J = 3.1, 9.5 Hz, 1H, Gal-H3), 3.22 (t, J = 9.6 Hz, 1H, 
MeCy-H2), 3.09 (dd, J = 4.6, 14.1 Hz, 1H, Lac-H3), 2.97 (dd, J = 8.2, 14.1 Hz, 1H, Lac-
H3’), 2.15 - 2.08 (m, 1H, MeCy-H6), 1.72 - 1.54 (m, 3H, MeCy-H3, MeCy-H5), 1.33 - 
1.22 (m, 2H, MeCy-H6’, MeCy-H4), 1.19 (d, J = 6.6 Hz, 3H, Fuc-H6), 1.10 (d, J = 6.3 
Hz, 3H, MeCy-Me), 1.14 – 1.04 (m, 1H, MCy-H4’); 13C NMR (125.8 MHz, D2O): δ = 
180.2 (Lac-C1), 135.1 (m, Ar-C), 125.7 (m, Ar-C), 118.3 (d, J = 17.0 Hz, Ar-C), 116.8 (d, 
J = 16.7 Hz, Ar-C), 99.7 (Gal-C1), 98.9 (Fuc-C1), 84.2 (MeCy-C2), 82.4 (Gal-C3), 81.6 
(Lac-C2),  78.7 (MeCy-C1), 74.1 (Gal-C2), 72.0 (Fuc-C2), 69.8 (Gal-C5), 69.3 (Fuc-C3), 
68.2 (Fuc-C4), 66.5 (Fuc-C5), 66.2 (Gal-C4), 61.7 (Gal-C6), 38.7 (Lac-C3), 38.4 (MeCy-
C3), 33.2 (MeCy-C4), 30.3 (MeCy-C6), 22.6 (MeCy-C5), 18.1 (MeCy-Me), 15.5 (Fuc-
C6); HR-MS: m/z: Calcd for  C28H39F2Na2O13+ [M+H]+: 667.2149, found: 667.2150. 
(1R,2R,3S)-2-[(α-L-Fucopyranosyl)oxy]-3-methyl-cyclohex-1-yl 3-O-[sodium (S)-1-
carboxy-2-(4-methylphenyl)-ethyl]-ß-D-galactopyranoside (8) 
A suspension of (24) (20 mg, 0.018 mmol) and Pd(OH)2/C (50 mg, 10% Pd) in THF (5 
mL) was hydrogenated (2 bar H2) at rt. After 2 h TLC (silica: petroleum ether/EtOAc, 
3:2; C-18: H2O/MeOH, 1:1) indicated completion of the reaction. The reaction mixture 
was filtered through celite and concentrated in vacuo. The residue was dissolved in 
dioxane/H2O/AcOH (4:2:1, 3.5 mL), treated with Rh/Al2O3 (50 mg, 5% Rh) for 24 h. 
The reaction mixture was filtered through celite and concentrated in vacuo. The residue 
was purified by reversed phase column chromatography (C-18, H2O/MeOH) followed by 
a flash chromatography (silica, DCM/MeOH gradient 10-40%, MeOH containing 5% 
H2O). The product was treated with Dowex 50 (Na+ form) ion exchange resin, then 
filtered through a Sephadex G15 column and lyophilization from water to yield the 
product (8) as white foam (2.4 mg, 0.004 mmol, 20%). Rf = (C-18, H2O/MeOH, 1:1) 
0.55; [α]D22 -76.6 (c 0.26, MeOH); 1H NMR (500.1 MHz, CDCl3): δ = 5.09 (d, J = 4.0 
Hz, 1H, Fuc-H1), 5.02 (dd, J = 8.4, 9.5 Hz, 1H, Gal-H2), 4.91 (q, J = 6.4 Hz, 1H, Fuc-
H5), 4.68 (d, J = 8.1 Hz, 1H, Gal-H1), 3.97 (d, J = 2.7 Hz, 1H, Gal-H4), 3.94 – 3.87 (m, 
2H, Lac-H2, Fuc-H3), 3.86 - 3.79 (m, 2H, Fuc-H2. Fuc-H4), 3.78 - 3.74 (m, 2H, Gal-H6), 
3.69 – 3.61 (m, 3H, MeCy-H1, Gal-H5, Gal-H3), 3.19 (t, J = 9.5 Hz, 1H, MeCy-H2), 
2.24 (s, 3H, Ar-CH3), 2.17 – 2.04 (m, 1H, MeCy), 1.82 – 1.46 (m, 9H, Cy, MeCy, Lac-
H3), 1.40 - 1.15 (m, 6H, Cy, MeCy), 1.25 (d, J = 6.2 Hz, 3H, Fuc-H6), 1.13 – 1.02 (m, 
1H, Cy or MeCy), 1.09 (d, J = 6.4 Hz, 3H, MeCy-Me), 1.02 – 0.85 (m, 2H, Cy, MeCy); 
13C NMR (125.8 MHz, D2O): δ = 182.5 (Lac-C1), 173.5 (CH3-CO), 98.8 (Fuc-C1), 98.5 
(Gal-C1), 83.6 (MeCy-C2), 80.8 (Gal-C3), 79.8 (MeCy-C1), 79.1 (Lac-C2), 74.2 (Gal-
C5), 72.0 (Fuc-C4, Gal-C2), 69.3 (Fuc-C3), 68.2 (Fuc-C2), 66.5 (Fuc-C5), 66.4 (Gal-C4), 
61.7 (Gal-C6), 41.5 (Lac-C3), 38.7, 33.7, 33.4, 33.1, 31.6, 30.7, 26.0, 26.0, 25.7, 22.5 (Cy, 
MeCy), 20.9 (Ar-CH3), 18.1 (MeCy-Me), 15.4 (Fuc-C6); HR-MS: m/z: Calcd for 
C30H49Na2O14 [M+Na]+: 679.2918, found: 679.2919 
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